{"PMC7344047": [["Our world is increasingly fragmented.", [["increasingly", "OBSERVATION_MODIFIER", 13, 25], ["fragmented", "OBSERVATION", 26, 36]]], ["The post-war consensus on a politics of multilateral treatises and international cooperation in trade and commerce is being challenged by a new wave of protectionism and populism.", [["protectionism", "DISEASE", 152, 165], ["populism", "DISEASE", 170, 178], ["multilateral treatises", "TREATMENT", 40, 62], ["populism", "PROBLEM", 170, 178]]], ["The temptation of isolationism promises greater national or local wealth but ends up reducing the economy to a zero-sum game that leaves all participants poorer, except for a few privileged players.", [["participants", "SPECIES", 141, 153]]], ["Mercantilism, trade wars, and even armed international conflict loom on the horizon.", [["Mercantilism", "CHEMICAL", 0, 12]]], ["In such a socio-political environment, the topic of the common good in business and management, as antidote to egoistic individualism and proud self-aggrandizement, is of unabated interest and growing importance for humanistic management.", [["humanistic management", "TREATMENT", 216, 237]]], ["The common good is a theme of reflection and study for business ethics, political philosophy, and other academic disciplines, and has many implications.", [["common", "OBSERVATION_MODIFIER", 4, 10], ["good", "OBSERVATION", 11, 15]]], ["It is especially relevant for humanistic management that \u201cemphasizes common human needs and is oriented to the development of human virtue, in all its forms, to its fullest extent.\u201d", [["human", "ORGANISM", 76, 81], ["human", "ORGANISM", 126, 131], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 126, 131], ["humanistic management", "TREATMENT", 30, 51]]]], "PMC7166358": [["CASE REPORTAn 11\u2010year\u2010old boy with an idiopathic seizure disorder since the age of 6 years was put on phenobarbitone (5 mg/kg per day) 2 weeks prior to his first admission.", [["idiopathic seizure disorder", "DISEASE", 38, 65], ["phenobarbitone", "CHEMICAL", 102, 116], ["phenobarbitone", "CHEMICAL", 102, 116], ["boy", "ORGANISM", 26, 29], ["phenobarbitone", "SIMPLE_CHEMICAL", 102, 116], ["boy", "SPECIES", 26, 29], ["an idiopathic seizure disorder", "PROBLEM", 35, 65], ["phenobarbitone", "TREATMENT", 102, 116], ["idiopathic", "OBSERVATION_MODIFIER", 38, 48], ["seizure", "OBSERVATION", 49, 56]]], ["He had a previous history of mild skin rash to carbamazepine.", [["skin", "ANATOMY", 34, 38], ["skin rash", "DISEASE", 34, 43], ["carbamazepine", "CHEMICAL", 47, 60], ["carbamazepine", "CHEMICAL", 47, 60], ["skin", "ORGAN", 34, 38], ["carbamazepine", "SIMPLE_CHEMICAL", 47, 60], ["mild skin rash", "PROBLEM", 29, 43], ["carbamazepine", "TREATMENT", 47, 60], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["skin", "ANATOMY", 34, 38], ["rash", "OBSERVATION", 39, 43]]], ["There was no other significant past medical or family history.CASE REPORTHe had developed flu\u2010like symptoms a few days prior to admission, for which he was given antibiotics by a general practitioner.", [["flu\u2010like symptoms", "PROBLEM", 90, 107], ["antibiotics", "TREATMENT", 162, 173], ["no other", "UNCERTAINTY", 10, 18], ["significant", "OBSERVATION_MODIFIER", 19, 30]]], ["On admission, he had fever and an itchy generalized urticarial skin rash and was treated as a case of antibiotic\u2010induced allergic reaction.", [["skin", "ANATOMY", 63, 67], ["fever", "DISEASE", 21, 26], ["skin rash", "DISEASE", 63, 72], ["allergic reaction", "DISEASE", 121, 138], ["skin", "ORGAN", 63, 67], ["fever", "PROBLEM", 21, 26], ["an itchy generalized urticarial skin rash", "PROBLEM", 31, 72], ["antibiotic\u2010induced allergic reaction", "PROBLEM", 102, 138], ["itchy", "OBSERVATION_MODIFIER", 34, 39], ["generalized", "OBSERVATION_MODIFIER", 40, 51], ["urticarial", "OBSERVATION_MODIFIER", 52, 62], ["skin", "ANATOMY", 63, 67], ["rash", "OBSERVATION", 68, 72]]], ["He was given a 3\u2010day course of prednisolone (1 mg/kg per day) and the rash and fever responded rapidly.", [["prednisolone", "CHEMICAL", 31, 43], ["rash", "DISEASE", 70, 74], ["fever", "DISEASE", 79, 84], ["prednisolone", "CHEMICAL", 31, 43], ["He", "ORGANISM", 0, 2], ["prednisolone", "SIMPLE_CHEMICAL", 31, 43], ["prednisolone", "TREATMENT", 31, 43], ["the rash", "PROBLEM", 66, 74], ["fever", "PROBLEM", 79, 84], ["rash", "OBSERVATION", 70, 74], ["fever", "OBSERVATION", 79, 84]]], ["Routine blood tests including liver function were normal.", [["blood", "ANATOMY", 8, 13], ["liver", "ANATOMY", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["liver", "ORGAN", 30, 35], ["Routine blood tests", "TEST", 0, 19], ["liver function", "TEST", 30, 44], ["liver", "ANATOMY", 30, 35], ["normal", "OBSERVATION", 50, 56]]], ["His seizures became more frequent and phenobarbitone was recommenced prior to discharge.CASE REPORTHe returned 2 days later with worsening skin rash and fever.", [["skin", "ANATOMY", 139, 143], ["seizures", "DISEASE", 4, 12], ["phenobarbitone", "CHEMICAL", 38, 52], ["skin rash", "DISEASE", 139, 148], ["fever", "DISEASE", 153, 158], ["phenobarbitone", "CHEMICAL", 38, 52], ["phenobarbitone", "SIMPLE_CHEMICAL", 38, 52], ["skin", "ORGAN", 139, 143], ["His seizures", "PROBLEM", 0, 12], ["phenobarbitone", "TREATMENT", 38, 52], ["worsening skin rash", "PROBLEM", 129, 148], ["fever", "PROBLEM", 153, 158], ["worsening", "OBSERVATION_MODIFIER", 129, 138], ["skin", "ANATOMY", 139, 143], ["rash", "OBSERVATION", 144, 148], ["fever", "OBSERVATION", 153, 158]]], ["On this occasion, the phenobarbitone was considered the likely cause of the reaction.", [["phenobarbitone", "CHEMICAL", 22, 36], ["phenobarbitone", "CHEMICAL", 22, 36], ["phenobarbitone", "SIMPLE_CHEMICAL", 22, 36], ["the phenobarbitone", "TREATMENT", 18, 36], ["the reaction", "PROBLEM", 72, 84]]], ["Examination revealed generalized lymphadenopathy and a widespread itchy erythematous maculopapular rash.", [["lymphadenopathy", "DISEASE", 33, 48], ["rash", "DISEASE", 99, 103], ["Examination", "TEST", 0, 11], ["generalized lymphadenopathy", "PROBLEM", 21, 48], ["a widespread itchy erythematous maculopapular rash", "PROBLEM", 53, 103], ["generalized", "OBSERVATION_MODIFIER", 21, 32], ["lymphadenopathy", "OBSERVATION", 33, 48], ["widespread", "OBSERVATION_MODIFIER", 55, 65], ["itchy", "OBSERVATION_MODIFIER", 66, 71], ["erythematous", "OBSERVATION_MODIFIER", 72, 84], ["maculopapular", "OBSERVATION_MODIFIER", 85, 98], ["rash", "OBSERVATION", 99, 103]]], ["Baseline blood investigations showed a haemoglobin level of 11.7 g/dL, total white cell count of 7.9 \u00d7 109/L of which 3% was eosinophils (0.2 \u00d7 109/L) and 7% was lymphocytes (0.6 \u00d7 109/L) and a platelet count of 104 \u00d7 109/L. Liver function was normal.", [["blood", "ANATOMY", 9, 14], ["white cell", "ANATOMY", 77, 87], ["eosinophils", "ANATOMY", 125, 136], ["lymphocytes", "ANATOMY", 162, 173], ["platelet", "ANATOMY", 194, 202], ["Liver", "ANATOMY", 225, 230], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 39, 50], ["white cell", "CELL", 77, 87], ["eosinophils", "CELL", 125, 136], ["lymphocytes", "CELL", 162, 173], ["platelet", "CELL", 194, 202], ["Liver", "ORGAN", 225, 230], ["eosinophils", "CELL_TYPE", 125, 136], ["lymphocytes", "CELL_TYPE", 162, 173], ["Baseline blood investigations", "TEST", 0, 29], ["a haemoglobin level", "TEST", 37, 56], ["total white cell count", "TEST", 71, 93], ["eosinophils", "TEST", 125, 136], ["lymphocytes", "TEST", 162, 173], ["a platelet count", "TEST", 192, 208], ["Liver function", "TEST", 225, 239], ["normal", "OBSERVATION", 244, 250]]], ["Chest radiograph did not reveal any pneumonic changes.", [["pneumonic", "DISEASE", 36, 45], ["Chest radiograph", "TEST", 0, 16], ["any pneumonic changes", "PROBLEM", 32, 53], ["pneumonic", "OBSERVATION", 36, 45]]], ["He remained febrile and a repeat liver function on day 4 showed evidence of hepatitis with a raised alanine aminotransferase (ALT) of 1361 IU/L and an international normalized ratio (INR) of 2.12.", [["liver", "ANATOMY", 33, 38], ["febrile", "DISEASE", 12, 19], ["hepatitis", "DISEASE", 76, 85], ["alanine", "CHEMICAL", 100, 107], ["alanine", "CHEMICAL", 100, 107], ["He", "ORGANISM", 0, 2], ["liver", "ORGAN", 33, 38], ["alanine", "AMINO_ACID", 100, 107], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 108, 124], ["ALT", "SIMPLE_CHEMICAL", 126, 129], ["alanine aminotransferase", "PROTEIN", 100, 124], ["ALT", "PROTEIN", 126, 129], ["febrile", "PROBLEM", 12, 19], ["a repeat liver function", "TEST", 24, 47], ["hepatitis", "PROBLEM", 76, 85], ["alanine aminotransferase", "TEST", 100, 124], ["ALT", "TEST", 126, 129], ["an international normalized ratio", "TEST", 148, 181], ["INR", "TEST", 183, 186], ["febrile", "OBSERVATION", 12, 19], ["liver", "ANATOMY", 33, 38], ["hepatitis", "OBSERVATION", 76, 85]]], ["The clinical picture was compatible with anti\u2010epileptic hypersensitivity syndrome (AHS).", [["anti\u2010epileptic hypersensitivity syndrome", "DISEASE", 41, 81], ["AHS", "DISEASE", 83, 86], ["anti\u2010epileptic hypersensitivity syndrome", "PROBLEM", 41, 81], ["compatible with", "UNCERTAINTY", 25, 40], ["anti\u2010epileptic hypersensitivity syndrome", "OBSERVATION", 41, 81]]], ["Prednisolone (1 mg/kg per day) was restarted on day 5 and associated with improvement allowing discharge 10 days after admission.", [["Prednisolone", "CHEMICAL", 0, 12], ["Prednisolone", "CHEMICAL", 0, 12], ["Prednisolone", "SIMPLE_CHEMICAL", 0, 12], ["Prednisolone", "TREATMENT", 0, 12]]], ["The ALT at the time of discharge was 1066 IU/L and INR was normal.", [["ALT", "SIMPLE_CHEMICAL", 4, 7], ["ALT", "PROTEIN", 4, 7], ["INR", "PROTEIN", 51, 54], ["The ALT", "TEST", 0, 7], ["INR", "TEST", 51, 54], ["normal", "OBSERVATION", 59, 65]]], ["During this admission, he stayed on the same isolation ward, but in a different cubicle to two patients with severe acute respiratory syndrome (SARS).CASE REPORTHe was re\u2010admitted 2 days later with a high swinging fever (up to 40\u00b0C), malaise, myalgia, dry cough and worsening of his skin rash.", [["skin", "ANATOMY", 283, 287], ["acute respiratory syndrome", "DISEASE", 116, 142], ["SARS", "DISEASE", 144, 148], ["fever", "DISEASE", 214, 219], ["myalgia", "DISEASE", 243, 250], ["dry cough", "DISEASE", 252, 261], ["skin rash", "DISEASE", 283, 292], ["patients", "ORGANISM", 95, 103], ["skin", "ORGAN", 283, 287], ["patients", "SPECIES", 95, 103], ["severe acute respiratory syndrome", "PROBLEM", 109, 142], ["a high swinging fever", "PROBLEM", 198, 219], ["malaise", "PROBLEM", 234, 241], ["myalgia", "PROBLEM", 243, 250], ["dry cough", "PROBLEM", 252, 261], ["his skin rash", "PROBLEM", 279, 292], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["respiratory syndrome", "OBSERVATION", 122, 142], ["myalgia", "ANATOMY", 243, 250], ["cough", "OBSERVATION", 256, 261], ["worsening", "OBSERVATION_MODIFIER", 266, 275], ["skin", "ANATOMY", 283, 287], ["rash", "OBSERVATION", 288, 292]]], ["On examination, the chest was clear and the liver was enlarged to 4 cm below the right costal margin.", [["chest", "ANATOMY", 20, 25], ["liver", "ANATOMY", 44, 49], ["right costal margin", "ANATOMY", 81, 100], ["chest", "ORGAN", 20, 25], ["liver", "ORGAN", 44, 49], ["costal margin", "MULTI-TISSUE_STRUCTURE", 87, 100], ["examination", "TEST", 3, 14], ["chest", "ANATOMY", 20, 25], ["clear", "OBSERVATION", 30, 35], ["liver", "ANATOMY", 44, 49], ["enlarged", "OBSERVATION", 54, 62], ["4 cm", "OBSERVATION_MODIFIER", 66, 70], ["right", "ANATOMY_MODIFIER", 81, 86], ["costal", "ANATOMY_MODIFIER", 87, 93], ["margin", "ANATOMY_MODIFIER", 94, 100]]], ["Chest radiograph showed bilateral basal haziness.", [["Chest radiograph", "TEST", 0, 16], ["bilateral basal haziness", "PROBLEM", 24, 48], ["bilateral", "ANATOMY_MODIFIER", 24, 33], ["basal", "ANATOMY_MODIFIER", 34, 39], ["haziness", "OBSERVATION", 40, 48]]], ["A possible diagnosis of SARS was suspected and he was managed according to our local guidelines at the time that included ribavirin.", [["SARS", "DISEASE", 24, 28], ["ribavirin", "CHEMICAL", 122, 131], ["ribavirin", "CHEMICAL", 122, 131], ["ribavirin", "SIMPLE_CHEMICAL", 122, 131], ["SARS", "PROBLEM", 24, 28], ["ribavirin", "TREATMENT", 122, 131], ["possible", "UNCERTAINTY", 2, 10], ["SARS", "OBSERVATION", 24, 28]]], ["ALT on admission was 1142 IU/L, INR was 1.5 and blood glucose and ammonia levels were normal.", [["blood", "ANATOMY", 48, 53], ["glucose", "CHEMICAL", 54, 61], ["ammonia", "CHEMICAL", 66, 73], ["glucose", "CHEMICAL", 54, 61], ["ammonia", "CHEMICAL", 66, 73], ["ALT", "SIMPLE_CHEMICAL", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["glucose", "SIMPLE_CHEMICAL", 54, 61], ["ammonia", "SIMPLE_CHEMICAL", 66, 73], ["ALT", "TEST", 0, 3], ["INR", "TEST", 32, 35], ["blood glucose", "TEST", 48, 61], ["ammonia levels", "TEST", 66, 80], ["normal", "OBSERVATION", 86, 92]]], ["Over the next 3 days, his temperature started to subside and there was no progression of the pneumonic changes on serial chest radiographs.", [["chest", "ANATOMY", 121, 126], ["pneumonic", "DISEASE", 93, 102], ["his temperature", "TEST", 22, 37], ["the pneumonic changes", "PROBLEM", 89, 110], ["serial chest radiographs", "TEST", 114, 138], ["no", "UNCERTAINTY", 71, 73], ["progression", "OBSERVATION_MODIFIER", 74, 85], ["pneumonic", "OBSERVATION", 93, 102], ["chest", "ANATOMY", 121, 126]]], ["Preliminary viral screen on nasopharyngeal aspirate sample, using rapid test polymerase chain reaction (RT\u2010PCR) was negative for coronavirus and ribavirin was stopped.", [["nasopharyngeal aspirate sample", "ANATOMY", 28, 58], ["ribavirin", "CHEMICAL", 145, 154], ["ribavirin", "CHEMICAL", 145, 154], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 28, 51], ["coronavirus", "ORGANISM", 129, 140], ["ribavirin", "SIMPLE_CHEMICAL", 145, 154], ["coronavirus", "SPECIES", 129, 140], ["Preliminary viral screen", "TEST", 0, 24], ["nasopharyngeal aspirate sample", "TEST", 28, 58], ["rapid test polymerase chain reaction", "TEST", 66, 102], ["RT\u2010PCR", "TEST", 104, 110], ["coronavirus", "PROBLEM", 129, 140], ["ribavirin", "TREATMENT", 145, 154], ["nasopharyngeal", "ANATOMY", 28, 42], ["negative for", "UNCERTAINTY", 116, 128], ["ribavirin", "OBSERVATION", 145, 154]]], ["His fever pattern (Fig. 1) once again became unsettled and his condition further deteriorated 3 days later when he became more tired, jaundiced and less responsive.", [["fever", "DISEASE", 4, 9], ["jaundiced", "DISEASE", 134, 143], ["His fever pattern", "PROBLEM", 0, 17], ["more tired", "PROBLEM", 122, 132], ["jaundiced", "PROBLEM", 134, 143], ["less responsive", "PROBLEM", 148, 163], ["fever", "OBSERVATION", 4, 9], ["jaundiced", "OBSERVATION", 134, 143]]], ["Urgent cranial computed tomography (CT) and ultrasound scan of the abdomen were unremarkable.", [["cranial", "ANATOMY", 7, 14], ["abdomen", "ANATOMY", 67, 74], ["abdomen", "ORGAN", 67, 74], ["Urgent cranial computed tomography (CT) and ultrasound scan of the abdomen", "TEST", 0, 74], ["cranial", "ANATOMY", 7, 14], ["abdomen", "ANATOMY", 67, 74], ["unremarkable", "OBSERVATION", 80, 92]]], ["INR subsequently went up to 4.94 and the highest ammonia level was 137, while the ALT has dropped to 433 IU/L. It was considered that this dramatic deterioration could be related to AHS and a dose of intravenous immune globulin (IVIG, 1 g/kg) was given prior to transfer to the regional liver unit for possible liver transplant.", [["intravenous", "ANATOMY", 200, 211], ["liver", "ANATOMY", 287, 292], ["liver", "ANATOMY", 311, 316], ["ammonia", "CHEMICAL", 49, 56], ["AHS", "DISEASE", 182, 185], ["immune globulin", "CHEMICAL", 212, 227], ["ammonia", "CHEMICAL", 49, 56], ["ammonia", "SIMPLE_CHEMICAL", 49, 56], ["ALT", "SIMPLE_CHEMICAL", 82, 85], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 200, 211], ["immune globulin", "SIMPLE_CHEMICAL", 212, 227], ["IVIG", "SIMPLE_CHEMICAL", 229, 233], ["liver", "ORGAN", 287, 292], ["liver", "ORGAN", 311, 316], ["INR", "PROTEIN", 0, 3], ["ALT", "PROTEIN", 82, 85], ["INR", "TEST", 0, 3], ["the highest ammonia level", "TEST", 37, 62], ["the ALT", "TEST", 78, 85], ["this dramatic deterioration", "PROBLEM", 134, 161], ["AHS", "PROBLEM", 182, 185], ["intravenous immune globulin", "TREATMENT", 200, 227], ["IVIG", "TREATMENT", 229, 233], ["liver transplant", "TREATMENT", 311, 327], ["dramatic", "OBSERVATION_MODIFIER", 139, 147], ["deterioration", "OBSERVATION", 148, 161], ["liver", "ANATOMY", 287, 292], ["liver", "ANATOMY", 311, 316], ["transplant", "OBSERVATION", 317, 327]]], ["The work\u2010up for other possible causes of liver failure was unrevealing.", [["liver", "ANATOMY", 41, 46], ["liver failure", "DISEASE", 41, 54], ["liver", "ORGAN", 41, 46], ["The work\u2010up", "TEST", 0, 11], ["liver failure", "PROBLEM", 41, 54], ["liver", "ANATOMY", 41, 46], ["failure", "OBSERVATION", 47, 54]]], ["His level of consciousness deteriorated further and he was intubated and ventilated.", [["intubated", "TREATMENT", 59, 68], ["ventilated", "TREATMENT", 73, 83]]], ["However, over the next 24 h, while being prepared for a living\u2010related liver transplant, his condition improved with the INR dropping to 2.7 and the ammonia level trending downward.", [["liver", "ANATOMY", 71, 76], ["ammonia", "CHEMICAL", 149, 156], ["ammonia", "CHEMICAL", 149, 156], ["liver", "ORGAN", 71, 76], ["ammonia", "SIMPLE_CHEMICAL", 149, 156], ["INR", "PROTEIN", 121, 124], ["a living\u2010related liver transplant", "TREATMENT", 54, 87], ["the INR", "TEST", 117, 124], ["the ammonia level", "TEST", 145, 162], ["liver", "ANATOMY", 71, 76], ["transplant", "OBSERVATION", 77, 87]]], ["He was extubated after 48 h, but developed thrombocytopaenia requiring platelet transfusion.", [["platelet", "ANATOMY", 71, 79], ["thrombocytopaenia", "DISEASE", 43, 60], ["He", "ORGANISM", 0, 2], ["platelet", "CELL", 71, 79], ["thrombocytopaenia", "PROBLEM", 43, 60], ["platelet transfusion", "TREATMENT", 71, 91], ["thrombocytopaenia", "OBSERVATION", 43, 60], ["platelet transfusion", "OBSERVATION", 71, 91]]], ["In view of the possibility of this being related to ongoing AHS a further dose of IVIG (1 g/kg) was given with a significant improvement in the platelet count.", [["platelet", "ANATOMY", 144, 152], ["AHS", "DISEASE", 60, 63], ["IVIG", "CHEMICAL", 82, 86], ["IVIG", "SIMPLE_CHEMICAL", 82, 86], ["platelet", "CELL", 144, 152], ["ongoing AHS", "PROBLEM", 52, 63], ["IVIG", "TREATMENT", 82, 86], ["the platelet count", "TEST", 140, 158], ["significant", "OBSERVATION_MODIFIER", 113, 124], ["improvement", "OBSERVATION_MODIFIER", 125, 136], ["platelet count", "OBSERVATION", 144, 158]]], ["Five days after the second dose of IVIG he developed high fever and increasing rash over the extremities.", [["extremities", "ANATOMY", 93, 104], ["fever", "DISEASE", 58, 63], ["rash", "DISEASE", 79, 83], ["extremities", "ORGANISM_SUBDIVISION", 93, 104], ["IVIG", "TREATMENT", 35, 39], ["high fever", "PROBLEM", 53, 63], ["increasing rash over the extremities", "PROBLEM", 68, 104], ["high", "OBSERVATION_MODIFIER", 53, 57], ["fever", "OBSERVATION", 58, 63], ["increasing", "OBSERVATION_MODIFIER", 68, 78], ["rash", "OBSERVATION", 79, 83], ["extremities", "ANATOMY", 93, 104]]], ["A third dose of IVIG (1 g/kg) and prednisolone (2 mg/kg/day) were given and associated with a dramatic drop in temperature and improvement in the rash and general condition within 24 h.DISCUSSIONAnti\u2010epileptic hypersensitivity syndrome (AHS) may be underrecognized and is potentially fatal.", [["IVIG", "CHEMICAL", 16, 20], ["prednisolone", "CHEMICAL", 34, 46], ["rash", "DISEASE", 146, 150], ["hypersensitivity syndrome", "DISEASE", 210, 235], ["AHS", "DISEASE", 237, 240], ["prednisolone", "CHEMICAL", 34, 46], ["IVIG", "SIMPLE_CHEMICAL", 16, 20], ["prednisolone", "SIMPLE_CHEMICAL", 34, 46], ["IVIG", "TREATMENT", 16, 20], ["prednisolone", "TREATMENT", 34, 46], ["a dramatic drop in temperature", "PROBLEM", 92, 122], ["the rash", "PROBLEM", 142, 150], ["general condition", "PROBLEM", 155, 172], ["hypersensitivity syndrome", "PROBLEM", 210, 235], ["dramatic", "OBSERVATION_MODIFIER", 94, 102], ["drop", "OBSERVATION", 103, 107], ["temperature", "OBSERVATION_MODIFIER", 111, 122], ["improvement", "OBSERVATION_MODIFIER", 127, 138], ["rash", "OBSERVATION", 146, 150]]], ["The course of recovery can be fluctuating and long, even in mild cases.1We described a child with severe AHS whose presentation was complicated by symptoms and signs that were compatible with the diagnosis of SARS.", [["AHS", "DISEASE", 105, 108], ["SARS", "DISEASE", 209, 213], ["child", "SPECIES", 87, 92], ["severe AHS", "PROBLEM", 98, 108], ["symptoms", "PROBLEM", 147, 155], ["signs", "PROBLEM", 160, 165], ["SARS", "PROBLEM", 209, 213], ["mild", "OBSERVATION_MODIFIER", 60, 64]]], ["His subsequent response to IVIG and steroid may suggest an underlying autoimmune type of pathogenesis.DISCUSSIONAHS is an idiosyncratic, non\u2010dose\u2010related adverse reaction reported to occur with anticonvulsants that contain an aromatic ring (carbamazepine, phenobarbital and phenytoin).", [["steroid", "CHEMICAL", 36, 43], ["carbamazepine", "CHEMICAL", 241, 254], ["phenobarbital", "CHEMICAL", 256, 269], ["phenytoin", "CHEMICAL", 274, 283], ["steroid", "CHEMICAL", 36, 43], ["carbamazepine", "CHEMICAL", 241, 254], ["phenobarbital", "CHEMICAL", 256, 269], ["phenytoin", "CHEMICAL", 274, 283], ["IVIG", "SIMPLE_CHEMICAL", 27, 31], ["steroid", "SIMPLE_CHEMICAL", 36, 43], ["carbamazepine", "SIMPLE_CHEMICAL", 241, 254], ["phenobarbital", "SIMPLE_CHEMICAL", 256, 269], ["phenytoin", "SIMPLE_CHEMICAL", 274, 283], ["IVIG", "TREATMENT", 27, 31], ["steroid", "TREATMENT", 36, 43], ["an underlying autoimmune type of pathogenesis", "PROBLEM", 56, 101], ["an idiosyncratic, non\u2010dose\u2010related adverse reaction", "PROBLEM", 119, 170], ["anticonvulsants", "TREATMENT", 194, 209], ["an aromatic ring (carbamazepine", "TREATMENT", 223, 254], ["phenobarbital", "TREATMENT", 256, 269], ["phenytoin", "TREATMENT", 274, 283], ["autoimmune", "OBSERVATION", 70, 80], ["aromatic ring", "OBSERVATION", 226, 239]]], ["Our patient had a previous mild reaction to carbamazepine and that could well be the early warning sign that he was prone to AHS.", [["carbamazepine", "CHEMICAL", 44, 57], ["AHS", "DISEASE", 125, 128], ["carbamazepine", "CHEMICAL", 44, 57], ["patient", "ORGANISM", 4, 11], ["carbamazepine", "SIMPLE_CHEMICAL", 44, 57], ["patient", "SPECIES", 4, 11], ["a previous mild reaction", "PROBLEM", 16, 40], ["carbamazepine", "TREATMENT", 44, 57], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["reaction", "OBSERVATION", 32, 40]]], ["The condition was first described with the use of phenytoin.2The true incidence is unknown and has been estimated to be between 1 in 1000 and 1 in 10 000 exposures.3In a review by Bessmertny et al.414 cases of AHS were identified over a period of 11 years.", [["phenytoin", "CHEMICAL", 50, 59], ["AHS", "DISEASE", 210, 213], ["phenytoin", "CHEMICAL", 50, 59], ["phenytoin", "SIMPLE_CHEMICAL", 50, 59], ["AHS", "CANCER", 210, 213], ["phenytoin", "TREATMENT", 50, 59], ["AHS", "PROBLEM", 210, 213]]], ["Eight patients were taking phenytoin, six carbamazepine and four phenobarbital alone or in combination.", [["phenytoin", "CHEMICAL", 27, 36], ["carbamazepine", "CHEMICAL", 42, 55], ["phenobarbital", "CHEMICAL", 65, 78], ["phenytoin", "CHEMICAL", 27, 36], ["carbamazepine", "CHEMICAL", 42, 55], ["phenobarbital", "CHEMICAL", 65, 78], ["patients", "ORGANISM", 6, 14], ["phenytoin", "SIMPLE_CHEMICAL", 27, 36], ["carbamazepine", "SIMPLE_CHEMICAL", 42, 55], ["phenobarbital", "SIMPLE_CHEMICAL", 65, 78], ["patients", "SPECIES", 6, 14], ["phenytoin", "TREATMENT", 27, 36], ["six carbamazepine", "TREATMENT", 38, 55], ["four phenobarbital", "TREATMENT", 60, 78]]], ["The mean age was 10.4 years and the mean time from exposure to development of symptoms was 23 days.", [["symptoms", "PROBLEM", 78, 86]]], ["The occurrence of AHS has no relationship with the underlying neurological condition for which anti\u2010epileptic treatment was started.", [["neurological", "ANATOMY", 62, 74], ["AHS", "DISEASE", 18, 21], ["AHS", "PROBLEM", 18, 21], ["the underlying neurological condition", "PROBLEM", 47, 84], ["anti\u2010epileptic treatment", "TREATMENT", 95, 119], ["no relationship with", "UNCERTAINTY", 26, 46]]], ["In addition to rash and fever (present in all patients by definition), other common features of AHS were lymphocytosis (71.4%), elevated erythrocyte sedimentation rate (64.3%), elevated aminotransferases (64.3%), lymphadenopathy (57.1%), eosinophilia (42.8%), coagulopathy (42.8%), leucocytosis (35.7%), leucopaenia (35.7%), hyperbilirubinaemia (35.7%) and nephritis (7.1%).", [["erythrocyte", "ANATOMY", 137, 148], ["rash", "DISEASE", 15, 19], ["fever", "DISEASE", 24, 29], ["AHS", "DISEASE", 96, 99], ["lymphocytosis", "DISEASE", 105, 118], ["lymphadenopathy", "DISEASE", 213, 228], ["eosinophilia", "DISEASE", 238, 250], ["coagulopathy", "DISEASE", 260, 272], ["leucocytosis", "DISEASE", 282, 294], ["leucopaenia", "DISEASE", 304, 315], ["hyperbilirubinaemia", "DISEASE", 325, 344], ["nephritis", "DISEASE", 357, 366], ["patients", "ORGANISM", 46, 54], ["erythrocyte", "CELL", 137, 148], ["patients", "SPECIES", 46, 54], ["rash", "PROBLEM", 15, 19], ["fever", "PROBLEM", 24, 29], ["AHS", "TEST", 96, 99], ["lymphocytosis", "TEST", 105, 118], ["elevated erythrocyte sedimentation rate", "PROBLEM", 128, 167], ["elevated aminotransferases", "PROBLEM", 177, 203], ["lymphadenopathy", "PROBLEM", 213, 228], ["eosinophilia", "TEST", 238, 250], ["coagulopathy", "PROBLEM", 260, 272], ["leucocytosis", "TEST", 282, 294], ["leucopaenia", "TEST", 304, 315], ["hyperbilirubinaemia", "TEST", 325, 344], ["nephritis", "PROBLEM", 357, 366], ["rash", "OBSERVATION", 15, 19], ["fever", "OBSERVATION", 24, 29], ["lymphocytosis", "OBSERVATION", 105, 118], ["erythrocyte sedimentation", "OBSERVATION", 137, 162], ["lymphadenopathy", "OBSERVATION", 213, 228], ["eosinophilia", "OBSERVATION", 238, 250], ["coagulopathy", "OBSERVATION", 260, 272], ["leucocytosis", "OBSERVATION", 282, 294], ["hyperbilirubinaemia", "OBSERVATION", 325, 344], ["nephritis", "OBSERVATION", 357, 366]]], ["In Bessmertny's series all children recovered except for one who died from liver failure.", [["liver", "ANATOMY", 75, 80], ["liver failure", "DISEASE", 75, 88], ["children", "ORGANISM", 27, 35], ["liver", "ORGAN", 75, 80], ["children", "SPECIES", 27, 35], ["liver failure", "PROBLEM", 75, 88], ["liver", "ANATOMY", 75, 80], ["failure", "OBSERVATION", 81, 88]]], ["This child was taking a combination of phenytoin and carbamazepine, and there was a delay of 2 weeks after the start of symptoms before the medications were stopped.DISCUSSIONThe underlying pathogenesis of AHS is unknown.", [["phenytoin", "CHEMICAL", 39, 48], ["carbamazepine", "CHEMICAL", 53, 66], ["AHS", "DISEASE", 206, 209], ["phenytoin", "CHEMICAL", 39, 48], ["carbamazepine", "CHEMICAL", 53, 66], ["child", "ORGANISM", 5, 10], ["phenytoin", "SIMPLE_CHEMICAL", 39, 48], ["carbamazepine", "SIMPLE_CHEMICAL", 53, 66], ["phenytoin", "TREATMENT", 39, 48], ["carbamazepine", "TREATMENT", 53, 66], ["symptoms", "PROBLEM", 120, 128], ["the medications", "TREATMENT", 136, 151], ["The underlying pathogenesis of AHS", "PROBLEM", 175, 209]]], ["There is evidence that the condition is immune mediated with autoimmune hypothyroidism being a recognized late complication following AHS.1Others have proposed that AHS is a form of graft\u2010versus\u2010host disease.5The use of steroids in this condition is controversial with both positive and negative results being reported in the literature.6,7,8,9In Bessmertny's series, the clinical outcome was similar between children who received systemic steroid therapy and those who did not.4There have been earlier reports on the use of IVIG for AHS,10,11,12improvements in terms of rise in platelet count, alleviation of symptoms of fever, rash, oedema and oral ulcers were seen within 24\u201348 h after single\u2010dose therapy.", [["platelet", "ANATOMY", 579, 587], ["oral", "ANATOMY", 646, 650], ["autoimmune hypothyroidism", "DISEASE", 61, 86], ["AHS", "DISEASE", 134, 137], ["AHS", "DISEASE", 165, 168], ["graft\u2010versus\u2010host disease", "DISEASE", 182, 207], ["steroids", "CHEMICAL", 220, 228], ["steroid", "CHEMICAL", 440, 447], ["AHS", "DISEASE", 534, 537], ["fever", "DISEASE", 622, 627], ["rash", "DISEASE", 629, 633], ["oedema", "DISEASE", 635, 641], ["ulcers", "DISEASE", 651, 657], ["steroids", "CHEMICAL", 220, 228], ["steroid", "CHEMICAL", 440, 447], ["graft\u2010versus\u2010host", "CANCER", 182, 199], ["steroids", "SIMPLE_CHEMICAL", 220, 228], ["children", "ORGANISM", 409, 417], ["steroid", "SIMPLE_CHEMICAL", 440, 447], ["IVIG", "SIMPLE_CHEMICAL", 525, 529], ["platelet", "CELL", 579, 587], ["oedema", "PATHOLOGICAL_FORMATION", 635, 641], ["oral ulcers", "PATHOLOGICAL_FORMATION", 646, 657], ["children", "SPECIES", 409, 417], ["autoimmune hypothyroidism", "PROBLEM", 61, 86], ["a recognized late complication", "PROBLEM", 93, 123], ["AHS", "PROBLEM", 134, 137], ["graft\u2010versus\u2010host disease", "PROBLEM", 182, 207], ["steroids", "TREATMENT", 220, 228], ["systemic steroid therapy", "TREATMENT", 431, 455], ["IVIG", "TREATMENT", 525, 529], ["AHS", "PROBLEM", 534, 537], ["platelet count", "TEST", 579, 593], ["symptoms", "PROBLEM", 610, 618], ["fever", "PROBLEM", 622, 627], ["rash", "PROBLEM", 629, 633], ["oedema", "PROBLEM", 635, 641], ["oral ulcers", "PROBLEM", 646, 657], ["single\u2010dose therapy", "TREATMENT", 689, 708], ["late", "OBSERVATION_MODIFIER", 106, 110], ["complication", "OBSERVATION", 111, 123], ["graft\u2010versus\u2010host disease", "OBSERVATION", 182, 207], ["rise", "OBSERVATION_MODIFIER", 571, 575], ["platelet count", "OBSERVATION", 579, 593], ["fever", "OBSERVATION", 622, 627], ["oedema", "OBSERVATION", 635, 641], ["oral", "ANATOMY", 646, 650], ["ulcers", "OBSERVATION", 651, 657]]], ["In our patient, the fluctuating course of AHS necessitated the use of multiple doses of IVIG and steroid, and on each occasion there was definite clinical and laboratory response.", [["AHS", "DISEASE", 42, 45], ["steroid", "CHEMICAL", 97, 104], ["steroid", "CHEMICAL", 97, 104], ["patient", "ORGANISM", 7, 14], ["IVIG", "SIMPLE_CHEMICAL", 88, 92], ["steroid", "SIMPLE_CHEMICAL", 97, 104], ["patient", "SPECIES", 7, 14], ["IVIG", "TREATMENT", 88, 92], ["steroid", "TREATMENT", 97, 104]]], ["It has been suggested that IVIG blocks CD95, a cell surface receptor on keratinocytes, which plays a role in triggering apoptosis.", [["cell surface", "ANATOMY", 47, 59], ["keratinocytes", "ANATOMY", 72, 85], ["IVIG", "SIMPLE_CHEMICAL", 27, 31], ["CD95", "GENE_OR_GENE_PRODUCT", 39, 43], ["cell", "CELL", 47, 51], ["keratinocytes", "CELL", 72, 85], ["CD95", "PROTEIN", 39, 43], ["cell surface receptor", "PROTEIN", 47, 68], ["keratinocytes", "CELL_TYPE", 72, 85], ["IVIG blocks CD95", "TREATMENT", 27, 43], ["a cell surface receptor", "TREATMENT", 45, 68], ["apoptosis", "OBSERVATION", 120, 129]]], ["Antibodies present in IVIG have also been shown to block CD95\u2010mediated keratinocyte death in vitro and in patients with toxic epidermal necrolysis and a similar mechanism could be responsible for improvement seen in AHS.1", [["keratinocyte", "ANATOMY", 71, 83], ["epidermal", "ANATOMY", 126, 135], ["death", "DISEASE", 84, 89], ["toxic epidermal necrolysis", "DISEASE", 120, 146], ["AHS", "DISEASE", 216, 219], ["IVIG", "SIMPLE_CHEMICAL", 22, 26], ["CD95", "GENE_OR_GENE_PRODUCT", 57, 61], ["keratinocyte", "CELL", 71, 83], ["patients", "ORGANISM", 106, 114], ["epidermal", "PATHOLOGICAL_FORMATION", 126, 135], ["CD95", "PROTEIN", 57, 61], ["patients", "SPECIES", 106, 114], ["Antibodies", "TEST", 0, 10], ["IVIG", "TREATMENT", 22, 26], ["CD95\u2010mediated keratinocyte death", "PROBLEM", 57, 89], ["toxic epidermal necrolysis", "PROBLEM", 120, 146], ["keratinocyte death", "OBSERVATION", 71, 89], ["necrolysis", "OBSERVATION", 136, 146]]]], "PMC7114189": [["IntroductionA number of RNA viruses are highly infectious, acutely pathogenic, and pose a significant threat to human health and public safety.", [["human", "ORGANISM", 112, 117], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["RNA viruses", "PROBLEM", 24, 35], ["acutely pathogenic", "PROBLEM", 59, 77], ["RNA viruses", "OBSERVATION", 24, 35], ["infectious", "OBSERVATION_MODIFIER", 47, 57]]], ["For example, influenza A virus infects up to 20% of the U.S. population each year, causing approximately 36,000 deaths (http://www.cdc.gov/flu/keyfacts), and poses the continuing threat of a global pandemic that could kill millions (Johnson and Mueller, 2002).", [["influenza A virus", "DISEASE", 13, 30], ["deaths", "DISEASE", 112, 118], ["influenza A virus", "ORGANISM", 13, 30], ["influenza A virus", "SPECIES", 13, 30], ["influenza A virus", "SPECIES", 13, 30], ["influenza A virus infects", "PROBLEM", 13, 38]]], ["Dengue virus is endemic to tropical regions around the world and is reported to infect 80 million people each year, causing 500,000 cases of dengue hemorrhagic fever (Halstead, 2007).", [["Dengue virus", "DISEASE", 0, 12], ["dengue hemorrhagic fever", "DISEASE", 141, 165], ["Dengue virus", "ORGANISM", 0, 12], ["people", "ORGANISM", 98, 104], ["Dengue virus", "SPECIES", 0, 12], ["people", "SPECIES", 98, 104], ["dengue hemorrhagic fever", "SPECIES", 141, 165], ["Dengue virus", "SPECIES", 0, 12], ["Dengue virus", "PROBLEM", 0, 12], ["dengue hemorrhagic fever", "PROBLEM", 141, 165], ["virus", "OBSERVATION", 7, 12], ["endemic", "OBSERVATION_MODIFIER", 16, 23], ["hemorrhagic", "OBSERVATION_MODIFIER", 148, 159]]], ["Newly emerging RNA viruses also endanger public health as evidenced by the 2002\u20132003 outbreak of severe acute respiratory syndrome (SARS), caused by a novel coronavirus, that claimed the lives of over 800 people after spreading to more than 30 countries (Drosten et al., 2003, Peiris et al., 2003, Satija and Lal, 2007).IntroductionCertain highly pathogenic RNA viruses may also impact public safety and national security through the intentional use of these agents as bioweapons.", [["acute respiratory syndrome", "DISEASE", 104, 130], ["SARS", "DISEASE", 132, 136], ["people", "ORGANISM", 205, 211], ["people", "SPECIES", 205, 211], ["severe acute respiratory syndrome", "PROBLEM", 97, 130], ["SARS", "PROBLEM", 132, 136], ["a novel coronavirus", "PROBLEM", 149, 168], ["IntroductionCertain highly pathogenic RNA viruses", "PROBLEM", 320, 369], ["these agents", "TREATMENT", 453, 465], ["RNA viruses", "OBSERVATION", 15, 26], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory syndrome", "OBSERVATION", 110, 130], ["RNA viruses", "OBSERVATION", 358, 369]]], ["The Centers for Disease Control and Prevention (CDC) classify a number of RNA viruses, including Ebola, Marburg, Lassa and Machupo viruses, as Category A bioterrorism agents.", [["Ebola, Marburg, Lassa and Machupo viruses", "DISEASE", 97, 138], ["Ebola", "ORGANISM", 97, 102], ["Lassa", "ORGANISM", 113, 118], ["Machupo viruses", "ORGANISM", 123, 138], ["Ebola", "SPECIES", 97, 102], ["Machupo viruses", "SPECIES", 123, 138], ["Disease Control", "TREATMENT", 16, 31], ["RNA viruses", "PROBLEM", 74, 85], ["Ebola", "PROBLEM", 97, 102], ["Lassa", "TREATMENT", 113, 118], ["Machupo viruses", "TREATMENT", 123, 138], ["RNA viruses", "OBSERVATION", 74, 85]]], ["High mortality rates, ease of production, potential dissemination by aerosol and lack of effective countermeasures characterize these pathogens.", [["High mortality rates", "PROBLEM", 0, 20], ["aerosol", "TREATMENT", 69, 76], ["effective countermeasures", "TREATMENT", 89, 114], ["these pathogens", "PROBLEM", 128, 143], ["pathogens", "OBSERVATION", 134, 143]]], ["For example, although not a natural mode of human-to-human transmission, filoviruses are highly infectious via the aerosol route (Leffel and Reed, 2004).", [["human", "ORGANISM", 44, 49], ["human", "ORGANISM", 53, 58], ["filoviruses", "GENE_OR_GENE_PRODUCT", 73, 84], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 53, 58], ["filoviruses", "PROBLEM", 73, 84], ["infectious", "OBSERVATION", 96, 106]]], ["There are reports investigating the stability of lyophilized Marburg virus, and the ability to aerosolize these samples for lethal infection of non-human primates (Bazhutin et al., 1992, Leffel and Reed, 2004).IntroductionEffective vaccines or postexposure therapeutics for many RNA viruses are at an infant stage and are badly needed.", [["samples", "ANATOMY", 112, 119], ["infection", "DISEASE", 131, 140], ["Marburg virus", "ORGANISM", 61, 74], ["non-human", "ORGANISM", 144, 153], ["primates", "ORGANISM", 154, 162], ["Marburg virus", "SPECIES", 61, 74], ["lyophilized Marburg virus", "PROBLEM", 49, 74], ["lethal infection", "PROBLEM", 124, 140], ["IntroductionEffective vaccines", "TREATMENT", 210, 240], ["postexposure therapeutics", "TREATMENT", 244, 269], ["many RNA viruses", "PROBLEM", 274, 290]]], ["Antisense oligonucleotides (ASOs) are single-stranded DNA oligonucleotides that inhibit translation or mediate RNase H-dependent degradation of complementary target RNAs.", [["DNA", "CELLULAR_COMPONENT", 54, 57], ["RNase H", "GENE_OR_GENE_PRODUCT", 111, 118], ["RNase H", "PROTEIN", 111, 118], ["complementary target RNAs", "RNA", 144, 169], ["Antisense oligonucleotides (ASOs)", "TREATMENT", 0, 33], ["single-stranded DNA oligonucleotides", "TREATMENT", 38, 74], ["dependent degradation of complementary target RNAs", "PROBLEM", 119, 169], ["target RNAs", "OBSERVATION", 158, 169]]], ["The introduction of small, double-stranded RNA oligonucleotides (siRNAs) mediates the cleavage of target transcripts through activation of the RNA interference pathway.", [["target transcripts", "RNA", 98, 116], ["small, double-stranded RNA oligonucleotides (siRNAs)", "TREATMENT", 20, 72], ["small", "OBSERVATION_MODIFIER", 20, 25]]], ["Small hairpin RNAs (shRNAs), expressed from DNA or viral vectors, also enter the RNA interference pathway after being processed into siRNAs.", [["Small hairpin RNAs", "GENE_OR_GENE_PRODUCT", 0, 18], ["shRNAs", "GENE_OR_GENE_PRODUCT", 20, 26], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["Small hairpin RNAs", "RNA", 0, 18], ["shRNAs", "DNA", 20, 26], ["Small hairpin RNAs (shRNAs)", "PROBLEM", 0, 27], ["viral vectors", "TREATMENT", 51, 64], ["hairpin RNAs", "OBSERVATION", 6, 18], ["viral vectors", "OBSERVATION", 51, 64]]], ["These reagents are being aggressively pursued as therapeutics for a variety of ailments, including viral infections.", [["viral infections", "DISEASE", 99, 115], ["therapeutics", "TREATMENT", 49, 61], ["a variety of ailments", "PROBLEM", 66, 87], ["viral infections", "PROBLEM", 99, 115], ["viral infections", "OBSERVATION", 99, 115]]], ["Viral genomic RNA, or viral mRNA molecules, can be directly targeted with the aim of disrupting viral replication and disease progression.", [["Viral genomic RNA", "RNA", 0, 17], ["viral mRNA molecules", "PROTEIN", 22, 42], ["Viral genomic RNA", "PROBLEM", 0, 17], ["viral mRNA molecules", "PROBLEM", 22, 42], ["disrupting viral replication", "TREATMENT", 85, 113], ["disease progression", "PROBLEM", 118, 137], ["genomic RNA", "OBSERVATION", 6, 17], ["viral mRNA molecules", "OBSERVATION", 22, 42], ["viral replication", "OBSERVATION", 96, 113]]], ["In this regard, there is continuing preclinical success in using nucleic acid-based techniques to treat viral infections in laboratory animals (Bennink and Palmore, 2004, Lee and Rossi, 2004, Lim et al., 2006, Warfield et al., 2006).", [["nucleic acid", "CHEMICAL", 65, 77], ["viral infections", "DISEASE", 104, 120], ["nucleic acid", "SIMPLE_CHEMICAL", 65, 77], ["nucleic acid-based techniques", "TREATMENT", 65, 94], ["viral infections", "PROBLEM", 104, 120], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["infections", "OBSERVATION", 110, 120]]], ["Here, we review various experimental oligonucleotide-based therapies and describe recent efforts to target RNA viruses (Table 1).Antisense oligonucleotides (ASOs)ASOs are single-stranded deoxyribonucleotide oligomers (\u223c20 nucleotides) with a nucleotide sequence designed to be complementary to a target mRNA transcript (Chan et al., 2006).", [["deoxyribonucleotide", "CHEMICAL", 187, 206], ["nucleotide", "CHEMICAL", 242, 252], ["deoxyribonucleotide", "CHEMICAL", 187, 206], ["nucleotide", "CHEMICAL", 242, 252], ["target mRNA transcript", "RNA", 296, 318], ["various experimental oligonucleotide-based therapies", "TREATMENT", 16, 68], ["Antisense oligonucleotides (ASOs)ASOs", "TREATMENT", 129, 166], ["single-stranded deoxyribonucleotide oligomers (\u223c20 nucleotides", "TREATMENT", 171, 233], ["a nucleotide sequence", "TREATMENT", 240, 261]]], ["The ASO must be long enough to confer target specificity and to form a DNA/RNA hybrid of sufficient stability.", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["a DNA/RNA hybrid", "PROBLEM", 69, 85], ["stability", "OBSERVATION_MODIFIER", 100, 109]]], ["However, as length increases, there is a greater probability the ASO will bind with partial complementarity to a non-target sequence.", [["non-target sequence", "DNA", 113, 132], ["a non-target sequence", "TEST", 111, 132], ["length", "OBSERVATION_MODIFIER", 12, 18], ["greater", "OBSERVATION_MODIFIER", 41, 48]]], ["Typically, specific base-pairing interactions between the ASO and target transcript result in the RNase H-mediated degradation of the target RNA and a subsequent reduction in the protein product of the targeted gene (Fig. 1).", [["ASO", "GENE_OR_GENE_PRODUCT", 58, 61], ["RNase H", "GENE_OR_GENE_PRODUCT", 98, 105], ["ASO and target transcript", "RNA", 58, 83], ["RNase H", "PROTEIN", 98, 105], ["target RNA", "RNA", 134, 144], ["targeted gene", "DNA", 202, 215], ["the ASO", "TREATMENT", 54, 61], ["the target RNA", "PROBLEM", 130, 144], ["a subsequent reduction in the protein product", "TREATMENT", 149, 194]]], ["RNase H activity in mammalian cells is ubiquitous, constitutive, and is thought to normally play a role in DNA replication and transcription (Busen et al., 1977, Busen, 1980, Eder et al., 1993, Turchi et al., 1994).", [["mammalian cells", "ANATOMY", 20, 35], ["RNase H", "GENE_OR_GENE_PRODUCT", 0, 7], ["mammalian cells", "CELL", 20, 35], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["RNase H", "PROTEIN", 0, 7], ["mammalian cells", "CELL_TYPE", 20, 35], ["activity", "OBSERVATION_MODIFIER", 8, 16], ["mammalian cells", "OBSERVATION", 20, 35]]], ["When targeted to ribosomal entry sites in the 5\u2032 untranslated region of mRNA, ASOs with particular chemical modifications (discussed below) can inhibit translation in the absence of mRNA degradation.Antisense oligonucleotides (ASOs)Unmodified oligonucleotides are highly unstable in vivo (in circulation and within cells) due to rapid nuclease digestion.", [["ribosomal", "ANATOMY", 17, 26], ["cells", "ANATOMY", 315, 320], ["ribosomal", "CELLULAR_COMPONENT", 17, 26], ["cells", "CELL", 315, 320], ["ribosomal entry sites", "DNA", 17, 38], ["5\u2032 untranslated region", "DNA", 46, 68], ["mRNA", "RNA", 72, 76], ["nuclease", "PROTEIN", 335, 343], ["particular chemical modifications", "TREATMENT", 88, 121], ["mRNA degradation", "PROBLEM", 182, 198], ["Antisense oligonucleotides (ASOs)Unmodified oligonucleotides", "TREATMENT", 199, 259], ["rapid nuclease digestion", "PROBLEM", 329, 353], ["unstable", "OBSERVATION_MODIFIER", 271, 279]]], ["Therefore, ASOs are routinely customized with chemical modifications that increase stability and confer other desirable attributes.", [["ASOs", "TREATMENT", 11, 15], ["chemical modifications", "TREATMENT", 46, 68]]], ["For example, Fomivirsen (Vitravene\u00ae, ISIS-2922) is an FDA-approved ASO antiviral drug with phosphodiester linkages that are modified by replacing a non-linking oxygen with a sulfur atom (phosphorothioate modification) (Fig. 2) (Orr, 2001, Geary et al., 2002).", [["Fomivirsen", "CHEMICAL", 13, 23], ["Vitravene\u00ae", "CHEMICAL", 25, 35], ["ISIS-2922", "CHEMICAL", 37, 46], ["phosphodiester", "CHEMICAL", 91, 105], ["oxygen", "CHEMICAL", 160, 166], ["sulfur atom", "CHEMICAL", 174, 185], ["phosphorothioate", "CHEMICAL", 187, 203], ["Fomivirsen", "CHEMICAL", 13, 23], ["Vitravene\u00ae", "CHEMICAL", 25, 35], ["ISIS-2922", "CHEMICAL", 37, 46], ["phosphodiester", "CHEMICAL", 91, 105], ["oxygen", "CHEMICAL", 160, 166], ["sulfur", "CHEMICAL", 174, 180], ["phosphorothioate", "CHEMICAL", 187, 203], ["Fomivirsen", "SIMPLE_CHEMICAL", 13, 23], ["Vitravene\u00ae", "SIMPLE_CHEMICAL", 25, 35], ["ISIS-2922", "SIMPLE_CHEMICAL", 37, 46], ["ASO", "SIMPLE_CHEMICAL", 67, 70], ["phosphodiester linkages", "SIMPLE_CHEMICAL", 91, 114], ["oxygen", "SIMPLE_CHEMICAL", 160, 166], ["sulfur atom", "SIMPLE_CHEMICAL", 174, 185], ["phosphorothioate", "SIMPLE_CHEMICAL", 187, 203], ["ISIS", "TEST", 37, 41], ["ASO antiviral drug with phosphodiester linkages", "TREATMENT", 67, 114], ["a non-linking oxygen", "TREATMENT", 146, 166], ["a sulfur atom (phosphorothioate modification", "TREATMENT", 172, 216]]], ["Phosphorothioate-modified ASOs are poor substrates for nucleases and thus show increased stability, increased serum half-life, and greater tissue retention.", [["serum", "ANATOMY", 110, 115], ["tissue", "ANATOMY", 139, 145], ["Phosphorothioate", "CHEMICAL", 0, 16], ["Phosphorothioate", "CHEMICAL", 0, 16], ["Phosphorothioate", "SIMPLE_CHEMICAL", 0, 16], ["ASOs", "SIMPLE_CHEMICAL", 26, 30], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["tissue", "TISSUE", 139, 145], ["nucleases", "PROTEIN", 55, 64], ["Phosphorothioate-modified ASOs", "TREATMENT", 0, 30], ["poor substrates for nucleases", "PROBLEM", 35, 64], ["increased stability", "PROBLEM", 79, 98], ["increased serum half-life", "PROBLEM", 100, 125], ["greater tissue retention", "PROBLEM", 131, 155], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["stability", "OBSERVATION_MODIFIER", 89, 98], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["serum", "OBSERVATION_MODIFIER", 110, 115], ["greater tissue retention", "OBSERVATION", 131, 155]]], ["Although improved in terms of stability, these highly charged oligos have decreased affinity for their target mRNA, are not taken up efficiently by cells, and readily bind to serum and intracellular proteins, which may lead to diminished activity or off-target effects such as triggering of the complement cascade (Stein and Krieg, 1994, Krieg and Stein, 1995).", [["cells", "ANATOMY", 148, 153], ["serum", "ANATOMY", 175, 180], ["intracellular", "ANATOMY", 185, 198], ["cells", "CELL", 148, 153], ["serum", "ORGANISM_SUBSTANCE", 175, 180], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 185, 198], ["target mRNA", "RNA", 103, 114], ["serum and intracellular proteins", "PROTEIN", 175, 207], ["serum and intracellular proteins", "TEST", 175, 207], ["diminished activity", "PROBLEM", 227, 246], ["improved", "OBSERVATION_MODIFIER", 9, 17], ["stability", "OBSERVATION", 30, 39], ["diminished", "OBSERVATION_MODIFIER", 227, 237], ["activity", "OBSERVATION_MODIFIER", 238, 246]]], ["Additional modifications to the 2\u2032 position on the ribose ring have been developed to increase affinity to target mRNA and provide further resistance to degradation (Prakash and Bhat, 2007).", [["ribose", "CHEMICAL", 51, 57], ["ribose", "CHEMICAL", 51, 57], ["ribose ring", "SIMPLE_CHEMICAL", 51, 62], ["2\u2032 position", "DNA", 32, 43], ["target mRNA", "RNA", 107, 118], ["Additional modifications", "TREATMENT", 0, 24], ["the ribose ring", "TREATMENT", 47, 62]]], ["Nucleotides with 2\u2032 modifications, such as 2\u2032-O-(2-methoxy)ethyl (2\u2032-MOE), are not substrates for RNase H cleavage when bound to their target RNA (Fig. 2).", [["2\u2032-O-(2-methoxy)ethyl (2\u2032-MOE", "CHEMICAL", 43, 72], ["Nucleotides", "CHEMICAL", 0, 11], ["2\u2032-O-(2-methoxy)ethyl", "CHEMICAL", 43, 64], ["2\u2032-MOE", "CHEMICAL", 66, 72], ["2\u2032-O-(2-methoxy)ethyl", "SIMPLE_CHEMICAL", 43, 64], ["2\u2032-MOE", "SIMPLE_CHEMICAL", 66, 72], ["RNase H", "GENE_OR_GENE_PRODUCT", 98, 105], ["RNase H", "PROTEIN", 98, 105], ["target RNA", "RNA", 135, 145], ["Nucleotides", "TREATMENT", 0, 11], ["2\u2032 modifications", "TREATMENT", 17, 33], ["(2-methoxy)ethyl (2\u2032-MOE)", "TREATMENT", 48, 73], ["RNase H cleavage", "PROBLEM", 98, 114]]], ["Therefore, to retain this property, ASOs are often designed with 2\u2032MOE \u201cwings\u201d: five 2\u2032-MOE-modified nucleotides on each side of approximately 10 central nucleotides without 2\u2032 modification.Antisense oligonucleotides (ASOs)Binding of serum proteins to ASOs with a charged backbone is thought to be a source of toxicity in some cases.", [["serum", "ANATOMY", 234, 239], ["toxicity", "DISEASE", 310, 318], ["nucleotides", "CHEMICAL", 101, 112], ["nucleotides", "CHEMICAL", 154, 165], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["serum proteins", "PROTEIN", 234, 248], ["modified nucleotides", "TREATMENT", 92, 112], ["central nucleotides", "TREATMENT", 146, 165], ["Antisense oligonucleotides (ASOs)", "TREATMENT", 190, 223], ["serum proteins to ASOs", "TREATMENT", 234, 256], ["a charged backbone", "TREATMENT", 262, 280], ["toxicity in some cases", "PROBLEM", 310, 332], ["thought to be", "UNCERTAINTY", 284, 297]]], ["For example, high doses of phosphorothioate-modified ASOs can activate the complement cascade, possibly through an interaction with the serum protein factor H (Jason et al., 2004, Chan et al., 2006).", [["serum", "ANATOMY", 136, 141], ["phosphorothioate", "CHEMICAL", 27, 43], ["ASOs", "CHEMICAL", 53, 57], ["phosphorothioate", "CHEMICAL", 27, 43], ["phosphorothioate", "SIMPLE_CHEMICAL", 27, 43], ["ASOs", "SIMPLE_CHEMICAL", 53, 57], ["serum", "ORGANISM_SUBSTANCE", 136, 141], ["serum protein factor H", "PROTEIN", 136, 158], ["phosphorothioate-modified ASOs", "TREATMENT", 27, 57]]], ["In an effort to reduce such unwanted effects, third-generation ASO reagents, phosphorodiamidate morpholino oligomers (PMOs), have been developed, in which the ribose ring of the nucleotide backbone is replaced with a morpholine ring (Fig. 3) (Summerton, 2007).", [["phosphorodiamidate", "CHEMICAL", 77, 95], ["PMOs", "CHEMICAL", 118, 122], ["ribose", "CHEMICAL", 159, 165], ["nucleotide", "CHEMICAL", 178, 188], ["morpholine", "CHEMICAL", 217, 227], ["phosphorodiamidate", "CHEMICAL", 77, 95], ["ribose", "CHEMICAL", 159, 165], ["nucleotide", "CHEMICAL", 178, 188], ["morpholine", "CHEMICAL", 217, 227], ["phosphorodiamidate morpholino oligomers", "SIMPLE_CHEMICAL", 77, 116], ["PMOs", "SIMPLE_CHEMICAL", 118, 122], ["third-generation ASO reagents", "TREATMENT", 46, 75], ["phosphorodiamidate morpholino oligomers", "TREATMENT", 77, 116], ["the ribose ring of the nucleotide backbone", "TREATMENT", 155, 197], ["a morpholine ring", "TREATMENT", 215, 232], ["ribose ring", "OBSERVATION", 159, 170]]], ["Additionally, negatively charged intersubunit linkages are replaced by uncharged phosphorodiamidate linkages.", [["phosphorodiamidate", "CHEMICAL", 81, 99], ["phosphorodiamidate", "CHEMICAL", 81, 99], ["phosphorodiamidate", "SIMPLE_CHEMICAL", 81, 99], ["uncharged phosphorodiamidate linkages", "PROBLEM", 71, 108], ["charged", "OBSERVATION_MODIFIER", 25, 32], ["intersubunit linkages", "OBSERVATION", 33, 54], ["uncharged phosphorodiamidate", "OBSERVATION", 71, 99]]], ["The presence of an uncharged nucleotide backbone greatly reduces interactions with serum and cellular proteins, which limits off-target toxicities.", [["serum", "ANATOMY", 83, 88], ["cellular", "ANATOMY", 93, 101], ["nucleotide", "CHEMICAL", 29, 39], ["toxicities", "DISEASE", 136, 146], ["nucleotide", "CHEMICAL", 29, 39], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["cellular", "CELL", 93, 101], ["serum and cellular proteins", "PROTEIN", 83, 110], ["an uncharged nucleotide backbone", "PROBLEM", 16, 48], ["serum and cellular proteins", "PROBLEM", 83, 110], ["target toxicities", "PROBLEM", 129, 146], ["uncharged", "OBSERVATION", 19, 28], ["backbone", "OBSERVATION_MODIFIER", 40, 48], ["greatly", "OBSERVATION_MODIFIER", 49, 56], ["reduces", "OBSERVATION_MODIFIER", 57, 64]]], ["PMO modifications also confer high stability and solubility, both desirable qualities for use in the clinic.", [["PMO", "SIMPLE_CHEMICAL", 0, 3], ["PMO modifications", "TREATMENT", 0, 17], ["high stability", "OBSERVATION_MODIFIER", 30, 44]]], ["PMOs bind to target mRNA sequences with higher affinity than other ASOs but do not mediate the catalytic degradation of target RNA transcripts via RNase H (Summerton, 1999).", [["PMOs", "SIMPLE_CHEMICAL", 0, 4], ["RNase H", "GENE_OR_GENE_PRODUCT", 147, 154], ["PMOs", "PROTEIN", 0, 4], ["target RNA transcripts", "RNA", 120, 142], ["RNase H", "PROTEIN", 147, 154], ["mRNA sequences", "TEST", 20, 34]]], ["Instead, PMOs are typically designed to target ribosome entry sites, the AUG start codon, splice junctions, or sites of critical RNA secondary structure, and thus reduce target protein levels by interfering with translation or mRNA processing (Fig. 1).Antisense oligonucleotides (ASOs)Several ASO compounds are currently being evaluated in clinical trials for the treatment of a variety of ailments, including cancer, diabetes and viral infections (www.clinicaltrials.gov).", [["ribosome", "ANATOMY", 47, 55], ["cancer", "ANATOMY", 410, 416], ["cancer", "DISEASE", 410, 416], ["diabetes", "DISEASE", 418, 426], ["viral infections", "DISEASE", 431, 447], ["PMOs", "GENE_OR_GENE_PRODUCT", 9, 13], ["splice junctions", "CELLULAR_COMPONENT", 90, 106], ["cancer", "CANCER", 410, 416], ["PMOs", "PROTEIN", 9, 13], ["ribosome entry sites", "DNA", 47, 67], ["AUG start codon", "DNA", 73, 88], ["codon, splice junctions", "TREATMENT", 83, 106], ["critical RNA secondary structure", "PROBLEM", 120, 152], ["target protein levels", "TEST", 170, 191], ["mRNA processing", "PROBLEM", 227, 242], ["Antisense oligonucleotides (ASOs", "TREATMENT", 252, 284], ["Several ASO compounds", "PROBLEM", 285, 306], ["the treatment", "TREATMENT", 360, 373], ["cancer", "PROBLEM", 410, 416], ["diabetes", "PROBLEM", 418, 426], ["viral infections", "PROBLEM", 431, 447], ["splice junctions", "OBSERVATION", 90, 106], ["cancer", "OBSERVATION", 410, 416], ["viral infections", "OBSERVATION", 431, 447]]], ["Trials are now under way studying the intravenous delivery of ASO drug candidates targeting Bcl-2 (Genasense\u00ae, Genta) and c-myc (Resten-NG\u00ae, AVI BioPharma), while completed trials have evaluated subcutaneously administered ASOs targeting protein tyrosine phosphatase 1B (ISIS 113715, Isis Pharmaceuticals), and hepatitis C virus (AVI-4065, AVI BioPharma).", [["intravenous", "ANATOMY", 38, 49], ["subcutaneously", "ANATOMY", 195, 209], ["tyrosine", "CHEMICAL", 246, 254], ["ISIS 113715", "CHEMICAL", 271, 282], ["hepatitis C", "DISEASE", 311, 322], ["AVI-4065", "CHEMICAL", 330, 338], ["tyrosine", "CHEMICAL", 246, 254], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 49], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 92, 97], ["Genasense\u00ae", "SIMPLE_CHEMICAL", 99, 109], ["Genta", "SIMPLE_CHEMICAL", 111, 116], ["c-myc", "SIMPLE_CHEMICAL", 122, 127], ["Resten-NG\u00ae", "SIMPLE_CHEMICAL", 129, 139], ["protein tyrosine phosphatase 1B", "GENE_OR_GENE_PRODUCT", 238, 269], ["hepatitis C virus", "ORGANISM", 311, 328], ["protein tyrosine phosphatase 1B", "PROTEIN", 238, 269], ["hepatitis C virus", "SPECIES", 311, 328], ["hepatitis C virus", "SPECIES", 311, 328], ["the intravenous delivery", "TREATMENT", 34, 58], ["ASO drug candidates", "TREATMENT", 62, 81], ["Bcl", "TEST", 92, 95], ["Genta", "TREATMENT", 111, 116], ["c-myc (Resten", "TREATMENT", 122, 135], ["protein tyrosine phosphatase", "TEST", 238, 266], ["ISIS", "TEST", 271, 275], ["Isis Pharmaceuticals", "TREATMENT", 284, 304], ["hepatitis C virus", "PROBLEM", 311, 328], ["AVI", "TEST", 330, 333]]], ["Despite these research efforts, effective compound delivery is still a major hurdle that must be overcome before ASO compounds find broad utility in the clinic.", [["effective compound delivery", "TREATMENT", 32, 59], ["ASO compounds", "TREATMENT", 113, 126]]], ["It is perhaps telling that the only ASO drug approved to date by the FDA, Fomivirsen, is administered locally into the confined space of the eye.", [["eye", "ANATOMY", 141, 144], ["Fomivirsen", "CHEMICAL", 74, 84], ["Fomivirsen", "SIMPLE_CHEMICAL", 74, 84], ["eye", "ORGAN", 141, 144], ["ASO drug", "TREATMENT", 36, 44], ["Fomivirsen", "TREATMENT", 74, 84], ["eye", "ANATOMY", 141, 144]]], ["Furthermore, despite some success of this ASO in the clinic, its use is now limited due to significant side effects (Mercorelli et al., 2007).Antisense oligonucleotides (ASOs)Conjugation of ASOs to cell-penetrating peptides is an increasingly common approach to improve cellular uptake (Pooga et al., 1998, Debart et al., 2007).", [["cell", "ANATOMY", 198, 202], ["cellular", "ANATOMY", 270, 278], ["cell", "CELL", 198, 202], ["cellular", "CELL", 270, 278], ["this ASO", "TREATMENT", 37, 45], ["significant side effects", "PROBLEM", 91, 115], ["Antisense oligonucleotides (ASOs)", "TREATMENT", 142, 175], ["Conjugation of ASOs", "TREATMENT", 175, 194], ["cell-penetrating peptides", "TREATMENT", 198, 223]]], ["A recent report demonstrates that conjugation of PMO (P-PMO) to the arginine-rich peptide (RXR)4 increases elimination half-life and tissue retention (Amantana et al., 2007).", [["tissue", "ANATOMY", 133, 139], ["PMO (P-PMO", "CHEMICAL", 49, 59], ["arginine", "CHEMICAL", 68, 76], ["PMO", "CHEMICAL", 49, 52], ["P-PMO", "CHEMICAL", 54, 59], ["arginine", "CHEMICAL", 68, 76], ["PMO", "SIMPLE_CHEMICAL", 49, 52], ["P-PMO", "SIMPLE_CHEMICAL", 54, 59], ["arginine-rich peptide", "SIMPLE_CHEMICAL", 68, 89], ["RXR)4", "GENE_OR_GENE_PRODUCT", 91, 96], ["tissue", "TISSUE", 133, 139], ["conjugation of PMO (P-PMO)", "TREATMENT", 34, 60], ["the arginine-rich peptide", "TREATMENT", 64, 89], ["tissue retention", "PROBLEM", 133, 149]]], ["However, the literature does not reveal a consistent correlation between peptide conjugation and increased efficacy (Enterlein et al., 2006, Tilley et al., 2007).", [["peptide conjugation", "TREATMENT", 73, 92], ["increased efficacy", "PROBLEM", 97, 115], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["efficacy", "OBSERVATION_MODIFIER", 107, 115]]], ["P-PMOs are generally well tolerated by animal recipients, although toxicity can be observed as the dose increases (Amantana et al., 2007, Tilley et al., 2007).", [["P-PMOs", "CHEMICAL", 0, 6], ["toxicity", "DISEASE", 67, 75], ["P-PMOs", "SIMPLE_CHEMICAL", 0, 6], ["recipients", "ORGANISM", 46, 56], ["toxicity", "PROBLEM", 67, 75]]], ["The nature of the treatment regimen may affect P-PMO toxicity.", [["toxicity", "DISEASE", 53, 61], ["P-PMO", "SIMPLE_CHEMICAL", 47, 52], ["the treatment regimen", "TREATMENT", 14, 35], ["P-PMO toxicity", "PROBLEM", 47, 61]]], ["For example, Burrer et al. (2007) observed no treatment-associated toxicity when P-PMOs were administered to healthy mice.", [["toxicity", "DISEASE", 67, 75], ["P-PMOs", "CHEMICAL", 81, 87], ["P-PMOs", "SIMPLE_CHEMICAL", 81, 87], ["mice", "ORGANISM", 117, 121], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 117, 121], ["treatment", "TREATMENT", 46, 55], ["associated toxicity", "PROBLEM", 56, 75], ["P-PMOs", "TREATMENT", 81, 87]]], ["However, when P-PMO treatment followed viral challenge, significant toxicity was observed.RNA interference (RNAi)RNA interference (RNAi) is an endogenous molecular pathway that plays a role in antiviral defense and gene regulation (Fritz et al., 2006).", [["P-PMO", "CHEMICAL", 14, 19], ["toxicity", "DISEASE", 68, 76], ["P-PMO", "SIMPLE_CHEMICAL", 14, 19], ["P-PMO treatment", "TREATMENT", 14, 29], ["viral challenge", "TREATMENT", 39, 54], ["significant toxicity", "PROBLEM", 56, 76], ["RNA interference (RNAi)RNA interference", "PROBLEM", 90, 129], ["antiviral defense", "TREATMENT", 193, 210], ["significant", "OBSERVATION_MODIFIER", 56, 67], ["toxicity", "OBSERVATION", 68, 76]]], ["The human genome encodes specialized, non-coding transcripts termed microRNAs (miRNAs) that regulate the expression of cellular genes (Bartel, 2004, Ying et al., 2006).", [["cellular", "ANATOMY", 119, 127], ["human", "ORGANISM", 4, 9], ["cellular", "CELL", 119, 127], ["human genome", "DNA", 4, 16], ["non-coding transcripts", "RNA", 38, 60], ["microRNAs", "RNA", 68, 77], ["miRNAs", "DNA", 79, 85], ["cellular genes", "DNA", 119, 133], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["non-coding transcripts termed microRNAs (miRNAs)", "PROBLEM", 38, 86], ["cellular genes", "OBSERVATION", 119, 133]]], ["The first miRNAs discovered have a role during development in Caenorhabditis elegans (Lee et al., 1993, Reinhart et al., 2000).", [["Caenorhabditis elegans", "ORGANISM", 62, 84], ["Caenorhabditis elegans", "SPECIES", 62, 84], ["Caenorhabditis elegans", "SPECIES", 62, 84]]], ["It is now estimated that 30% of all mammalian protein-coding genes, and diverse cellular processes, are regulated by miRNAs (le Sage and Agami, 2006).", [["cellular", "ANATOMY", 80, 88], ["cellular", "CELL", 80, 88], ["mammalian protein-coding genes", "DNA", 36, 66], ["miRNAs", "DNA", 117, 123], ["all mammalian protein", "TREATMENT", 32, 53], ["mammalian protein", "OBSERVATION", 36, 53], ["diverse", "OBSERVATION_MODIFIER", 72, 79], ["cellular processes", "OBSERVATION", 80, 98]]], ["Long, polyadenylated primary miRNA transcripts, containing a hairpin structure with sequence homology to the target gene, are first processed in the nucleus to yield a shorter miRNA precursor (pre-miRNA).", [["nucleus", "ANATOMY", 149, 156], ["nucleus", "CELLULAR_COMPONENT", 149, 156], ["Long, polyadenylated primary miRNA transcripts", "RNA", 0, 46], ["target gene", "DNA", 109, 120], ["miRNA precursor", "RNA", 176, 191], ["pre-miRNA", "RNA", 193, 202], ["Long, polyadenylated primary miRNA transcripts", "PROBLEM", 0, 46], ["a hairpin structure", "PROBLEM", 59, 78], ["a shorter miRNA precursor", "PROBLEM", 166, 191], ["polyadenylated", "OBSERVATION_MODIFIER", 6, 20], ["primary miRNA transcripts", "OBSERVATION", 21, 46], ["hairpin structure", "OBSERVATION", 61, 78], ["nucleus", "ANATOMY", 149, 156]]], ["Pre-miRNAs are then shuttled to the cytoplasm where they are further processed by Dicer to yield mature, short, double stranded miRNAs (Lee et al., 2003).", [["cytoplasm", "ANATOMY", 36, 45], ["Pre-miRNAs", "GENE_OR_GENE_PRODUCT", 0, 10], ["cytoplasm", "ORGANISM_SUBSTANCE", 36, 45], ["Dicer", "GENE_OR_GENE_PRODUCT", 82, 87], ["Pre-miRNAs", "PROTEIN", 0, 10], ["Dicer", "PROTEIN", 82, 87]]], ["These are loaded into the RNA-induced silencing complex (RISC) where they guide hybridization to the target mRNA.", [["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 26, 55], ["RNA-induced silencing complex", "PROTEIN", 26, 55], ["RISC", "PROTEIN", 57, 61], ["target mRNA", "RNA", 101, 112], ["silencing", "OBSERVATION_MODIFIER", 38, 47], ["complex", "OBSERVATION_MODIFIER", 48, 55]]], ["Binding of an activated RISC complex to a target transcript leads to transcript degradation or inhibition of translation (Sontheimer, 2005).RNA interference (RNAi)The RNAi pathway is now widely exploited as a tool to silence the expression of specific target genes for experimental or therapeutic benefit (Lee and Sinko, 2006).", [["RISC", "GENE_OR_GENE_PRODUCT", 24, 28], ["RISC complex", "PROTEIN", 24, 36], ["target genes", "DNA", 252, 264], ["an activated RISC complex", "PROBLEM", 11, 36]]], ["The RNAi pathway can be activated by introducing synthetic, double-stranded small interfering RNAs (siRNAs) into cells.", [["cells", "ANATOMY", 113, 118], ["cells", "CELL", 113, 118], ["double-stranded small interfering RNAs", "RNA", 60, 98], ["siRNAs", "RNA", 100, 106], ["stranded small interfering RNAs (siRNAs) into cells", "PROBLEM", 67, 118], ["small", "OBSERVATION_MODIFIER", 76, 81], ["interfering RNAs", "OBSERVATION", 82, 98]]], ["Alternatively, small hairpin RNAs (shRNAs) can be expressed from transfected DNA plasmid vectors or from replication-deficient viral vectors (i.e., adenovirus, and lentivirus, among others). siRNAs are loaded directly into the RISC to mediate target hybridization and cleavage (Fig. 1).", [["plasmid", "ANATOMY", 81, 88], ["small hairpin RNAs", "GENE_OR_GENE_PRODUCT", 15, 33], ["shRNAs", "GENE_OR_GENE_PRODUCT", 35, 41], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["adenovirus", "ORGANISM", 148, 158], ["lentivirus", "ORGANISM", 164, 174], ["RISC", "GENE_OR_GENE_PRODUCT", 227, 231], ["small hairpin RNAs", "RNA", 15, 33], ["shRNAs", "DNA", 35, 41], ["transfected DNA plasmid vectors", "DNA", 65, 96], ["replication-deficient viral vectors", "DNA", 105, 140], ["RISC", "DNA", 227, 231], ["adenovirus", "SPECIES", 148, 158], ["small hairpin RNAs (shRNAs)", "PROBLEM", 15, 42], ["transfected DNA plasmid vectors", "TREATMENT", 65, 96], ["replication", "PROBLEM", 105, 116], ["deficient viral vectors", "PROBLEM", 117, 140], ["adenovirus", "PROBLEM", 148, 158], ["lentivirus", "PROBLEM", 164, 174], ["siRNAs", "TREATMENT", 191, 197], ["small", "OBSERVATION_MODIFIER", 15, 20], ["hairpin RNAs", "OBSERVATION", 21, 33], ["viral vectors", "OBSERVATION", 127, 140]]], ["In contrast, shRNAs are cleaved by DICER before incorporation into the RISC.", [["DICER", "GENE_OR_GENE_PRODUCT", 35, 40], ["RISC", "GENE_OR_GENE_PRODUCT", 71, 75], ["shRNAs", "DNA", 13, 19], ["DICER", "PROTEIN", 35, 40], ["RISC", "DNA", 71, 75], ["RISC", "ANATOMY", 71, 75]]], ["Sequence-based rules for designing siRNA molecules with optimal activity are becoming increasingly sophisticated and are available to the general research community (Elbashir et al., 2002, Henschel et al., 2004, Pei and Tuschl, 2006, Shah et al., 2007).", [["Sequence", "TEST", 0, 8], ["designing siRNA molecules", "PROBLEM", 25, 50]]], ["Additionally, pre-designed siRNAs, and shRNA expression vectors, targeting nearly every gene in the human and mouse genome are available from commercial sources.RNA interference (RNAi)For in vivo use, siRNAs and ASOs face similar pitfalls, including stability, delivery and off-target effects.", [["human", "ORGANISM", 100, 105], ["mouse", "ORGANISM", 110, 115], ["pre-designed siRNAs", "DNA", 14, 33], ["shRNA expression vectors", "DNA", 39, 63], ["human and mouse genome", "DNA", 100, 122], ["human", "SPECIES", 100, 105], ["mouse", "SPECIES", 110, 115], ["human", "SPECIES", 100, 105], ["mouse", "SPECIES", 110, 115], ["pre-designed siRNAs", "TREATMENT", 14, 33], ["shRNA expression vectors", "TREATMENT", 39, 63], ["RNA interference", "PROBLEM", 161, 177], ["siRNAs", "TREATMENT", 201, 207], ["delivery", "TREATMENT", 261, 269], ["siRNAs", "OBSERVATION", 27, 33], ["mouse genome", "OBSERVATION", 110, 122]]], ["Phosphorothioate linkage and 2\u2032-O-methyl sugar modifications protect siRNAs from nuclease digestion and help prevent off-target stimulation of the type I interferon system (Sioud, 2007).", [["Phosphorothioate", "CHEMICAL", 0, 16], ["2\u2032-O-methyl", "CHEMICAL", 29, 40], ["Phosphorothioate", "CHEMICAL", 0, 16], ["2\u2032-O-methyl sugar", "CHEMICAL", 29, 46], ["Phosphorothioate", "SIMPLE_CHEMICAL", 0, 16], ["2\u2032-O-methyl sugar", "SIMPLE_CHEMICAL", 29, 46], ["type I interferon", "GENE_OR_GENE_PRODUCT", 147, 164], ["nuclease", "PROTEIN", 81, 89], ["Phosphorothioate linkage", "TEST", 0, 24], ["methyl sugar modifications", "TREATMENT", 34, 60], ["nuclease digestion", "TREATMENT", 81, 99]]], ["In the pursuit of systemic and targeted delivery, siRNAs have been delivered within liposomes or conjugated to antibodies, cholesterol, RNA aptamers, or peptides (de Fougerolles et al., 2007).", [["cholesterol", "CHEMICAL", 123, 134], ["cholesterol", "CHEMICAL", 123, 134], ["liposomes", "SIMPLE_CHEMICAL", 84, 93], ["cholesterol", "SIMPLE_CHEMICAL", 123, 134], ["antibodies", "PROTEIN", 111, 121], ["systemic and targeted delivery", "TREATMENT", 18, 48], ["siRNAs", "TREATMENT", 50, 56], ["cholesterol", "TEST", 123, 134], ["RNA aptamers", "TEST", 136, 148]]], ["A recent report demonstrates the feasibility of organ-specific delivery of siRNA when given intravenously (Kumar et al., 2007).", [["organ", "ANATOMY", 48, 53], ["intravenously", "ANATOMY", 92, 105], ["organ", "ORGAN", 48, 53], ["siRNA", "PROBLEM", 75, 80]]], ["The authors utilized the ability of rabies virus glycoprotein G (RVG) to bind acetylcholine receptor on neuronal cells.", [["neuronal cells", "ANATOMY", 104, 118], ["acetylcholine", "CHEMICAL", 78, 91], ["acetylcholine", "CHEMICAL", 78, 91], ["rabies virus", "ORGANISM", 36, 48], ["glycoprotein G", "GENE_OR_GENE_PRODUCT", 49, 63], ["RVG", "GENE_OR_GENE_PRODUCT", 65, 68], ["acetylcholine receptor", "GENE_OR_GENE_PRODUCT", 78, 100], ["neuronal cells", "CELL", 104, 118], ["rabies virus glycoprotein G", "PROTEIN", 36, 63], ["RVG", "PROTEIN", 65, 68], ["acetylcholine receptor", "PROTEIN", 78, 100], ["neuronal cells", "CELL_TYPE", 104, 118], ["rabies virus", "SPECIES", 36, 48], ["rabies virus", "SPECIES", 36, 48], ["rabies virus glycoprotein G (RVG)", "TREATMENT", 36, 69], ["neuronal cells", "OBSERVATION", 104, 118]]], ["A peptide from RVG shows neuronal cell specificity, and when conjugated to siRNA, enables delivery into this cell type.", [["neuronal cell", "ANATOMY", 25, 38], ["cell", "ANATOMY", 109, 113], ["RVG", "CHEMICAL", 15, 18], ["RVG", "SIMPLE_CHEMICAL", 15, 18], ["neuronal cell", "CELL", 25, 38], ["cell type", "CELL", 109, 118], ["A peptide from RVG", "TEST", 0, 18], ["neuronal cell specificity", "PROBLEM", 25, 50], ["neuronal cell specificity", "OBSERVATION", 25, 50]]], ["Importantly, RVG-siRNA, when administered to mice intravenously, is delivered to the brain, without accumulating in spleen or liver (Kumar et al., 2007).", [["intravenously", "ANATOMY", 50, 63], ["brain", "ANATOMY", 85, 90], ["spleen", "ANATOMY", 116, 122], ["liver", "ANATOMY", 126, 131], ["RVG", "GENE_OR_GENE_PRODUCT", 13, 16], ["mice", "ORGANISM", 45, 49], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["brain", "ORGAN", 85, 90], ["spleen", "ORGAN", 116, 122], ["liver", "ORGAN", 126, 131], ["RVG", "PROTEIN", 13, 16], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["RVG-siRNA", "TREATMENT", 13, 22], ["siRNA", "ANATOMY", 17, 22], ["brain", "ANATOMY", 85, 90], ["without", "UNCERTAINTY", 92, 99], ["spleen", "ANATOMY", 116, 122], ["liver", "ANATOMY", 126, 131]]], ["Although a highly successful siRNA delivery method in this animal model, it remains to be studied whether this general approach is safe in humans.RNA interference (RNAi)Often cited as an advantage of siRNAs and shRNAs, these molecules utilize an endogenous molecular pathway to achieve a desired effect.", [["humans", "ORGANISM", 139, 145], ["siRNAs", "DNA", 200, 206], ["shRNAs", "DNA", 211, 217], ["humans", "SPECIES", 139, 145], ["humans", "SPECIES", 139, 145], ["a highly successful siRNA delivery method", "TREATMENT", 9, 50], ["RNA interference (RNAi)", "PROBLEM", 146, 169], ["siRNAs and shRNAs", "TREATMENT", 200, 217], ["an endogenous molecular pathway", "TREATMENT", 243, 274], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["successful", "OBSERVATION_MODIFIER", 18, 28], ["siRNA", "OBSERVATION", 29, 34]]], ["However, in some cases, this could account for observed treatment-induced toxicity.", [["toxicity", "DISEASE", 74, 82], ["induced toxicity", "PROBLEM", 66, 82]]], ["Grimm et al. (2006) using a total of 49 different shRNAs expressed from an adeno-associated virus vector, achieved high-level shRNA expression in mouse liver after intravenous injection.", [["liver", "ANATOMY", 152, 157], ["intravenous", "ANATOMY", 164, 175], ["adeno-associated virus", "ORGANISM", 75, 97], ["mouse", "ORGANISM", 146, 151], ["liver", "ORGAN", 152, 157], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 164, 175], ["shRNAs", "DNA", 50, 56], ["mouse", "SPECIES", 146, 151], ["adeno-associated virus", "SPECIES", 75, 97], ["mouse", "SPECIES", 146, 151], ["a total of 49 different shRNAs", "TREATMENT", 26, 56], ["an adeno-associated virus vector", "TREATMENT", 72, 104], ["high-level shRNA expression", "TREATMENT", 115, 142], ["intravenous injection", "TREATMENT", 164, 185], ["liver", "ANATOMY", 152, 157]]], ["Forty seven percent of treated mice died within 2 months.", [["mice", "ORGANISM", 31, 35], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35]]], ["Interestingly, morbidity correlated with an observed decrease in liver miRNA levels.", [["liver", "ANATOMY", 65, 70], ["liver", "ORGAN", 65, 70], ["an observed decrease in liver miRNA levels", "PROBLEM", 41, 83], ["morbidity", "OBSERVATION", 15, 24], ["decrease", "OBSERVATION_MODIFIER", 53, 61], ["liver", "ANATOMY", 65, 70], ["miRNA levels", "OBSERVATION", 71, 83]]], ["The authors demonstrate that high-level shRNA expression can saturate, and interfere with, components of the endogenous miRNA pathway.", [["high-level shRNA expression", "PROBLEM", 29, 56], ["high", "OBSERVATION_MODIFIER", 29, 33], ["endogenous miRNA", "OBSERVATION", 109, 125]]], ["Specifically, this saturation may involve the protein exportin-5 and occur at the level of miRNA nuclear export.", [["nuclear", "ANATOMY", 97, 104], ["exportin-5", "GENE_OR_GENE_PRODUCT", 54, 64], ["nuclear", "CELLULAR_COMPONENT", 97, 104], ["protein exportin-5", "PROTEIN", 46, 64], ["this saturation", "TEST", 14, 29], ["the protein exportin", "TEST", 42, 62], ["miRNA", "ANATOMY", 91, 96], ["nuclear export", "OBSERVATION", 97, 111]]], ["In contrast, systemic administration of siRNAs can achieve gene silencing in the liver without toxicity and without a disruption in liver miRNA processing (John et al., 2007).", [["liver", "ANATOMY", 81, 86], ["liver", "ANATOMY", 132, 137], ["toxicity", "DISEASE", 95, 103], ["liver", "ORGAN", 81, 86], ["liver", "ORGAN", 132, 137], ["systemic administration of siRNAs", "TREATMENT", 13, 46], ["gene silencing in the liver", "PROBLEM", 59, 86], ["toxicity", "PROBLEM", 95, 103], ["a disruption in liver miRNA processing", "PROBLEM", 116, 154], ["gene silencing", "OBSERVATION", 59, 73], ["liver", "ANATOMY", 81, 86], ["without", "UNCERTAINTY", 87, 94], ["toxicity", "OBSERVATION", 95, 103], ["without", "UNCERTAINTY", 108, 115], ["disruption", "OBSERVATION", 118, 128], ["liver", "ANATOMY", 132, 137]]], ["One obvious explanation is that introduced siRNAs bypass early processing steps of miRNAs and shRNAs, and are loaded directly into the RISC complex.", [["shRNAs", "GENE_OR_GENE_PRODUCT", 94, 100], ["RISC", "GENE_OR_GENE_PRODUCT", 135, 139], ["miRNAs", "RNA", 83, 89], ["shRNAs", "DNA", 94, 100], ["RISC complex", "PROTEIN", 135, 147], ["introduced siRNAs bypass", "TREATMENT", 32, 56], ["miRNAs and shRNAs", "TREATMENT", 83, 100], ["siRNAs bypass", "OBSERVATION", 43, 56], ["RISC complex", "OBSERVATION", 135, 147]]], ["John et al. (2007) demonstrated siRNA-dependent silencing of liver-expressed transcripts, without a decrease in liver miRNA levels or a disruption in liver miRNA target-gene expression.", [["liver", "ANATOMY", 61, 66], ["liver", "ANATOMY", 112, 117], ["liver", "ANATOMY", 150, 155], ["liver", "ORGAN", 61, 66], ["liver", "ORGAN", 112, 117], ["liver", "ORGAN", 150, 155], ["liver-expressed transcripts", "RNA", 61, 88], ["siRNA-dependent silencing of liver", "PROBLEM", 32, 66], ["a decrease in liver miRNA levels", "PROBLEM", 98, 130], ["a disruption in liver miRNA target", "PROBLEM", 134, 168], ["liver", "ANATOMY", 61, 66], ["decrease", "OBSERVATION_MODIFIER", 100, 108], ["liver", "ANATOMY", 112, 117], ["miRNA levels", "OBSERVATION", 118, 130], ["disruption", "OBSERVATION", 136, 146], ["liver", "ANATOMY", 150, 155], ["miRNA target", "OBSERVATION", 156, 168]]], ["Importantly, positive safety results have been achieved in phase I and II clinical trials for locally delivered siRNAs.", [["locally delivered siRNAs", "PROBLEM", 94, 118]]], ["These treatments include bevasiranib (Cand5), a siRNA for intravitreal inoculation, which targets vascular endothelial growth factor (Acuity Pharmaceuticals), and ALN-RSV01, an intranasally delivered product that targets the transcript for the nucleocapsid protein of respiratory syncytial virus (Alnylam Pharmaceuticals).Filoviruses ::: Antisense and siRNA as antiviral therapeuticsEbola (EBOV) and Marburg (MARV) viruses have a single-stranded, negative-sense 19 kb RNA genome that codes for seven proteins.", [["bevasiranib", "CHEMICAL", 25, 36], ["Cand5", "CHEMICAL", 38, 43], ["ALN-RSV01", "CHEMICAL", 163, 172], ["respiratory syncytial virus", "DISEASE", 268, 295], ["Ebola (EBOV) and Marburg (MARV) viruses", "DISEASE", 383, 422], ["bevasiranib", "CHEMICAL", 25, 36], ["Cand5", "CHEMICAL", 38, 43], ["ALN", "CHEMICAL", 163, 166], ["bevasiranib", "SIMPLE_CHEMICAL", 25, 36], ["Cand5", "SIMPLE_CHEMICAL", 38, 43], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 98, 132], ["ALN-RSV01", "SIMPLE_CHEMICAL", 163, 172], ["respiratory syncytial virus", "ORGANISM", 268, 295], ["Alnylam Pharmaceuticals", "ORGANISM", 297, 320], ["Ebola (EBOV)", "ORGANISM", 383, 395], ["Marburg (MARV) viruses", "ORGANISM", 400, 422], ["vascular endothelial growth factor", "PROTEIN", 98, 132], ["nucleocapsid protein", "PROTEIN", 244, 264], ["19 kb RNA genome", "DNA", 462, 478], ["respiratory syncytial virus", "SPECIES", 268, 295], ["Ebola", "SPECIES", 383, 388], ["respiratory syncytial virus", "SPECIES", 268, 295], ["EBOV", "SPECIES", 390, 394], ["MARV", "SPECIES", 409, 413], ["These treatments", "TREATMENT", 0, 16], ["bevasiranib (Cand5)", "TREATMENT", 25, 44], ["a siRNA", "TREATMENT", 46, 53], ["intravitreal inoculation", "TREATMENT", 58, 82], ["Acuity Pharmaceuticals", "TEST", 134, 156], ["ALN-RSV01", "TREATMENT", 163, 172], ["an intranasally delivered product", "TREATMENT", 174, 207], ["the nucleocapsid protein", "TREATMENT", 240, 264], ["respiratory syncytial virus (Alnylam Pharmaceuticals", "TREATMENT", 268, 320], ["Antisense and siRNA", "TREATMENT", 338, 357], ["antiviral therapeutics", "TREATMENT", 361, 383], ["Ebola", "PROBLEM", 383, 388], ["Marburg (MARV) viruses", "PROBLEM", 400, 422], ["vascular endothelial", "ANATOMY", 98, 118], ["respiratory syncytial virus", "OBSERVATION", 268, 295]]], ["Viral replication and transcription depend on a complex of nucleoprotein (NP), VP30, VP35 and the RNA polymerase L. VP24 and VP40 are involved in budding of mature virions from the cell surface while glycoprotein (GP) is found embedded in the lipid bilayer surrounding the nucleocapsid.", [["virions", "ANATOMY", 164, 171], ["cell surface", "ANATOMY", 181, 193], ["lipid bilayer", "ANATOMY", 243, 256], ["NP", "GENE_OR_GENE_PRODUCT", 74, 76], ["VP30", "GENE_OR_GENE_PRODUCT", 79, 83], ["VP35", "GENE_OR_GENE_PRODUCT", 85, 89], ["VP24", "GENE_OR_GENE_PRODUCT", 116, 120], ["VP40", "GENE_OR_GENE_PRODUCT", 125, 129], ["cell surface", "CELLULAR_COMPONENT", 181, 193], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 200, 212], ["GP", "GENE_OR_GENE_PRODUCT", 214, 216], ["lipid bilayer", "CELLULAR_COMPONENT", 243, 256], ["nucleocapsid", "CELLULAR_COMPONENT", 273, 285], ["nucleoprotein", "PROTEIN", 59, 72], ["NP", "PROTEIN", 74, 76], ["VP30", "PROTEIN", 79, 83], ["VP35", "PROTEIN", 85, 89], ["RNA polymerase", "PROTEIN", 98, 112], ["VP24", "PROTEIN", 116, 120], ["VP40", "PROTEIN", 125, 129], ["glycoprotein", "PROTEIN", 200, 212], ["GP", "PROTEIN", 214, 216], ["Viral replication", "TREATMENT", 0, 17], ["nucleoprotein (NP)", "TREATMENT", 59, 77], ["VP30", "TEST", 79, 83], ["VP35", "TEST", 85, 89], ["the RNA polymerase", "TEST", 94, 112], ["VP40", "PROBLEM", 125, 129], ["mature virions", "OBSERVATION", 157, 171], ["cell", "OBSERVATION_MODIFIER", 181, 185], ["surface", "OBSERVATION_MODIFIER", 186, 193], ["lipid", "ANATOMY_MODIFIER", 243, 248], ["bilayer", "ANATOMY_MODIFIER", 249, 256], ["nucleocapsid", "OBSERVATION", 273, 285]]], ["The filoviruses are listed as Category A bioterrorism agents by the CDC and must be handled under biosafety level 4 conditions.", [["filoviruses", "CANCER", 4, 15]]], ["Both viruses cause severe hemorrhagic fever in humans with mortality rates of 30\u201390% (Thacker, 2003, Feldmann, 2006).", [["hemorrhagic fever", "DISEASE", 26, 43], ["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["severe hemorrhagic fever", "PROBLEM", 19, 43], ["mortality rates", "TEST", 59, 74], ["viruses", "OBSERVATION", 5, 12], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["hemorrhagic", "OBSERVATION_MODIFIER", 26, 37], ["fever", "OBSERVATION", 38, 43]]], ["Currently, there are no vaccines or therapeutics for treating filovirus infections in humans.", [["filovirus infections", "DISEASE", 62, 82], ["filovirus", "ORGANISM", 62, 71], ["humans", "ORGANISM", 86, 92], ["humans", "SPECIES", 86, 92], ["humans", "SPECIES", 86, 92], ["vaccines", "TREATMENT", 24, 32], ["therapeutics", "TREATMENT", 36, 48], ["treating filovirus infections in humans", "PROBLEM", 53, 92], ["no", "UNCERTAINTY", 21, 23]]], ["For further information and perspective on filovirus drug development, see the article by Bausch et al. (2008).Filoviruses ::: Antisense and siRNA as antiviral therapeuticsTwo preclinical studies have been published investigating PMOs as a treatment for EBOV infection, with both showing efficacy in animal models.", [["PMOs", "CHEMICAL", 230, 234], ["EBOV infection", "DISEASE", 254, 268], ["PMOs", "CHEMICAL", 230, 234], ["PMOs", "SIMPLE_CHEMICAL", 230, 234], ["EBOV", "ORGANISM", 254, 258], ["EBOV", "SPECIES", 254, 258], ["Antisense and siRNA", "TREATMENT", 127, 146], ["antiviral therapeutics", "TREATMENT", 150, 172], ["Two preclinical studies", "TEST", 172, 195], ["a treatment", "TREATMENT", 238, 249], ["EBOV infection", "PROBLEM", 254, 268], ["infection", "OBSERVATION", 259, 268]]], ["PMOs were designed to inhibit translation of EBOV VP35, VP24, and L transcripts (Warfield et al., 2006).", [["PMOs", "CHEMICAL", 0, 4], ["PMOs", "SIMPLE_CHEMICAL", 0, 4], ["EBOV", "ORGANISM", 45, 49], ["VP35", "GENE_OR_GENE_PRODUCT", 50, 54], ["VP24", "GENE_OR_GENE_PRODUCT", 56, 60], ["EBOV VP35", "PROTEIN", 45, 54], ["VP24", "PROTEIN", 56, 60], ["L transcripts", "PROTEIN", 66, 79], ["EBOV VP35", "SPECIES", 45, 54], ["EBOV VP35", "TREATMENT", 45, 54], ["VP24", "TREATMENT", 56, 60]]], ["All three PMOs showed activity using an in vitro translation assay and reduced viral titer in cell culture.", [["cell culture", "ANATOMY", 94, 106], ["PMOs", "SIMPLE_CHEMICAL", 10, 14], ["cell culture", "CELL", 94, 106], ["an in vitro translation assay", "TEST", 37, 66], ["reduced viral titer in cell culture", "PROBLEM", 71, 106]]], ["In a similar study, a different VP35-specific PMO also reduced virus yield in cell culture (Enterlein et al., 2006).", [["cell", "ANATOMY", 78, 82], ["PMO", "CHEMICAL", 46, 49], ["VP35", "GENE_OR_GENE_PRODUCT", 32, 36], ["PMO", "SIMPLE_CHEMICAL", 46, 49], ["cell", "CELL", 78, 82], ["VP35", "PROTEIN", 32, 36], ["a similar study", "TEST", 3, 18], ["a different VP35", "TREATMENT", 20, 36], ["reduced virus", "PROBLEM", 55, 68], ["cell culture", "TEST", 78, 90]]], ["This PMO targeting VP35 was conjugated to an arginine-rich peptide (P-PMO), or left unconjugated, and tested in a mouse model of EBOV infection.", [["PMO", "CHEMICAL", 5, 8], ["arginine", "CHEMICAL", 45, 53], ["EBOV infection", "DISEASE", 129, 143], ["arginine", "CHEMICAL", 45, 53], ["PMO", "SIMPLE_CHEMICAL", 5, 8], ["VP35", "GENE_OR_GENE_PRODUCT", 19, 23], ["arginine-rich peptide", "SIMPLE_CHEMICAL", 45, 66], ["mouse", "ORGANISM", 114, 119], ["EBOV", "ORGANISM", 129, 133], ["VP35", "PROTEIN", 19, 23], ["mouse", "SPECIES", 114, 119], ["mouse", "SPECIES", 114, 119], ["EBOV", "SPECIES", 129, 133], ["This PMO targeting VP35", "TREATMENT", 0, 23], ["an arginine-rich peptide", "TREATMENT", 42, 66], ["left unconjugated", "PROBLEM", 79, 96], ["EBOV infection", "PROBLEM", 129, 143], ["left", "ANATOMY_MODIFIER", 79, 83], ["unconjugated", "OBSERVATION", 84, 96], ["EBOV", "OBSERVATION_MODIFIER", 129, 133], ["infection", "OBSERVATION", 134, 143]]], ["Five hundred micrograms of VP35 PMO or P-PMO was delivered to mice by intraperitoneal injection (i.p.) 24 h and 4 h before EBOV challenge.", [["intraperitoneal", "ANATOMY", 70, 85], ["PMO", "CHEMICAL", 32, 35], ["P-PMO", "CHEMICAL", 39, 44], ["VP35", "ORGANISM", 27, 31], ["PMO", "SIMPLE_CHEMICAL", 32, 35], ["P-PMO", "SIMPLE_CHEMICAL", 39, 44], ["mice", "ORGANISM", 62, 66], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 85], ["EBOV", "ORGANISM", 123, 127], ["mice", "SPECIES", 62, 66], ["VP35", "SPECIES", 27, 31], ["mice", "SPECIES", 62, 66], ["EBOV", "SPECIES", 123, 127], ["VP35 PMO", "TREATMENT", 27, 35], ["P-PMO", "TREATMENT", 39, 44]]], ["With this treatment regimen, VP35 PMO protected 75% of the mice from lethal infection, while 100% of the P-PMO-treated mice survived.", [["PMO", "CHEMICAL", 34, 37], ["infection", "DISEASE", 76, 85], ["P-PMO", "CHEMICAL", 105, 110], ["VP35", "ORGANISM", 29, 33], ["PMO", "SIMPLE_CHEMICAL", 34, 37], ["mice", "ORGANISM", 59, 63], ["P-PMO", "SIMPLE_CHEMICAL", 105, 110], ["mice", "ORGANISM", 119, 123], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 119, 123], ["VP35", "SPECIES", 29, 33], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 119, 123], ["this treatment regimen", "TREATMENT", 5, 27], ["VP35 PMO", "TREATMENT", 29, 37], ["lethal infection", "PROBLEM", 69, 85], ["the P-PMO", "TREATMENT", 101, 110], ["infection", "OBSERVATION", 76, 85]]], ["Similarly, 100% of mice survived when treated with VP35 P-PMO 24 h after EBOV challenge.", [["VP35 P-PMO", "CHEMICAL", 51, 61], ["mice", "ORGANISM", 19, 23], ["VP35", "ORGANISM", 51, 55], ["EBOV", "ORGANISM", 73, 77], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["EBOV", "SPECIES", 73, 77], ["VP35 P-PMO", "TREATMENT", 51, 61], ["EBOV challenge", "TREATMENT", 73, 87]]], ["A more comprehensive investigation of VP35, VP24, and L PMOs utilized three animal models to test for efficacy (Warfield et al., 2006).", [["VP35", "GENE_OR_GENE_PRODUCT", 38, 42], ["VP24", "GENE_OR_GENE_PRODUCT", 44, 48], ["L PMOs", "GENE_OR_GENE_PRODUCT", 54, 60], ["VP35", "PROTEIN", 38, 42], ["VP24", "PROTEIN", 44, 48], ["L PMOs", "PROTEIN", 54, 60], ["VP35", "TEST", 38, 42], ["VP24", "TEST", 44, 48], ["L PMOs", "TREATMENT", 54, 60]]], ["In mice, VP35 and VP24 unconjugated PMOs provided complete, and near complete, protection, respectively, when delivered by i.p. injection twice before EBOV infection.", [["EBOV infection", "DISEASE", 151, 165], ["mice", "ORGANISM", 3, 7], ["VP35", "GENE_OR_GENE_PRODUCT", 9, 13], ["VP24", "GENE_OR_GENE_PRODUCT", 18, 22], ["PMOs", "SIMPLE_CHEMICAL", 36, 40], ["EBOV", "ORGANISM", 151, 155], ["VP35", "PROTEIN", 9, 13], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["VP35", "SPECIES", 9, 13], ["EBOV", "SPECIES", 151, 155], ["VP35", "TREATMENT", 9, 13], ["VP24 unconjugated PMOs", "TREATMENT", 18, 40], ["EBOV infection", "PROBLEM", 151, 165], ["infection", "OBSERVATION", 156, 165]]], ["Importantly, a combination treatment of all three PMOs, given 24 h after EBOV infection, provided complete protection.", [["PMOs", "CHEMICAL", 50, 54], ["EBOV infection", "DISEASE", 73, 87], ["PMOs", "SIMPLE_CHEMICAL", 50, 54], ["EBOV", "ORGANISM", 73, 77], ["EBOV", "SPECIES", 73, 77], ["a combination treatment", "TREATMENT", 13, 36], ["all three PMOs", "TREATMENT", 40, 54], ["EBOV infection", "PROBLEM", 73, 87], ["infection", "OBSERVATION", 78, 87]]], ["Surviving mice developed an immune response to EBOV and were protected from subsequent challenge.", [["mice", "ORGANISM", 10, 14], ["EBOV", "ORGANISM", 47, 51], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["EBOV", "SPECIES", 47, 51], ["EBOV", "TREATMENT", 47, 51], ["immune response", "OBSERVATION", 28, 43]]], ["In guinea pigs, maximum efficacy was seen when the combination treatment was given 96 h postchallenge, compared to treatment with a single PMO given closer to challenge; probably due to differences in pharmacokinetics and bioavailability between treatment regimens.", [["PMO", "CHEMICAL", 139, 142], ["guinea pigs", "ORGANISM", 3, 14], ["guinea pigs", "SPECIES", 3, 14], ["the combination treatment", "TREATMENT", 47, 72], ["treatment", "TREATMENT", 115, 124], ["a single PMO", "TREATMENT", 130, 142], ["differences in pharmacokinetics", "PROBLEM", 186, 217], ["bioavailability", "TREATMENT", 222, 237], ["treatment regimens", "TREATMENT", 246, 264]]], ["Finally, anti-EBOV PMO treatment was investigated in rhesus macaques (Warfield et al., 2006).", [["PMO", "CHEMICAL", 19, 22], ["anti-EBOV PMO", "SIMPLE_CHEMICAL", 9, 22], ["rhesus", "ORGANISM", 53, 59], ["macaques", "ORGANISM", 60, 68], ["rhesus macaques", "SPECIES", 53, 68], ["rhesus macaques", "SPECIES", 53, 68], ["anti-EBOV PMO treatment", "TREATMENT", 9, 32]]], ["Monkeys were administered a single PMO (VP35) or a combination of three PMOs (VP35, VP24 and L) from 2 days before, through 9 days after EBOV challenge by a combination of parenteral routes.", [["PMO", "CHEMICAL", 35, 38], ["Monkeys", "ORGANISM", 0, 7], ["PMO", "SIMPLE_CHEMICAL", 35, 38], ["VP35", "ORGANISM", 40, 44], ["PMOs", "SIMPLE_CHEMICAL", 72, 76], ["VP35", "ORGANISM", 78, 82], ["EBOV", "ORGANISM", 137, 141], ["VP35", "PROTEIN", 78, 82], ["EBOV", "SPECIES", 137, 141], ["a single PMO (VP35", "TREATMENT", 26, 44], ["a combination of three PMOs", "TREATMENT", 49, 76], ["VP35", "TREATMENT", 78, 82], ["EBOV challenge", "TREATMENT", 137, 151], ["parenteral routes", "TREATMENT", 172, 189]]], ["No monkeys treated with the single VP35-targeting PMO survived EBOV infection, but two of four monkeys receiving the combination PMO treatment survived lethal EBOV challenge.", [["PMO", "CHEMICAL", 50, 53], ["EBOV infection", "DISEASE", 63, 77], ["PMO", "CHEMICAL", 129, 132], ["EBOV", "DISEASE", 159, 163], ["monkeys", "ORGANISM", 3, 10], ["VP35", "GENE_OR_GENE_PRODUCT", 35, 39], ["PMO", "SIMPLE_CHEMICAL", 50, 53], ["EBOV", "ORGANISM", 63, 67], ["monkeys", "ORGANISM", 95, 102], ["PMO", "SIMPLE_CHEMICAL", 129, 132], ["EBOV", "ORGANISM", 159, 163], ["VP35", "PROTEIN", 35, 39], ["EBOV", "SPECIES", 63, 67], ["EBOV", "SPECIES", 159, 163], ["the single VP35", "TREATMENT", 24, 39], ["EBOV infection", "PROBLEM", 63, 77], ["the combination PMO treatment", "TREATMENT", 113, 142], ["lethal EBOV challenge", "TREATMENT", 152, 173]]], ["A third monkey in this treatment group remained aviremic, but succumbed to a secondary bacterial infection.Filoviruses ::: Antisense and siRNA as antiviral therapeuticsIn addition to these promising PMO studies, siRNA may prove to be an effective therapy against filovirus infection.", [["bacterial infection", "DISEASE", 87, 106], ["filovirus infection", "DISEASE", 263, 282], ["monkey", "ORGANISM", 8, 14], ["filovirus", "ORGANISM", 263, 272], ["aviremic", "PROBLEM", 48, 56], ["a secondary bacterial infection", "PROBLEM", 75, 106], ["Antisense and siRNA", "TREATMENT", 123, 142], ["antiviral therapeutics", "TREATMENT", 146, 168], ["these promising PMO studies", "TEST", 183, 210], ["siRNA", "TREATMENT", 212, 217], ["an effective therapy", "TREATMENT", 234, 254], ["filovirus infection", "PROBLEM", 263, 282], ["secondary", "OBSERVATION_MODIFIER", 77, 86], ["bacterial", "OBSERVATION_MODIFIER", 87, 96], ["infection", "OBSERVATION", 97, 106]]], ["To increase the serum half-life of siRNAs in vivo, specialized liposomes can be used to form a stable nucleic acid-lipid particle (SNALP) (Geisbert et al., 2006).", [["serum", "ANATOMY", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["liposomes", "SIMPLE_CHEMICAL", 63, 72], ["the serum half-life of siRNAs in vivo", "TREATMENT", 12, 49], ["specialized liposomes", "TREATMENT", 51, 72], ["stable", "OBSERVATION_MODIFIER", 95, 101]]], ["SNALP-encapsulated siRNAs against EBOV L gene were efficacious in a guinea pig model of EBOV infection when given daily by i.p. injection, beginning 1 h after challenge.", [["SNALP", "CHEMICAL", 0, 5], ["EBOV infection", "DISEASE", 88, 102], ["SNALP", "SIMPLE_CHEMICAL", 0, 5], ["EBOV L", "GENE_OR_GENE_PRODUCT", 34, 40], ["guinea pig", "ORGANISM", 68, 78], ["EBOV", "ORGANISM", 88, 92], ["SNALP", "PROTEIN", 0, 5], ["EBOV L gene", "DNA", 34, 45], ["guinea pig", "SPECIES", 68, 78], ["EBOV", "SPECIES", 34, 38], ["pig", "SPECIES", 75, 78], ["EBOV", "SPECIES", 88, 92], ["SNALP-encapsulated siRNAs", "TREATMENT", 0, 25], ["EBOV L gene", "TREATMENT", 34, 45], ["EBOV infection", "PROBLEM", 88, 102], ["encapsulated", "OBSERVATION_MODIFIER", 6, 18], ["siRNAs", "OBSERVATION", 19, 25], ["efficacious", "OBSERVATION_MODIFIER", 51, 62], ["EBOV", "OBSERVATION_MODIFIER", 88, 92], ["infection", "OBSERVATION", 93, 102]]], ["Viremia was not detected in any of the siRNA-treated animals, although two of five siRNA-treated guinea pigs died (compared to five out of five dead control animals).", [["Viremia", "DISEASE", 0, 7], ["guinea", "ORGANISM", 97, 103], ["pigs", "ORGANISM", 104, 108], ["guinea pigs", "SPECIES", 97, 108], ["pigs", "SPECIES", 104, 108], ["Viremia", "PROBLEM", 0, 7], ["the siRNA", "PROBLEM", 35, 44], ["five siRNA", "TREATMENT", 78, 88], ["guinea pigs", "TREATMENT", 97, 108], ["siRNA", "ANATOMY", 39, 44]]], ["Because these results could indicate therapy-dependent toxicity, a trial with a lower dose of SNALP L siRNAs was performed, and successfully protected 100% of challenged animals.Filoviruses ::: Antisense and siRNA as antiviral therapeuticsRecently, siRNAs were also generated to target MARV NP, VP30 and VP35 transcripts (Fowler et al., 2005).", [["toxicity", "DISEASE", 55, 63], ["SNALP L", "GENE_OR_GENE_PRODUCT", 94, 101], ["MARV", "ORGANISM", 286, 290], ["NP", "GENE_OR_GENE_PRODUCT", 291, 293], ["VP30", "GENE_OR_GENE_PRODUCT", 295, 299], ["VP35", "GENE_OR_GENE_PRODUCT", 304, 308], ["MARV NP, VP30 and VP35 transcripts", "RNA", 286, 320], ["MARV", "SPECIES", 286, 290], ["dependent toxicity", "PROBLEM", 45, 63], ["a lower dose of SNALP L siRNAs", "TREATMENT", 78, 108], ["Antisense and siRNA", "TREATMENT", 194, 213], ["antiviral therapeutics", "TREATMENT", 217, 239], ["MARV NP", "TREATMENT", 286, 293]]], ["Each siRNA efficiently reduced the level of its target transcript in a co-transfection assay or after MARV infection in Vero cells.", [["Vero cells", "ANATOMY", 120, 130], ["MARV infection", "DISEASE", 102, 116], ["MARV", "ORGANISM", 102, 106], ["Vero cells", "CELL", 120, 130], ["Vero cells", "CELL_LINE", 120, 130], ["MARV", "SPECIES", 102, 106], ["Each siRNA", "PROBLEM", 0, 10], ["a co-transfection assay", "TEST", 69, 92], ["MARV infection in Vero cells", "PROBLEM", 102, 130], ["infection", "OBSERVATION", 107, 116], ["Vero cells", "OBSERVATION", 120, 130]]], ["As expected, this decreased the yield of virus released from Vero cells 24 h after infection.", [["Vero cells", "ANATOMY", 61, 71], ["infection", "DISEASE", 83, 92], ["Vero cells", "CELL", 61, 71], ["Vero cells", "CELL_LINE", 61, 71], ["virus", "PROBLEM", 41, 46], ["Vero cells", "PROBLEM", 61, 71], ["infection", "PROBLEM", 83, 92], ["virus", "OBSERVATION", 41, 46], ["Vero cells", "OBSERVATION", 61, 71]]], ["Together, these studies suggest that filovirus infections are susceptible to antisense and siRNA-mediated therapy and warrant further investigation as therapeutics for eventual use in humans.Filoviruses ::: Antisense and siRNA as antiviral therapeuticsA growing consideration for those developing antiviral RNAi-based drug candidates is the presence of virus-encoded RNA silencing suppressors (RSSs) (Voinnet, 2005).", [["filovirus infections", "DISEASE", 37, 57], ["filovirus", "ORGANISM", 37, 46], ["humans", "ORGANISM", 184, 190], ["RSSs", "DNA", 394, 398], ["humans", "SPECIES", 184, 190], ["humans", "SPECIES", 184, 190], ["these studies", "TEST", 10, 23], ["filovirus infections", "PROBLEM", 37, 57], ["antisense and siRNA-mediated therapy", "TREATMENT", 77, 113], ["further investigation", "TEST", 126, 147], ["Antisense and siRNA", "TREATMENT", 207, 226], ["antiviral therapeutics", "TREATMENT", 230, 252], ["antiviral RNAi", "TREATMENT", 297, 311], ["virus", "PROBLEM", 353, 358], ["encoded RNA silencing suppressors", "TREATMENT", 359, 392], ["filovirus infections", "OBSERVATION", 37, 57]]], ["Although the presence and significance of an endogenous RNAi antiviral response in mammalian cells is still under scrutiny, it has been well established in plants, insects, and nematodes.", [["mammalian cells", "ANATOMY", 83, 98], ["mammalian cells", "CELL", 83, 98], ["mammalian cells", "CELL_TYPE", 83, 98], ["an endogenous RNAi antiviral response in mammalian cells", "PROBLEM", 42, 98], ["endogenous RNAi", "OBSERVATION", 45, 60], ["antiviral response", "OBSERVATION", 61, 79], ["mammalian cells", "OBSERVATION", 83, 98]]], ["It is now suggested that EBOV VP35 has RSS activity, as this protein can inhibit shRNA-mediated silencing of luciferase expression in cotransfection assays (Haasnoot et al., 2007).", [["EBOV", "ORGANISM", 25, 29], ["VP35", "GENE_OR_GENE_PRODUCT", 30, 34], ["luciferase", "GENE_OR_GENE_PRODUCT", 109, 119], ["EBOV VP35", "PROTEIN", 25, 34], ["luciferase", "PROTEIN", 109, 119], ["EBOV", "SPECIES", 25, 29], ["EBOV VP35", "TREATMENT", 25, 34], ["shRNA", "PROBLEM", 81, 86], ["luciferase expression in cotransfection assays", "PROBLEM", 109, 155]]], ["This RNAi inhibition by VP35 could not be attributed to interferon (IFN) antagonism, as this effect was also observed in Vero cells, which have a defective interferon pathway.", [["Vero cells", "ANATOMY", 121, 131], ["VP35", "GENE_OR_GENE_PRODUCT", 24, 28], ["interferon", "GENE_OR_GENE_PRODUCT", 56, 66], ["IFN", "GENE_OR_GENE_PRODUCT", 68, 71], ["Vero cells", "CELL", 121, 131], ["interferon", "GENE_OR_GENE_PRODUCT", 156, 166], ["VP35", "PROTEIN", 24, 28], ["interferon", "PROTEIN", 56, 66], ["IFN", "PROTEIN", 68, 71], ["Vero cells", "CELL_LINE", 121, 131], ["interferon", "PROTEIN", 156, 166], ["VP35", "PROBLEM", 24, 28], ["interferon (IFN) antagonism", "PROBLEM", 56, 83], ["Vero cells", "PROBLEM", 121, 131], ["a defective interferon pathway", "TREATMENT", 144, 174], ["Vero cells", "OBSERVATION", 121, 131]]], ["Additionally, VP35 can functionally complement a mutant HIV-1 Tat protein.", [["VP35", "GENE_OR_GENE_PRODUCT", 14, 18], ["HIV-1", "ORGANISM", 56, 61], ["Tat", "GENE_OR_GENE_PRODUCT", 62, 65], ["VP35", "PROTEIN", 14, 18], ["mutant HIV-1 Tat protein", "PROTEIN", 49, 73], ["HIV-1", "SPECIES", 56, 61], ["HIV-1", "SPECIES", 56, 61]]], ["HIV-1 Tat exhibits RSS activity that is required for viral replication (Bennasser et al., 2005, Haasnoot et al., 2007).", [["HIV-1", "ORGANISM", 0, 5], ["Tat", "GENE_OR_GENE_PRODUCT", 6, 9], ["HIV-1 Tat", "PROTEIN", 0, 9], ["RSS", "DNA", 19, 22], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["RSS activity", "PROBLEM", 19, 31]]], ["It is tempting to speculate that siRNA or ASO/PMO treatments targeting RSS protein encoding sequences, whether as part of a pool or as individual compounds, will be more efficacious than treatments that do not reduce RSS protein levels.", [["RSS protein encoding sequences", "DNA", 71, 101], ["ASO/PMO treatments", "TREATMENT", 42, 60], ["RSS protein encoding sequences", "TREATMENT", 71, 101], ["treatments", "TREATMENT", 187, 197], ["RSS protein levels", "TEST", 217, 235]]], ["This will likely be an important area of investigation in the near future.Flaviviruses ::: Antisense and siRNA as antiviral therapeuticsFlaviviruses contain a \u223c11 kb, plus-sense orientation, single-stranded RNA genome that encodes a single long polyprotein.", [["single-stranded RNA genome", "DNA", 191, 217], ["Antisense and siRNA", "TREATMENT", 91, 110], ["antiviral therapeutics", "TREATMENT", 114, 136], ["Flaviviruses", "PROBLEM", 136, 148], ["single-stranded RNA genome", "PROBLEM", 191, 217], ["a single long polyprotein", "TREATMENT", 231, 256]]], ["Once generated, this polyprotein is cleaved to produce three structural, and seven non-structural proteins (Samuel and Diamond, 2006).", [["non-structural proteins", "PROTEIN", 83, 106], ["this polyprotein", "PROBLEM", 16, 32]]], ["The family Flaviviridae contains a number of important human pathogens.", [["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60]]], ["These include West Nile (WNV), yellow fever (YFV), Japanese encephalitis (JEV), and dengue (DENV) viruses.", [["West Nile (WNV), yellow fever", "DISEASE", 14, 43], ["YFV", "DISEASE", 45, 48], ["Japanese encephalitis (JEV), and dengue (DENV) viruses", "DISEASE", 51, 105], ["West Nile", "ORGANISM", 14, 23], ["WNV", "ORGANISM", 25, 28], ["yellow fever", "ORGANISM", 31, 43], ["YFV", "ORGANISM", 45, 48], ["Japanese encephalitis", "ORGANISM", 51, 72], ["JEV", "ORGANISM", 74, 77], ["yellow fever", "SPECIES", 31, 43], ["West Nile", "SPECIES", 14, 23], ["WNV", "SPECIES", 25, 28], ["yellow fever (", "SPECIES", 31, 45], ["YFV", "SPECIES", 45, 48], ["JEV", "SPECIES", 74, 77], ["dengue", "SPECIES", 84, 90], ["DENV", "SPECIES", 92, 96], ["West Nile (WNV", "PROBLEM", 14, 28], ["yellow fever (YFV)", "PROBLEM", 31, 49], ["Japanese encephalitis (JEV)", "PROBLEM", 51, 78], ["dengue (DENV) viruses", "PROBLEM", 84, 105]]], ["The significance of DENV infections has already been cited, and the increasing public health toll of JEV is described in another paper in this issue (Gould et al., 2008).", [["DENV infections", "DISEASE", 20, 35], ["JEV", "DISEASE", 101, 104], ["DENV", "ORGANISM", 20, 24], ["JEV", "ORGANISM", 101, 104], ["DENV", "SPECIES", 20, 24], ["JEV", "SPECIES", 101, 104], ["DENV infections", "PROBLEM", 20, 35], ["JEV", "PROBLEM", 101, 104], ["DENV", "OBSERVATION_MODIFIER", 20, 24], ["infections", "OBSERVATION", 25, 35], ["increasing", "OBSERVATION_MODIFIER", 68, 78]]], ["In 2006 there were more than 4000 reported cases of WNV infection in the United States alone; most were neuroinvasive (http://www.cdc.gov).", [["WNV infection", "DISEASE", 52, 65], ["WNV", "ORGANISM", 52, 55], ["WNV", "SPECIES", 52, 55], ["WNV infection", "PROBLEM", 52, 65], ["WNV", "OBSERVATION_MODIFIER", 52, 55], ["infection", "OBSERVATION", 56, 65]]], ["Importantly, there are currently no approved vaccines or antiviral therapies against DENV or WNV for use in humans.Flaviviruses ::: Antisense and siRNA as antiviral therapeuticsPMOs have been used to inhibit flavivirus infections (WNV, JEV, SLEV and DENV) by targeting conserved sequences within the 5\u2032 and 3\u2032 untranslated regions of the viral genome (Deas et al., 2005, Deas et al., 2007, Kinney et al., 2005, Holden et al., 2006).", [["PMOs", "CHEMICAL", 177, 181], ["flavivirus infections", "DISEASE", 208, 229], ["PMOs", "CHEMICAL", 177, 181], ["DENV", "ORGANISM", 85, 89], ["WNV", "ORGANISM", 93, 96], ["humans", "ORGANISM", 108, 114], ["PMOs", "SIMPLE_CHEMICAL", 177, 181], ["flavivirus", "ORGANISM", 208, 218], ["JEV", "ORGANISM", 236, 239], ["SLEV", "GENE_OR_GENE_PRODUCT", 241, 245], ["DENV", "ORGANISM", 250, 254], ["\u2032", "GENE_OR_GENE_PRODUCT", 301, 302], ["5\u2032 and 3\u2032 untranslated regions", "DNA", 300, 330], ["viral genome", "DNA", 338, 350], ["humans", "SPECIES", 108, 114], ["DENV", "SPECIES", 85, 89], ["WNV", "SPECIES", 93, 96], ["humans", "SPECIES", 108, 114], ["WNV", "SPECIES", 231, 234], ["JEV", "SPECIES", 236, 239], ["SLEV", "SPECIES", 241, 245], ["DENV", "SPECIES", 250, 254], ["approved vaccines", "TREATMENT", 36, 53], ["antiviral therapies", "TREATMENT", 57, 76], ["DENV", "PROBLEM", 85, 89], ["WNV", "PROBLEM", 93, 96], ["Antisense and siRNA", "TREATMENT", 132, 151], ["antiviral therapeutics", "TREATMENT", 155, 177], ["flavivirus infections", "PROBLEM", 208, 229], ["WNV", "PROBLEM", 231, 234], ["JEV", "PROBLEM", 236, 239], ["DENV", "PROBLEM", 250, 254], ["no", "UNCERTAINTY", 33, 35], ["viral genome", "OBSERVATION", 338, 350]]], ["These areas of the genome form critical secondary structures that are necessary for viral replication (Khromykh et al., 2003).", [["genome", "CELLULAR_COMPONENT", 19, 25], ["viral replication", "PROBLEM", 84, 101], ["secondary structures", "OBSERVATION", 40, 60]]], ["Deas et al. (2005) identified a peptide-conjugated PMO (PPMO) targeting a highly conserved 3\u2032 sequence element that exhibited potent anti-WNV activity in cell culture.", [["cell culture", "ANATOMY", 154, 166], ["PMO", "CHEMICAL", 51, 54], ["PPMO", "CHEMICAL", 56, 60], ["PMO", "CHEMICAL", 51, 54], ["PPMO", "CHEMICAL", 56, 60], ["PMO", "SIMPLE_CHEMICAL", 51, 54], ["PPMO", "SIMPLE_CHEMICAL", 56, 60], ["anti-WNV", "CANCER", 133, 141], ["cell culture", "CELL", 154, 166], ["3\u2032 sequence element", "DNA", 91, 110], ["anti-WNV", "PROTEIN", 133, 141], ["a peptide-conjugated PMO (PPMO)", "TREATMENT", 30, 61], ["a highly conserved 3\u2032 sequence element", "PROBLEM", 72, 110], ["cell culture", "TEST", 154, 166]]], ["In a subsequent report, this PMO was redesigned to achieve perfect complementarity to this sequence element in WNV, JEV, and St. Louis encephalitis virus (SLEV) (Deas et al., 2007).", [["JEV", "DISEASE", 116, 119], ["encephalitis", "DISEASE", 135, 147], ["WNV", "ORGANISM", 111, 114], ["JEV", "ORGANISM", 116, 119], ["St. Louis encephalitis virus", "ORGANISM", 125, 153], ["SLEV", "ORGANISM", 155, 159], ["encephalitis virus", "SPECIES", 135, 153], ["WNV", "SPECIES", 111, 114], ["JEV", "SPECIES", 116, 119], ["St. Louis encephalitis virus", "SPECIES", 125, 153], ["SLEV", "SPECIES", 155, 159], ["this sequence element", "TEST", 86, 107], ["WNV", "PROBLEM", 111, 114], ["JEV", "PROBLEM", 116, 119]]], ["The redesigned oligo was effective against all three viruses in cell culture.", [["cell culture", "ANATOMY", 64, 76], ["oligo", "CHEMICAL", 15, 20], ["cell culture", "CELL", 64, 76], ["The redesigned oligo", "TREATMENT", 0, 20], ["cell culture", "TEST", 64, 76]]], ["PPMO and PMO targeting this 3\u2032 sequence element were then tested in a mouse model of WNV infection.", [["PPMO", "CHEMICAL", 0, 4], ["PMO", "CHEMICAL", 9, 12], ["WNV infection", "DISEASE", 85, 98], ["PPMO", "CHEMICAL", 0, 4], ["PMO", "CHEMICAL", 9, 12], ["PPMO", "SIMPLE_CHEMICAL", 0, 4], ["PMO", "SIMPLE_CHEMICAL", 9, 12], ["mouse", "ORGANISM", 70, 75], ["WNV", "ORGANISM", 85, 88], ["3\u2032 sequence element", "DNA", 28, 47], ["mouse", "SPECIES", 70, 75], ["mouse", "SPECIES", 70, 75], ["WNV", "SPECIES", 85, 88], ["PPMO", "TREATMENT", 0, 4], ["PMO", "TREATMENT", 9, 12], ["this 3\u2032 sequence element", "TREATMENT", 23, 47], ["WNV infection", "PROBLEM", 85, 98], ["WNV", "OBSERVATION_MODIFIER", 85, 88], ["infection", "OBSERVATION", 89, 98]]], ["Although mice could tolerate higher doses of the PMO, compared to PPMO, this reagent did not protect virus-infected mice.", [["PMO", "CHEMICAL", 49, 52], ["PPMO", "CHEMICAL", 66, 70], ["PPMO", "CHEMICAL", 66, 70], ["mice", "ORGANISM", 9, 13], ["PMO", "SIMPLE_CHEMICAL", 49, 52], ["PPMO", "SIMPLE_CHEMICAL", 66, 70], ["mice", "ORGANISM", 116, 120], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 116, 120], ["the PMO", "TREATMENT", 45, 52], ["PPMO", "TEST", 66, 70], ["virus", "PROBLEM", 101, 106], ["infected", "OBSERVATION", 107, 115]]], ["In contrast, the PPMO, even when given at a more than 10-fold lower dose, increased survival and improved clinical correlates in mice infected with WNV.", [["PPMO", "CHEMICAL", 17, 21], ["WNV", "DISEASE", 148, 151], ["PPMO", "CHEMICAL", 17, 21], ["PPMO", "SIMPLE_CHEMICAL", 17, 21], ["mice", "ORGANISM", 129, 133], ["WNV", "ORGANISM", 148, 151], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["WNV", "SPECIES", 148, 151], ["increased survival", "PROBLEM", 74, 92], ["WNV", "PROBLEM", 148, 151]]], ["One can speculate that the conjugated peptide improved cellular uptake of the PMO and in this way improved efficacy.Flaviviruses ::: Antisense and siRNA as antiviral therapeuticsSeveral groups have successfully inhibited WNV replication using siRNA-based approaches (Kachko et al., 2006, Ong et al., 2006).", [["cellular", "ANATOMY", 55, 63], ["PMO", "CHEMICAL", 78, 81], ["cellular", "CELL", 55, 63], ["PMO", "SIMPLE_CHEMICAL", 78, 81], ["WNV", "ORGANISM", 221, 224], ["WNV", "SPECIES", 221, 224], ["the PMO", "TREATMENT", 74, 81], ["Antisense and siRNA", "TREATMENT", 133, 152], ["antiviral therapeutics", "TREATMENT", 156, 178], ["siRNA", "TREATMENT", 243, 248], ["improved", "OBSERVATION_MODIFIER", 98, 106], ["efficacy", "OBSERVATION_MODIFIER", 107, 115]]], ["Importantly, by targeting highly conserved sequences, progress has been made in designing antisense or RNAi-based therapies that protect mice from challenge with multiple flaviviruses.", [["flaviviruses", "DISEASE", 171, 183], ["mice", "ORGANISM", 137, 141], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 137, 141], ["RNAi-based therapies", "TREATMENT", 103, 123], ["multiple flaviviruses", "PROBLEM", 162, 183]]], ["By screening several siRNAs against the JEV genome, Kumar et al. (2006) identified a siRNA targeting the envelope protein (E) that provided significant protection from JEV infection in cell culture.", [["cell culture", "ANATOMY", 185, 197], ["JEV infection", "DISEASE", 168, 181], ["JEV", "ORGANISM", 40, 43], ["JEV", "ORGANISM", 168, 171], ["cell culture", "CELL", 185, 197], ["JEV genome", "DNA", 40, 50], ["envelope protein", "PROTEIN", 105, 121], ["E", "PROTEIN", 123, 124], ["JEV", "SPECIES", 40, 43], ["JEV", "SPECIES", 168, 171], ["a siRNA", "TREATMENT", 83, 90], ["JEV infection in cell culture", "PROBLEM", 168, 197], ["JEV infection", "OBSERVATION", 168, 181]]], ["A single dose of E-specific shRNA-expressing neurotropic lentivirus was able to provide complete protection (100% of mice survive) against lethal JEV challenge in mice when administered by intracranial (IC) injection.", [["intracranial", "ANATOMY", 189, 201], ["JEV", "DISEASE", 146, 149], ["lentivirus", "ORGANISM", 57, 67], ["mice", "ORGANISM", 117, 121], ["JEV", "ORGANISM", 146, 149], ["mice", "ORGANISM", 163, 167], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 201], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 163, 167], ["lentivirus", "SPECIES", 57, 67], ["mice", "SPECIES", 117, 121], ["JEV", "SPECIES", 146, 149], ["mice", "SPECIES", 163, 167], ["E-specific shRNA", "TREATMENT", 17, 33], ["neurotropic lentivirus", "TREATMENT", 45, 67], ["mice survive", "TREATMENT", 117, 129], ["lethal JEV challenge", "TREATMENT", 139, 159], ["intracranial (IC) injection", "TREATMENT", 189, 216]]], ["Although this approach successfully protected mice from JEV, lentivirus-based therapies may have a hard time finding their way into the clinic due to safety concerns stemming from viral integration.Flaviviruses ::: Antisense and siRNA as antiviral therapeuticssiRNAs may offer a better choice because of the transient nature of their effect and the ease of dose regimen optimization.", [["JEV", "DISEASE", 56, 59], ["mice", "ORGANISM", 46, 50], ["JEV", "ORGANISM", 56, 59], ["lentivirus", "ORGANISM", 61, 71], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["JEV", "SPECIES", 56, 59], ["lentivirus", "SPECIES", 61, 71], ["lentivirus-based therapies", "TREATMENT", 61, 87], ["viral integration", "PROBLEM", 180, 197], ["Flaviviruses", "PROBLEM", 198, 210], ["Antisense", "TREATMENT", 215, 224], ["siRNA", "TREATMENT", 229, 234], ["antiviral therapeuticssiRNAs", "TREATMENT", 238, 266], ["dose regimen optimization", "TREATMENT", 357, 382], ["viral integration", "OBSERVATION", 180, 197]]], ["One hundred percent of mice injected IC with lipid-encapsulated siRNA targeting E, 30 min and 6 h after challenge, were protected from lethal JEV infection.", [["JEV infection", "DISEASE", 142, 155], ["mice", "ORGANISM", 23, 27], ["lipid", "SIMPLE_CHEMICAL", 45, 50], ["JEV", "ORGANISM", 142, 145], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["JEV", "SPECIES", 142, 145], ["lipid-encapsulated siRNA targeting E", "TREATMENT", 45, 81], ["lethal JEV infection", "PROBLEM", 135, 155], ["lethal", "OBSERVATION_MODIFIER", 135, 141], ["JEV infection", "OBSERVATION", 142, 155]]], ["Importantly, the authors were able to design a siRNA with near-perfect homology to a region in the E gene of both JEV and WNV.", [["E", "GENE_OR_GENE_PRODUCT", 99, 100], ["JEV", "ORGANISM", 114, 117], ["WNV", "ORGANISM", 122, 125], ["E gene", "DNA", 99, 105], ["JEV", "SPECIES", 114, 117], ["WNV", "SPECIES", 122, 125], ["a siRNA", "TREATMENT", 45, 52]]], ["IC injection 30 min or 6 h after challenge provided almost complete protection against both JEV and WNV.", [["JEV", "DISEASE", 92, 95], ["WNV", "DISEASE", 100, 103], ["JEV", "ORGANISM", 92, 95], ["WNV", "ORGANISM", 100, 103], ["JEV", "SPECIES", 92, 95], ["WNV", "SPECIES", 100, 103], ["IC injection", "TREATMENT", 0, 12], ["WNV", "OBSERVATION", 100, 103]]], ["Kumar et al. (2007) further demonstrated the in vivo efficacy of intravenously (IV) administered siRNA against JEV.", [["intravenously", "ANATOMY", 65, 78], ["JEV", "DISEASE", 111, 114], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 78], ["JEV", "ORGANISM", 111, 114], ["JEV", "SPECIES", 111, 114], ["intravenously (IV) administered siRNA", "TREATMENT", 65, 102], ["JEV", "PROBLEM", 111, 114]]], ["A peptide derived from the glycoprotein of rabies virus (RVG) enables brain-specific delivery of conjugated siRNAs when given IV.", [["brain", "ANATOMY", 70, 75], ["rabies virus", "ORGANISM", 43, 55], ["RVG", "CANCER", 57, 60], ["brain", "ORGAN", 70, 75], ["glycoprotein", "PROTEIN", 27, 39], ["rabies virus", "SPECIES", 43, 55], ["rabies virus", "SPECIES", 43, 55], ["A peptide", "PROBLEM", 0, 9], ["rabies virus", "PROBLEM", 43, 55], ["conjugated siRNAs", "TREATMENT", 97, 114], ["IV", "TREATMENT", 126, 128], ["brain", "ANATOMY", 70, 75]]], ["Treatment with RVG-conjugated siRNA (against E protein) was initiated 4 h after challenge, and was repeated daily for 3 days.", [["RVG", "CHEMICAL", 15, 18], ["RVG", "CHEMICAL", 15, 18], ["RVG-conjugated siRNA", "SIMPLE_CHEMICAL", 15, 35], ["E protein", "GENE_OR_GENE_PRODUCT", 45, 54], ["RVG", "PROTEIN", 15, 18], ["E protein", "PROTEIN", 45, 54], ["RVG-conjugated siRNA (against E protein)", "TREATMENT", 15, 55]]], ["This treatment regimen did not induce a type I IFN response and protected 80% of mice from lethal encephalitis.", [["encephalitis", "DISEASE", 98, 110], ["type I IFN", "GENE_OR_GENE_PRODUCT", 40, 50], ["mice", "ORGANISM", 81, 85], ["IFN", "PROTEIN", 47, 50], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["This treatment regimen", "TREATMENT", 0, 22], ["lethal encephalitis", "PROBLEM", 91, 110], ["encephalitis", "OBSERVATION", 98, 110]]], ["Additional information on antiviral therapy for JEV is available in this issue (Gould et al., 2008).Arenaviruses ::: Antisense and siRNA as antiviral therapeuticsLike the filoviruses and flaviviruses, several viruses of the family Arenaviridae cause severe hemorrhagic fever in humans.", [["JEV", "DISEASE", 48, 51], ["hemorrhagic fever", "DISEASE", 257, 274], ["JEV", "ORGANISM", 48, 51], ["filoviruses", "GENE_OR_GENE_PRODUCT", 171, 182], ["Arenaviridae", "GENE_OR_GENE_PRODUCT", 231, 243], ["humans", "ORGANISM", 278, 284], ["humans", "SPECIES", 278, 284], ["JEV", "SPECIES", 48, 51], ["humans", "SPECIES", 278, 284], ["antiviral therapy", "TREATMENT", 26, 43], ["JEV", "PROBLEM", 48, 51], ["Antisense and siRNA", "TREATMENT", 117, 136], ["antiviral therapeutics", "TREATMENT", 140, 162], ["the filoviruses", "PROBLEM", 167, 182], ["flaviviruses", "PROBLEM", 187, 199], ["severe hemorrhagic fever in humans", "PROBLEM", 250, 284], ["filoviruses", "OBSERVATION", 171, 182], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["hemorrhagic", "OBSERVATION_MODIFIER", 257, 268], ["fever", "OBSERVATION", 269, 274]]], ["These include the NIAID category A priority pathogens Lassa, Junin and Machupo viruses (Gunther and Lenz, 2004).", [["Lassa, Junin and Machupo viruses", "DISEASE", 54, 86], ["Lassa", "ORGANISM", 54, 59], ["Junin", "ORGANISM", 61, 66], ["Machupo viruses", "ORGANISM", 71, 86], ["Junin and Machupo viruses", "TREATMENT", 61, 86]]], ["The genome of arenaviruses is composed of two single-stranded RNA segments, each harboring two genes, one in the sense and one in the antisense direction.", [["arenaviruses", "ORGANISM", 14, 26], ["single-stranded RNA segments", "RNA", 46, 74], ["arenaviruses", "PROBLEM", 14, 26], ["arenaviruses", "OBSERVATION", 14, 26], ["RNA segments", "ANATOMY_MODIFIER", 62, 74], ["two genes", "OBSERVATION", 91, 100]]], ["The larger RNA segment codes for a zinc-binding protein (Z) and the viral polymerase (L), while the smaller segment codes for the glycoprotein precursor (GPC) and nucleoprotein (NP).", [["zinc", "CHEMICAL", 35, 39], ["zinc", "CHEMICAL", 35, 39], ["zinc-binding protein (Z)", "GENE_OR_GENE_PRODUCT", 35, 59], ["glycoprotein precursor (GPC)", "GENE_OR_GENE_PRODUCT", 130, 158], ["zinc-binding protein", "PROTEIN", 35, 55], ["Z", "PROTEIN", 57, 58], ["viral polymerase", "PROTEIN", 68, 84], ["L", "PROTEIN", 86, 87], ["glycoprotein precursor", "PROTEIN", 130, 152], ["GPC", "PROTEIN", 154, 157], ["nucleoprotein", "PROTEIN", 163, 176], ["NP", "PROTEIN", 178, 180], ["The larger RNA segment codes", "PROBLEM", 0, 28], ["a zinc-binding protein", "TEST", 33, 55], ["the viral polymerase", "TEST", 64, 84], ["the glycoprotein precursor", "TEST", 126, 152], ["nucleoprotein (NP)", "TREATMENT", 163, 181], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["RNA segment", "OBSERVATION_MODIFIER", 11, 22]]], ["The 5\u2032 and 3\u2032 termini of each RNA segment are highly conserved among the arenaviruses, act as promoters for replication and transcription, and are included in viral mRNA transcripts (Gunther and Lenz, 2004).", [["5\u2032 and 3\u2032 termini", "DNA", 4, 21], ["promoters", "DNA", 94, 103], ["viral mRNA transcripts", "RNA", 159, 181], ["The 5\u2032 and 3\u2032 termini of each RNA segment", "TREATMENT", 0, 41], ["replication and transcription", "TREATMENT", 108, 137], ["segment", "ANATOMY_MODIFIER", 34, 41], ["arenaviruses", "OBSERVATION", 73, 85]]], ["As such, these sequences provide attractive targets for sequence-based therapies.Arenaviruses ::: Antisense and siRNA as antiviral therapeuticsIn a recent report, siRNAs targeting conserved termini sequences of the NP, L and GPC/Z were investigated (Muller and Gunther, 2007). siRNAs against NP and L showed activity in an in vitro Lassa virus minigenome replicon system.", [["Lassa virus", "ORGANISM", 332, 343], ["conserved termini sequences", "DNA", 180, 207], ["NP, L and GPC/Z", "DNA", 215, 230], ["Lassa virus", "SPECIES", 332, 343], ["Lassa virus", "SPECIES", 332, 343], ["these sequences", "TEST", 9, 24], ["sequence-based therapies", "TREATMENT", 56, 80], ["Antisense and siRNA", "TREATMENT", 98, 117], ["antiviral therapeutics", "TREATMENT", 121, 143], ["the NP", "TEST", 211, 217], ["siRNAs", "TEST", 277, 283], ["NP", "TEST", 292, 294]]], ["Importantly, these same siRNAs inhibited replication of five different Lassa virus isolates, along with two other arenaviruses (lymphocytic choriomeningitis virus and Mopeia) in cell culture.", [["cell culture", "ANATOMY", 178, 190], ["lymphocytic choriomeningitis virus", "DISEASE", 128, 162], ["Lassa virus", "ORGANISM", 71, 82], ["lymphocytic choriomeningitis virus", "ORGANISM", 128, 162], ["cell culture", "CELL", 178, 190], ["Lassa virus", "SPECIES", 71, 82], ["choriomeningitis virus", "SPECIES", 140, 162], ["Lassa virus", "SPECIES", 71, 82], ["lymphocytic choriomeningitis virus", "SPECIES", 128, 162], ["five different Lassa virus isolates", "PROBLEM", 56, 91], ["two other arenaviruses", "PROBLEM", 104, 126], ["lymphocytic choriomeningitis virus", "PROBLEM", 128, 162], ["cell culture", "TEST", 178, 190], ["lymphocytic choriomeningitis", "OBSERVATION", 128, 156]]], ["Vero cells were transfected with siRNA and then, 4 h later, infected with these various arenaviruses.", [["Vero cells", "ANATOMY", 0, 10], ["Vero cells", "CELL", 0, 10], ["arenaviruses", "ORGANISM", 88, 100], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["siRNA", "TREATMENT", 33, 38], ["these various arenaviruses", "PROBLEM", 74, 100], ["arenaviruses", "OBSERVATION", 88, 100]]], ["Cell culture supernatants were harvested and viral titer measured by immunological focus assay.", [["Cell", "ANATOMY", 0, 4], ["supernatants", "ANATOMY", 13, 25], ["Cell", "CELL", 0, 4], ["Cell culture supernatants", "TEST", 0, 25], ["viral titer", "TEST", 45, 56], ["immunological focus assay", "TEST", 69, 94]]], ["For further information on the treatment of Lassa fever, see the article by Khan et al. (2008).Alphaviruses ::: Antisense and siRNA as antiviral therapeuticsVenezuelan equine encephalitis virus (VEEV) is a mosquito-borne, enveloped RNA virus of the genus Alphavirus that is found in Central and South America, and has been extensively studied in the laboratory (Weaver et al., 2004).", [["Lassa fever", "DISEASE", 44, 55], ["Venezuelan equine encephalitis", "DISEASE", 157, 187], ["VEEV", "DISEASE", 195, 199], ["Venezuelan equine encephalitis virus", "ORGANISM", 157, 193], ["VEEV", "ORGANISM", 195, 199], ["Venezuelan equine encephalitis virus", "SPECIES", 157, 193], ["Venezuelan equine encephalitis virus", "SPECIES", 157, 193], ["VEEV", "SPECIES", 195, 199], ["Lassa fever", "PROBLEM", 44, 55], ["Antisense and siRNA", "TREATMENT", 112, 131], ["antiviral therapeutics", "TREATMENT", 135, 157], ["Venezuelan equine encephalitis virus", "PROBLEM", 157, 193], ["the genus Alphavirus", "PROBLEM", 245, 265], ["RNA virus", "OBSERVATION", 232, 241], ["genus Alphavirus", "OBSERVATION", 249, 265], ["Central", "ANATOMY_MODIFIER", 283, 290]]], ["Its positive-sense, single-stranded RNA genome codes for seven genes, four non-structural proteins (nsp1-nsp4) and three structural proteins (E1, E2, and capsid).", [["nsp1-nsp4", "GENE_OR_GENE_PRODUCT", 100, 109], ["E1", "GENE_OR_GENE_PRODUCT", 142, 144], ["E2", "GENE_OR_GENE_PRODUCT", 146, 148], ["capsid", "GENE_OR_GENE_PRODUCT", 154, 160], ["single-stranded RNA genome", "DNA", 20, 46], ["non-structural proteins", "PROTEIN", 75, 98], ["nsp1", "PROTEIN", 100, 104], ["nsp4", "PROTEIN", 105, 109], ["structural proteins", "PROTEIN", 121, 140], ["E1", "PROTEIN", 142, 144], ["E2", "PROTEIN", 146, 148], ["capsid", "PROTEIN", 154, 160], ["four non-structural proteins", "TEST", 70, 98], ["nsp1", "TEST", 100, 104], ["nsp4", "TEST", 105, 109], ["positive", "OBSERVATION_MODIFIER", 4, 12]]], ["Although lethal human infections are rare, acute encephalitis can develop after exposure.", [["human infections", "DISEASE", 16, 32], ["encephalitis", "DISEASE", 49, 61], ["human", "ORGANISM", 16, 21], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["lethal human infections", "PROBLEM", 9, 32], ["acute encephalitis", "PROBLEM", 43, 61], ["infections", "OBSERVATION", 22, 32], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["encephalitis", "OBSERVATION", 49, 61]]], ["VEEV can also be easily transmitted by aerosol, and is considered a possible agent of bioterrorism.", [["VEEV", "DISEASE", 0, 4], ["VEEV", "ORGANISM", 0, 4], ["VEEV", "SPECIES", 0, 4], ["VEEV", "PROBLEM", 0, 4], ["bioterrorism", "PROBLEM", 86, 98], ["bioterrorism", "OBSERVATION", 86, 98]]], ["There is currently no licensed vaccine or antiviral therapy for human use.Alphaviruses ::: Antisense and siRNA as antiviral therapeuticssiRNAs against nsp1, nsp4, and E1 have been investigated for the ability to inhibit VEEV replication in vitro (O\u2019Brien, 2007).", [["human", "ORGANISM", 64, 69], ["nsp1", "GENE_OR_GENE_PRODUCT", 151, 155], ["nsp4", "GENE_OR_GENE_PRODUCT", 157, 161], ["E1", "GENE_OR_GENE_PRODUCT", 167, 169], ["VEEV", "ORGANISM", 220, 224], ["nsp1", "PROTEIN", 151, 155], ["nsp4", "PROTEIN", 157, 161], ["E1", "DNA", 167, 169], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["VEEV", "SPECIES", 220, 224], ["licensed vaccine", "TREATMENT", 22, 38], ["antiviral therapy", "TREATMENT", 42, 59], ["Antisense", "TREATMENT", 91, 100], ["siRNA", "TREATMENT", 105, 110], ["antiviral therapeuticssiRNAs", "TREATMENT", 114, 142], ["nsp1", "PROBLEM", 151, 155], ["nsp4", "PROBLEM", 157, 161], ["no", "UNCERTAINTY", 19, 21], ["antiviral therapy", "OBSERVATION", 42, 59]]], ["Four individual siRNAs were designed to target sequences in these genes conserved in six VEEV strains.", [["VEEV", "ORGANISM", 89, 93], ["VEEV", "SPECIES", 89, 93], ["Four individual siRNAs", "PROBLEM", 0, 22], ["siRNAs", "OBSERVATION", 16, 22]]], ["When a pool of all four siRNAs was transfected into BHK 21 cells (defective for IFN production), antiviral activity was observed against all VEEV strains tested.", [["BHK 21 cells", "ANATOMY", 52, 64], ["BHK 21 cells", "CELL", 52, 64], ["IFN", "GENE_OR_GENE_PRODUCT", 80, 83], ["VEEV", "ORGANISM", 141, 145], ["BHK 21 cells", "CELL_LINE", 52, 64], ["IFN", "PROTEIN", 80, 83], ["BHK", "SPECIES", 52, 55], ["VEEV", "SPECIES", 141, 145], ["all four siRNAs", "TREATMENT", 15, 30], ["IFN production", "TREATMENT", 80, 94], ["antiviral activity", "TREATMENT", 97, 115], ["all VEEV strains", "PROBLEM", 137, 153]]], ["Although the inhibition of viral replication was only transient, this study raises the possibility that pools of siRNAs could be used to target multiple genetic strains of a particular virus.SARS-associated coronavirus (SARS Co-V) ::: Antisense and siRNA as antiviral therapeuticsSARS emerged as an atypical pneumonia in Guangdong Province, China, in late 2002, then quickly spread to southeast Asia and North America, eventually appearing in more than 30 countries and causing more than 800 deaths (Satija and Lal, 2007).", [["SARS", "DISEASE", 191, 195], ["SARS", "DISEASE", 280, 284], ["pneumonia", "DISEASE", 308, 317], ["deaths", "DISEASE", 492, 498], ["coronavirus", "ORGANISM", 207, 218], ["viral replication", "PROBLEM", 27, 44], ["this study", "TEST", 65, 75], ["pools of siRNAs", "PROBLEM", 104, 119], ["a particular virus", "PROBLEM", 172, 190], ["SARS", "PROBLEM", 191, 195], ["coronavirus", "PROBLEM", 207, 218], ["Antisense and siRNA", "TREATMENT", 235, 254], ["antiviral therapeutics", "TREATMENT", 258, 280], ["an atypical pneumonia", "PROBLEM", 296, 317], ["viral replication", "OBSERVATION", 27, 44], ["raises the possibility", "UNCERTAINTY", 76, 98], ["siRNA", "ANATOMY", 249, 254], ["atypical", "OBSERVATION_MODIFIER", 299, 307], ["pneumonia", "OBSERVATION", 308, 317]]], ["Death occurred in approximately 3\u201310% of infected individuals following flu-like symptoms, which included fever, malaise and dry cough, leading to acute respiratory distress with diffuse alveolar damage.", [["respiratory", "ANATOMY", 153, 164], ["alveolar", "ANATOMY", 187, 195], ["Death", "DISEASE", 0, 5], ["flu-like symptoms", "DISEASE", 72, 89], ["fever", "DISEASE", 106, 111], ["dry cough", "DISEASE", 125, 134], ["respiratory distress", "DISEASE", 153, 173], ["alveolar damage", "DISEASE", 187, 202], ["alveolar", "MULTI-TISSUE_STRUCTURE", 187, 195], ["Death", "PROBLEM", 0, 5], ["infected individuals", "PROBLEM", 41, 61], ["flu-like symptoms", "PROBLEM", 72, 89], ["fever", "PROBLEM", 106, 111], ["malaise", "PROBLEM", 113, 120], ["dry cough", "PROBLEM", 125, 134], ["acute respiratory distress", "PROBLEM", 147, 173], ["diffuse alveolar damage", "PROBLEM", 179, 202], ["cough", "OBSERVATION", 129, 134], ["acute", "OBSERVATION_MODIFIER", 147, 152], ["respiratory", "ANATOMY", 153, 164], ["distress", "OBSERVATION", 165, 173], ["diffuse", "OBSERVATION_MODIFIER", 179, 186], ["alveolar damage", "OBSERVATION", 187, 202]]], ["An intensive research effort identified a novel coronavirus (SARS Co-V) as the causative agent of SARS (Drosten et al., 2003, Peiris et al., 2003, Rota et al., 2003).SARS-associated coronavirus (SARS Co-V) ::: Antisense and siRNA as antiviral therapeuticsLike other coronaviruses, the RNA genome of SARS Co-V is large (\u223c30 kb), single-stranded, in the positive sense orientation, capped, and polyadenylated.", [["SARS", "DISEASE", 98, 102], ["SARS", "DISEASE", 166, 170], ["coronavirus", "ORGANISM", 48, 59], ["Co-V", "GENE_OR_GENE_PRODUCT", 66, 70], ["coronavirus", "ORGANISM", 182, 193], ["Co-V", "GENE_OR_GENE_PRODUCT", 304, 308], ["RNA genome", "DNA", 285, 295], ["SARS Co-V", "DNA", 299, 308], ["a novel coronavirus", "PROBLEM", 40, 59], ["SARS", "PROBLEM", 98, 102], ["SARS", "PROBLEM", 166, 170], ["coronavirus", "PROBLEM", 182, 193], ["Antisense and siRNA", "TREATMENT", 210, 229], ["antiviral therapeutics", "TREATMENT", 233, 255], ["other coronaviruses", "PROBLEM", 260, 279], ["SARS Co", "TEST", 299, 306], ["coronaviruses", "OBSERVATION", 266, 279], ["large", "OBSERVATION_MODIFIER", 312, 317]]], ["Neuman et al. (2005) describe the design and testing of peptide-conjugated PMOs complementary to several regions of the SARS Co-V genome.", [["PMOs", "SIMPLE_CHEMICAL", 75, 79], ["Co-V", "GENE_OR_GENE_PRODUCT", 125, 129], ["PMOs", "PROTEIN", 75, 79], ["SARS Co-V genome", "DNA", 120, 136], ["peptide-conjugated PMOs", "TREATMENT", 56, 79], ["the SARS Co-V genome", "PROBLEM", 116, 136], ["SARS", "OBSERVATION", 120, 124], ["V genome", "OBSERVATION", 128, 136]]], ["These targeted regions include the AUG start codon of the replicase gene (orf 1a/1b), the orf 1b ribosomal frameshift point, the 5\u2032 UTR transcription regulatory sequence (TRS), and the 3\u2032 UTR.", [["orf 1a/1b", "GENE_OR_GENE_PRODUCT", 74, 83], ["orf 1b", "GENE_OR_GENE_PRODUCT", 90, 96], ["AUG start codon", "DNA", 35, 50], ["replicase gene", "DNA", 58, 72], ["orf 1a/1b", "DNA", 74, 83], ["orf 1b ribosomal frameshift point", "DNA", 90, 123], ["UTR transcription regulatory sequence", "DNA", 132, 169], ["TRS", "DNA", 171, 174], ["UTR", "DNA", 188, 191], ["UTR transcription regulatory sequence", "TEST", 132, 169], ["ribosomal frameshift", "OBSERVATION", 97, 117]]], ["PMOs TRS1 and TRS2 were designed to target the TRS consensus sequence and disrupt secondary structure formed at this point in the genome.", [["TRS1", "GENE_OR_GENE_PRODUCT", 5, 9], ["TRS2", "GENE_OR_GENE_PRODUCT", 14, 18], ["genome", "CELLULAR_COMPONENT", 130, 136], ["PMOs", "PROTEIN", 0, 4], ["TRS1", "PROTEIN", 5, 9], ["TRS2", "DNA", 14, 18], ["TRS consensus sequence", "DNA", 47, 69], ["PMOs TRS1", "TEST", 0, 9], ["TRS2", "TEST", 14, 18], ["the TRS consensus sequence", "TEST", 43, 69], ["genome", "ANATOMY", 130, 136]]], ["Vero cells were treated with PMOs and then infected with SARS Co-V.", [["Vero cells", "ANATOMY", 0, 10], ["PMOs", "CHEMICAL", 29, 33], ["Vero cells", "CELL", 0, 10], ["PMOs", "SIMPLE_CHEMICAL", 29, 33], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["PMOs", "TREATMENT", 29, 33], ["SARS Co", "TEST", 57, 64]]], ["TRS1 and TRS2, more so than other tested PMOs, reduced the cytopathic effects of viral infection, reduced viral yield and viral spread, and inhibited viral genomic RNA synthesis.SARS-associated coronavirus (SARS Co-V) ::: Antisense and siRNA as antiviral therapeuticsA number of preclinical studies have been completed investigating the ability of siRNAs to prevent SARS Co-V replication and cytopathic effects, and were recently reviewed (Wu and Chan, 2006).", [["viral infection", "DISEASE", 81, 96], ["SARS", "DISEASE", 178, 182], ["PMOs", "CHEMICAL", 41, 45], ["TRS1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TRS2", "GENE_OR_GENE_PRODUCT", 9, 13], ["PMOs", "GENE_OR_GENE_PRODUCT", 41, 45], ["coronavirus", "ORGANISM", 194, 205], ["Co-V", "GENE_OR_GENE_PRODUCT", 371, 375], ["TRS1", "PROTEIN", 0, 4], ["TRS2", "PROTEIN", 9, 13], ["viral genomic RNA", "RNA", 150, 167], ["TRS1", "TEST", 0, 4], ["TRS2", "TEST", 9, 13], ["viral infection", "PROBLEM", 81, 96], ["reduced viral yield", "PROBLEM", 98, 117], ["viral spread", "PROBLEM", 122, 134], ["viral genomic RNA synthesis", "PROBLEM", 150, 177], ["SARS", "PROBLEM", 178, 182], ["coronavirus", "PROBLEM", 194, 205], ["Antisense and siRNA", "TREATMENT", 222, 241], ["antiviral therapeutics", "TREATMENT", 245, 267], ["preclinical studies", "TEST", 279, 298], ["siRNAs", "TREATMENT", 348, 354], ["SARS Co-V replication", "PROBLEM", 366, 387], ["cytopathic effects", "PROBLEM", 392, 410], ["cytopathic", "OBSERVATION_MODIFIER", 59, 69], ["viral infection", "OBSERVATION", 81, 96], ["viral spread", "OBSERVATION", 122, 134], ["viral genomic RNA synthesis", "OBSERVATION", 150, 177], ["cytopathic", "OBSERVATION_MODIFIER", 392, 402]]], ["These experiments, which targeted several regions of the SARS Co-V genome, demonstrated that siRNAs, or shRNAs, can reduce target gene expression, viral RNA levels, and viral yield.", [["Co-V", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS Co-V genome", "DNA", 57, 73], ["siRNAs", "DNA", 93, 99], ["shRNAs", "DNA", 104, 110], ["the SARS Co-V genome", "PROBLEM", 53, 73], ["siRNAs", "PROBLEM", 93, 99], ["shRNAs", "PROBLEM", 104, 110], ["viral RNA levels", "TEST", 147, 163], ["siRNAs", "OBSERVATION", 93, 99]]], ["Zheng et al. (2004) conducted an initial in vitro screen of 48 siRNAs covering the entire SARS Co-V genome that identified two promising siRNAs targeting the spike protein-coding region and the NSP12 region.", [["NSP12", "GENE_OR_GENE_PRODUCT", 194, 199], ["SARS Co-V genome", "DNA", 90, 106], ["spike protein-coding region", "DNA", 158, 185], ["NSP12 region", "DNA", 194, 206], ["an initial in vitro screen", "TEST", 30, 56], ["siRNAs", "PROBLEM", 63, 69], ["the entire SARS Co-V genome", "PROBLEM", 79, 106], ["promising siRNAs", "OBSERVATION", 127, 143]]], ["These siRNAs were further evaluated in vivo. siRNAs were administered in combination, intranasally, to rhesus macaques before, during, or after intranasal challenge with SARS Co-V (Li et al., 2005a).", [["intranasally", "ANATOMY", 86, 98], ["rhesus", "ORGANISM", 103, 109], ["macaques", "ORGANISM", 110, 118], ["rhesus macaques", "SPECIES", 103, 118], ["rhesus macaques", "SPECIES", 103, 118], ["These siRNAs", "TREATMENT", 0, 12], ["siRNAs", "TREATMENT", 45, 51], ["siRNAs", "OBSERVATION", 6, 12]]], ["Each siRNA treatment regimen successfully repressed viral replication and spread in the lungs, and prevented the development of clinical signs of SARS.", [["lungs", "ANATOMY", 88, 93], ["SARS", "DISEASE", 146, 150], ["lungs", "ORGAN", 88, 93], ["Each siRNA treatment regimen", "TREATMENT", 0, 28], ["viral replication", "TREATMENT", 52, 69], ["SARS", "PROBLEM", 146, 150], ["viral replication", "OBSERVATION", 52, 69], ["lungs", "ANATOMY", 88, 93]]], ["Although siRNA treatment did not completely eliminate the presence of SARS Co-V, efficacy was demonstrated by reduced viral loads in oropharyngeal swabs and lung tissue sections, less severe diffuse alveolar damage and diminished fever with no treatment-associated toxicities or safety concerns (Li et al., 2005a).Influenza A ::: Antisense and siRNA as antiviral therapeuticsInfluenza A viruses contain eight segments of single-stranded, negative sense genomic RNA which code for 11 known proteins (Cheung and Poon, 2007).", [["oropharyngeal swabs", "ANATOMY", 133, 152], ["lung tissue sections", "ANATOMY", 157, 177], ["alveolar", "ANATOMY", 199, 207], ["alveolar damage", "DISEASE", 199, 214], ["fever", "DISEASE", 230, 235], ["toxicities", "DISEASE", 265, 275], ["Influenza", "DISEASE", 314, 323], ["Co-V", "GENE_OR_GENE_PRODUCT", 75, 79], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 133, 152], ["lung tissue sections", "MULTI-TISSUE_STRUCTURE", 157, 177], ["alveolar", "TISSUE", 199, 207], ["Influenza A viruses", "ORGANISM", 375, 394], ["single-stranded, negative sense genomic RNA", "RNA", 421, 464], ["Influenza A viruses", "SPECIES", 375, 394], ["siRNA treatment", "TREATMENT", 9, 24], ["SARS Co-V", "PROBLEM", 70, 79], ["reduced viral loads in oropharyngeal swabs", "PROBLEM", 110, 152], ["lung tissue sections", "TEST", 157, 177], ["less severe diffuse alveolar damage", "PROBLEM", 179, 214], ["diminished fever", "PROBLEM", 219, 235], ["associated toxicities", "PROBLEM", 254, 275], ["Influenza", "PROBLEM", 314, 323], ["Antisense and siRNA", "TREATMENT", 330, 349], ["antiviral therapeutics", "TREATMENT", 353, 375], ["Influenza", "PROBLEM", 375, 384], ["reduced", "OBSERVATION_MODIFIER", 110, 117], ["viral loads", "OBSERVATION", 118, 129], ["oropharyngeal swabs", "ANATOMY", 133, 152], ["lung tissue", "ANATOMY", 157, 168], ["less", "OBSERVATION_MODIFIER", 179, 183], ["severe", "OBSERVATION_MODIFIER", 184, 190], ["diffuse", "OBSERVATION_MODIFIER", 191, 198], ["alveolar damage", "OBSERVATION", 199, 214], ["diminished", "OBSERVATION_MODIFIER", 219, 229], ["fever", "OBSERVATION", 230, 235], ["eight segments", "OBSERVATION_MODIFIER", 403, 417], ["genomic RNA", "OBSERVATION", 453, 464]]], ["Multiple subtypes of influenza A virus exist based on antigenic variation of envelope-associated hemagglutinin (HA) and neuramidase (NA) proteins (i.e., H1N1, H3N2 and H5N1).", [["influenza A virus", "DISEASE", 21, 38], ["influenza A virus", "ORGANISM", 21, 38], ["envelope-associated hemagglutinin", "GENE_OR_GENE_PRODUCT", 77, 110], ["neuramidase (NA) proteins", "GENE_OR_GENE_PRODUCT", 120, 145], ["H5N1", "ORGANISM", 168, 172], ["envelope-associated hemagglutinin (HA) and neuramidase (NA) proteins", "PROTEIN", 77, 145], ["influenza A virus", "SPECIES", 21, 38], ["H5N1", "SPECIES", 168, 172], ["influenza A virus", "SPECIES", 21, 38], ["influenza A virus", "PROBLEM", 21, 38], ["antigenic variation", "TEST", 54, 73], ["envelope", "TEST", 77, 85], ["associated hemagglutinin (HA)", "PROBLEM", 86, 115], ["neuramidase (NA) proteins", "TEST", 120, 145], ["H1N1", "PROBLEM", 153, 157], ["H3N2", "PROBLEM", 159, 163], ["H5N1", "PROBLEM", 168, 172], ["influenza", "OBSERVATION", 21, 30]]], ["While vaccines can protect individuals from specific viral subtypes, the emergence of novel strains poses the risk of deadly pandemic (Johnson and Mueller, 2002).", [["vaccines", "TREATMENT", 6, 14], ["specific viral subtypes", "PROBLEM", 44, 67], ["viral subtypes", "OBSERVATION", 53, 67]]], ["H5N1 is a highly virulent avian influenza virus that can also infect humans.", [["H5N1", "DISEASE", 0, 4], ["avian influenza virus", "DISEASE", 26, 47], ["H5N1", "ORGANISM", 0, 4], ["avian influenza virus", "ORGANISM", 26, 47], ["humans", "ORGANISM", 69, 75], ["H5N1", "SPECIES", 0, 4], ["avian influenza virus", "SPECIES", 26, 47], ["humans", "SPECIES", 69, 75], ["avian influenza virus", "SPECIES", 26, 47], ["humans", "SPECIES", 69, 75], ["H5N1", "PROBLEM", 0, 4], ["a highly virulent avian influenza virus", "PROBLEM", 8, 47]]], ["Currently, the virus does not spread easily from person to person.", [["person", "SPECIES", 49, 55], ["person", "SPECIES", 59, 65], ["the virus", "PROBLEM", 11, 20], ["virus", "OBSERVATION", 15, 20]]], ["With the acquisition of this ability, the consequences of an influenza H5N1 pandemic could be truly devastating.Influenza A ::: Antisense and siRNA as antiviral therapeuticsSince the mid-1990s, ASOs have been investigated as potential therapies for influenza A virus infection.", [["influenza H5N1 pandemic", "DISEASE", 61, 84], ["Influenza", "DISEASE", 112, 121], ["influenza A virus infection", "DISEASE", 249, 276], ["influenza H5N1", "ORGANISM", 61, 75], ["influenza A virus", "ORGANISM", 249, 266], ["influenza H5N1 pandemic", "SPECIES", 61, 84], ["influenza A virus", "SPECIES", 249, 266], ["influenza A virus", "SPECIES", 249, 266], ["an influenza H5N1 pandemic", "PROBLEM", 58, 84], ["Influenza", "PROBLEM", 112, 121], ["Antisense and siRNA", "TREATMENT", 128, 147], ["antiviral therapeutics", "TREATMENT", 151, 173], ["ASOs", "TREATMENT", 194, 198], ["potential therapies", "TREATMENT", 225, 244], ["influenza A virus infection", "PROBLEM", 249, 276]]], ["Antisense phosphodiester and phosphorothioate oligos can successfully decrease expression of viral proteins PB2 and PA in cell culture (Hatta et al., 1996, Hatta et al., 1997).", [["cell culture", "ANATOMY", 122, 134], ["phosphodiester", "CHEMICAL", 10, 24], ["phosphorothioate", "CHEMICAL", 29, 45], ["phosphodiester", "CHEMICAL", 10, 24], ["phosphorothioate", "CHEMICAL", 29, 45], ["phosphodiester", "SIMPLE_CHEMICAL", 10, 24], ["phosphorothioate oligos", "SIMPLE_CHEMICAL", 29, 52], ["PB2", "GENE_OR_GENE_PRODUCT", 108, 111], ["PA", "GENE_OR_GENE_PRODUCT", 116, 118], ["cell", "CELL", 122, 126], ["viral proteins", "PROTEIN", 93, 107], ["PB2", "PROTEIN", 108, 111], ["Antisense phosphodiester and phosphorothioate oligos", "TREATMENT", 0, 52], ["viral proteins PB2", "TEST", 93, 111], ["PA in cell culture", "TEST", 116, 134]]], ["Phosphorothioate oligos targeting PB2 have also shown efficacy in vivo.", [["Phosphorothioate", "CHEMICAL", 0, 16], ["Phosphorothioate", "CHEMICAL", 0, 16], ["PB2", "GENE_OR_GENE_PRODUCT", 34, 37], ["PB2", "DNA", 34, 37], ["Phosphorothioate oligos targeting PB2", "TREATMENT", 0, 37]]], ["Lipid encapsulated ASOs targeting the AUG start codon of PB2, given IV, protected mice from lethal challenge with influenza A/PR/8/34 (Mizuta et al., 1999).", [["ASOs", "CHEMICAL", 19, 23], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["ASOs", "SIMPLE_CHEMICAL", 19, 23], ["mice", "ORGANISM", 82, 86], ["AUG start codon", "DNA", 38, 53], ["PB2", "DNA", 57, 60], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["influenza A/PR/8/34", "SPECIES", 114, 133], ["Lipid encapsulated ASOs", "TREATMENT", 0, 23], ["codon of PB2", "TREATMENT", 48, 60], ["IV", "TREATMENT", 68, 70], ["influenza", "PROBLEM", 114, 123]]], ["This treatment effectively reduced viral RNA levels in mouse lung, decreased viral titers in the lung, and limited damage to lung tissue.", [["lung", "ANATOMY", 61, 65], ["lung", "ANATOMY", 97, 101], ["lung tissue", "ANATOMY", 125, 136], ["mouse", "ORGANISM", 55, 60], ["lung", "ORGAN", 61, 65], ["lung", "ORGAN", 97, 101], ["lung tissue", "TISSUE", 125, 136], ["mouse", "SPECIES", 55, 60], ["mouse", "SPECIES", 55, 60], ["This treatment", "TREATMENT", 0, 14], ["reduced viral RNA levels in mouse lung", "PROBLEM", 27, 65], ["decreased viral titers in the lung", "PROBLEM", 67, 101], ["limited damage to lung tissue", "PROBLEM", 107, 136], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["viral RNA levels", "OBSERVATION", 35, 51], ["lung", "ANATOMY", 61, 65], ["decreased", "OBSERVATION_MODIFIER", 67, 76], ["viral titers", "OBSERVATION", 77, 89], ["lung", "ANATOMY", 97, 101], ["damage", "OBSERVATION", 115, 121], ["lung", "ANATOMY", 125, 129], ["tissue", "OBSERVATION", 130, 136]]], ["More recently, it was reported that 2\u2032-O-methyl-modified ASOs targeting NS1, delivered intranasally, protected chickens from lethal H5N1 infection (Wu et al., 2008).", [["intranasally", "ANATOMY", 87, 99], ["2\u2032-O-methyl", "CHEMICAL", 36, 47], ["H5N1 infection", "DISEASE", 132, 146], ["2\u2032-O-methyl", "CHEMICAL", 36, 47], ["2\u2032-O-methyl-modified ASOs", "SIMPLE_CHEMICAL", 36, 61], ["NS1", "GENE_OR_GENE_PRODUCT", 72, 75], ["chickens", "ORGANISM", 111, 119], ["lethal H5N1", "ORGANISM", 125, 136], ["NS1", "PROTEIN", 72, 75], ["chickens", "SPECIES", 111, 119], ["chickens", "SPECIES", 111, 119], ["methyl-modified ASOs targeting NS1", "TREATMENT", 41, 75], ["lethal H5N1 infection", "PROBLEM", 125, 146], ["lethal", "OBSERVATION_MODIFIER", 125, 131], ["H5N1", "OBSERVATION_MODIFIER", 132, 136], ["infection", "OBSERVATION", 137, 146]]], ["PMOs have also been designed and found to inhibit multiple strains of influenza A virus (Ge et al., 2006).", [["PMOs", "CHEMICAL", 0, 4], ["influenza A virus", "DISEASE", 70, 87], ["PMOs", "CHEMICAL", 0, 4], ["PMOs", "SIMPLE_CHEMICAL", 0, 4], ["influenza A virus", "ORGANISM", 70, 87], ["influenza A virus", "SPECIES", 70, 87], ["influenza A virus", "SPECIES", 70, 87], ["influenza A virus", "PROBLEM", 70, 87], ["influenza", "OBSERVATION", 70, 79]]], ["Peptide-conjugated PMOs (P-PMOs) were designed to bind to the AUG start codon region of four genes (PA, PB1, PB2, and NP).", [["PMOs", "CHEMICAL", 19, 23], ["P-PMOs", "CHEMICAL", 25, 31], ["PMOs", "CHEMICAL", 19, 23], ["Peptide-conjugated PMOs", "SIMPLE_CHEMICAL", 0, 23], ["P-PMOs", "SIMPLE_CHEMICAL", 25, 31], ["PA", "GENE_OR_GENE_PRODUCT", 100, 102], ["PB1", "GENE_OR_GENE_PRODUCT", 104, 107], ["PB2", "GENE_OR_GENE_PRODUCT", 109, 112], ["NP", "GENE_OR_GENE_PRODUCT", 118, 120], ["P", "PROTEIN", 25, 26], ["PMOs", "PROTEIN", 27, 31], ["AUG start codon region", "DNA", 62, 84], ["PA", "DNA", 100, 102], ["PB1", "DNA", 104, 107], ["PB2", "DNA", 109, 112], ["NP", "DNA", 118, 120], ["Peptide-conjugated PMOs", "TREATMENT", 0, 23], ["PB2", "TREATMENT", 109, 112]]], ["Additional P-PMOs were designed to target four terminal regions of the NP gene, which should interrupt viral RNA/RNA interactions required for RNA synthesis.", [["P-PMOs", "SIMPLE_CHEMICAL", 11, 17], ["NP", "GENE_OR_GENE_PRODUCT", 71, 73], ["P-PMOs", "DNA", 11, 17], ["terminal regions", "DNA", 47, 63], ["NP gene", "DNA", 71, 78], ["viral RNA", "RNA", 103, 112], ["Additional P-PMOs", "TREATMENT", 0, 17], ["the NP gene", "TREATMENT", 67, 78], ["viral RNA/RNA interactions", "TREATMENT", 103, 129], ["RNA synthesis", "TREATMENT", 143, 156], ["NP gene", "OBSERVATION", 71, 78]]], ["Six of eight P-PMOs successfully inhibited H1N1 production in Vero cells.", [["Vero cells", "ANATOMY", 62, 72], ["P-PMOs", "CHEMICAL", 13, 19], ["H1N1", "DISEASE", 43, 47], ["P-PMOs", "CHEMICAL", 13, 19], ["P-PMOs", "SIMPLE_CHEMICAL", 13, 19], ["Vero cells", "CELL", 62, 72], ["P", "DNA", 13, 14], ["Vero cells", "CELL_LINE", 62, 72], ["H1N1 production in Vero cells", "PROBLEM", 43, 72], ["H1N1", "OBSERVATION", 43, 47], ["Vero cells", "OBSERVATION", 62, 72]]], ["Based on these results, two P-PMOs were tested for activity against a panel of influenza A subtypes, including the highly pathogenic H5N1.", [["H5N1", "DISEASE", 133, 137], ["P-PMOs", "SIMPLE_CHEMICAL", 28, 34], ["influenza A", "ORGANISM", 79, 90], ["H5N1", "ORGANISM", 133, 137], ["P", "DNA", 28, 29], ["influenza A", "SPECIES", 79, 90], ["two P-PMOs", "TEST", 24, 34], ["influenza A subtypes", "PROBLEM", 79, 99], ["the highly pathogenic H5N1", "PROBLEM", 111, 137], ["influenza", "OBSERVATION", 79, 88], ["pathogenic", "OBSERVATION_MODIFIER", 122, 132], ["H5N1", "OBSERVATION", 133, 137]]], ["Notably, pretreatment with P-PMOs targeting the start codon of PB1, or the terminal region of NP, effectively inhibited H5N1 growth in MDCK cells.", [["MDCK cells", "ANATOMY", 135, 145], ["P-PMOs", "CHEMICAL", 27, 33], ["P-PMOs", "SIMPLE_CHEMICAL", 27, 33], ["PB1", "GENE_OR_GENE_PRODUCT", 63, 66], ["MDCK cells", "CELL", 135, 145], ["P-PMOs", "DNA", 27, 33], ["start codon", "DNA", 48, 59], ["PB1", "DNA", 63, 66], ["terminal region", "DNA", 75, 90], ["NP", "DNA", 94, 96], ["MDCK cells", "CELL_LINE", 135, 145], ["H5N1", "SPECIES", 120, 124], ["P-PMOs", "TREATMENT", 27, 33], ["the start codon of PB1", "TREATMENT", 44, 66], ["H5N1 growth in MDCK cells", "PROBLEM", 120, 145], ["terminal", "ANATOMY_MODIFIER", 75, 83], ["NP", "ANATOMY", 94, 96], ["MDCK cells", "OBSERVATION", 135, 145]]], ["Postinfection protocols also showed some success (Ge et al., 2006).Influenza A ::: Antisense and siRNA as antiviral therapeuticsInfluenza A-specific siRNAs have proven efficacious in mice.", [["Influenza", "DISEASE", 67, 76], ["mice", "ORGANISM", 183, 187], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["Postinfection protocols", "TEST", 0, 23], ["Influenza", "PROBLEM", 67, 76], ["Antisense and siRNA", "TREATMENT", 83, 102], ["antiviral therapeutics", "TREATMENT", 106, 128], ["Influenza A-specific siRNAs", "TREATMENT", 128, 155]]], ["In a protocol that preferentially delivers nucleic acids to the lung, siRNAs specific for NP and PA (Ge et al., 2004), or shRNAs targeting NP and M2 (Zhou et al., 2007) were administered intravenously in complex with a cationic polymer (PEI).", [["lung", "ANATOMY", 64, 68], ["intravenously", "ANATOMY", 187, 200], ["nucleic acids", "CHEMICAL", 43, 56], ["PEI", "CHEMICAL", 237, 240], ["PEI", "CHEMICAL", 237, 240], ["lung", "ORGAN", 64, 68], ["PA", "GENE_OR_GENE_PRODUCT", 97, 99], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 200], ["PEI", "SIMPLE_CHEMICAL", 237, 240], ["a protocol", "TREATMENT", 3, 13], ["nucleic acids", "TREATMENT", 43, 56], ["NP", "TEST", 90, 92], ["a cationic polymer (PEI", "TREATMENT", 217, 240], ["lung", "ANATOMY", 64, 68]]], ["In both studies, siRNA or shRNA treatment reduced viral titers in lung tissue. shRNAs against NP and M2 also increased survival in mice infected with influenza A strains H1N1 or H5N1.", [["lung tissue", "ANATOMY", 66, 77], ["H5N1", "DISEASE", 178, 182], ["lung tissue", "TISSUE", 66, 77], ["NP", "GENE_OR_GENE_PRODUCT", 94, 96], ["M2", "GENE_OR_GENE_PRODUCT", 101, 103], ["mice", "ORGANISM", 131, 135], ["influenza A strains H1N1", "ORGANISM", 150, 174], ["H5N1", "ORGANISM", 178, 182], ["mice", "SPECIES", 131, 135], ["H5N1", "SPECIES", 178, 182], ["mice", "SPECIES", 131, 135], ["siRNA", "PROBLEM", 17, 22], ["shRNA treatment", "TREATMENT", 26, 41], ["reduced viral titers in lung tissue", "PROBLEM", 42, 77], ["NP", "PROBLEM", 94, 96], ["influenza A strains H1N1", "PROBLEM", 150, 174], ["H5N1", "PROBLEM", 178, 182], ["siRNA", "ANATOMY", 17, 22], ["viral titers", "OBSERVATION", 50, 62], ["lung", "ANATOMY", 66, 70], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["survival", "OBSERVATION_MODIFIER", 119, 127]]], ["Another group also has demonstrated that siRNAs targeting PA and NP can reduce influenza A virus production in the lungs of infected mice and increase survival (Tompkins et al., 2004).", [["lungs", "ANATOMY", 115, 120], ["PA", "GENE_OR_GENE_PRODUCT", 58, 60], ["NP", "GENE_OR_GENE_PRODUCT", 65, 67], ["influenza A virus", "ORGANISM", 79, 96], ["lungs", "ORGAN", 115, 120], ["mice", "ORGANISM", 133, 137], ["mice", "SPECIES", 133, 137], ["influenza A virus", "SPECIES", 79, 96], ["mice", "SPECIES", 133, 137], ["siRNAs targeting PA", "TREATMENT", 41, 60], ["influenza", "PROBLEM", 79, 88], ["A virus production", "PROBLEM", 89, 107], ["siRNAs", "OBSERVATION", 41, 47], ["influenza", "OBSERVATION", 79, 88], ["virus", "OBSERVATION", 91, 96], ["lungs", "ANATOMY", 115, 120], ["infected", "OBSERVATION", 124, 132], ["increase", "OBSERVATION_MODIFIER", 142, 150], ["survival", "OBSERVATION_MODIFIER", 151, 159]]], ["Combination treatment with PA and NP siRNAs provided 100% protection from lethal challenge.", [["PA", "GENE_OR_GENE_PRODUCT", 27, 29], ["PA and NP siRNAs", "TREATMENT", 27, 43], ["lethal challenge", "TREATMENT", 74, 90]]], ["Importantly, this same antiviral activity was seen against multiple strains of influenza A, including H5N1.", [["influenza A", "DISEASE", 79, 90], ["H5N1", "DISEASE", 102, 106], ["influenza A", "ORGANISM", 79, 90], ["H5N1", "ORGANISM", 102, 106], ["influenza A", "SPECIES", 79, 90], ["influenza A", "PROBLEM", 79, 90], ["H5N1", "PROBLEM", 102, 106], ["antiviral activity", "OBSERVATION", 23, 41], ["influenza", "OBSERVATION", 79, 88]]], ["IFN-\u03b1 was not detected in serum or lung tissue homogenates from mice treated with siRNA; evidence that the observed antiviral effect is not due to IFN production.", [["serum", "ANATOMY", 26, 31], ["lung tissue homogenates", "ANATOMY", 35, 58], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["lung tissue homogenates", "ORGANISM_SUBSTANCE", 35, 58], ["mice", "ORGANISM", 64, 68], ["IFN", "GENE_OR_GENE_PRODUCT", 147, 150], ["IFN", "PROTEIN", 0, 3], ["\u03b1", "PROTEIN", 4, 5], ["IFN", "PROTEIN", 147, 150], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["IFN", "TEST", 0, 3], ["siRNA", "TREATMENT", 82, 87], ["the observed antiviral effect", "PROBLEM", 103, 132], ["IFN production", "PROBLEM", 147, 161], ["lung", "ANATOMY", 35, 39], ["antiviral effect", "OBSERVATION", 116, 132]]], ["For additional information on treating seasonal and avian influenza, see the review by Beigel and Bray (2008).ConclusionBased on preclinical studies, antisense and siRNA-based antiviral compounds appear to hold a great deal of promise and will increasingly find their way through the FDA approval process and into the clinic.", [["influenza", "DISEASE", 58, 67], ["avian", "SPECIES", 52, 57], ["seasonal and avian influenza", "PROBLEM", 39, 67], ["preclinical studies", "TEST", 129, 148], ["antisense and siRNA", "TREATMENT", 150, 169], ["antiviral compounds", "TREATMENT", 176, 195]]], ["However, delivery remains a significant challenge.", [["delivery", "TREATMENT", 9, 17]]], ["As mentioned, the only FDA-approved ASO drug is administered locally.", [["ASO", "SIMPLE_CHEMICAL", 36, 39], ["ASO drug", "TREATMENT", 36, 44]]], ["A recent report of peptide-mediated, organ-specific delivery of siRNA after systemic administration is an important advance.", [["organ", "ANATOMY", 37, 42], ["organ", "ORGAN", 37, 42], ["siRNA", "TREATMENT", 64, 69], ["systemic administration", "TREATMENT", 76, 99], ["organ", "ANATOMY", 37, 42]]], ["Such delivery methods have the potential to increase the efficacy of many ASO and siRNA compounds.", [["ASO", "SIMPLE_CHEMICAL", 74, 77], ["Such delivery methods", "TREATMENT", 0, 21], ["many ASO and siRNA compounds", "PROBLEM", 69, 97]]], ["The development of systemic and postexposure treatment regimens will be critical for the successful and widespread use of these compounds.", [["systemic and postexposure treatment regimens", "TREATMENT", 19, 63], ["these compounds", "TREATMENT", 122, 137], ["systemic", "OBSERVATION_MODIFIER", 19, 27]]], ["Further, we expect the efficacy of these drug candidates to improve as ASO and siRNA design rules become even better understood and entire viral genomes are systematically screened for appropriate targets.", [["viral genomes", "DNA", 139, 152], ["these drug candidates", "TREATMENT", 35, 56], ["ASO", "TREATMENT", 71, 74], ["siRNA design rules", "PROBLEM", 79, 97], ["entire viral genomes", "PROBLEM", 132, 152]]]], "0759bf9448d42d717fa28615accff93c62a92b61": [["Data Usage and PreprocessingWe used the county-level cumulative and daily death reporting from the New York times [1] , as well as the county-level active cases reporting from Johns Hopkins University [2] .", [["death", "DISEASE", 74, 79]]], ["We loaded these data into a data frame by matching the county FIPS codes from each source, and computed a moving average death statistic as an additional feature, using a window of size three days.", [["death", "DISEASE", 121, 126], ["county FIPS codes", "DNA", 55, 72]]], ["We dealt with missing values in the FIPS codes and death reporting by removing the corresponding observations.", [["death", "DISEASE", 51, 56]]], ["The only exception to this was the county 36061, which represents New York City.", [["New", "OBSERVATION_MODIFIER", 66, 69]]], ["This county had a missing FIPS code, but had well reported data.", [["FIPS code", "DNA", 26, 35]]], ["Since New York City is the most active Covid-19 hotspot in the United States, its manual inclusion was necessary.", [["its manual inclusion", "TREATMENT", 78, 98]]], ["In addition to the aforementioned data sources, we experimented with mobility data, but this did not make it into our final epidemiological model because there was no simple mapping to any of the model variables, and we believed the policy dating information was sufficient to establish distinct regimes in the data.PECAIQR Epidemiological ModelThe traditional SIR epidemiological model breaks up a region\u00e2\u0102\u0179s population into three separate groups: Susceptible, Infected, and Removed [3] .", [["mobility data", "TEST", 69, 82], ["model breaks", "OBSERVATION", 381, 393], ["Susceptible", "OBSERVATION_MODIFIER", 449, 460], ["Infected", "OBSERVATION", 462, 470]]], ["The primary flaw of applying this model to the current Covid-19 pandemic is the poor approximation of assuming that all people in each group have uniform experiences.", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126]]], ["Clumping the population into only three groups is an example of omitted-variable bias, excluding major realities caused by the scale of the pandemic.", [["omitted-variable bias", "PROBLEM", 64, 85], ["population", "OBSERVATION_MODIFIER", 13, 23], ["pandemic", "OBSERVATION", 140, 148]]], ["The PECAIQR model that is described below takes each group in the SIR model and breaks them down into another level of classification.", [["PECAIQR model", "DNA", 4, 17], ["The PECAIQR model", "TREATMENT", 0, 17]]], ["The variables in our model are developed following simple logical arguments based on current global realities and widely accepted scientific and epidemiological results.PECAIQR Epidemiological ModelWe first break down the Susceptible class of the SIR model.", [["simple logical arguments", "TREATMENT", 51, 75], ["SIR model", "OBSERVATION", 247, 256]]], ["It is sensible then that each day only a fraction of the Susceptible population are exposed to potentially getting the virus from the outside world.", [["the Susceptible population", "PROBLEM", 53, 79], ["Susceptible", "OBSERVATION_MODIFIER", 57, 68], ["population", "OBSERVATION", 69, 79]]], ["Next, we consider the Infected group of SIR.", [["SIR", "DISEASE", 40, 43]]], ["There is evidence from the large data sets gathered in South Korea and other well-respected global scientific efforts that a significant fraction of people infected with Covid-19 do not display visible symptoms [5] .", [["people", "ORGANISM", 149, 155], ["people", "SPECIES", 149, 155], ["Covid-19", "SPECIES", 170, 178], ["Covid", "TEST", 170, 175], ["visible symptoms", "PROBLEM", 194, 210], ["large", "OBSERVATION_MODIFIER", 27, 32]]], ["Using this line of logic our model breaks the Infected group into two classes: Asymptomatic and Infectious.", [["Asymptomatic", "PROBLEM", 79, 91], ["Asymptomatic", "OBSERVATION", 79, 91], ["Infectious", "OBSERVATION", 96, 106]]], ["An important note is that we assume these Asymptomatic and Infectious people still actively participate in the community, enabling them to come in contact with Exposed people.", [["people", "ORGANISM", 70, 76], ["people", "ORGANISM", 168, 174], ["people", "SPECIES", 70, 76], ["people", "SPECIES", 168, 174], ["Infectious", "OBSERVATION", 59, 69]]], ["Finally, we are left with the Removed group.", [["left", "ANATOMY_MODIFIER", 16, 20]]], ["Our model incorporates two lines of logic in the breakdown of this group.", [["two lines", "OBSERVATION", 23, 32], ["breakdown", "OBSERVATION_MODIFIER", 49, 58]]], ["First, it is sensible that a portion of the members of the Asymptomatic and Infectious classes end up self-quarantining (at least in effect) as a result of: getting tested, showing initial symptoms, or having an \u00e2\u0102\u0132intuition\u00e2\u0102\u0130 they contracted the disease.", [["Asymptomatic", "DISEASE", 59, 71], ["initial symptoms", "PROBLEM", 181, 197], ["the disease", "PROBLEM", 244, 255], ["Infectious", "OBSERVATION", 76, 86], ["disease", "OBSERVATION", 248, 255]]], ["Second, much of the evidence about Covid-19 so far shows that an individual who contracts the disease cannot get the disease again (at least on the order of a few months) [6] .", [["Covid", "TEST", 35, 40], ["the disease", "PROBLEM", 90, 101], ["the disease", "PROBLEM", 113, 124], ["disease", "OBSERVATION", 94, 101], ["disease", "OBSERVATION", 117, 124]]], ["Removed further has subclasses of Dead people and Recovered people, who are assumed to be immune from the virus.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 39, 45], ["people", "SPECIES", 60, 66], ["the virus", "PROBLEM", 102, 111], ["subclasses", "OBSERVATION_MODIFIER", 20, 30], ["virus", "OBSERVATION", 106, 111]]], ["We describe the variables for a given time t (associated with some given day T ).PECAIQR Epidemiological ModelProtected : People who did not go outside to expose themselves to any infected individuals (Asymptomatic or Infectious) on t, though they have a chance of coming in contact with a Carrier.", [["People", "ORGANISM", 122, 128], ["People", "SPECIES", 122, 128]]], ["Any person in Protected also has a chance of joining the Exposed class at a later time t + \u03b4 (interpreted as the next day: T + 1), as they may wish to travel outside that day for any reason.", [["person", "SPECIES", 4, 10]]], ["Exposed: People who went outside on t and therefore had a chance of coming into contact with an infected individual (Asymptomatic or Infectious) to become a Carrier.", [["People", "ORGANISM", 9, 15], ["People", "SPECIES", 9, 15]]], ["Any member also has a chance of joining the Protected class on the following day t + \u03b4, as they may wish to self-isolate the next day for any reason.PECAIQR Epidemiological ModelExposed : People who went outside on t and therefore had a chance of coming into contact with an infected individual (Asymptomatic or Infectious) to become a Carrier.", [["People", "ORGANISM", 188, 194], ["People", "SPECIES", 188, 194]]], ["Any member also has a chance of joining the Protected class on the following day t + \u03b4, as they may wish to self-isolate the next day for any reason.PECAIQR Epidemiological ModelCarrier : People in the model in a purposely temporary position.", [["People", "SPECIES", 188, 194]]], ["They are people in the Exposed class who came into contact with an Asymptomatic or Infectious person and got the disease \u00e2\u0102\u0132on their hands\u00e2\u0102\u0130 to some degree.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["person", "SPECIES", 94, 100], ["some degree", "OBSERVATION_MODIFIER", 145, 156]]], ["Carriers returning home on t have a chance of spreading the disease to some Protected people living at their home, making those people either Asymptomatic or Infectious on t+\u03b4.", [["people", "ORGANISM", 86, 92], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 86, 92], ["people", "SPECIES", 128, 134], ["the disease", "PROBLEM", 56, 67], ["Infectious", "OBSERVATION", 158, 168]]], ["Carriers at time t can also have a chance to either \u00e2\u0102\u0132touch their face\u00e2\u0102\u0130 and contract the disease themselves (becoming Asymptomatic or Infectious on t + \u03b4), or \u00e2\u0102\u0132wash their hands\u00e2\u0102\u0130 and return to being a member of the Exposed class on t + \u03b4.PECAIQR Epidemiological ModelAsymptomatic: People who were infected by Covid-19 and are contagious on t, but show no symptoms.", [["People", "ORGANISM", 287, 293], ["People", "SPECIES", 287, 293], ["Covid-19", "SPECIES", 315, 323], ["the disease themselves", "PROBLEM", 88, 110], ["Asymptomatic", "PROBLEM", 121, 133], ["Covid", "TEST", 315, 320], ["symptoms", "PROBLEM", 361, 369], ["disease", "OBSERVATION", 92, 99], ["no", "UNCERTAINTY", 358, 360]]], ["These people are assumed to be active in the public, in that they have a chance to spread the virus to Exposed people in public areas on t.", [["people", "ORGANISM", 6, 12], ["people", "ORGANISM", 111, 117], ["people", "SPECIES", 6, 12], ["people", "SPECIES", 111, 117], ["the virus", "PROBLEM", 90, 99], ["assumed to be", "UNCERTAINTY", 17, 30], ["active", "OBSERVATION_MODIFIER", 31, 37], ["virus", "OBSERVATION", 94, 99]]], ["An Asymptomatic person on t + \u03b4 has a chance of becoming a member of Infectious on after showing initial symptoms, a member of Quarantined after somehow finding that they contracted the virus, or a member of Removed after having the disease pass through their immune system.", [["immune system", "ANATOMY", 260, 273], ["immune system", "ANATOMICAL_SYSTEM", 260, 273], ["person", "SPECIES", 16, 22], ["initial symptoms", "PROBLEM", 97, 113], ["the virus", "PROBLEM", 182, 191], ["the disease pass", "PROBLEM", 229, 245], ["Asymptomatic", "OBSERVATION", 3, 15], ["Infectious", "OBSERVATION", 69, 79]]], ["Here, all the people going from Asymptomatic to Removed would go to the Recovered subclass.PECAIQR Epidemiological ModelInfectious: People who were infected by Covid-19, are contagious on t, and show symptoms.", [["people", "ORGANISM", 14, 20], ["People", "ORGANISM", 132, 138], ["people", "SPECIES", 14, 20], ["People", "SPECIES", 132, 138], ["Covid-19", "SPECIES", 160, 168], ["Covid", "TEST", 160, 165], ["symptoms", "PROBLEM", 200, 208]]], ["These people are assumed to be active in the public, in that they have a chance to spread the virus to Exposed people in public areas on t.", [["people", "ORGANISM", 6, 12], ["people", "ORGANISM", 111, 117], ["people", "SPECIES", 6, 12], ["people", "SPECIES", 111, 117], ["the virus", "PROBLEM", 90, 99], ["assumed to be", "UNCERTAINTY", 17, 30], ["active", "OBSERVATION_MODIFIER", 31, 37], ["virus", "OBSERVATION", 94, 99]]], ["An Infectious person on t + \u03b4 has a chance of becoming a member of Quarantined after figuring that they contracted the virus and a chance of becoming a member of Removed after having the disease pass through their immune system.", [["immune system", "ANATOMY", 214, 227], ["immune system", "ANATOMICAL_SYSTEM", 214, 227], ["person", "SPECIES", 14, 20], ["the virus", "PROBLEM", 115, 124], ["the disease pass", "PROBLEM", 183, 199], ["Infectious", "OBSERVATION", 3, 13]]], ["When these Infectious people become a member of Removed they have a chance of dying, to become a member of the Dead, or living and becoming a member of Recovered.PECAIQR Epidemiological ModelQuarantined : People who were originally Asymptomatic or Infectious and subsequently removed themselves from the public and are self-quarantining on t .", [["people", "ORGANISM", 22, 28], ["People", "ORGANISM", 205, 211], ["people", "SPECIES", 22, 28], ["People", "SPECIES", 205, 211], ["Infectious", "OBSERVATION", 11, 21], ["Infectious", "OBSERVATION", 248, 258]]], ["These people are assumed to not be able to spread the disease to any people, so this group includes people who have Covid-19 but are in a non-contagious stage.", [["people", "ORGANISM", 6, 12], ["people", "ORGANISM", 69, 75], ["people", "ORGANISM", 100, 106], ["people", "SPECIES", 6, 12], ["people", "SPECIES", 69, 75], ["people", "SPECIES", 100, 106], ["the disease", "PROBLEM", 50, 61]]], ["A Quarantined person on t + \u03b4 has a chance of becoming a member of Removed.", [["person", "SPECIES", 14, 20]]], ["When these Quarantined people become a member of Removed they have a chance of dying, to become a member of the Dead, or living and becoming a member of Recovered.PECAIQR Epidemiological ModelRemoved : People who were originally Asymptomatic, Infectious, or Quarantined, and had the disease fully pass through their immune system on or before t.", [["people", "ORGANISM", 23, 29], ["People", "ORGANISM", 202, 208], ["people", "SPECIES", 23, 29], ["People", "SPECIES", 202, 208], ["the disease", "PROBLEM", 279, 290], ["Infectious", "OBSERVATION", 243, 253]]], ["These people belong to one of two subclasses: Dead and Recovered.", [["people", "ORGANISM", 6, 12], ["people", "SPECIES", 6, 12]]], ["Recovered people are assumed to have survived the disease, and will not get infected again.Training StrategyTo fit the deaths data to the system of differential equations in the PECAIQR model, we performed numerical integration using the scipy odeint package [7] , and traversed the parameter space to find a set of parameters that minimized the least squares error of each fit variable in relation to its observed variables.", [["deaths", "DISEASE", 119, 125], ["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16], ["the disease", "PROBLEM", 46, 57], ["the scipy odeint package", "TREATMENT", 234, 258], ["disease", "OBSERVATION", 50, 57]]], ["Due to the size of the parameter space, this requires an initial guess for the parameters and the initial conditions of each of the 7 PECAIQR variables, as well as defined ranges to restrict the size of the parameter space.", [["the parameters", "TEST", 75, 89], ["size", "OBSERVATION_MODIFIER", 11, 15], ["parameter space", "OBSERVATION", 23, 38], ["size", "OBSERVATION_MODIFIER", 195, 199]]], ["First, we will elaborate more on the fitting procedure.FittingInitially, we only fit the death variable (D) to the observed death reporting.", [["death", "DISEASE", 89, 94], ["death", "DISEASE", 124, 129], ["the fitting procedure", "TREATMENT", 33, 54]]], ["Early on, we decided not to fit our infection curves to daily case statistics, as they have inconsistent and unreliable reporting, so this would only diminish the accuracy of the fit to observed deaths, which is a much more reliable statistic.", [["infection", "DISEASE", 36, 45], ["deaths", "DISEASE", 195, 201], ["our infection curves", "PROBLEM", 32, 52], ["infection", "OBSERVATION", 36, 45]]], ["Of course, this does not capture all the self-quarantined individuals, so we permitted a large degree of fuzziness in the fit of the quarantined variable (Q) to active cases.", [["fuzziness", "PROBLEM", 105, 114], ["large", "OBSERVATION_MODIFIER", 89, 94], ["degree", "OBSERVATION_MODIFIER", 95, 101], ["fuzziness", "OBSERVATION", 105, 114]]], ["We achieved this with a bias scaled factor that gave much more weight to observed deaths in the fit of the death variable (D).", [["deaths", "DISEASE", 82, 88], ["death", "DISEASE", 107, 112], ["a bias scaled factor", "TREATMENT", 22, 42]]], ["This causes the model to prioritize the deaths fit over the active cases fit, so the active cases fit becomes more of a suggestion rather than a constraint.", [["deaths", "DISEASE", 40, 46]]], ["The hope is that the least squares error on the active cases is not large enough in magnitude to compromise the deaths fit and force the parameter space into a different minimum, but will rather provide a subtle correction around the local minimum discovered by the minimization of the least squares error on the deaths.", [["deaths", "DISEASE", 112, 118], ["deaths", "DISEASE", 313, 319]]], ["Unfortunately, a fit to active cases is not helpful for most counties, as most counties do not maintain their active cases reporting well, and moreover we discovered that the criteria for an active case may vary widely across different states.FittingWe also realized that the PECAIQR epidemiological model parameters are not static, due to the dynamic and rapidly evolving state of the pandemic, caused mainly by external forces such as social distancing protocols and lock down policies.", [["an active case", "PROBLEM", 188, 202], ["the PECAIQR epidemiological model parameters", "TEST", 272, 316], ["the pandemic", "PROBLEM", 382, 394], ["social distancing protocols", "TREATMENT", 437, 464], ["pandemic", "OBSERVATION", 386, 394]]], ["But since we only care about the most recent characteristics of the death and infection curves when making predictions into the future, we can do better than this by affording the more recent data points more weight in the least squares error calculation.", [["death", "DISEASE", 68, 73], ["infection", "DISEASE", 78, 87], ["the death", "PROBLEM", 64, 73], ["infection curves", "PROBLEM", 78, 94], ["error calculation", "TEST", 237, 254], ["infection", "OBSERVATION", 78, 87]]], ["This forces the minimization to favor a solution that fits more heavily on a more recent window of time, while still retaining the effects of the past data to some degree.", [["a solution", "TREATMENT", 38, 48]]], ["We called this method training on the tail.FittingAnother method to separate more recent parameters from the data is to use the assumption that there are distinct parameter regimes correlating to the start of policies -the stay at home orders in particular.", [["tail", "ANATOMY", 38, 42], ["tail", "ORGANISM_SUBDIVISION", 38, 42], ["distinct parameter regimes", "TREATMENT", 154, 180], ["tail", "ANATOMY", 38, 42]]], ["Note that these policies directly affect the infection curves because they limit the spread of disease.", [["infection", "DISEASE", 45, 54], ["the infection curves", "PROBLEM", 41, 61], ["disease", "PROBLEM", 95, 102], ["infection", "OBSERVATION", 45, 54]]], ["For the death curve, there is typically an offset between the date of policy implementation and the date at which the effects become apparent in the death data, this offset approximately equal to the average time till death for Covid-19.FittingWith this assumption, we separate the deaths data into two training regimes -one for dates before the policy implementation plus the offset, and one for dates after the policy implementation plus the offset.", [["death", "DISEASE", 8, 13], ["death", "DISEASE", 149, 154], ["death", "DISEASE", 218, 223], ["deaths", "DISEASE", 282, 288], ["the death curve", "TEST", 4, 19], ["Covid", "TEST", 228, 233], ["two training regimes", "TREATMENT", 299, 319]]], ["Then, we train one fit on the the first regime, and feed the fitted parameters and predicted variables on the date of the policy implementation as the guesses and initial conditions, respectively of a second fit on the second regime.FittingWe called this method training on the policy regime.Predictions and ErrorsWe perform procedures described above on a county-level, and then use the fitted parameters with the numerical integration to extrapolate into the future to get county-specific predictions.", [["the second regime", "TREATMENT", 215, 232], ["the policy regime", "TREATMENT", 274, 291], ["procedures", "TREATMENT", 325, 335]]], ["Note that the predictions and their errors are in cumulative deaths, but for the sake of visualization, we converted to daily deaths later.Predictions and ErrorsTo get the errors, we initially used a method that calculated error bounds by finding the parameter variance from the residual variance using the covariance matrix of residuals and the Jacobian around the fitted parameters.Predictions and ErrorsHaving obtained the mean and standard deviation for each of the parameters, we assumed that each parameter had normally distributed values, and so we sampled 100 parameter sets.", [["deaths", "DISEASE", 61, 67], ["deaths", "DISEASE", 126, 132], ["the residual variance", "PROBLEM", 275, 296], ["the covariance matrix of residuals", "TREATMENT", 303, 337], ["residual variance", "OBSERVATION", 279, 296], ["distributed", "OBSERVATION_MODIFIER", 526, 537], ["values", "OBSERVATION_MODIFIER", 538, 544]]], ["We could not simply apply calculate the parameters for each confidence interval from their mean and standard deviation because it is not obvious which parameters are positively correlated or negatively correlated with the deaths predictions.", [["deaths", "DISEASE", 222, 228], ["not obvious", "UNCERTAINTY", 133, 144]]], ["This method turned out not to be ideal in all cases, as there are certain regions in the parameter space that are invalid and cause the error bars to spike.Predictions and ErrorsWe then developed a bounding method that allowed a reliable way to accurately tighten our confidence intervals.", [["This method", "TREATMENT", 0, 11], ["the error bars to spike", "PROBLEM", 132, 155], ["a bounding method", "PROBLEM", 196, 213], ["error bars", "OBSERVATION", 136, 146]]], ["This method infers the error bars from the deviation relative to the predicted fit, of a smoothed version of the residuals calculated from the moving average of daily deaths, which is equivalent to the moving average of the slope of the cumulative deaths.", [["deaths", "DISEASE", 167, 173], ["deaths", "DISEASE", 248, 254], ["the residuals", "PROBLEM", 109, 122], ["residuals", "OBSERVATION", 113, 122], ["equivalent", "OBSERVATION_MODIFIER", 184, 194], ["cumulative deaths", "OBSERVATION", 237, 254]]], ["Generate a PDF of deaths around the best fit prediction.", [["deaths", "DISEASE", 18, 24]]], ["For each time t in the training range, compute the difference in \u00e2\u0102\u0132slope\u00e2\u0102\u0130 between the fit and the actual data.", [["the actual data", "TEST", 97, 112]]], ["The slope in the fit is simply the current predicted death minus the previous death on the fit curve.", [["death", "DISEASE", 53, 58], ["death", "DISEASE", 78, 83], ["slope", "OBSERVATION_MODIFIER", 4, 9]]], ["We then define a normal distribution of slope ratios.", [["slope ratios", "PROBLEM", 40, 52], ["normal", "OBSERVATION", 17, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36], ["slope ratios", "OBSERVATION", 40, 52]]], ["For each time t in the training data, we find the ratio of the actual (moving average) slope and the fit slope, and fill a list of these ratios.", [["the training data", "TEST", 19, 36], ["these ratios", "TEST", 131, 143], ["fit slope", "OBSERVATION", 101, 110]]], ["Next we find the mean and standard deviation of the distribution as the mean and (sample) standard deviation of the ratios list.", [["deviation", "OBSERVATION", 35, 44], ["distribution", "OBSERVATION_MODIFIER", 52, 64]]], ["This is necessary because the ratios are unrealistically high in the small number limit.", [["the ratios", "TEST", 26, 36], ["unrealistically", "OBSERVATION_MODIFIER", 41, 56], ["high", "OBSERVATION_MODIFIER", 57, 61], ["small number limit", "OBSERVATION_MODIFIER", 69, 87]]], ["We find the slope at the extrapolated time as the predicted death minus the predicted death at the previous time.", [["death", "DISEASE", 60, 65], ["death", "DISEASE", 86, 91], ["the predicted death", "PROBLEM", 72, 91]]], ["This slope is multiplied by a random scaler sampled from the normal distribution of ratios and denoted as s.", [["a random scaler", "TEST", 28, 43], ["normal", "OBSERVATION", 61, 67]]], ["We multiply the predicted death at the previous time t \u2212 1 in the fit by 1 + s and add this as a point in the PDF at time t.", [["death", "DISEASE", 26, 31]]], ["We get the discrete 10, 20, 30, 40, 50, 60, 70, 80, 90 CDF percentiles by sampling the PDF.ValidationThe methods described in the past two subsections are implemented as options that can be activated with hyper parameters, and collectively they provide several different ways to fit the PECAIQR model and generate the confidence intervals.", [["the PECAIQR model", "TREATMENT", 283, 300]]], ["Due to the time constraint of the competition, we were not able to develop a sophisticated blending method to optimize on the hyper-parameter space.", [["a sophisticated blending method", "TREATMENT", 75, 106], ["hyper", "OBSERVATION", 126, 131]]], ["However, we were able to sample a few different combinations of hyper-parameters and determine on a county-level which one works the best for each county, by modifying the evaluation script provided by the TAs.", [["hyper-parameters", "PROBLEM", 64, 80], ["the evaluation", "TEST", 168, 182]]], ["To determine a good set of hyperparameters for each county, we simply trained using a two week cutoff in the data, and scored the predictions for the subsequent two weeks using the evaluation script.Model PerformanceFor predictions made from training data up to May 25th, we were able to obtain an average pinball loss of 0.096 for all counties with scoring on a 14 day forecast.Model PerformanceOur greatest weakness was the lack of a second working model with which we could cross validate, as well as the lack of a sophisticated blending method to optimize on the hyper-parameter space for the single model.", [["the evaluation", "TEST", 177, 191], ["Model PerformanceOur greatest weakness", "PROBLEM", 379, 417], ["a sophisticated blending method", "TREATMENT", 516, 547], ["the hyper-parameter space", "TREATMENT", 563, 588], ["greatest", "OBSERVATION_MODIFIER", 400, 408], ["weakness", "OBSERVATION", 409, 417]]], ["Having two different models would have allowed us to mitigate their individual weaknesses and account for their individual edge cases with the other's strengths.Model PerformanceThe epidemiological model has several major weaknesses.", [["several major weaknesses", "PROBLEM", 208, 232], ["several", "OBSERVATION_MODIFIER", 208, 215], ["major", "OBSERVATION_MODIFIER", 216, 221], ["weaknesses", "OBSERVATION", 222, 232]]], ["Although it works well for counties with well recorded data, it fails for the vast majority of counties, which have low or noisy death statistics.", [["death", "DISEASE", 129, 134]]], ["The curves for the PECAIQR variables in the left column of the preceding figures make sense intuitively.", [["left column", "ANATOMY", 44, 55], ["the PECAIQR variables", "TEST", 15, 36], ["left", "ANATOMY_MODIFIER", 44, 48], ["column", "ANATOMY_MODIFIER", 49, 55]]], ["We also expect the carrier population to peak before the infected population, which should have a similar shape to the asymptomatic population, and lastly we expect the infected and asymptomatic populations to peak before the deceased population peaks.", [["the carrier population", "PROBLEM", 15, 37], ["the infected population", "PROBLEM", 53, 76], ["the infected and asymptomatic populations", "PROBLEM", 165, 206], ["the deceased population peaks", "PROBLEM", 222, 251], ["infected", "OBSERVATION_MODIFIER", 57, 65], ["population", "OBSERVATION", 66, 76], ["asymptomatic", "OBSERVATION_MODIFIER", 119, 131], ["population", "OBSERVATION", 132, 142], ["infected", "OBSERVATION_MODIFIER", 169, 177]]], ["Lastly, the second figure, which uses the \"fit on tail\" method, more closely captures the uncertainty of the tail end of the curve, as expected.Results for Selected Counties(a) (b) (c) (d) (e) (f) (g) (h)Parameter VisualizationFor the \"nonconvergent counties,\" we attempted to skip over the parameter fitting step by guessing parameters based on the parameters of similar counties.", [["tail", "OBSERVATION_MODIFIER", 109, 113], ["curve", "OBSERVATION_MODIFIER", 125, 130]]], ["In order to do this, we need to first establish proof of concept that there is some correlation between the non-covid features of a county and its PECAIQR parameters.", [["its PECAIQR parameters", "TEST", 143, 165]]], ["So we visualized the parameters for all the \"convergent\" counties by using dimension reduction algorithms.", [["dimension reduction algorithms", "TREATMENT", 75, 105]]], ["We used Principal Component Analysis [9] , Singular Value Decomposition [10], and t-Distributed Stochastic Neighbor Embedding Figure 3 : Several different visualizations of the parameter space using dimension reduction algorithms.", [["Singular Value Decomposition", "TREATMENT", 43, 71], ["dimension reduction algorithms", "TREATMENT", 199, 229]]], ["Each point represents a count, and its size correlates with the county population.Parameter VisualizationFor SVD, we plotted the first two columns of the left matrix against each other, which produces an visualization how similar the counties are by distance, based on their abstract preferences in the parameter space.", [["left matrix", "ANATOMY", 154, 165], ["a count", "TEST", 22, 29], ["Parameter Visualization", "TEST", 82, 105], ["SVD", "PROBLEM", 109, 112], ["size", "OBSERVATION_MODIFIER", 39, 43], ["left", "ANATOMY_MODIFIER", 154, 158]]], ["Although we did not have time to further explore the possible correlation between parameter clusters and non-covid county-specific features, we were excited to see that there are some distinct intrinsic patterns in the parameter space.", [["some distinct intrinsic patterns in the parameter space", "PROBLEM", 179, 234], ["distinct", "OBSERVATION_MODIFIER", 184, 192], ["intrinsic patterns", "OBSERVATION", 193, 211]]], ["Further research would involve classifying these clusters with a clustering algorithm, and then attempting to predict the cluster labels or quantified distances of specific counties with a regression algorithm from the non-covid feature space.Degeneracy and StiffnessWe also realized that, even for the larger counties, there was some uncertainty caused by the complexity of our model.", [["a clustering algorithm", "TEST", 63, 85], ["a regression algorithm", "TEST", 187, 209], ["Degeneracy and Stiffness", "PROBLEM", 243, 267], ["Stiffness", "OBSERVATION", 258, 267]]], ["Since our parameter space has so many dimensions, there is an issue with degeneracy.", [["many dimensions", "OBSERVATION_MODIFIER", 33, 48]]], ["The least squares minimization settles on a parameter set that yields a minimum in the least squares error metric, but this is not necessarily the only minimum or even the best minimum.", [["least", "OBSERVATION_MODIFIER", 4, 9], ["squares", "OBSERVATION_MODIFIER", 10, 17]]], ["We were convinced of this when we discovered that for each county, we could get distinct parameter regimes with different initial guesses, and that these solutions are similarly valid.", [["distinct parameter regimes", "TREATMENT", 80, 106]]], ["We will show this in the figures below, by repeating the procedure from the previous section, but with a different set of parameters as the initial guess for the least squares minimization.", [["the procedure", "TREATMENT", 53, 66]]], ["In order to get better parameter guesses, further research should focus on deriving reasonable values for the more intuitive parameters of the model, such as those concerning the rate of infection, from existing data.", [["infection", "DISEASE", 187, 196], ["infection", "PROBLEM", 187, 196], ["infection", "OBSERVATION", 187, 196]]], ["This also illuminates the issue of ODE stiffness.", [["ODE stiffness", "PROBLEM", 35, 48], ["stiffness", "OBSERVATION", 39, 48]]], ["We believe the functionality of the scipy odeint package is quite limited.", [["the scipy odeint package", "TREATMENT", 32, 56]]], ["Given more time, we would explore other statistical packages like Stan, which has a state of the art implementation of 4th order Runge Kutta numerical integration for stiff ODEs [11] .", [["stiff ODEs", "PROBLEM", 167, 177]]], ["Another improvement would be to use a numerical integrator that solve handle delay differential equations, which would allow us to have more control over the time delay in expression between infected and death states.Advantages of the PECAQIR ModelWe believe that overall the PECAIQR model is very promising, and reveals the benefit of attempting more ambitious, complex epidemiological models.", [["death", "DISEASE", 204, 209], ["a numerical integrator", "TREATMENT", 36, 58], ["the PECAQIR ModelWe", "TREATMENT", 231, 250], ["infected", "OBSERVATION", 191, 199]]], ["The shape of the solutions of the PECAIQR are also quite interesting, as they resemble heavy tail distributions similar to the Frechet/Weibull distribution.", [["PECAIQR", "DNA", 34, 41], ["shape", "OBSERVATION_MODIFIER", 4, 9], ["Weibull distribution", "OBSERVATION", 135, 155]]], ["The heavy tail is especially important for pandemic forecasting, as we expect the daily deaths to fluctuate around a low value for some time, instead of decaying immediately to zero.", [["deaths", "DISEASE", 88, 94], ["heavy tail", "OBSERVATION_MODIFIER", 4, 14]]], ["In this respect, the tail end of the curve is almost stochastic in nature, once the infection curves lose enough momentum.HMM Supervised Learning PredictionDue to the high variability found in the data for Reported Deaths for each county, with some counties reporting unrealistic jumps in the numbers of deaths, it seemed sensible to try using a stochastic model to make some predictions of death counts for counties.", [["tail", "ANATOMY", 21, 25], ["infection", "DISEASE", 84, 93], ["deaths", "DISEASE", 304, 310], ["death", "DISEASE", 391, 396], ["the infection curves", "PROBLEM", 80, 100], ["a stochastic model", "TREATMENT", 344, 362], ["tail", "OBSERVATION_MODIFIER", 21, 25], ["curve", "OBSERVATION_MODIFIER", 37, 42], ["almost", "OBSERVATION_MODIFIER", 46, 52], ["stochastic", "OBSERVATION", 53, 63], ["infection", "OBSERVATION", 84, 93]]], ["In order to best preprocess the county data for training, we explored possible clustering methods that would be able to cluster time series of varying lengths.", [["training", "TREATMENT", 48, 56], ["clustering methods", "PROBLEM", 79, 97]]], ["Dynamic-Time Warping (DTW) was picked to be the distance measure of choice as it is able to compare time series of different lengths and provide a \u00e2\u0102\u0132warped distance\u00e2\u0102\u0130 between each series of Daily Reported Deaths.HMM Supervised Learning PredictionThe Daily Reported Deaths were preprocessed by first removing the series with all 0\u00e2\u0102\u0179s, and then performing a z-normalization on each data series.", [["a z-normalization on each data series", "TEST", 357, 394]]], ["The data series were then compared with Dynamic-Time Warping, and a hierarchical clustering was developed based on the DTW distance matrix.", [["matrix", "CELLULAR_COMPONENT", 132, 138], ["The data series", "TEST", 0, 15]]], ["The number of clusters was determined using the elbow method.", [["elbow", "ORGANISM_SUBDIVISION", 48, 53], ["the elbow method", "TREATMENT", 44, 60], ["clusters", "OBSERVATION_MODIFIER", 14, 22], ["elbow", "ANATOMY", 48, 53]]], ["The ideal setup would be a clustering based on an iterative DTW-HMM clustering algorithm, in order to fully extract similarities between county Reported Deaths.", [["an iterative DTW", "TEST", 47, 63]]], ["Unfortunately we did not have time to fully develop this idea.Dynamic Time Warping Clustering of Daily Reported Deaths Plot of Loss vs Number of ClustersOnce the clusterings were developed, each cluster was used to train an HMM model.", [["Loss vs Number of Clusters", "PROBLEM", 127, 153]]], ["We used HMMLearn\u00e2\u0102\u0179s GaussianHMM model in order to have the Gaussian emissions needed for this kind of data (a multinomial model with discrete output would be stretched thin with \u223c100 states).", [["HMMLearn\u00e2\u0102\u0179s GaussianHMM model", "TREATMENT", 8, 38], ["the Gaussian emissions", "TREATMENT", 56, 78], ["discrete output", "PROBLEM", 134, 149]]], ["The number of states each Gaus-sianHMM was given per cluster was chosen by doing a modified version of the elbow method, to ensure that the HMM is complex/simple enough to match the variance in Reported Deaths.", [["elbow", "ORGANISM_SUBDIVISION", 107, 112], ["the elbow method", "TREATMENT", 103, 119], ["elbow", "ANATOMY", 107, 112]]], ["As the model only allowed for predictions based off of an entire cluster, there needed to be a secondary layer of scaling to allow a cluster prediction to be mapped to each individual county.", [["a secondary layer of scaling", "PROBLEM", 93, 121]]], ["An idea of attempting to do some time-series comparison and do some sort of series stretching/scaling was developed, but was never fully formed.", [["series stretching/scaling", "PROBLEM", 76, 101]]], ["One fundamental issue is that perhaps the small number of states of the GaussianMM limits the complexity of each HMM per cluster.", [["fundamental", "OBSERVATION_MODIFIER", 4, 15], ["issue", "OBSERVATION", 16, 21], ["small", "OBSERVATION_MODIFIER", 42, 47], ["number", "OBSERVATION_MODIFIER", 48, 54], ["GaussianMM", "OBSERVATION", 72, 82]]], ["If this random element is able to be removed or smoothed away,however, perhaps this model would not be so useful any longer.Gaussian ProcessWhen attempting to use statistical regression to model nonlinear correlations in data, a common approach is to employ a Bayesian non-parametric strategy, such as the Gaussian process.", [["a Bayesian non-parametric strategy", "TREATMENT", 258, 292]]], ["Bayesian non-parametric strategies like the Gaussian process are essentially extensions of Bayesian Inference on an infinite-dimensional parameter space.", [["Bayesian non-parametric strategies", "PROBLEM", 0, 34], ["the Gaussian process", "PROBLEM", 40, 60]]], ["Very loosely, this allows us to model the data as the combination of many different Gaussians (each quite accurate in its local region), stitched together to create a single model [12] .", [["many different Gaussians", "TREATMENT", 69, 93]]], ["This technique was attempted in the latter stages of the course to create predictions for counties where the predictions from the PECAIQR did not converge, an issue at the time for counties with poor data.Gaussian ProcessWe used a custom implementation of Gaussian Processes, using a mean function of 0 and an exponential squared kernel.", [["This technique", "TREATMENT", 0, 14], ["a mean function", "TEST", 282, 297]]], ["The data used was the rolling average of deaths over a three day window vs time.", [["deaths", "DISEASE", 41, 47]]], ["In this model, there are three parameters: l which is the length parameter for the kernel, \u03c3 f which is vertical variation parameter for the kernel, and \u03c3 y which is the noise parameter.", [["vertical variation", "OBSERVATION", 104, 122]]], ["Here, the bounds on the parameters 5.0 \u2264 l \u2264 15.0, 0.1 \u2264 \u03c3 f \u2264 m 500.0 , 0.1 \u2264 \u03c3 \u2264 m 10.0 where m was the maximum value of rolling three day average deaths over the past 14 days.", [["deaths", "DISEASE", 149, 155], ["the parameters", "TEST", 20, 34]]], ["The error function was the root mean squared error (RMSE) over the last 30 days.", [["The error function", "TEST", 0, 18]]], ["These bounds and the error function were determined with validation procedures.", [["the error function", "TEST", 17, 35], ["validation procedures", "TREATMENT", 57, 78]]], ["The Gaussian process seems to fit quite accurately in the short term, but the predictions quickly drop to zero, as demonstrated in the plots above.", [["short term", "OBSERVATION_MODIFIER", 58, 68]]], ["Unlike the PECAIQR model, it does not retain a heavy tail.", [["heavy tail", "PROTEIN", 47, 57]]], ["We can possibly improve the Gaussian process and overcome the issue by setting a custom mean instead of using the default zero mean, which likely contributes to the rapid decay of the tail.", [["tail", "ANATOMY", 184, 188], ["the Gaussian process", "PROBLEM", 24, 44], ["the rapid decay of the tail", "PROBLEM", 161, 188], ["rapid", "OBSERVATION_MODIFIER", 165, 170], ["decay", "OBSERVATION", 171, 176], ["tail", "ANATOMY", 184, 188]]], ["It was attempted since a custom mean function could be used [14] ; similarities were noted between the graph of the number of deaths vs time in New York County and the Weibull distribution, so the Weibull distribution was this custom mean.", [["deaths", "DISEASE", 126, 132], ["a custom mean function", "TEST", 23, 45], ["Weibull distribution", "OBSERVATION", 168, 188]]], ["We can conclude that the Gaussian process fits very well on the training data, but fails to present long term predictive power.Gaussian ProcessAgain, these failures in the Gaussian process model may be overcome by setting a custom mean.", [["the training data", "TEST", 60, 77], ["Gaussian ProcessAgain", "PROBLEM", 127, 148], ["these failures", "PROBLEM", 150, 164], ["failures", "OBSERVATION", 156, 164], ["may be", "UNCERTAINTY", 195, 201]]], ["This is because the epidemiological model has some sort of intuition in the form of the rules established by its differential equations, while the Gaussian process is purely curve fitting.", [["intuition", "OBSERVATION", 59, 68]]], ["Perhaps, given more time, we could have combined these two models to utilize both the short term accuracy of the Gaussian process and the long term predictive power of the Epidemiological model.", [["long term", "OBSERVATION_MODIFIER", 138, 147]]], ["Analysis of model predictions for different cutoff dates in the training data shows that the model is quite stable and consistent when predicting on the region past the peak.", [["model predictions", "TEST", 12, 29], ["different cutoff dates", "TEST", 34, 56], ["the training data", "TEST", 60, 77], ["quite", "OBSERVATION_MODIFIER", 102, 107], ["stable", "OBSERVATION", 108, 114], ["peak", "OBSERVATION_MODIFIER", 169, 173]]], ["However, predicting before the peak is much harder, as we are no longer operating with the assumption that the infection curves are dying down.", [["infection", "DISEASE", 111, 120], ["the infection curves", "PROBLEM", 107, 127], ["no longer", "UNCERTAINTY", 62, 71], ["infection", "OBSERVATION", 111, 120]]], ["In sub-figure d) we see that the peak daily deaths value predicted by the model is significantly less than the actual peak that is revealed with more data.", [["deaths", "DISEASE", 44, 50]]], ["However, the location of the peak is correct.", [["peak", "OBSERVATION_MODIFIER", 29, 33]]], ["We realized that the training data at this early cutoff is largely dominated by data in the regime before the first stay at home order, but we were training using an initial parameter guess that accounted for the effects of a stay at home order, and so in sub-figure e), we tried a different set of parameters for the initial parameter guess in the fitting procedure, inspired from the parameters obtained from a fit on similar early curves in Italian regions.", [["the training data", "TEST", 17, 34], ["the fitting procedure", "TREATMENT", 345, 366]]], ["This modification yielded a more accurate prediction of the peak daily deaths value, but a less accurate placement of the peak.", [["deaths", "DISEASE", 71, 77]]], ["The prediction curve becomes extended when we use this alternative parameter set because the model no longer assumes that there will be a stay at home order, and therefore the curve will not flatten to the same degree.", [["The prediction curve", "TEST", 0, 20], ["this alternative parameter", "TREATMENT", 50, 76], ["the curve", "TEST", 172, 181]]], ["Analysis of model predictions for different cutoff dates in the training data shows that the model is quite stable and consistent when predicting on the region past the peak.", [["model predictions", "TEST", 12, 29], ["different cutoff dates", "TEST", 34, 56], ["the training data", "TEST", 60, 77], ["quite", "OBSERVATION_MODIFIER", 102, 107], ["stable", "OBSERVATION", 108, 114], ["peak", "OBSERVATION_MODIFIER", 169, 173]]], ["One thing to note is that sub-figure a), trained on the most recent data, seems to have a much longer tail.", [["tail", "ANATOMY", 102, 106]]], ["This is a result of the high level of noise in the more recent data points, which are not included in the other cutoffs.Longer Time Horizon PredictionsPredicting before the peak is much harder, as we are no longer operating with the assumption that the infection curves are dying down.", [["infection", "DISEASE", 253, 262], ["the infection curves", "PROBLEM", 249, 269], ["infection", "OBSERVATION", 253, 262]]], ["In sub-figure d), we see that the fit is quite different from the fits with later cutoffs.Longer Time Horizon PredictionsThe data before this cutoff is quite noisy, so the model cannot accurately predict when the infection curves will begin to die off.", [["infection", "DISEASE", 213, 222], ["The data", "TEST", 121, 129], ["the infection curves", "PROBLEM", 209, 229], ["infection", "OBSERVATION", 213, 222]]], ["The model is able to use the active case statistic to determine that the infection curve dies down earlier than it otherwise would predict.", [["infection", "DISEASE", 73, 82], ["the infection curve", "PROBLEM", 69, 88]]], ["Here, we fit each of the three counties using the policy regime method described in section 3.1 Fitting.", [["the policy regime method", "TREATMENT", 46, 70]]], ["The faint gray curve shows the predicted infection curve on the data regime before the date of the stay at home order, plus the time of death, and the dark gray curve shows the predicted infection curve on the data regime after the stay at home order.", [["infection", "DISEASE", 41, 50], ["death", "DISEASE", 136, 141], ["infection", "DISEASE", 187, 196], ["The faint gray curve", "TEST", 0, 20], ["the predicted infection curve", "PROBLEM", 27, 56], ["the dark gray curve", "TEST", 147, 166], ["the predicted infection curve", "PROBLEM", 173, 202], ["faint", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 41, 50], ["infection", "OBSERVATION", 187, 196]]], ["In counties 36059 and 27053, the stay at home order seems to have flattened the curve, but in county 36061 the effects are more ambiguous.", [["flattened the curve", "PROBLEM", 66, 85]]], ["The is likely relates to factors specific to New York that worsened the outbreak, such as the high population density of New York City, and the shortage of hospital resources later on.", [["likely relates to", "UNCERTAINTY", 7, 24]]], ["The model can be easily adapted to train on International data.", [["International data", "TEST", 44, 62]]], ["At the bare minimum, the model only requires death reporting and population.", [["death", "DISEASE", 45, 50], ["bare minimum", "OBSERVATION_MODIFIER", 7, 19]]], ["The predictions made from the May 4th cutoff, roughly a month before the June 3rd cutoff, shows that the prediction fit is quite stable and is consistent.Policy Effect Predictions(a) (b) (c) (d)Resource Use Predictions(e) (f) Figure 13 : The first column of figures shows daily deaths and currently hospitalized, daily hospitalized, and currently in ICU plotted, respectively, plotted against time.", [["deaths", "DISEASE", 278, 284], ["quite", "OBSERVATION_MODIFIER", 123, 128], ["stable", "OBSERVATION", 129, 135]]], ["The second column shows the linear regression for daily deaths vs currently hospitalized, daily deaths vs daily hospitalized, and daily deaths vs currently on ventilator, respectively.Resource Use PredictionsTo smooth out the data, we used a moving average with a window of 7 data points.", [["deaths", "DISEASE", 56, 62], ["deaths", "DISEASE", 96, 102], ["deaths", "DISEASE", 136, 142], ["ventilator", "TREATMENT", 159, 169], ["linear", "OBSERVATION_MODIFIER", 28, 34], ["regression", "OBSERVATION_MODIFIER", 35, 45]]], ["We then aligned the peaks for each hospital statistic to match the peak of the daily deaths, in order to account for the offset term that corresponds with the average time between hospital admittance and death.", [["deaths", "DISEASE", 85, 91], ["death", "DISEASE", 204, 209], ["death", "PROBLEM", 204, 209]]], ["The first column shows the hospital statistics before they were aligned with the death statistic, and there is clearly an shift, although only by a few days.", [["death", "DISEASE", 81, 86], ["shift", "OBSERVATION", 122, 127]]], ["This makes sense, as patients who are admitted to the hospital are likely patients who have already developed a severe condition.Resource Use PredictionsNote that the hospital statistics and the death statistics are both Gaussian.", [["death", "DISEASE", 195, 200], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 74, 82], ["a severe condition", "PROBLEM", 110, 128], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["condition", "OBSERVATION", 119, 128]]], ["This suggests that we can find some scaling factor once we align their peaks.", [["some scaling factor", "PROBLEM", 31, 50]]], ["For this, we perform a linear regression against the death statistic, revealing a definitive linear correlation for all the statistics.", [["death", "DISEASE", 53, 58]]], ["Note that there is a slight nonlinearity in the regression between currently hospitalized and daily deaths, as the daily deaths increases beyond a certain point.", [["deaths", "DISEASE", 100, 106], ["deaths", "DISEASE", 121, 127], ["a slight nonlinearity", "PROBLEM", 19, 40], ["slight", "OBSERVATION_MODIFIER", 21, 27], ["nonlinearity", "OBSERVATION_MODIFIER", 28, 40]]], ["This may indicate that we are nearing the hospital capacity, and so the change in number of currently hospitalized patients begins to lag behind the change in daily deaths.", [["deaths", "DISEASE", 165, 171], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["Also note that there is an extreme outlier in the regression between currently on ventilator and daily deaths at the peak daily deaths value.", [["deaths", "DISEASE", 103, 109], ["deaths", "DISEASE", 128, 134], ["an extreme outlier", "PROBLEM", 24, 42], ["ventilator", "TREATMENT", 82, 92], ["extreme", "OBSERVATION_MODIFIER", 27, 34], ["outlier", "OBSERVATION", 35, 42]]], ["Similarly, this is also likely caused by some limit on the number of ventilators available.", [["also likely caused", "UNCERTAINTY", 19, 37]]], ["Indeed, there seems to be a ceiling to the number of people on ventilators past a certain number of daily deaths.Resource Use PredictionsUsing the linear regression fit, we can now directly convert any of our model predictions, as well as their confidence intervals, to predictions for hospital resources.Data ChallengesWe noticed that the vast majority of counties have inconsistent reporting of deaths.", [["deaths", "DISEASE", 106, 112], ["deaths", "DISEASE", 397, 403], ["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59], ["ventilators", "TREATMENT", 63, 74]]], ["Some counties even had cumulative death statistics that decreased on certain dates.", [["death", "DISEASE", 34, 39], ["cumulative death statistics", "PROBLEM", 23, 50], ["decreased", "OBSERVATION_MODIFIER", 56, 65]]], ["Clearly this is not possible, as death is permanent.", [["death", "DISEASE", 33, 38], ["not possible", "UNCERTAINTY", 16, 28], ["permanent", "OBSERVATION", 42, 51]]], ["Other counties report constant values for cumulative deaths (zero values for daily deaths) for an extended period of time, followed by a quick spike.", [["deaths", "DISEASE", 53, 59], ["deaths", "DISEASE", 83, 89], ["cumulative deaths", "PROBLEM", 42, 59], ["a quick spike", "PROBLEM", 135, 148]]], ["It is doubtful that all deaths suddenly occur in a single day, so this observation suggests that the deaths reporting might not be distributed correctly, perhaps due to administrative lag.", [["deaths", "DISEASE", 24, 30], ["deaths", "DISEASE", 101, 107]]], ["For counties with low numbers of deaths, this creates large amounts of variance in the data, which makes it hard to fit.", [["deaths", "DISEASE", 33, 39], ["large", "OBSERVATION_MODIFIER", 54, 59], ["amounts", "OBSERVATION_MODIFIER", 60, 67]]], ["It seems like the deaths reporting also seems to be correlated with the day of the week.", [["deaths", "DISEASE", 18, 24]]], ["For many counties there is an interesting trend that the daily deaths increase over consecutive days before the weekend.", [["deaths", "DISEASE", 63, 69]]], ["Again, this might be due to administrative lag in the hospitals that report deaths.Data ChallengesThe active cases statistics also seem to be poorly recorded, and this makes sense given how ambiguous the classification of an active case can be, especially with the limitations on testing.", [["deaths", "DISEASE", 76, 82], ["testing", "TEST", 280, 287], ["active", "OBSERVATION_MODIFIER", 102, 108]]], ["Many counties completely lack useful active case statistics, and in other cases, it is only available very late into the infection curve.", [["infection", "DISEASE", 121, 130], ["the infection curve", "PROBLEM", 117, 136], ["infection", "OBSERVATION", 121, 130]]], ["In general, statistics that attempt to quantify the number of cases, whether active, cumulative, or daily, are intrinsically unreliable, as they depend on the availability of tests, which can vary greatly over time.", [["tests", "TEST", 175, 180], ["active", "OBSERVATION_MODIFIER", 77, 83]]], ["Perhaps a more reliable statistic is the ratio of positive tests to administered test on any given day.Data ChallengesAnother issue was with the non time-series data.", [["positive tests", "PROBLEM", 50, 64], ["test", "TEST", 81, 85]]], ["Some files, such as the Age Race file from [15] and the Aggregate JHU file from [16] , had valuable information but also numerous holes.", [["holes", "OBSERVATION", 130, 135]]], ["Such holes proved difficult to fill in.", [["Such holes", "PROBLEM", 0, 10]]], ["The filling in was done by using the data from the nearest county if a given entry was missing for a certain county.", [["filling", "OBSERVATION_MODIFIER", 4, 11]]]], "182bb537f37bac287d6ee1b8c0d1483efe92ee10": [["IntroductionSocial life is essential for good health [1, 2] but often poor health detrimentally affects a person's ability to form and maintain supportive social bonds [3] leading to a vicious cycle in which health and well-being are impacted negatively.", [["person", "SPECIES", 106, 112]]], ["This is especially true for individuals dealing with health conditions that require long-term assistance.", [["long-term assistance", "TREATMENT", 84, 104]]], ["Whether the impairment that restricts social life is physical as in the case of people with neuromotor disabilities, cognitive as in the case of dementia, emotional as seen in depression, or due to a neurodevelopmental disorder as in the case of autism, the effects of an impoverished social life on health range from reduced quality of life to reduced life-span [4] .IntroductionAs robots are becoming more common in healthcare, the social management of health is an aspect in which their assis-B Meia Chita-Tegmark mihaela.chita_tegmark@tufts.edu 1 Tufts University, 200 Boston Avenue, Medford, MA 01255, USA tance could be extremely valuable.", [["neuromotor disabilities", "DISEASE", 92, 115], ["dementia", "DISEASE", 145, 153], ["depression", "DISEASE", 176, 186], ["neurodevelopmental disorder", "DISEASE", 200, 227], ["autism", "DISEASE", 246, 252], ["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86], ["the impairment", "PROBLEM", 8, 22], ["neuromotor disabilities", "PROBLEM", 92, 115], ["dementia", "PROBLEM", 145, 153], ["depression", "PROBLEM", 176, 186], ["a neurodevelopmental disorder", "PROBLEM", 198, 227], ["autism", "PROBLEM", 246, 252], ["impairment", "OBSERVATION", 12, 22]]], ["Tickle-Degnen et al. [5] define the social self-management of health as \"the selfcare practices that ensure social comfort while supporting mental and physical well-being, such as by participating in valued social activities, maintaining rewarding interpersonal relationships, and seeking help from capable people\" (p.1).", [["people", "ORGANISM", 307, 313], ["people", "SPECIES", 307, 313], ["the selfcare practices", "TREATMENT", 73, 95]]], ["Developed at the intersection of assistive robotics and social robotics, the focus of SARs is to provide necessary aid for humans and to do so by engaging humans socially [7] .", [["humans", "ORGANISM", 123, 129], ["humans", "ORGANISM", 155, 161], ["humans", "SPECIES", 123, 129], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 123, 129], ["humans", "SPECIES", 155, 161], ["assistive robotics", "TREATMENT", 33, 51], ["social robotics", "TREATMENT", 56, 71]]], ["In healthcare, SARs are envisioned to play roles such as taking medical interviews [8] , monitoring and keeping a record of symptoms [9] , helping with pill sorting and medication schedules [10] , guiding people through therapeutic tasks [11] , providing companionship [12] , acting as stress reducers and mood enhancers [13] , and supporting social interactions between humans [14, 15] .IntroductionIn this paper we focus on the last role, that of robots assisting social interactions between people.", [["people", "ORGANISM", 205, 211], ["humans", "ORGANISM", 371, 377], ["people", "ORGANISM", 494, 500], ["people", "SPECIES", 205, 211], ["humans", "SPECIES", 371, 377], ["people", "SPECIES", 494, 500], ["symptoms", "PROBLEM", 124, 132], ["pill sorting and medication schedules", "TREATMENT", 152, 189]]], ["More specifically, we are interested in the application of SARs to the social manage-ment of health of people with health conditions that restrict or negatively impact their social life.", [["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109]]], ["We see these robots as assistants in breaking the above-mentioned vicious cycle in which poor health negatively impacts social bonds, the weakening of which, in turn, leads to further decline in health.IntroductionSeveral participatory science studies have shown that people with health conditions as well as their caregivers and therapists welcome support from robots not just for physical tasks, but also for social interaction.", [["people", "ORGANISM", 268, 274], ["people", "SPECIES", 268, 274]]], ["For example, Williams et al. [16] explored ways in which robots could augment workers with intellectual and developmental disabilities.", [["intellectual and developmental disabilities", "DISEASE", 91, 134]]], ["The study found that among the three most desired features for a SAR (as expressed by the workers) was the robot's ability to help facilitate more human connection between the workers during work, breaks and outside of work.IntroductionAnother study, by Moharana et al. [17] , focused on informal careregivers of people with dementia (usually spouses and close family members) and their requests in terms of robotic help with caregiving tasks.", [["dementia", "DISEASE", 325, 333], ["human", "ORGANISM", 147, 152], ["people", "ORGANISM", 313, 319], ["human", "SPECIES", 147, 152], ["people", "SPECIES", 313, 319], ["human", "SPECIES", 147, 152], ["The study", "TEST", 0, 9], ["Another study", "TEST", 236, 249], ["dementia", "PROBLEM", 325, 333], ["dementia", "OBSERVATION", 325, 333]]], ["In addition to functions such as regulating food intake, prompting and delivering medication, coaching the person with dementia through physical therapy exercises and motivating the person to be active, caregivers expressed desire for the robot to also support interactions between them and the person they were caring for.", [["dementia", "DISEASE", 119, 127], ["person", "SPECIES", 107, 113], ["person", "SPECIES", 182, 188], ["person", "SPECIES", 295, 301], ["medication", "TREATMENT", 82, 92], ["dementia", "PROBLEM", 119, 127], ["physical therapy exercises", "TREATMENT", 136, 162]]], ["Caregivers wanted robots that could facilitate positive interactions with the person they were providing care for, such as playing favorite songs and inviting both of them to share a dance.", [["person", "SPECIES", 78, 84], ["robots", "TREATMENT", 18, 24]]], ["They also wanted the robot to lessen the emotional stress of the interaction when the person requiring care was agitated and asked repetitive questions.", [["person", "SPECIES", 86, 92], ["agitated", "PROBLEM", 112, 120]]], ["In this situation, caregivers wanted the robot to answer in their place, distract the agitated person, and redirect the conversation to more enjoyable topics.", [["person", "SPECIES", 95, 101]]], ["Finally, since their emotional attachment to the person they were caring for made it difficult to deprive them of personal freedoms, caregivers wanted robots to act as neutral third parties in interactions and make the person cared for do things they did not want to do, for example take their medication, exercise, or stop eating unhealthy things.IntroductionRobot assistance in social interactions is also desired for children with disabilities.", [["children", "ORGANISM", 420, 428], ["person", "SPECIES", 49, 55], ["person", "SPECIES", 219, 225], ["children", "SPECIES", 420, 428]]], ["Most social interactions that children engage in happen in the context of play.", [["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38]]], ["Introducing structure to play scenarios through robotic facilitation can therefore be helpful for children with special needs.", [["children", "ORGANISM", 98, 106], ["children", "SPECIES", 98, 106], ["robotic facilitation", "TREATMENT", 48, 68]]], ["Robins et al. [18] interviewed a panel of experts comprised of therapists, teachers and parents of children with autism to investigate how robotic toys can assist social interactions and help children discover different play styles, including cooperative play.", [["autism", "DISEASE", 113, 119], ["children", "ORGANISM", 99, 107], ["children", "ORGANISM", 192, 200], ["children", "SPECIES", 99, 107], ["children", "SPECIES", 192, 200]]], ["A recurring theme in the panel's conversation was the need for motivating children with autism to play with others, sustain their interest in collaborative play and offer them support for how to engage others.", [["autism", "DISEASE", 88, 94], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82]]], ["Using data from this panel as well as from a review of the literature, Robins et al. [19] then explored designing robots that could facilitate different types of play with therapeutic benefits for children with autism.", [["autism", "DISEASE", 211, 217], ["children", "ORGANISM", 197, 205], ["children", "SPECIES", 197, 205], ["this panel", "TEST", 16, 26], ["robots", "TREATMENT", 114, 120], ["autism", "PROBLEM", 211, 217]]], ["The goal of the project was to design robots that empower children with special needs, to prevent isolation and build different skills including social ones.IntroductionThese findings suggest a few ways in which robots could assist social interactions between people for a better social management of health.", [["children", "ORGANISM", 58, 66], ["people", "ORGANISM", 260, 266], ["children", "SPECIES", 58, 66], ["people", "SPECIES", 260, 266], ["isolation", "TREATMENT", 98, 107]]], ["While the other roles for SARs such as providing companionship or coaching focus on human-robot interaction, assisting with social life focuses on humanhuman interactions and how robots can provide assistance during the interaction.", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["SARs", "PROBLEM", 26, 30]]], ["The functions that the robot has to fulfill and the capabilities it needs to have to provide effective social support for human-human interactions can be quite different from what is required of a robot for successful human-robot interaction alone.", [["human", "ORGANISM", 122, 127], ["human", "ORGANISM", 128, 133], ["human", "ORGANISM", 218, 223], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 218, 223], ["human-human interactions", "TREATMENT", 122, 146]]], ["At this point there doesn't seem to be a concerted effort towards designing robots that can effectively support social interactions between people, but such an effort would be highly beneficial for the development of SARs that could contribute to the social management of health.IntroductionMost of the studies in social HRI focus on the role of the robot as interactant rather than as assistant to human-human social interactions.", [["people", "ORGANISM", 140, 146], ["human", "ORGANISM", 399, 404], ["human", "ORGANISM", 405, 410], ["HRI", "PROTEIN", 321, 324], ["people", "SPECIES", 140, 146], ["human", "SPECIES", 399, 404], ["human", "SPECIES", 405, 410], ["human", "SPECIES", 399, 404], ["human", "SPECIES", 405, 410], ["robots", "TREATMENT", 76, 82], ["SARs", "PROBLEM", 217, 221], ["the studies", "TEST", 299, 310]]], ["However, the field has begun to pay more attention to robots being part of and even intervening in social interactions between humans in roles such as group member [20, 21] , facilitator [22, 23] , or moderator [24, 25] .", [["humans", "ORGANISM", 127, 133], ["humans", "SPECIES", 127, 133], ["humans", "SPECIES", 127, 133]]], ["HRI studies of robots intervening in human-human interactions vary widely in their scope, and are scattered across domains of application, using very different robot designs in a variety of context.", [["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 43, 48], ["HRI", "PROTEIN", 0, 3], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 43, 48], ["HRI studies", "TEST", 0, 11], ["scattered", "OBSERVATION_MODIFIER", 98, 107]]], ["Some are simply case studies (e.g., [26] ), others engage larger participant samples (e.g., [27] ), some studies investigate the effects of the robot in the context of specific tasks (e.g., [20] ), some leave the interaction free and open to what participants want to make of it, constrained just by the robot's capabilities (e.g., [28] ).", [["participants", "SPECIES", 247, 259], ["simply case studies", "TEST", 9, 28], ["some studies", "TEST", 100, 112]]], ["Some of the robots used are designed with clinical applications in mind, such as assisting children with autism (e.g., [29] ) or providing couple's therapy (e.g., [30] ), but many of them are intended for general use, for purposes such as promoting inter-generational interactions (e.g., [31] ).", [["autism", "DISEASE", 105, 111], ["children", "ORGANISM", 91, 99], ["children", "SPECIES", 91, 99]]], ["Finally, some of these studies were conducted in lab settings (e.g., [27] ) while others in more naturalistic settings such as nursing homes (e.g., [32] ).", [["these studies", "TEST", 17, 30]]], ["In this paper we draw on this growing, although disparate, literature, for insights into how robots could assist individuals with health conditions in the management of their social lives.IntroductionThe contribution of this paper is threefold: (a) we offer a framework for functions that a mediator robot could perform that are motivated by the special social needs that people with health conditions have; (b) we thematically organize and review the existing literature on robots supporting human-human interactions in both clinical and non-clinical settings and explain how the findings and ideas in these studies fit in the proposed framework; and (c) we identify and discuss the challenges of designing SARs for supporting social interactions between humans.", [["people", "ORGANISM", 372, 378], ["human", "ORGANISM", 493, 498], ["human", "ORGANISM", 499, 504], ["humans", "ORGANISM", 756, 762], ["people", "SPECIES", 372, 378], ["human", "SPECIES", 493, 498], ["human", "SPECIES", 499, 504], ["humans", "SPECIES", 756, 762], ["human", "SPECIES", 493, 498], ["humans", "SPECIES", 756, 762], ["a mediator robot", "TREATMENT", 289, 305]]], ["Our framework and the summaries of the reviewed studies highlight opportunities for robot design as well as future HRI research.Functions of Mediator Robots for the Social Management of HealthThe social lives of people with serious health conditions are different from the norm in several important ways.", [["people", "ORGANISM", 212, 218], ["HRI", "PROTEIN", 115, 118], ["people", "SPECIES", 212, 218], ["robot design", "TREATMENT", 84, 96], ["Mediator Robots", "TREATMENT", 141, 156]]], ["First, people with health conditions can have disability-specific difficulties in interacting with others.", [["people", "ORGANISM", 7, 13], ["people", "SPECIES", 7, 13], ["disability", "PROBLEM", 46, 56]]], ["For example, people with Parkinson's Disease, a neuromotor disorder, might have difficulty in expressing emotions in conversations with others due to poor control of their facial muscles [33, 34] , while children with autism might have difficulty decoding the emotions of others in interactions [35] .", [["facial muscles", "ANATOMY", 172, 186], ["Parkinson's Disease", "DISEASE", 25, 44], ["neuromotor disorder", "DISEASE", 48, 67], ["autism", "DISEASE", 218, 224], ["people", "ORGANISM", 13, 19], ["facial muscles", "ORGANISM_SUBDIVISION", 172, 186], ["children", "ORGANISM", 204, 212], ["people", "SPECIES", 13, 19], ["children", "SPECIES", 204, 212], ["Parkinson's Disease", "PROBLEM", 25, 44], ["a neuromotor disorder", "PROBLEM", 46, 67], ["facial muscles", "ANATOMY", 172, 186]]], ["Second, people with serious health conditions tend to be more dependent on others for daily functioning than their healthy peers and this can shape the types of interactions they have within a relationship.", [["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14], ["serious health conditions", "PROBLEM", 20, 45]]], ["For example, people with severe health conditions, such as Alzheimer's disease, in later stages, might need round-the-clock supervision and the extent to which they can make autonomous decisions about their lives and interactions with others can be limited [36] .", [["Alzheimer's disease", "DISEASE", 59, 78], ["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["severe health conditions", "PROBLEM", 25, 49], ["Alzheimer's disease", "PROBLEM", 59, 78], ["severe", "OBSERVATION_MODIFIER", 25, 31]]], ["Finally, there are types of social relationships that are unique to people with chronic health conditions, namely the relationships they form with healthcare professionals such as doctors and therapists, and their relationships with caregivers.", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["chronic health conditions", "PROBLEM", 80, 105]]], ["These can pose specific challenges such as forming and sustaining fruitful therapeutic relationships [37] , and adjusting to the dynamics of caregiver-care recipient relationships, which can often be fraught with frustration on both sides.", [["frustration on both sides", "PROBLEM", 213, 238]]], ["Given these special social circumstances of people with health conditions, we propose that SARs supporting humanhuman interactions can assist people with health conditions in their management of social life by fulfilling these functions (for a summary see Fig. 1 ):Functions of Mediator Robots for the Social Management of Health1.", [["people", "ORGANISM", 44, 50], ["people", "ORGANISM", 142, 148], ["people", "SPECIES", 44, 50], ["people", "SPECIES", 142, 148]]], ["Changing how the person with a health condition is perceived by others (e.g., by correcting other's misconceptions about impairments); 2.", [["person", "SPECIES", 17, 23]]], ["Enhancing the social behavior of the person with a health condition (e.g., by supplementing social behavior that the person is not able to convey); 3.", [["person", "SPECIES", 37, 43], ["person", "SPECIES", 117, 123], ["social behavior", "OBSERVATION_MODIFIER", 14, 29]]], ["Modifying the social behavior of others towards the person with a health condition (e.g., by modeling good behavior or by raising awareness of problematic behavior); 4.", [["person", "SPECIES", 52, 58]]], ["Providing structure for interactions between people with health conditions and others (e.g., by guiding conversation partners through a therapeutic conversation protocol); 5.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["Changing how the person with a health condition feels in a social context (e.g., by making the person feel listened to or at ease in a stressful social interaction).Functions of Mediator Robots for the Social Management of HealthIn what follows we will look closely at each of these functions and explain why they are necessary or desirable and how studies in HRI have begun to research these functions in robots (for a summary see Fig. 2 ).", [["HRI", "PROTEIN", 360, 363], ["person", "SPECIES", 17, 23], ["person", "SPECIES", 95, 101], ["Mediator Robots", "TREATMENT", 178, 193]]], ["We also offer ideas about possible robot design directions and gaps in our HRI knowledge.Changing How a Person with a Health Condition is PerceivedPeople react in different ways to a health condition, from impressive resilience to major distress, which can profoundly influence the prosocial responses they receive from others [38] .", [["HRI", "PROTEIN", 75, 78], ["People", "SPECIES", 147, 153], ["robot design directions", "TREATMENT", 35, 58], ["major distress", "PROBLEM", 231, 245]]], ["The way in which people with health conditions are perceived by others can have a major impact on their health.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23]]], ["In the context of healthcare, how positive an impression a patient can make can directly affect how much care they receive.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66]]], ["Studies have shown that doctors are more inclined to prescribe more care for more likable patients.", [["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98]]], ["However, doctors seem to be influenced by a patient's perceived traits at an unconscious level.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51]]], ["For example, in a study of doctors making decisions about Intensive Care Unit (ICU) admissions, the doctors ranked the patient's \"emotional state\" as an important consideration only 6 percent of the times.", [["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126]]], ["However, when a vignette described a hypothetical patient as being \"upbead and courageous\" as opposed to \"sad and discouraged\" the same doctors were three times more likely to recommend admission to ICU [39] .", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57]]], ["Other studies have similarly shown that \"likable and competent\" simulated patients elicited from doctors more recommendations for follow-up visits as well as more staff time spent on the patient's education [40] .", [["patients", "ORGANISM", 74, 82], ["patient", "ORGANISM", 187, 194], ["patients", "SPECIES", 74, 82], ["patient", "SPECIES", 187, 194], ["Other studies", "TEST", 0, 13]]], ["Doctors are not the only ones influenced by patients' character attributes and affect.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["In a study of empathetic responses to naturally-varying affect in real hospital patients, participants (who were not medical professionals) watched videointerviews of chronically or terminally ill patients talking about their quality of life.", [["terminally ill", "DISEASE", 182, 196], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 80, 88], ["participants", "SPECIES", 90, 102], ["patients", "SPECIES", 197, 205], ["a study", "TEST", 3, 10]]], ["Participants showed willingness to aid those patients displaying negative affect slightly more than those displaying positive affect, but patients showing little affect were offered the least amount of help (Fig. 2 ).Showcasing Positive AttributesAlthough there is much opportunity for exploring ways in which robots could accentuate one's positive and empathyinviting features and behaviors, to our knowledge only one HRI study has investigated how a robot can change people's perceptions of a person with a health condition.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 138, 146], ["people", "ORGANISM", 469, 475], ["HRI", "PROTEIN", 419, 422], ["Participants", "SPECIES", 0, 12], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 138, 146], ["people", "SPECIES", 469, 475], ["person", "SPECIES", 495, 501], ["HRI study", "TEST", 419, 428]]], ["Chita-Tegmark et al. [41] conducted a vignette study in which robots partook in a conversation between a patient and a health-care provider: the robot gave a summary of the patient's treatment progress.", [["patient", "ORGANISM", 105, 112], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 105, 112], ["patient", "SPECIES", 173, 180], ["a vignette study", "TEST", 36, 52]]], ["In doing so, the robot used either task-centered language, emphasizing the patient's level of compliance to the treatment plan, or patient-centered language emphasizing the patient's choices and difficulties with regards to the treatment plan.", [["patient", "ORGANISM", 75, 82], ["patient", "ORGANISM", 131, 138], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 75, 82], ["patient", "SPECIES", 131, 138], ["patient", "SPECIES", 173, 180], ["the treatment plan", "TREATMENT", 108, 126], ["the treatment plan", "TREATMENT", 224, 242]]], ["Through its use of language, the robot was able to manipulate participants' impressions of the patient: in the patient-centered condition people perceived the patient more positively: they thought the patient was more competent, honest and self-disciplined rather than disruptive, hostile and disorganized.", [["patient", "ORGANISM", 95, 102], ["patient", "ORGANISM", 111, 118], ["people", "ORGANISM", 138, 144], ["patient", "ORGANISM", 159, 166], ["patient", "ORGANISM", 201, 208], ["participants", "SPECIES", 62, 74], ["patient", "SPECIES", 95, 102], ["patient", "SPECIES", 111, 118], ["people", "SPECIES", 138, 144], ["patient", "SPECIES", 159, 166], ["patient", "SPECIES", 201, 208]]], ["Given how important it is for people with health conditions to be perceived in a favorable way by others, there is a great opportunity for SARs to positively impact these people's health through social support.", [["people", "ORGANISM", 30, 36], ["people", "ORGANISM", 171, 177], ["people", "SPECIES", 30, 36], ["people", "SPECIES", 171, 177]]], ["SARs could contribute to interactions between people with health conditions and others in such a way that highlights the positive attributes of the person with the health condition.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["person", "SPECIES", 148, 154], ["SARs", "PROBLEM", 0, 4]]], ["SARs could do this very subtly through choosing language that focuses on the person's agency, resilience, competence etc., like the study above has done.Facilitating Demonstrations of Agency and AchievementsAnother way for robots to influence how a person with a health condition is perceived is to introduce in conversations topics that individuate, personalize, and highlight the achievements of the person.", [["person", "SPECIES", 77, 83], ["person", "SPECIES", 249, 255], ["person", "SPECIES", 402, 408], ["the study", "TEST", 128, 137]]], ["To humanize patients, Haque and Waytz recommend that, at a minimum, reminders be offered to the medical professionals and others about the patient's past or present profession, hobbies and family life [42] .", [["patients", "ORGANISM", 12, 20], ["patient", "ORGANISM", 139, 146], ["patients", "SPECIES", 12, 20], ["patient", "SPECIES", 139, 146]]], ["Additionally, creating opportunities to reflect on the creative overcoming of challenges caused by the health condition, instead of the impairments associated with it, can be a fruitful way of changing for the better the way the person with the health condition is perceived.", [["person", "SPECIES", 229, 235], ["the impairments", "PROBLEM", 132, 147]]], ["This is especially important for interactions between patients and healthcare providers, which tend to be focused on the disease and its negative effects on the patient, with little room for discussing the patient's achievements and thus with little opportunity to observe the patient exhibit positive affect.Correcting MisimpressionsAdditionally, it is often the health condition itself that leads to negative impression formation.", [["patients", "ORGANISM", 54, 62], ["patient", "ORGANISM", 161, 168], ["patient", "ORGANISM", 206, 213], ["patient", "ORGANISM", 277, 284], ["patients", "SPECIES", 54, 62], ["patient", "SPECIES", 161, 168], ["patient", "SPECIES", 206, 213], ["patient", "SPECIES", 277, 284], ["the disease", "PROBLEM", 117, 128], ["positive affect", "PROBLEM", 293, 308]]], ["For example, people with Parkinson's Disease are often perceived to be less extraverted and more neurotic [43] and, if a woman, as less supportive [34] .", [["Parkinson's Disease", "DISEASE", 25, 44], ["neurotic", "DISEASE", 97, 105], ["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["woman", "SPECIES", 121, 126], ["Parkinson's Disease", "PROBLEM", 25, 44]]], ["This is due to a symptom of Parkinson's Disease called facial masking, which affects facial muscles and facial expression.", [["facial", "ANATOMY", 55, 61], ["facial muscles", "ANATOMY", 85, 99], ["facial", "ANATOMY", 104, 110], ["Parkinson's Disease", "DISEASE", 28, 47], ["facial", "ORGAN", 55, 61], ["facial muscles", "ORGAN", 85, 99], ["facial", "ORGAN", 104, 110], ["Parkinson's Disease", "PROBLEM", 28, 47], ["facial masking", "PROBLEM", 55, 69], ["Parkinson", "OBSERVATION", 28, 37], ["facial", "ANATOMY", 55, 61], ["masking", "OBSERVATION", 62, 69], ["facial muscles", "ANATOMY", 85, 99], ["facial", "ANATOMY", 104, 110], ["expression", "OBSERVATION", 111, 121]]], ["In these situations, in which the health condition is the root cause of the misimpression, SARs could intervene by correcting misconceptions and alerting people to which behavioral cues are valid, and which are not.", [["root", "ANATOMY", 58, 62], ["people", "ORGANISM", 154, 160], ["people", "SPECIES", 154, 160], ["the misimpression", "PROBLEM", 72, 89], ["SARs", "PROBLEM", 91, 95]]], ["In the context of Parkinson's Disease, for example, SARs could instruct interactants to pay attention to what the person with Parkinson's Disease is saying as a better indicator of their personality and mood, rather than their facial expression, which is affected by the disease [44] .", [["facial", "ANATOMY", 227, 233], ["Parkinson's Disease", "DISEASE", 18, 37], ["Parkinson's Disease", "DISEASE", 126, 145], ["person", "SPECIES", 114, 120], ["Parkinson's Disease", "PROBLEM", 18, 37], ["SARs", "PROBLEM", 52, 56], ["Parkinson's Disease", "PROBLEM", 126, 145], ["Parkinson", "OBSERVATION", 18, 27]]], ["In addition to supporting others in forming better impressions of people with health conditions, SARs could also assist people with health conditions by compensating for a variety of social impairments caused by the health condition itself.Enhancing the Social Behavior of a Person with a Health ConditionMany health conditions can affect a person's ability to engage in positive social behaviors.", [["social impairments", "DISEASE", 183, 201], ["people", "ORGANISM", 66, 72], ["people", "ORGANISM", 120, 126], ["people", "SPECIES", 66, 72], ["people", "SPECIES", 120, 126], ["person", "SPECIES", 341, 347], ["social impairments", "PROBLEM", 183, 201]]], ["A disorder that has received much attention from the robotics community is Autism Spectrum Disorder (ASD).", [["disorder", "DISEASE", 2, 10], ["Autism Spectrum Disorder", "DISEASE", 75, 99], ["ASD", "DISEASE", 101, 104], ["A disorder", "PROBLEM", 0, 10], ["Autism Spectrum Disorder (ASD)", "PROBLEM", 75, 105], ["disorder", "OBSERVATION", 2, 10]]], ["Social impairments are a core symtpom of ASD, a neurodevelopmental disorder affecting 1 in 59 individuals [45] .", [["Social impairments", "DISEASE", 0, 18], ["ASD", "DISEASE", 41, 44], ["neurodevelopmental disorder", "DISEASE", 48, 75], ["ASD", "PROBLEM", 41, 44], ["a neurodevelopmental disorder", "PROBLEM", 46, 75]]], ["ASD is characterized by persistent social deficits across multiple contexts, such as: abnormal social approach, failure to initiate and respond to social interactions, abnormalities in in eye contact and body language, difficulties in sharing imaginative play or absence of interest in peers.", [["eye", "ANATOMY", 188, 191], ["body", "ANATOMY", 204, 208], ["ASD", "DISEASE", 0, 3], ["eye", "ORGANISM_SUBDIVISION", 188, 191], ["body", "ORGANISM_SUBDIVISION", 204, 208], ["ASD", "PROBLEM", 0, 3], ["persistent social deficits", "PROBLEM", 24, 50], ["abnormal social approach", "PROBLEM", 86, 110], ["abnormalities in in eye contact", "PROBLEM", 168, 199], ["persistent", "OBSERVATION_MODIFIER", 24, 34], ["social deficits", "OBSERVATION", 35, 50], ["eye", "ANATOMY", 188, 191]]], ["Several case-studies have documented the potential for robots to support social behavior in children with ASD by incentivizing communication and evoking, eliciting rewarding and reinforcing social behavior.Increasing Social MotivationGiannopulu and Pradel [26] have documented a case of a child with autism using a robot as a mediator for his interaction with a therapist in a free play scenario.", [["ASD", "DISEASE", 106, 109], ["autism", "DISEASE", 300, 306], ["children", "ORGANISM", 92, 100], ["children", "SPECIES", 92, 100], ["child", "SPECIES", 289, 294], ["ASD", "PROBLEM", 106, 109]]], ["The robot had a very simple design: a schematic face-like cover made of geometric shapes (circles for eyes and mouth, and triangle for nose) on top of a remote-controlled locomotion hardware, able to move forward, move back and swivel.", [["eyes", "ANATOMY", 102, 106], ["mouth", "ANATOMY", 111, 116], ["nose", "ANATOMY", 135, 139], ["eyes", "MULTI-TISSUE_STRUCTURE", 102, 106], ["mouth", "ORGANISM_SUBDIVISION", 111, 116], ["nose", "ORGANISM_SUBDIVISION", 135, 139], ["a schematic face", "PROBLEM", 36, 52], ["a remote-controlled locomotion hardware", "TREATMENT", 151, 190], ["geometric shapes", "OBSERVATION", 72, 88], ["mouth", "ANATOMY", 111, 116], ["locomotion hardware", "OBSERVATION", 171, 190]]], ["An operator manipulated the robot wirelessly in the following way: if the child approached, the robot moved back; if the child moved away, the robot followed the child; and if the child was motionless, the robot turned itself around to grab the child's attention.", [["child", "ORGANISM", 180, 185]]], ["After establishing an interaction with the robot, the child began to use the robot to express positive emotion, an interaction cue directed at the therapist.", [["the robot", "TREATMENT", 73, 82]]], ["When the child interacted in a standalone manner with the robot, the positive emotion expression was quasi-absent, leading the authors to believe that the expression of enjoyment was the indication of a 'passage' from child-robot interaction to a child-therapist interaction.", [["child", "ORGANISM", 9, 14]]], ["The authors interpret this as an indication that the child was using the robot as a tool for human-human interaction and that the interest elicited by the robot was an essential stepping stone for facilitating the interaction with another person.", [["human", "ORGANISM", 93, 98], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 99, 104], ["person", "SPECIES", 239, 245], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 99, 104], ["an essential stepping stone", "PROBLEM", 165, 192], ["stone", "OBSERVATION", 187, 192]]], ["Robins et al. [29] described three case studies conducted with minimally verbal, low functioning children with autism.", [["autism", "DISEASE", 111, 117], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["case studies", "TEST", 35, 47], ["autism", "PROBLEM", 111, 117]]], ["In the studies, a humanoid robot facilitated interactions between these low functioning autistic children and other people.", [["low functioning autistic", "DISEASE", 72, 96], ["children", "ORGANISM", 97, 105], ["people", "ORGANISM", 116, 122], ["children", "SPECIES", 97, 105], ["people", "SPECIES", 116, 122], ["the studies", "TEST", 3, 14], ["a humanoid robot", "TREATMENT", 16, 32]]], ["Notable behaviors that the children engaged in included reaching for the experimenter's hand, which was surprising to both the experimenter, parent and therapist given the autism severity of the child.", [["hand", "ANATOMY", 88, 92], ["autism", "DISEASE", 172, 178], ["children", "ORGANISM", 27, 35], ["hand", "ORGANISM_SUBDIVISION", 88, 92], ["children", "SPECIES", 27, 35]]], ["Another example of engaging in social behavior in the context of playing with the robot was exploring the teacher's eyes and face after exploring the robot's eyes and face as well as sharing excitement with the teacher by reaching out to her and asking her to join in the game.", [["eyes", "ANATOMY", 116, 120], ["eyes", "ANATOMY", 158, 162], ["eyes", "ORGAN", 116, 120], ["eyes", "ORGAN", 158, 162]]], ["Eventually the child was able to successfully engage in the same imitation game with another child.", [["child", "ORGANISM", 15, 20]]], ["The authors argue that the robot allowed the children to demonstrate some interactional competencies and generalize this behavior to the co-present others.Increasing Social MotivationBeyond case studies, Kim et al. [46] showed that in a structured play interaction, children with autism spoke more with an adult confederate when the interaction partner was a robot than when it was another human or a computer game.", [["autism", "DISEASE", 280, 286], ["children", "ORGANISM", 45, 53], ["children", "ORGANISM", 266, 274], ["human", "ORGANISM", 390, 395], ["children", "SPECIES", 45, 53], ["children", "SPECIES", 266, 274], ["human", "SPECIES", 390, 395], ["human", "SPECIES", 390, 395]]], ["The researchers used Pleo, a dinosaur shaped robot which was programmed to show interest in different objects and exhibit positive and negative emotions.", [["a dinosaur shaped robot", "TREATMENT", 27, 50], ["positive", "OBSERVATION", 122, 130], ["negative emotions", "OBSERVATION", 135, 152]]], ["The children were excited and interested in the robot and were thus motivated to ask how the robot works, whether it \"was real\" and what the robot was doing.", [["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12]]], ["The authors suggest that the inclusion of the robot in the task can thus serve as an embedded reinforcer of social behavior.Increasing Social MotivationIn the case of autism elicitation and maintenance of social behavior is a challenge specific to the disorder and robots can help by increasing social motivation and evoking and reinforcing social engagement.", [["autism", "DISEASE", 167, 173], ["autism elicitation", "PROBLEM", 167, 185], ["the disorder", "PROBLEM", 248, 260]]], ["For example, this type of assistance might also be useful for people with depression or anxiety where social behavior might be absent or insufficient because of emotional difficulties [47] .Augmenting and Modifying Social Behaviors Affected by DiseaseIn the context of other health conditions robots might be useful in enhancing social behavior not by eliciting more of it, but by modifying or adding to it in specific ways.", [["depression", "DISEASE", 74, 84], ["anxiety", "DISEASE", 88, 95], ["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68], ["depression", "PROBLEM", 74, 84], ["anxiety", "PROBLEM", 88, 95], ["emotional difficulties", "PROBLEM", 161, 183]]], ["For example, in the case of Parkinson's Disease, it has been proposed that a robot could be used to convey emotions that the person with Parkinson't Disease is incapable of expressing due to facial masking [5] .", [["facial", "ANATOMY", 191, 197], ["Parkinson's Disease", "DISEASE", 28, 47], ["person", "SPECIES", 125, 131], ["Parkinson's Disease", "PROBLEM", 28, 47], ["Parkinson't Disease", "PROBLEM", 137, 156], ["facial masking", "PROBLEM", 191, 205], ["Parkinson", "OBSERVATION", 28, 37]]], ["Arkin and Pettinati [48] have proposed the development of a robot co-mediator that would increase the emotional communicative bandwidth of the person with PD in such a way that would facilitate empathic response in a caregiver.", [["Arkin", "CHEMICAL", 0, 5], ["PD", "DISEASE", 155, 157], ["Arkin", "SIMPLE_CHEMICAL", 0, 5], ["person", "SPECIES", 143, 149], ["PD", "TREATMENT", 155, 157]]], ["The robot would express through body motions and postures the mental states of the person with Parkinson's Disease with the goal of eliciting empathy when incongruences arise between the mental state of the person with Parkinson's Disease and the other interactant.Augmenting and Modifying Social Behaviors Affected by DiseaseMost of the studies on how robots can help enhance the social behavior of people with health conditions are observational case studies or conceptual proposals.", [["body", "ANATOMY", 32, 36], ["Parkinson's Disease", "DISEASE", 95, 114], ["Parkinson's Disease", "DISEASE", 219, 238], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["people", "ORGANISM", 400, 406], ["person", "SPECIES", 83, 89], ["person", "SPECIES", 207, 213], ["people", "SPECIES", 400, 406], ["Parkinson's Disease", "PROBLEM", 95, 114], ["Parkinson's Disease", "PROBLEM", 219, 238], ["observational case studies", "TEST", 434, 460]]], ["More HRI studies are needed to determine how robots can address social interaction needs that are specific to various health conditions.", [["HRI", "PROTEIN", 5, 8], ["More HRI studies", "TEST", 0, 16]]], ["Most of the studies in which robots help with social interactions focus on autism, but there are many other health conditions that negatively impact the ability to engage in effective and appropriate social behavior that SARs could assist with.", [["autism", "DISEASE", 75, 81], ["the studies", "TEST", 8, 19]]], ["However, in social interactions it is not only the social behavior of the person with the health condition that matters, but also that of the interaction partner.", [["person", "SPECIES", 74, 80]]], ["Robots could provide support for those interacting with people with health care conditions with the aim of making such relationships stronger and more positive.Supporting the Social Behavior of Healthcare Providers, Caregivers and OthersIn social interactions people with health conditions run the risk of being reduced to their impairments.", [["people", "ORGANISM", 56, 62], ["people", "ORGANISM", 260, 266], ["people", "SPECIES", 56, 62], ["people", "SPECIES", 260, 266]]], ["Specifically, people with health conditions may be treated less like persons and more like objects or nonhuman animals [42, 49] .", [["people", "ORGANISM", 14, 20], ["persons", "ORGANISM", 69, 76], ["people", "SPECIES", 14, 20], ["persons", "SPECIES", 69, 76]]], ["It is not that empathetic and humanizing care is not an aspiration of those providing it; in fact, it very much is, but often dehumanization ensues because of the need of health care providers and caregivers to create distance and emotional barriers to protect themselves from the emotional drain ensued by dealing with health care problems on a daily basis [42, 50, 51] .", [["empathetic and humanizing care", "TREATMENT", 15, 45], ["health care providers", "TREATMENT", 171, 192], ["emotional barriers", "TREATMENT", 231, 249], ["the emotional drain", "TREATMENT", 277, 296], ["aspiration", "OBSERVATION", 56, 66]]], ["However, empathy and humanization of care has been shown to be beneficial for health outcomes and many studies highlight the importance of empathy and patient-centered approaches in medical practice [52] [53] [54] .", [["patient", "ORGANISM", 151, 158], ["patient", "SPECIES", 151, 158], ["many studies", "TEST", 98, 110]]], ["SARs could be used to support health care providers and caregivers when interacting with people with health conditions to ensure that dehumanization is avoided.", [["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95]]], ["Based on studies in HRI so far, we propose four main ways in which SARs could support the social behavior of health care providers and caregivers: (a) by raising awareness of one's social behavior and its effects on others, (b) by providing feedback that supports empathetic behavior, (c) by helping people set and maintain empathy goals for their interactions, and (d) by detecting and intervening when problematic interactions occur.Raising Awareness of Effects of Social BehaviorA first requirement for self-correcting one's problematic social behavior is being aware of it and of its effects on others.", [["people", "ORGANISM", 300, 306], ["HRI", "PROTEIN", 20, 23], ["people", "SPECIES", 300, 306], ["studies", "TEST", 9, 16]]], ["However, oftentimes people remain oblivious to what they are doing and how it affects those around.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["Hoffman et al. [57] used an emoting and empathy-evoking robot, Kip1, to increase awareness of the effect of one's behavior in an interaction.", [["Kip1", "GENE_OR_GENE_PRODUCT", 63, 67], ["Kip1", "PROTEIN", 63, 67]]], ["Also, couples attributed social human characteristics to the reactive robot.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["reactive robot", "OBSERVATION", 61, 75]]], ["Such capabilities in robots could also be used in the context of caregiving.", [["robots", "TREATMENT", 21, 27]]], ["This could assist health care providers and caregivers in monitoring their own social behavior and correcting unintended, dehumanizing or unempathetic aspects of the interaction.Providing Feedback that Supports Positive Social InteractionsA step further in assisting people with the management of their social behavior is to provide feedback that supports positive social behavior.", [["people", "ORGANISM", 267, 273], ["people", "SPECIES", 267, 273]]], ["Tahir et al. [58] used a Nao robot for providing real-time feedback to participants in a dyadic conversation.", [["participants", "SPECIES", 71, 83], ["a Nao robot", "TREATMENT", 23, 34]]], ["The Nao sensed and recorded conversational cues (e.g., number of natural turns, speaking percentage, interruptions etc.) and prosodic cues (e.g., amplitude) and then used machine learning algorithms to determine the social state of the participants (level of interest, agreement and dominance).", [["participants", "SPECIES", 236, 248], ["prosodic cues", "TEST", 125, 138], ["learning algorithms", "TREATMENT", 179, 198]]], ["Based on its model of the participants' state, Nao would alert the speakers when their voice was too high or too low or when the conversation was problematic due to too many disagreements or interruptions.", [["participants", "SPECIES", 26, 38]]], ["The robot provided sociofeedback, alerts through speech accompanied by body postures in the following situations: when the conversation partners seemed uninterested in the discussion (\"You both seem uninterested.\"), when one person was speaking too much (\"You are talking a lot.\"), when one person was being too aggressive (\"Please calm down.\"), when someone's voice was too loud (\"Please lower your volume.\") or not loud enough (\"I am sorry, I cannot hear you.\") and when the conversation was proceeding normally (\"Good, carry on.\").", [["body", "ANATOMY", 71, 75], ["aggressive", "DISEASE", 312, 322], ["body", "ORGANISM_SUBDIVISION", 71, 75], ["person", "SPECIES", 225, 231], ["person", "SPECIES", 291, 297]]], ["To validate the use of the robot as a social mediator, participants were asked to produce certain behaviors such as talk too loud, too much or to interrupt frequently.", [["participants", "SPECIES", 55, 67]]], ["Participants felt that Nao's performance was good in terms of clarity: whom it was addressing and what it was saying.", [["Participants", "SPECIES", 0, 12], ["Nao's performance", "TEST", 23, 40]]], ["In terms of timing, some participants felt interrupted by the Nao.", [["participants", "SPECIES", 25, 37]]], ["Most importantly participants indicated that they liked receiving socio-feedback from Nao and voted the Nao as their second favorite platform for receiving sociofeedback after virtual humans.Providing Feedback that Supports Positive Social InteractionsAs opposed to the study by Hoffman et al. [57] , in which the robot had a peripheral role in the interaction, in this study the robot intervened in the conversation.", [["humans", "ORGANISM", 184, 190], ["participants", "SPECIES", 17, 29], ["humans", "SPECIES", 184, 190], ["humans", "SPECIES", 184, 190], ["the study", "TEST", 266, 275]]], ["Also, while in the study by Hoffman et al. the robot's behavior was evocative, in this study it was evaluative.", [["this study", "TEST", 82, 92]]], ["Although the results of the study seem promising (participants reported favorable impressions of the robot and a desire to receive sociofeedback), it is unclear how welcome the sociofeedback would be in a real interaction, one in which behavior was not acted, especially when the robot points out undesired behavior.", [["participants", "SPECIES", 50, 62], ["the study", "TEST", 24, 33], ["undesired behavior", "PROBLEM", 297, 315]]], ["People might feel uncomfortable having their interaction evaluated in this manner by the robot.Providing Feedback that Supports Positive Social InteractionsAlthough research remains to be done to determine the ecological validity of this particular approach, the general idea of having robots infuse interactions with supportive social cognitions through sociofeedback merits further attention.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["uncomfortable", "PROBLEM", 18, 31], ["robots infuse interactions", "TREATMENT", 286, 312]]], ["In the context of caregiving, sociofeedback could help rapidly deescalate tense interactions and further encourage positive ones.", [["tense interactions", "PROBLEM", 74, 92]]], ["Moharana et al. [17] recounts the desire of a caregiver who wanted a robot that could remind her that her husband's anger was not because of her poor care towards him but because of his dementia.", [["dementia", "DISEASE", 186, 194], ["his dementia", "PROBLEM", 182, 194], ["dementia", "OBSERVATION", 186, 194]]], ["Such cognitions could perhaps be empathy-inducing for the caregiver and humanize the person receiving care.Promoting Positive Interaction GoalsAnother way in which robots could support caregivers is by helping them set and maintain positive goals for their interactions.", [["person", "SPECIES", 85, 91], ["Positive", "OBSERVATION_MODIFIER", 117, 125], ["Interaction", "OBSERVATION", 126, 137]]], ["This could be highly beneficial in care scenarios especially in interactions that have competing and perhaps even conflicting goals, for example, making sure a person with dementia takes their medication on time, while also maintaining a patient, tolerant attitude in the face of their forgetfulness.", [["dementia", "DISEASE", 172, 180], ["forgetfulness", "DISEASE", 286, 299], ["patient", "ORGANISM", 238, 245], ["person", "SPECIES", 160, 166], ["patient", "SPECIES", 238, 245], ["dementia", "PROBLEM", 172, 180], ["their forgetfulness", "PROBLEM", 280, 299], ["forgetfulness", "OBSERVATION", 286, 299]]], ["Wilson et al. [59] have developed a framework for evaluating the design of human-robot relationships when tradoffs appear between the succesful completion of task, and the maintainance of positive relationships with the human user.", [["human", "ORGANISM", 75, 80], ["human", "ORGANISM", 220, 225], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 220, 225], ["tradoffs", "TREATMENT", 106, 114]]], ["This framework could be adapted to scenarios involing robot mediation of human-human interactions that require the balancing of different types of goals.Promoting Positive Interaction GoalsShort and Matari\u0107 [20] used robots as mediators in collaborative tasks, which influenced the interactions by promoting different types of goals.", [["human", "ORGANISM", 73, 78], ["human", "ORGANISM", 79, 84], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 79, 84], ["human-human interactions", "TREATMENT", 73, 97], ["Positive", "OBSERVATION_MODIFIER", 163, 171], ["Interaction", "OBSERVATION", 172, 183]]], ["They developed two algorithms to specify the robot's behavior: one in which the robot suggests goals that are optimal from a performance-maximizing standpoint (performance-reinforcing) and an algorithm in which the robot suggests goals that the poorest-performing team member can help accomplish (performance-equalizing), thus increasing the collaborative contribution of this member.", [["an algorithm", "TEST", 189, 201]]], ["Contrary to their hypothesis they found that group cohesion was higher in the performance-reinforcing rather than the performance equalizing-condition.", [["group cohesion", "PROBLEM", 45, 59], ["higher", "OBSERVATION_MODIFIER", 64, 70]]], ["Group performance was also higher in the performance-reinforcing condition.", [["Group performance", "TEST", 0, 17], ["higher", "OBSERVATION_MODIFIER", 27, 33]]], ["They also found that the more a robot spoke to a participant, the higher the group cohesion they reported and the more they helped the other participants in the group.", [["participants", "SPECIES", 141, 153]]], ["Participants completed over half of the robot's suggestions, although as the authors note there are further opportunities for improving the timing and salience of the robot's suggestions.", [["Participants", "SPECIES", 0, 12]]], ["Also, participants took more of the robot's advice in the performance-reinforcing condition than in the performance-equalizing condition.", [["participants", "SPECIES", 6, 18]]], ["After the task, participants' attitudes towards robots on the Attitudes towards Situations and Interactions with Robots subscale of the Negative Attitudes towards Rorobts Scale became more negative.Promoting Positive Interaction GoalsThe findings of this study are particularly promising because they clearly show that robots can modify people's social behavior in interactions.", [["people", "ORGANISM", 337, 343], ["participants", "SPECIES", 16, 28], ["people", "SPECIES", 337, 343], ["Rorobts Scale", "TEST", 163, 176], ["this study", "TEST", 250, 260], ["Positive", "OBSERVATION_MODIFIER", 208, 216], ["Interaction", "OBSERVATION", 217, 228]]], ["Additionally, the study develops and tests two different ways in which the robot could behave.", [["the study", "TEST", 14, 23], ["tests", "TEST", 37, 42]]], ["This is important because further development of SARs for the social management of health will require a lot of fine-tuning and personalization of the robot's behavior to meet the specific needs of the user, determined by the user's particular health situation as well as personality and preferences.", [["SARs", "PROBLEM", 49, 53]]], ["Through future research, it will be important to understand which suggestions or types of suggestions people readily take from robots and which they ignore.", [["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108]]], ["Also, a cause for slight concern is that participants seemed to have a more negative attitude towards the robot after completing the task, thus it will be important to understand how that would affect long-term use.Detecting and Intervening in Problematic InteractionsFinally, SARs could help detect and intervene in problematic interactions between people with health conditions and their caregivers or health care providers.", [["people", "ORGANISM", 350, 356], ["participants", "SPECIES", 41, 53], ["people", "SPECIES", 350, 356]]], ["The idea is that when an interaction becomes problematic and a person with a health condition is misunderstood, rushed, blamed, deprived of agency, stigmatized, or met with insufficient empathy, the robot would intervene to remedy the situation.", [["person", "SPECIES", 63, 69]]], ["The robot's intervention could take different forms, focusing on adjusting the behavior of the person with the health condition as a way of helping the caregiver, focus on adjusting the caregiver's behavior or both.Detecting and Intervening in Problematic InteractionsShim et al. [60] implemented and evaluated a mediator robot that intervenes in situations that might lead to the stigmatization of people with health conditions.", [["people", "ORGANISM", 399, 405], ["person", "SPECIES", 95, 101], ["people", "SPECIES", 399, 405], ["The robot's intervention", "TREATMENT", 0, 24], ["a mediator robot", "TREATMENT", 311, 327]]], ["Their approach was to focus on modifying the behavior of the person with the health condition, however, evaluative data from participants indicated that this might not be the preferred approach.", [["person", "SPECIES", 61, 67], ["participants", "SPECIES", 125, 137]]], ["The researchers implemented an intervening ethical governor model onto a robotic platform (the Nao robot), which models the relationship between the patient and caregiver, detects discordances between the patient's level of embarrassment and the caregiver's level of empathy, and intervenes through speech and movement to correct these gaps in communication and incompatibilities between emotional states.", [["patient", "ORGANISM", 149, 156], ["patient", "ORGANISM", 205, 212], ["patient", "SPECIES", 149, 156], ["patient", "SPECIES", 205, 212], ["a robotic platform", "TREATMENT", 71, 89]]], ["The researchers devised four different scenarios illustrative of four ethical rules of interacting: prohibition of angry outbursts from the patient, prohibition of withdrawal from the patient, obligation of the patient to stay in the therapeutic activity/session, and the obligation of the patient to follow safety requirements.", [["angry outbursts", "DISEASE", 115, 130], ["patient", "ORGANISM", 140, 147], ["patient", "ORGANISM", 184, 191], ["patient", "ORGANISM", 211, 218], ["patient", "ORGANISM", 290, 297], ["patient", "SPECIES", 140, 147], ["patient", "SPECIES", 184, 191], ["patient", "SPECIES", 211, 218], ["patient", "SPECIES", 290, 297], ["withdrawal", "PROBLEM", 164, 174]]], ["Four videos were recorded of acted problematic interactions illustrating the intervention of a mediator robot who followed the rules above.", [["a mediator robot", "TREATMENT", 93, 109]]], ["Qualitative data was obtained from nine elderly participants who were shown the videos and who were guided through standardized open-ended interviews about the scenarios depicted in the videos.", [["participants", "SPECIES", 48, 60], ["Qualitative data", "TEST", 0, 16]]], ["Participants felt that the most appropriate and essential type of intervention of the robot was the one corresponding to the \"safety-first\" rule, in which the robot made sure the patient follows safety requirements.", [["patient", "ORGANISM", 179, 186], ["Participants", "SPECIES", 0, 12], ["patient", "SPECIES", 179, 186]]], ["Participants had a negative reaction to the robot's intervention in the other scenarios, feeling that the robot sounded judgmental, commanding and critical of patients, which was deemed unacceptable.", [["patients", "ORGANISM", 159, 167], ["Participants", "SPECIES", 0, 12], ["patients", "SPECIES", 159, 167], ["a negative reaction", "PROBLEM", 17, 36], ["the robot's intervention", "TREATMENT", 40, 64]]], ["In the videos, the robot always addressed the patient rather than the caregiver and the rules referred to the patient's behavior rather than that of the caregiver.", [["patient", "ORGANISM", 46, 53], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 46, 53], ["patient", "SPECIES", 110, 117]]], ["Participants indicated that it would be more appropriate for the robot to indicate to the caretiver situations needing intervention.", [["Participants", "SPECIES", 0, 12], ["intervention", "TREATMENT", 119, 131]]], ["As we have seen, the robot intervention itself can increase the feeling of blame and criticism, which was perceived as unacceptable.", [["the robot intervention", "TREATMENT", 17, 39], ["criticism", "PROBLEM", 85, 94]]], ["Also, as participants imply when talking about their preference for the caregiver to handle the remediation, some actions might be seen as appropriate coming from a human interactant but not from a robot.", [["human", "ORGANISM", 165, 170], ["participants", "SPECIES", 9, 21], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170], ["the remediation", "TREATMENT", 92, 107]]], ["An example, perhaps not of an appropriate intervention per se in the social management of health context, but of a study that has systematically attempted to compare human with robot intervention is [61] .", [["human", "ORGANISM", 166, 171], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["an appropriate intervention", "TREATMENT", 27, 54], ["a study", "TEST", 113, 120], ["robot intervention", "TREATMENT", 177, 195], ["perhaps not of", "UNCERTAINTY", 12, 26]]], ["Stoll et al. [61] studied the use of humor by robots for conflict mitigation.", [["humor", "ORGANISM_SUBSTANCE", 37, 42], ["conflict mitigation", "TREATMENT", 57, 76]]], ["Participants watched videos of robots or humans using humor to diffuse a conflict situation between two roommates.", [["humans", "ORGANISM", 41, 47], ["humor", "ORGANISM_SUBSTANCE", 54, 59], ["Participants", "SPECIES", 0, 12], ["humans", "SPECIES", 41, 47], ["humans", "SPECIES", 41, 47]]], ["Although affiliative and aggressive humor was perceived as less appropriate when used by a robot rather than a human, self-defeating humor was well received from both.", [["humor", "ORGANISM_SUBSTANCE", 36, 41], ["human", "ORGANISM", 111, 116], ["humor", "ORGANISM", 133, 138], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116]]], ["Unfortunately, the study does not report how effective people felt the humor was at diffusing conflict.Detecting and Intervening in Problematic InteractionsOftentimes the behavior of both interactants needs to be adjusted for a problematic situation to be remedied.", [["people", "ORGANISM", 55, 61], ["humor", "ORGANISM_SUBSTANCE", 71, 76], ["people", "SPECIES", 55, 61], ["the study", "TEST", 15, 24]]], ["A study by Shen et al. [23] offers an example of how a robot could intervene and guide the remediation of a problematic situation.", [["A study", "TEST", 0, 7], ["a robot", "TREATMENT", 53, 60]]], ["Principles from this study could be extended and adapted to applications in the context of caregiver-care recipient relationships.", [["this study", "TEST", 16, 26]]], ["Shen, Slovak and Jung used a mediator robot to support children in resolving interpersonal conflicts constructively.", [["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["a mediator robot", "TREATMENT", 27, 43]]], ["What is interesting about this robot is that its actions were programmed around formalized steps from a conflict negotiation procedure: Teaching Students to be Peacemakers (TSP).", [["a conflict negotiation procedure", "TREATMENT", 102, 134]]], ["The robot facilitated the conflict resolution by identifying when a conflict was happening, alerting the children and then guiding them through the negotiation steps by using prompts matched to the protocol steps, such as: \"Telling each other what you want/how you feel can help.", [["children", "ORGANISM", 105, 113], ["children", "SPECIES", 105, 113]]], ["This robot was operated in a Wizard-of-Oz manner, so more development is needed in terms of making the robot autonomous and robust to the messiness of natural dialogue.", [["natural dialogue", "OBSERVATION", 151, 167]]], ["Attention should be paid to proper timing and pacing so that the robot can intervene at the right time and follow an appropriate progression through the protocol steps.", [["pacing", "TREATMENT", 46, 52], ["the robot", "TREATMENT", 61, 70], ["right", "ANATOMY_MODIFIER", 92, 97]]], ["Using protocols for supporting interactions can, however, be a very fruitful approach for designing mediator robots, because of the scripted nature of conversation protocols, which are easier to handle by robots.", [["designing mediator robots", "TREATMENT", 90, 115]]], ["In the following section we summarize and expand on studies which have investigated how robots can provide structure to interactions through conversation protocols and other methods.Providing Structure to Social InteractionsProviding structured interactions for people is perhaps the most valuable way in which SARs could support the social management of health.", [["people", "ORGANISM", 262, 268], ["people", "SPECIES", 262, 268], ["studies", "TEST", 52, 59]]], ["People with health conditions, especially the elderly, are at high-risk for isolation, which can have serious detrimental effects on health [63] .", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["It is thus valuable for SARs to create opportunities for people with health conditions to interact with others and participate fully in social life.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63]]], ["Structuring social interactions in ways that make it easier for people with health conditions to join in and follow along is thus crucial.", [["people", "ORGANISM", 64, 70], ["people", "SPECIES", 64, 70]]], ["There are different levels, of increasing complexity, at which SARs could structure social interactions for people: (a) by serving as the focus of attention and anchoring the interaction, (b) by moderating an interaction, providing participation opportunities through speech and acts of encouragement, and overall promoting inclusiveness, and (c) by guiding people through standard interaction protocols or exercises.Anchoring Interactions and Focusing AttentionThe lowest level of structure for an interaction is offering anchoring, serving as a point of focus and through that creating an opportunity (or an excuse) for interaction.", [["people", "ORGANISM", 108, 114], ["people", "ORGANISM", 358, 364], ["people", "SPECIES", 108, 114], ["people", "SPECIES", 358, 364], ["increasing complexity", "PROBLEM", 31, 52], ["standard interaction protocols", "TREATMENT", 373, 403], ["different", "OBSERVATION_MODIFIER", 10, 19], ["levels", "OBSERVATION_MODIFIER", 20, 26], ["increasing", "OBSERVATION_MODIFIER", 31, 41], ["complexity", "OBSERVATION_MODIFIER", 42, 52], ["interaction", "OBSERVATION", 499, 510]]], ["To accomplish this, the SAR does not need to have very sophisticated capabilities, it simply needs to behave in a way captivating enough that it prompts conversation between people interacting with it.", [["people", "ORGANISM", 174, 180], ["people", "SPECIES", 174, 180]]], ["This low-level support for structuring human-human interactions by robots has already been fairly widely explored especially with older adults.Anchoring Interactions and Focusing AttentionWada and Shibata [32] used the Paro robot in a carehouse for the elderly in Japan.", [["human", "ORGANISM", 39, 44], ["human", "ORGANISM", 45, 50], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 45, 50], ["This low-level support", "TREATMENT", 0, 22], ["the Paro robot", "TREATMENT", 215, 229]]], ["Paro is a pet-like robot in the form of a seal pup which responds to sounds and touch by making noises and moving.", [["Paro", "CHEMICAL", 0, 4], ["pup", "ORGANISM_SUBDIVISION", 47, 50], ["seal", "ANATOMY", 42, 46], ["pup", "OBSERVATION", 47, 50]]], ["The robot was placed in a public area where the residents of the house could meet to interact with each other and was activated for 9 hours every day.", [["The robot", "TREATMENT", 0, 9], ["robot", "OBSERVATION", 4, 9]]], ["The researchers found an increase in density of the residents' social networks after the introduction of Paro, which suggests that the robot stimulated communication among residents, strengthening their social ties.", [["social networks", "MULTI-TISSUE_STRUCTURE", 63, 78], ["increase", "OBSERVATION_MODIFIER", 25, 33], ["density", "OBSERVATION_MODIFIER", 37, 44]]], ["Additional data from this research project presented by Wada and Shibata [64] showed that the time residents spent in the public area increased after the introduction of Paro.", [["the introduction of Paro", "TREATMENT", 150, 174]]], ["People who interacted with Paro in its \"On\" mode had more social interactions and this effect was further increased by the presence of caregivers or experimenters participating in the interactions.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["The authors conclude, drawing also from previous experience with using robots in nursing homes, that robots could be useful at stimulating small group engagement and could be a beneficial addition to the very impoverished social setting of eldercare facilities, which usually consists of the TV room where people, even if in each other's presence, do not engage in conversation with each other.Anchoring Interactions and Focusing AttentionRobinson, MacDonald et al. [65] also used the Paro robot in a residential care facility and compared its effect on social interactions with the effect of an actual pet.", [["people", "ORGANISM", 306, 312], ["people", "SPECIES", 306, 312], ["an actual pet", "TEST", 593, 606]]], ["The facility benefited from visits from a dog belonging to the activities coordinator.", [["dog", "ORGANISM", 42, 45]]], ["The behavior of the residents was observed during various activities, during the dog's visit and during group interactions with the Paro robot.", [["the Paro robot", "TREATMENT", 128, 142]]], ["Observations showed that more residents were involved in discussions about the robot in comparison to discussions about the resident dog, and the robot appeared in more conversations amongst residents and with staff members than the dog.", [["dog", "ORGANISM", 133, 136], ["dog", "ORGANISM", 233, 236], ["dog", "SPECIES", 233, 236]]], ["This could simply be due to the fact that no special activities were organized around the dog, while group gatherings to interact with Paro were organized, even though the specific way in which participants interacted with the robot was not prescribed.Anchoring Interactions and Focusing AttentionFor a more systematic (although perhaps less ecologically valid) investigation of Paro's effects on social interactions, Wood et al. [27] conducted an in-lab study using the Paro robot for social mediation in human-human interactions.", [["dog", "ORGANISM", 90, 93], ["participants", "ORGANISM", 194, 206], ["human", "ORGANISM", 506, 511], ["human", "ORGANISM", 512, 517], ["participants", "SPECIES", 194, 206], ["human", "SPECIES", 506, 511], ["human", "SPECIES", 512, 517], ["human", "SPECIES", 506, 511], ["human", "SPECIES", 512, 517], ["Paro's effects", "PROBLEM", 379, 393], ["the Paro robot", "TREATMENT", 467, 481]]], ["Participants were asked to interact with the robot together in any way they wanted to.", [["Participants", "SPECIES", 0, 12]]], ["The study presents more direct, quantitative data on the effects of the robot on social interactions.", [["The study", "TEST", 0, 9]]], ["Participants in the active Paro condition (the robot being \"On\") rated the quality of the interaction and the enjoyment of interacting with the other person as higher.", [["Participants", "SPECIES", 0, 12], ["person", "SPECIES", 150, 156]]], ["Although Paro is not designed specifically to encourage interaction between people, the robot's social mediation effect likely came from serving as a focus for the interaction.Anchoring Interactions and Focusing AttentionParo, is not the only robot that has been used to elicit human-human interactions.", [["people", "ORGANISM", 76, 82], ["human", "ORGANISM", 278, 283], ["human", "ORGANISM", 284, 289], ["people", "SPECIES", 76, 82], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 284, 289], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 284, 289]]], ["Joshi and \u0160abanovi\u0107 [66] investigate the use of a variety of robots for stimulating intergenerational interactions in a nonfamilial setting: a co-located preschool and assisted living center for older individuals with dementia.", [["dementia", "DISEASE", 218, 226], ["\u0160abanovi\u0107", "TREATMENT", 10, 19], ["a variety of robots", "TREATMENT", 48, 67], ["dementia", "PROBLEM", 218, 226]]], ["Nao is a humanoid robot that can speak, move and track people, and Cozmo is a palm-held robot that can drive, speak in short sentences and express emotions.", [["Nao", "CHEMICAL", 0, 3], ["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61]]], ["The experimenters worked in collaboration with the preschool and assistive living center staff to design activities that would lead to interactions between the residents and the preschoolers, customizing for the values and goals promoted by the center: increased inter-generational contact, increased peer engagement, meaningful interactions for both adults and children, opportunities to collaborate and share, and reduced need for outside management of the activity.", [["children", "ORGANISM", 362, 370], ["children", "SPECIES", 362, 370], ["outside management", "TREATMENT", 433, 451]]], ["By observing the behavior of the participants during the interactions, the experimenters found that activities involving robots were often able to provide more opportunities for intergenerational interactions than other types of activities such as drawing, puzzle solving and making music, and also required less intervention from staff members.", [["participants", "SPECIES", 33, 45]]], ["The best robots for inter-generational interactions were Paro and Joy given their slow pace for responding which prevented older adults from getting overwhelmed and made the children impatient and inquisitive, giving the older adults opportunities to interact with the children.", [["children", "ORGANISM", 174, 182], ["children", "ORGANISM", 269, 277], ["children", "SPECIES", 174, 182], ["children", "SPECIES", 269, 277]]], ["The Cozmo robot, although it facilitated peer interactions among children was not engaging for the older adults.", [["children", "ORGANISM", 65, 73], ["children", "SPECIES", 65, 73], ["The Cozmo robot", "TREATMENT", 0, 15]]], ["The study is a great example of possibilities for introducing robots that can enhance interactions in real-world settings by working closely with the community members involved.Anchoring Interactions and Focusing AttentionRobots' abilities to stimulate social interactions has also been studied with children with autism.", [["autism", "DISEASE", 314, 320], ["children", "ORGANISM", 300, 308], ["children", "SPECIES", 300, 308], ["The study", "TEST", 0, 9], ["introducing robots", "TREATMENT", 50, 68]]], ["Werry et al. [67] used a mobile robot in dyadic play interactions between children with autism.", [["autism", "DISEASE", 88, 94], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["a mobile robot", "TREATMENT", 23, 37]]], ["They observed three pairs of children interact with the robot and with each other, and concluded that by serving as a focus of attention, the robot facilitated interesting types of interaction structures between children, such as instruction, cooperation and even possibly imitation.", [["children", "ORGANISM", 29, 37], ["children", "ORGANISM", 212, 220], ["children", "SPECIES", 29, 37], ["children", "SPECIES", 212, 220]]], ["This was one of the first observational studies exploring interaction structures in autism afforded by the introduction of robots as an anchor for human-human interactions.Anchoring Interactions and Focusing AttentionA more sophisticated way of anchoring and eliciting interaction between people is to go beyond using the robot simply as an attention focus, and instead have a robot play different active roles in an interaction.", [["autism", "DISEASE", 84, 90], ["human", "ORGANISM", 147, 152], ["human", "ORGANISM", 153, 158], ["people", "ORGANISM", 289, 295], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 153, 158], ["people", "SPECIES", 289, 295], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 153, 158], ["robots", "TREATMENT", 123, 129], ["human-human interactions", "TREATMENT", 147, 171]]], ["Given the current limitations of robots, and the fairly narrow number of tasks any given robot can perform, games can be a suitable context in which mediator robots can be used.", [["robots", "TREATMENT", 33, 39], ["mediator robots", "TREATMENT", 149, 164]]], ["Unfortunately, the study does not explicitly measure how specific robot behaviors affected the interaction between family members.", [["the study", "TEST", 15, 24]]], ["The study was instead focused more on how the different group members perceived and interacted with the robot and their engagement with and thoughts about the games.", [["The study", "TEST", 0, 9]]], ["However, this study is a great example of a protocol that could be used to study robot support for \"gamified\" interactions.", [["this study", "TEST", 9, 19], ["a protocol", "TREATMENT", 42, 52], ["robot support", "TREATMENT", 81, 94]]], ["For people with health conditions, especially for children with health conditions, therapeutic game-play supported by SARs can be a motivating way to develop and practice social skills.Moderating Interactions and Promoting InclusivenessThe studies explored so far in this section focus on increasing the motivation of people to participate in social interactions.", [["people", "ORGANISM", 4, 10], ["children", "ORGANISM", 50, 58], ["people", "ORGANISM", 318, 324], ["people", "SPECIES", 4, 10], ["children", "SPECIES", 50, 58], ["people", "SPECIES", 318, 324], ["The studies", "TEST", 236, 247]]], ["However, even when the motivation to interact exists, people with health conditions often encounter challenges in terms of entering ongoing interactions and keeping up with them.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60]]], ["For example, people with Parkinson's Disease, due to slowness of speech and word-finding difficulties, have a hard time entering a conversation or keeping up with the rapid pace of one [68, 69] .", [["Parkinson's Disease", "DISEASE", 25, 44], ["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["Parkinson's Disease", "PROBLEM", 25, 44], ["slowness of speech", "PROBLEM", 53, 71], ["word-finding difficulties", "PROBLEM", 76, 101]]], ["Children with autism have difficulties producing appropriate social behaviors to initiate and maintain social interactions [70] .", [["autism", "DISEASE", 14, 20], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["People with social anxiety or simply people that are unusually shy can also have a difficult time to get a piece in edgewise in a conversation.", [["social anxiety", "DISEASE", 12, 26], ["People", "ORGANISM", 0, 6], ["people", "ORGANISM", 37, 43], ["People", "SPECIES", 0, 6], ["people", "SPECIES", 37, 43], ["social anxiety", "PROBLEM", 12, 26]]], ["SARs could support these people by moderating social interactions, offering assistance for conversation and group entry, and generally promoting social behaviors that lead to inclusiveness.Moderating Interactions and Promoting InclusivenessFor example, Short et al. [25] used a robot to moderate a group storytelling activity.", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["a robot", "TREATMENT", 276, 283]]], ["They found marginally significant results for an increase in group cohesion in the moderated condition and increased speech in the moderated as opposed to the unmoderated condition.Moderating Interactions and Promoting InclusivenessAnother example of study in which a robot was used to promote conversation inclusiveness was conducted by Tennent et al. [71] who used a peripheral robotic object to increase group engagement and also to improve problem solving performance.", [["an increase in group cohesion in the moderated condition", "PROBLEM", 46, 102], ["increased speech", "PROBLEM", 107, 123], ["the unmoderated condition", "PROBLEM", 155, 180], ["study", "TEST", 251, 256], ["a peripheral robotic object", "TREATMENT", 367, 394], ["marginally", "OBSERVATION_MODIFIER", 11, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["group cohesion", "OBSERVATION", 61, 75], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["speech", "OBSERVATION", 117, 123]]], ["They designed a robotic microphone that exhibited two engaging behaviors: following-turning towards the person speaking, and encouraging-rotating towards the participant who spoke the least and leaning towards that participant as an invitation to speak.", [["person", "SPECIES", 104, 110], ["participant", "SPECIES", 158, 169], ["a robotic microphone", "TREATMENT", 14, 34]]], ["The authors found that the robotic device, when operating according to the above described engagement algorithm, increased evenness in backchanneling: namely the participants took a more even number of turns to engage in active listening of oneanother.", [["participants", "SPECIES", 162, 174], ["the robotic device", "TREATMENT", 23, 41], ["increased", "OBSERVATION_MODIFIER", 113, 122], ["evenness", "OBSERVATION_MODIFIER", 123, 131]]], ["The evenness of group backchanneling turns then significantly predicted problem-solving performance on the Desert Survival task (participants were discussing the rank order of 15 most useful items for surviving in the desert, their response as a team being compared to that of experts).Moderating Interactions and Promoting InclusivenessThese studies show that speech, and even minimal nonverbal gestures can be successfully used by robots to promote inclusion of others in social activities.", [["participants", "SPECIES", 129, 141], ["group backchanneling turns", "TREATMENT", 16, 42], ["These studies", "TEST", 337, 350]]], ["Furthermore, Mutlu et al. [24] have shown that robots with fairly low capabilities can be effective in shaping the roles of people in conversations: as addressees, bystanders or overhearers.", [["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130]]], ["Through gaze cues alone, by looking or not looking at the participant when talking, the robot was able to manipulate who participated and attended to a conversation as well as the participant's feelings of groupness and their liking of the robot.", [["participant", "SPECIES", 58, 69]]], ["Participants to whom the robot communicated the role of addressee attended to the task more and felt stronger feelings of groupness.", [["groupness", "DISEASE", 122, 131], ["Participants", "SPECIES", 0, 12]]], ["Participants whose presence was acknowledged by the robot, those in the role of addressee or bystander liked the robot more.Moderating Interactions and Promoting InclusivenessA more detailed investigation into the specifics of how a robot should act to make sure people can participate meaningfully and equally in conversation is described by Matsuyama et al. [21] .", [["people", "ORGANISM", 263, 269], ["Participants", "SPECIES", 0, 12], ["people", "SPECIES", 263, 269]]], ["They used a robot for facilitating a conversation between three participants in which two participants had a strong engagement with each other evidenced by lots of backand-forth conversation turns, and one of the participants was left out (side-participant).", [["participants", "SPECIES", 64, 76], ["participants", "SPECIES", 90, 102], ["participants", "SPECIES", 213, 225]]], ["The robot acted as a fourth participant to the conversation and its goal was to \"harmonize\" the conversation, by engaging the person left out.", [["person", "SPECIES", 126, 132]]], ["The robot had to detect the strength of the engagement between participants and identify the participant who had a side role.", [["participants", "SPECIES", 63, 75], ["participant", "SPECIES", 93, 104]]], ["Then the robot intervened to include the unengaged participant.", [["participant", "SPECIES", 51, 62]]], ["Videos were recorded of conversation scenarios and participants were asked to rate the appropriateness of the robot's behavior, the feeling of groupness and the timing of the robot's intervention.", [["groupness", "DISEASE", 143, 152], ["participants", "SPECIES", 51, 63], ["the robot's intervention", "TREATMENT", 171, 195]]], ["The robot intervened in the conversation either by directly addressing the participant who was left-out or by initiating a procedure: first addressing a comment to one of the engaged participants (i.e., claiming an initiative), waiting for a response (i.e., approval of the initiative) and then yielding the floor to the left-out participant.", [["participants", "SPECIES", 183, 195], ["a procedure", "TREATMENT", 121, 132], ["left", "ANATOMY_MODIFIER", 321, 325]]], ["Participants felt that the robot behaved most appropriately and there was a stronger sense of groupness when the robot attempted to include the side-participant by initiating a procedure without shifting the topic of conversation.", [["Participants", "SPECIES", 0, 12], ["a procedure", "TREATMENT", 175, 186]]], ["Participants felt that intervening after two rounds of back-and-forth between the engaged participants was more appropriate than after the first round.Moderating Interactions and Promoting InclusivenessThese studies demonstrate that robots can meaningfully moderate interactions to encourage the inclusions of people who would otherwise be left out.", [["people", "ORGANISM", 310, 316], ["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 90, 102], ["people", "SPECIES", 310, 316], ["These studies", "TEST", 202, 215]]], ["All these studies were conducted with healthy participants, but the robot design features presented can be applied also to the social management of health, addressing the needs of people with health conditions for participating more fully in social life.", [["people", "ORGANISM", 180, 186], ["participants", "SPECIES", 46, 58], ["people", "SPECIES", 180, 186], ["All these studies", "TEST", 0, 17]]], ["For example, robots might need to engage in additional special behavior in order to slow down a conversation to make sure someone with poor processing capacities has enough time for comprehension.Guiding Interactions Through Therapeutic Protocols and ExercisesThe highest level of interaction structuring that SARs could provide is to guide people through structured interaction tasks or protocols.", [["people", "ORGANISM", 341, 347], ["people", "SPECIES", 341, 347], ["robots", "TREATMENT", 13, 19], ["poor processing capacities", "PROBLEM", 135, 161], ["Therapeutic Protocols", "TREATMENT", 225, 246]]], ["Therapeutic programs often incorporate structured interaction exercises, which are easier for robots to handle than free dialogue.", [["Therapeutic programs", "TREATMENT", 0, 20]]], ["SARs could be used as facilitators of such therapeutic exercises focused on improving interactions between people as a supplement and reinforcer to human-delivered therapy.", [["people", "ORGANISM", 107, 113], ["human", "ORGANISM", 148, 153], ["people", "SPECIES", 107, 113], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["SARs", "PROBLEM", 0, 4], ["such therapeutic exercises", "TREATMENT", 38, 64], ["human-delivered therapy", "TREATMENT", 148, 171]]], ["For example, Utami and Bickmore [30] explored robot-driven couples counseling using a humanoid robotic head.", [["head", "ANATOMY", 103, 107], ["head", "ORGANISM_SUBDIVISION", 103, 107], ["a humanoid robotic head", "TREATMENT", 84, 107]]], ["The robot was operated in a Wizard-of-Oz manner and it guided couples through a rapport-building task and two counseling exercises: a gratitude exercise in which the couples were asked to recall and share three recent positive behaviors of their partner and the Caring Days exercises (commonly used in the Behavioral Couples Therapy) in which each partner made a request for a behavior that the other member of the couple could perform to show that they cared.", [["the Behavioral Couples Therapy", "TREATMENT", 302, 332]]], ["The study found a significant decrease in participant's negative affect post-intervention and a signifi-cant increase in self-reported intimacy.", [["participant", "SPECIES", 42, 53], ["The study", "TEST", 0, 9], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["decrease", "OBSERVATION_MODIFIER", 30, 38]]], ["The post-session openended interviews revealed interesting insights about people's experience with the robot.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["the robot", "TREATMENT", 99, 108]]], ["Participants felt that the robot's responses were very generic and that the interaction was too structured, which could perhaps be improved in future iterations of the study by having the robot engage in some naturalistic, random behavior extraneous to the task.", [["Participants", "SPECIES", 0, 12], ["the study", "TEST", 164, 173]]], ["However, what is encouraging is that even though participants thought that a human counselor would be more genuine and better at understanding non-verbal behaviors (such as facial expressions) some participants felt that the advantage of the robot was its ability to stay non-judgmental and unbiased.", [["facial", "ANATOMY", 173, 179], ["human", "ORGANISM", 77, 82], ["participants", "SPECIES", 49, 61], ["human", "SPECIES", 77, 82], ["participants", "SPECIES", 198, 210], ["human", "SPECIES", 77, 82]]], ["Also, very promising is that participants indicated that the interaction with the robot was preferable to reading self-help material and practicing exercises by themselves.", [["participants", "SPECIES", 29, 41]]], ["Using SARs for therapeutic exercises like these which could also be relevant for strengthening the bonds between caregivers and care recipients are very much in line with what participants in the study by Moharana et al. [17] expressed: a desire for robots to help accentuate positive shared moments with the person they were caring for and act as neutral parties to diffuse tension when unwanted tasks needed to be completed (e.g., adherence to treatment).", [["participants", "SPECIES", 176, 188], ["person", "SPECIES", 309, 315], ["therapeutic exercises", "TREATMENT", 15, 36], ["care recipients", "TREATMENT", 128, 143], ["robots", "TREATMENT", 250, 256], ["treatment", "TREATMENT", 446, 455]]], ["Guidance through structured interactions can be used not just for creating positive connections but also for remedying strained ones.", [["creating positive connections", "PROBLEM", 66, 95], ["remedying strained ones", "PROBLEM", 109, 132]]], ["We have already discussed in the previous section the study by Shen et al. [23] which is an example of an interaction protocol for conflict resolution.", [["an interaction protocol", "TREATMENT", 103, 126]]], ["Finally, robots can assist people assist others by guiding them through assistance-giving protocols.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33]]], ["Many caregivers are family members, not trained professionals, and it can often be difficult for non-professionals to gauge the right amount of support needed by the person requiring care, so that their autonomy does not get impaired.", [["person", "SPECIES", 166, 172], ["right", "ANATOMY_MODIFIER", 128, 133]]], ["Robots are far from being able to replace human caregivers altogether, not to mention that for most situations this is likely an undesirable goal.", [["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47]]], ["Therefore, the teaming of humans and robots in assistance-giving is the objective we are proposing.", [["humans", "ORGANISM", 26, 32], ["humans", "SPECIES", 26, 32], ["humans", "SPECIES", 26, 32]]], ["Robots can help structure assistance giving interactions between caregivers and care recipients.", [["Robots", "TREATMENT", 0, 6], ["care recipients", "TREATMENT", 80, 95]]], ["An example that doesn't come from the health care context, but from teaching, illustrates some possible functions for the robot: providing instructions for the task, assigning roles, and prompting the caregiver to offer different types of input that could be corrective feedback, praise, encouragement etc. Chandra et al. [22] compared a robot and a human facilitator of a collaborative learning activity.", [["human", "ORGANISM", 350, 355], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 350, 355]]], ["Children engaged in a learning-by-teaching task, in which one child taught the other how to write different letters or words.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["Either a robot or a human acted as facilitators by introducing the task, assigning roles (teacher or learner), providing instruction throughout the task and prompting the teacher-child to provide corrective feedback to the learner child.", [["human", "ORGANISM", 20, 25], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25]]], ["The video and audio recordings of the session were coded.", [["The video", "TEST", 0, 9], ["audio recordings", "TEST", 14, 30]]], ["Teacher-children provided more extended corrective feedback with the robot facilitator and more minimal corrective feedback with the human facilitator.", [["children", "ORGANISM", 8, 16], ["human", "ORGANISM", 133, 138], ["children", "SPECIES", 8, 16], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["the robot facilitator", "TREATMENT", 65, 86]]], ["Authors argue that the teacher-children felt more responsible regarding their performance in the presence of the robot.", [["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39]]], ["Combining these results with the duration of gaze that the facilitator directed towards the children (the robot made longer-duration gazes than the human facilitator) the authors conclude that two different patterns of interpersonal distancing emerged: in the case of the robot facilitator children followed the reciprocity model (responding to closeness with closeness), in the case of the human facilitator they followed the compensation model (responding to distancing with closeness).Guiding Interactions Through Therapeutic Protocols and ExercisesThe overall goal of having structured interactions is to ensure that they are meaningful, positive and inclusive.", [["children", "ORGANISM", 92, 100], ["human", "ORGANISM", 148, 153], ["children", "ORGANISM", 290, 298], ["human", "ORGANISM", 391, 396], ["children", "SPECIES", 92, 100], ["human", "SPECIES", 148, 153], ["children", "SPECIES", 290, 298], ["human", "SPECIES", 391, 396], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 391, 396], ["Therapeutic Protocols", "TREATMENT", 517, 538]]], ["This is beneficial for the strengthening of relationships between people with health care conditions and health care providers, caregivers, and others.", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]], ["Most importantly, these robot-assisted interactions should improve the quality of life and sense of well-being of the person with the health-condition.", [["person", "SPECIES", 118, 124]]], ["This is why one of the functions of SARs needs to be that of engendering positive feelings for people with health conditions in social contexts.Changing How a Person with Chronic Illness Feels in a Social ContextSocial situations can be stressful for people with health conditions.", [["people", "ORGANISM", 95, 101], ["people", "ORGANISM", 251, 257], ["people", "SPECIES", 95, 101], ["people", "SPECIES", 251, 257]]], ["This can be due to the specifics of the health condition, for example, people with Post-Traumatic Stress Disorder can feel uncomfortable in social situations that trigger traumatic memories [72] , but more generally it can be caused by the stigma associated with health conditions [73] .", [["Traumatic Stress Disorder", "DISEASE", 88, 113], ["traumatic memories", "DISEASE", 171, 189], ["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["Post-Traumatic Stress Disorder", "PROBLEM", 83, 113], ["traumatic memories", "PROBLEM", 171, 189]]], ["Many people with health conditions experience psychological distress from perceived stigma from others [75] .Promoting Positive Feelings in InteractionsWe've already discussed studies of robots that can help people experience more positive feelings in social interactions.", [["people", "ORGANISM", 5, 11], ["people", "ORGANISM", 208, 214], ["people", "SPECIES", 5, 11], ["people", "SPECIES", 208, 214], ["psychological distress", "PROBLEM", 46, 68], ["Positive", "OBSERVATION_MODIFIER", 119, 127]]], ["These ideas can be used to create SARs that help combat some of the negative effects of stigma.", [["stigma", "PROBLEM", 88, 94]]], ["For example, behaviors of the robot used by Tennent et al. [71] , such as inviting people to join a conversation through movement, could be used for developing and testing robots that help people with health conditions feel welcomed and encouraged to participate in social interactions.", [["people", "ORGANISM", 83, 89], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 83, 89], ["people", "SPECIES", 189, 195]]], ["Also, behaviors from the robot used by Mutlu et al. [24] , such as the use of gaze to suggest conversation roles, could be adapted to create feelings of inclusiveness for people with health conditions.", [["people", "ORGANISM", 171, 177], ["people", "SPECIES", 171, 177]]], ["An example of a robot specifically designed for influencing how a person feels in a social interaction with another human was tested by Pettinati et al. [76] .", [["human", "ORGANISM", 116, 121], ["person", "SPECIES", 66, 72], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121]]], ["The robot was envisioned as a peripheral addition to an interaction between two people.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["The robot indicated active listening by turning its head towards the person speaking.", [["head", "ANATOMY", 52, 56], ["head", "ORGANISM_SUBDIVISION", 52, 56], ["person", "SPECIES", 69, 75], ["active", "OBSERVATION_MODIFIER", 20, 26], ["listening", "OBSERVATION", 27, 36]]], ["Participants perceived the active robot as having more of a social presence than the controls (a non-active Nao and a plush toy) but participants felt equally comfortable self-disclosing in front of the active robot.", [["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 133, 145]]], ["The lack of a negative impact of the robot's presence for selfdisclosure is encouraging for the prospects of designing a mediator robot that does not detract from the interaction between humans.", [["humans", "ORGANISM", 187, 193], ["humans", "SPECIES", 187, 193], ["humans", "SPECIES", 187, 193], ["a mediator robot", "TREATMENT", 119, 135]]], ["The absence of negative effects is a start, but further research is needed to establish whether the robot contributed any additional positive psychological effects of feeling listened to when disclosing personal information to another person.Mitigating Negative Feelings in InteractionsIn this paper we specifically review studies that used robots to support social interactions between people, but many ideas from human-robot interaction studies can be adapted to the social mediation context.", [["people", "ORGANISM", 387, 393], ["human", "ORGANISM", 415, 420], ["person", "SPECIES", 235, 241], ["people", "SPECIES", 387, 393], ["human", "SPECIES", 415, 420], ["human", "SPECIES", 415, 420], ["review studies", "TEST", 316, 330], ["negative effects", "OBSERVATION_MODIFIER", 15, 31]]], ["For example, roboticists are developing pet-like robots to assist with stress reduction during counseling sessions [77] .", [["stress reduction", "TREATMENT", 71, 87]]], ["Stress-reducing robots could also be used to help people with social anxiety in a variety of social circumstances.Mitigating Negative Feelings in InteractionsAlthough still in its initial stages, the development of mediator SARs for the social management of health is replete with opportunities for further design and HRI research.", [["social anxiety", "DISEASE", 62, 76], ["people", "ORGANISM", 50, 56], ["HRI", "PROTEIN", 318, 321], ["people", "SPECIES", 50, 56], ["Stress-reducing robots", "TREATMENT", 0, 22], ["social anxiety", "PROBLEM", 62, 76], ["mediator SARs", "PROBLEM", 215, 228]]], ["However, challenges of designing, testing and beneficially integrating these systems into our lives and health management also warrant discussion.Challenges of Designing and Using Mediator SARsThere are four classes of challenges that exist with regards to designing and using SARs for the social management of health: (a) challenges related to the status and well-being of the person with the health condition, (b) challenges related to the impact of SARs on human-human interactions, especially the unforeseen or unwanted effects, (c) challenges related to the broader social and cultural context and (d) challenges related to the features and usefulness of the robot itself.", [["human", "ORGANISM", 460, 465], ["human", "ORGANISM", 466, 471], ["person", "SPECIES", 378, 384], ["human", "SPECIES", 460, 465], ["human", "SPECIES", 466, 471], ["human", "SPECIES", 460, 465], ["human", "SPECIES", 466, 471], ["testing", "TEST", 34, 41], ["health management", "TREATMENT", 104, 121]]], ["For a successful embedding of SARs in the caregiving context, these challenges will need to be overcome through ingenious design and most importantly careful research.Preservation of Autonomy and DignityIn a mediator role, SARs will assist interactions between two or more people.", [["people", "ORGANISM", 273, 279], ["people", "SPECIES", 273, 279], ["a successful embedding of SARs", "TREATMENT", 4, 34], ["SARs", "OBSERVATION", 30, 34], ["Autonomy", "OBSERVATION", 183, 191], ["Dignity", "OBSERVATION_MODIFIER", 196, 203]]], ["However, the health and well-being of the person with the health condition using the SAR is of primary importance, as this is the reason for developing SARs in the first place.", [["person", "SPECIES", 42, 48], ["developing SARs", "PROBLEM", 141, 156], ["SARs", "OBSERVATION", 152, 156]]], ["The challenge with giving any type of assistance (but perhaps even more importantly when giving assistance through the use robots) is the preservation of the person's autonomy and dignity.", [["person", "SPECIES", 158, 164]]], ["Sharkey and Sharkey [78] , warned that careless use of assistive robots could lead to a loss of control of important aspects of one's life and feelings of objectification, and Wilson et al. [79] proppose that the concepts of autonomy and personal dignity, which are guiding ethical principles in occupational therapy, should be incorporated into the desgin process of social robots.", [["assistive robots", "TREATMENT", 55, 71], ["occupational therapy", "TREATMENT", 296, 316]]], ["Because people with health conditions are a vulnerable population, there is concern that robotic assistance would lead to a loss of personal liberty.", [["loss of personal liberty", "DISEASE", 124, 148], ["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14], ["robotic assistance", "TREATMENT", 89, 107], ["a loss of personal liberty", "PROBLEM", 122, 148]]], ["If the robot completely takes over a certain task or important aspects of it (with regards to the robot functions proposed by this paper, one such task is the management of interactions) the worry is that people might lose the ability to perform the task themselves.", [["people", "ORGANISM", 205, 211], ["people", "SPECIES", 205, 211]]], ["For example, if a person becomes overly reliant on the robot alerting them to problematic nonveral aspects of a conversation (a function explored in Sect.", [["person", "SPECIES", 18, 24]]], ["2.3.1) instead of using the robot's feedback to improve one's attention to cues from the interlocutor, this might lead to more problematic interactions in the future when the robot is not present.", [["the robot's feedback", "TREATMENT", 24, 44]]], ["With some tasks this might be fine, as the person might have already lost that ability because of the health condition (for example, for severe dementia the function of redirecting conversation to non-repetitive topics might be needed for the remainder of the person's care), but with others, effortful attempts to maintain abilities might be desirable for independence.", [["dementia", "DISEASE", 144, 152], ["person", "SPECIES", 43, 49], ["person", "SPECIES", 260, 266], ["severe dementia", "PROBLEM", 137, 152]]], ["SARs involved in the social management of health should thus support rather than take over the task of initiating and sustaining interactions between people.", [["people", "ORGANISM", 150, 156], ["people", "SPECIES", 150, 156]]], ["As mentioned above, the right level of direction and assistance should be established through research.Ownership, Control and Authority of the SARAnother way in which personal liberty of people could be encroached on has to do with the status of the person with the health care condition with regards to the SAR: who owns the SAR and who controls it? [80] Also, what obligations does that SAR have towards the different people that are part of the caregiving ecosystem? [81] This is an especially important consideration for the SAR functions that we propose in this paper.", [["people", "ORGANISM", 187, 193], ["people", "ORGANISM", 420, 426], ["people", "SPECIES", 187, 193], ["person", "SPECIES", 250, 256], ["people", "SPECIES", 420, 426], ["right", "ANATOMY_MODIFIER", 24, 29]]], ["We are focusing on robots that can manage social interactions between people, and although the ultimate goal of the robot is to support the social management of health of the person with the health condition, precisely because it is a robot designed for supporting interactions between humans, the robot would serve multiple people, including health care providers, caregivers and other people belonging to the social circle of the person with the health condition.", [["people", "ORGANISM", 70, 76], ["humans", "ORGANISM", 286, 292], ["people", "ORGANISM", 325, 331], ["people", "ORGANISM", 387, 393], ["people", "SPECIES", 70, 76], ["person", "SPECIES", 175, 181], ["humans", "SPECIES", 286, 292], ["people", "SPECIES", 325, 331], ["people", "SPECIES", 387, 393], ["person", "SPECIES", 432, 438], ["humans", "SPECIES", 286, 292], ["robots", "TREATMENT", 19, 25]]], ["Also, given that health conditions can impair people's judgement, it is not always feasible that the authority over the robot and its use remains with the person with the health condition.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["person", "SPECIES", 155, 161]]], ["In fact, in some situations it might be desirable that the robot itself exert authority over the person with the health condition.", [["person", "SPECIES", 97, 103]]], ["We learned from the study by Shim et al. [60] that people felt that the robot should never have the authority to judge patients.", [["people", "ORGANISM", 51, 57], ["patients", "ORGANISM", 119, 127], ["people", "SPECIES", 51, 57], ["patients", "SPECIES", 119, 127], ["the study", "TEST", 16, 25]]], ["On the other hand, participants in the Utami and Bickmore study [30] welcomed the mild social pressure from the robot when the robot successfully prompted them to perform the therapeutic interaction exercises.", [["participants", "SPECIES", 19, 31], ["Bickmore study", "TEST", 49, 63], ["the therapeutic interaction exercises", "TREATMENT", 171, 208], ["mild", "OBSERVATION_MODIFIER", 82, 86]]], ["Even more so, caregivers participating in the study by Moharana et al. [17] wanted a robot to have much more authority and adopt the role of a neutral third party who would determine the person receiving care to do things that they do not wish to do, but need to for their own good, for example, taking their medication.", [["person", "SPECIES", 187, 193], ["the study", "TEST", 42, 51], ["their medication", "TREATMENT", 303, 319]]], ["Some participants even envisioned that the robot would do this using the doctor's voice.", [["participants", "SPECIES", 5, 17]]], ["However, the functions we specify in this paper are very much subservient to the goals they try to achieve, which is not just preventing isolation, but also preserving autonomy and preventing dehumanization and stigma.Deception and Unidirectional Emotional BondsAnother aspect of using SARs that has been flagged as potentially contributing negatively to the life and dignity of the person assisted is the issue of deception [17] , infantilization [78] and inauthenticity of the human-robot interaction [82] .", [["dehumanization", "DISEASE", 192, 206], ["human", "ORGANISM", 479, 484], ["person", "SPECIES", 383, 389], ["human", "SPECIES", 479, 484], ["human", "SPECIES", 479, 484], ["stigma", "PROBLEM", 211, 217], ["stigma", "OBSERVATION", 211, 217]]], ["SARs capitalize on the deeply ingrained human propensity to engage with lifelike social behavior and use this engagement for natural interaction with people [6] .", [["human", "ORGANISM", 40, 45], ["people", "ORGANISM", 150, 156], ["human", "SPECIES", 40, 45], ["people", "SPECIES", 150, 156], ["human", "SPECIES", 40, 45]]], ["But the person assisted by the robot, especially those who are struggling with cognitive impairments, can be tricked (much like children are), by the robot's behav-ior into believing the robot is something it is not.", [["cognitive impairments", "DISEASE", 79, 100], ["children", "ORGANISM", 128, 136], ["person", "SPECIES", 8, 14], ["children", "SPECIES", 128, 136], ["cognitive impairments", "PROBLEM", 79, 100]]], ["This could lead to the formation of unidirectional emotional bonds in which the person harbors feeling for the robot but the robot is ontologically unable to reciprocate [84] .", [["person", "SPECIES", 80, 86], ["unidirectional emotional bonds", "PROBLEM", 36, 66]]], ["The functions we envision for SARs in this paper, namely that of supporting social interactions, could perhaps mitigate some of the concerns regarding deception and formation of problematic emotional bonds.", [["SARs", "PROBLEM", 30, 34], ["problematic emotional bonds", "PROBLEM", 178, 205]]], ["In its most offending form, deception from SARs is when people start believing that the SAR is a companion that understands and shares their deepest feelings.", [["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62]]], ["The functions we propose for SARs shift the focus from the human-robot relationships to the human-human relationships, for which the robot simply offers support.", [["human", "ORGANISM", 59, 64], ["human", "ORGANISM", 92, 97], ["human", "ORGANISM", 98, 103], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 59, 64], ["human-human", "SPECIES", 92, 103]]], ["The purpose of the robot intervening is not for it to offer companionship, but to optimize the ways in which people offer companionship to each other.", [["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115]]], ["Additionally, having another human in the loop (often the caregiver), can help with the supervision and correction of any problematic aspects of the relationship between the robot and the person assisted.Challenges Related to the Impact of SARs onHuman-Human InteractionsPotential Reduction in Human ContactWith regards to human-human interactions, a common concern raised in relation to SARs in general is the potential drastic reduction in human contact [17, 78] .", [["human", "ORGANISM", 29, 34], ["Human", "ORGANISM", 253, 258], ["Human", "ORGANISM", 294, 299], ["human", "ORGANISM", 323, 328], ["human", "ORGANISM", 329, 334], ["human", "ORGANISM", 442, 447], ["human", "SPECIES", 29, 34], ["person", "SPECIES", 188, 194], ["Human", "SPECIES", 253, 258], ["Human", "SPECIES", 294, 299], ["human", "SPECIES", 323, 328], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 442, 447], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 323, 328], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 442, 447], ["SARs onHuman", "TREATMENT", 240, 252]]], ["If caregiving tasks are taken over by robots, the fear is that humans needing assistance will end up interacting mostly with robots rather than other fellow humans, and this will have detrimental effects on their social life and health.", [["humans", "ORGANISM", 63, 69], ["humans", "ORGANISM", 157, 163], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 157, 163], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 157, 163]]], ["We suggest that SARs should adopt mediator roles and assist people with health conditions in their social management of health.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66]]], ["We propose not for robots to diminish or replace human social contact, but on the contrary, to increase and enhance it.", [["human", "ORGANISM", 49, 54], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["robots", "TREATMENT", 19, 25]]], ["This paper thus proposes functions for SARs that are different from the ones evaluated by Sharkey and Sharkey, which focused on SARs assisting with daily tasks, monitoring behavior and health and providing companionship.Alteration of Human-Human InteractionsHowever, our vision is subject to a different concern: that mediator robots would inadvertently alter and negatively impact human-human interactions.", [["Human", "ORGANISM", 234, 239], ["Human", "ORGANISM", 240, 245], ["human", "ORGANISM", 382, 387], ["human", "ORGANISM", 388, 393], ["Human", "SPECIES", 234, 239], ["Human", "SPECIES", 240, 245], ["human", "SPECIES", 382, 387], ["human", "SPECIES", 388, 393], ["human", "SPECIES", 382, 387], ["human", "SPECIES", 388, 393], ["SARs", "PROBLEM", 39, 43]]], ["A robot embedded in an interaction could detract from it by being an unwelcomed distraction [71] .", [["an unwelcomed distraction", "TREATMENT", 66, 91]]], ["Instead of focusing on each other, people would instead focus on the robot and change their interaction to accommodate the robot.", [["people", "ORGANISM", 35, 41], ["people", "SPECIES", 35, 41], ["the robot", "TREATMENT", 65, 74], ["the robot", "TREATMENT", 119, 128]]], ["Based on the specific needs of the interaction and of the interactants, the robot could take a peripheral role, subtly cueing people to potential opportunities or problems in their interactions, or a more leading role, directing the interaction between people.", [["people", "ORGANISM", 253, 259], ["people", "SPECIES", 126, 132], ["people", "SPECIES", 253, 259]]], ["Moharana et al. suggest for example that in the early stages of dementia, and when the interaction is positive and satisfying for both the caregiver and the person receiving care, a mediator SAR could have a peripheral role in interactions.", [["dementia", "DISEASE", 64, 72], ["person", "SPECIES", 157, 163], ["dementia", "PROBLEM", 64, 72], ["early stages", "OBSERVATION_MODIFIER", 48, 60], ["dementia", "OBSERVATION", 64, 72]]], ["However, as the disease progresses and interactions become more frustrating, for example, because of agitation and forgetfulness, the robot could take on more the role of conversation partner in the interaction, taking over the stressful task of answering repetitive questions and providing redirection.", [["agitation", "DISEASE", 101, 110], ["forgetfulness", "DISEASE", 115, 128], ["agitation", "PROBLEM", 101, 110], ["forgetfulness", "PROBLEM", 115, 128], ["disease", "OBSERVATION", 16, 23]]], ["However, it is important for the robot to not only intervene in negative situations, but also when it detects opportunities for positive social interactions, lest it be perceived as a \"watchdog\" and its interventions associated with unpleasant events [23] .", [["unpleasant events", "PROBLEM", 233, 250]]], ["In the sections above, we've seen examples of mediation from both peripheral robotic devices, such as the ones from Hoffman et al. [57] and Tennent et al. [71] , and also mediation from robots in leading roles, offering high amounts of direction such as those developed by Shen et al. [23] or Utami and Bickmore [30] .", [["sections", "ANATOMY", 7, 15], ["both peripheral robotic devices", "TREATMENT", 61, 92], ["peripheral", "ANATOMY_MODIFIER", 66, 76], ["robotic devices", "OBSERVATION", 77, 92]]], ["Further research is needed to establish the factors that should dictate the degree of robot involvement in an interaction.", [["robot", "OBSERVATION", 86, 91]]], ["As we've seen, Pettinati et al. [76] found promisingly that the robot's presence did not have any negative effects on self-disclosure when embedded in an interaction between two people, however more research is needed to establish that this is the case across contexts.", [["people", "ORGANISM", 178, 184], ["people", "SPECIES", 178, 184]]], ["Pettinati et al. only showed this in the context of a conversation between two strangers, an interviewer and an interviewee, not between, for example, people who know each other and have a long relationship history.", [["people", "ORGANISM", 151, 157], ["people", "SPECIES", 151, 157]]], ["On the other hand, the robot's presence might in some cases be more tolerable than that of another person.", [["person", "SPECIES", 99, 105]]], ["Participants in the couple's therapy study by Utami and Bickmore [30] indicated that it was easier for them to perform the exercises and disclose things in front of the robot than it would have been in front of a human therapist.", [["human", "ORGANISM", 213, 218], ["Participants", "SPECIES", 0, 12], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 213, 218]]], ["More generally, Mutlu et al. [24] showed that robots can have an effect on how people feel about an interaction.", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85]]], ["Of course, this possibility is a great opportunity to use the robot's leverage to create positive interactions between people, but it is also a warning sign that unintended negative effects might also occur, and they should be carefully researched.Challenges Related to the Broader Social and Cultural ContextThe caregivers and the care recipients assisted by the robot are not the only ones that need to be considered in designing the SAR.", [["people", "ORGANISM", 119, 125], ["recipients", "ORGANISM", 337, 347], ["people", "SPECIES", 119, 125], ["the robot's leverage", "TREATMENT", 58, 78], ["the care recipients", "TREATMENT", 328, 347]]], ["Cultural differences exist with regards to caregiving and illness [17] which result in different roles, degrees of autonomy, and experiences for the caregiver and the person being cared for.", [["illness", "DISEASE", 58, 65], ["person", "SPECIES", 167, 173], ["Cultural differences", "PROBLEM", 0, 20], ["illness", "PROBLEM", 58, 65]]], ["Also, different cultures may have different attitudes towards robots, their form and functions [85] .", [["different cultures", "TEST", 6, 24]]], ["For example, prior to designing the activities and introducing the robots, Joshi and \u0160abanovi\u0107, conducted extensive interviews with the staff at the preschool and the assistive living-dementia care center where the robots would be used.", [["dementia", "DISEASE", 184, 192], ["the robots", "TREATMENT", 63, 73], ["Joshi", "TREATMENT", 75, 80], ["\u0160abanovi\u0107", "TREATMENT", 85, 94], ["the robots", "TREATMENT", 211, 221]]], ["The interviews helped them identify the following community goal: to engage older adults and children in activities that were meaningful for both groups, with the purpose of facilitating relations similar to grandparents and grandchildren.", [["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101]]], ["The authors then systematically investigated the usefulenes of different robots for achieving this goal.", [["different robots", "TREATMENT", 63, 79]]], ["For example the Cozmo robot led to activities that were too fast-paced for the older adults, and which distracted the children from meaningful intergenerational engagement rather than facilitating interaction.Ability to AdaptA key challenge and feature of the SAR, in order for it to be successful, will be its ability to adapt [6, 17] .", [["children", "ORGANISM", 118, 126], ["AdaptA", "PROTEIN", 220, 226], ["children", "SPECIES", 118, 126], ["the Cozmo robot", "TREATMENT", 12, 27]]], ["Adaptability is important to keep pace with the progression of the health condition and the changing needs and contexts of the person assisted.", [["person", "SPECIES", 127, 133]]], ["In many of the studies discussed, the positive effect of the robot on social interactions stems from the robot being an interesting gadget that prompted people to interact with each other about it.", [["people", "ORGANISM", 153, 159], ["people", "SPECIES", 153, 159], ["the studies", "TEST", 11, 22]]], ["Ideally, the robot and its repertoire of interventions would continue to change over time both as technology progresses and as more research establishes new effective interventions.", [["interventions", "TREATMENT", 41, 54], ["new effective interventions", "TREATMENT", 153, 180]]], ["The SAR should also be personalized to the preferences and needs of the person using it [6, 17] .", [["person", "SPECIES", 72, 78]]], ["People react differently to different intervention styles.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["A major gap in the literature describing uses of robots as mediators of human-human interactions, is the lack of studies focusing on individual differences and how they modulate the robot's effect.Creation and Meeting of ExpectationsConnected to the challenge of deception explored above, SARs should be designed in mindful ways that do not create expectations that are not met [71] .", [["human", "ORGANISM", 72, 77], ["human", "ORGANISM", 78, 83], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 72, 77], ["A major gap", "PROBLEM", 0, 11], ["robots", "TREATMENT", 49, 55], ["SARs", "PROBLEM", 289, 293], ["major", "OBSERVATION_MODIFIER", 2, 7], ["gap", "OBSERVATION", 8, 11]]], ["For example, just because a robot can offer suggestions of conversation topics, it does not mean that it has an understanding of what people talk about.", [["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140]]], ["As discussed above, the SAR should not lead to enfeeblement and loss of autonomy.Robustness and SafetyFinally, SARs need to be robust in terms of their ability to carry out the functions they are designed for.", [["loss of autonomy", "DISEASE", 64, 80], ["loss of autonomy", "PROBLEM", 64, 80], ["SARs", "PROBLEM", 111, 115]]], ["Since SARs for the social management of health are envisioned to assist vulnerable populations, potential technical problems need to be reduced to a minimum [71] .", [["potential technical problems", "PROBLEM", 96, 124]]], ["When robots that simply provide entertainment fail, the failure might be more tolerable and less costly, but when people rely on robots for tasks that have significance for their health, technical issues become seriously problematic.ConclusionIn this paper we proposed five classes of functions for SARs that would support the social management of health by assisting human-human interactions.", [["people", "ORGANISM", 114, 120], ["human", "ORGANISM", 368, 373], ["human", "ORGANISM", 374, 379], ["people", "SPECIES", 114, 120], ["human", "SPECIES", 368, 373], ["human", "SPECIES", 374, 379], ["human", "SPECIES", 368, 373], ["human", "SPECIES", 374, 379], ["the failure", "PROBLEM", 52, 63], ["SARs", "PROBLEM", 299, 303], ["failure", "OBSERVATION", 56, 63]]], ["We've identified the research gaps in our understanding of how a robot could change the way a person with a health condition is perceived by others.", [["person", "SPECIES", 94, 100]]], ["We have illustrated through some previous results, mainly from case studies, how robots could enhance the social behavior of people with health conditions by addressing the impairments specific to the health condition.", [["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["case studies", "TEST", 63, 75], ["the impairments", "PROBLEM", 169, 184]]], ["We summarized the research on how robots can modify the social behavior of people both for further enhancing positive interactions and for correcting negative ones.", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["further enhancing positive interactions", "PROBLEM", 91, 130]]], ["We surveyed the research studies that have used various levels of robot intervention to structure human-human interactions in both clinical and non-clinical settings.", [["human", "ORGANISM", 98, 103], ["human", "ORGANISM", 104, 109], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 104, 109], ["the research studies", "TEST", 12, 32], ["robot intervention", "TREATMENT", 66, 84]]], ["Finally, we exemplified through previous findings how people's feelings in a social context might be changed for the better by the introduction of a robot into the interaction.", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60]]], ["We discussed potential challenges in the design and use of SARs and showed that when the focus of the SAR's intervention is on the enhancement of the human-human interaction not on the replacement of caregivers, many of the general concerns with regards to SARs can be mitigated.", [["human", "ORGANISM", 150, 155], ["human", "ORGANISM", 156, 161], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 156, 161], ["the SAR's intervention", "TREATMENT", 98, 120], ["the replacement of caregivers", "TREATMENT", 181, 210]]], ["The existing literature and the promising research avenues identified suggest that the development of SARs for the management of social interactions could yield important benefits for health.ConclusionFunding This project was supported by the National Science Foundation Grant IIS-1316809.", [["IIS-1316809", "CHEMICAL", 277, 288], ["SARs", "PROBLEM", 102, 106]]]], "cd6a9ec0877037ed074cc2b646b0bc9c479258a8": [["I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (\"BMJ\") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.", [["CC", "CHEMICAL", 284, 286], ["right", "ANATOMY_MODIFIER", 33, 38]]]], "4f464dca9855a7840bc627f02b59c95b16477bf6": [["INTRODUCTIONFlaviviruses are significant human pathogens that cause widespread mortality around the world.", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["significant human pathogens", "PROBLEM", 29, 56], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["human pathogens", "OBSERVATION", 41, 56], ["widespread", "OBSERVATION_MODIFIER", 68, 78], ["mortality", "OBSERVATION", 79, 88]]], ["The genus encompasses several arthropod-borne viruses including Dengue (DENV), Yellow Fever (YFV), and Zika (ZIKV) (Bhatt et al., 2013; Daep et al., 2014; Weaver et al., 2016) .", [["Dengue", "DISEASE", 64, 70], ["Yellow Fever (YFV), and Zika (ZIKV)", "DISEASE", 79, 114], ["Dengue", "ORGANISM", 64, 70], ["Yellow Fever", "ORGANISM", 79, 91], ["YFV", "ORGANISM", 93, 96], ["DENV", "SPECIES", 72, 76], ["Yellow Fever (YFV)", "SPECIES", 79, 97], ["ZIKV", "SPECIES", 109, 113], ["Dengue (DENV", "PROBLEM", 64, 76], ["Yellow Fever (YFV)", "PROBLEM", 79, 97], ["Zika", "PROBLEM", 103, 107], ["genus", "ANATOMY", 4, 9], ["borne viruses", "OBSERVATION", 40, 53]]], ["These viruses pose serious public health threats, particularly as increased global travel and climate change have caused an increase in the spread of both the virus and their mosquito vectors (A. albopictus and A. aegypti) (Tatem et al., 2012; Whitehorn and Yacoub, 2019) .", [["A. albopictus", "ORGANISM", 193, 206], ["A. aegypti", "ORGANISM", 211, 221], ["A. albopictus", "SPECIES", 193, 206], ["A. aegypti", "SPECIES", 211, 221], ["A. albopictus", "SPECIES", 193, 206], ["A. aegypti", "SPECIES", 211, 221], ["an increase", "PROBLEM", 121, 132], ["the virus", "PROBLEM", 155, 164], ["serious", "OBSERVATION_MODIFIER", 19, 26], ["increase", "OBSERVATION_MODIFIER", 124, 132], ["spread", "OBSERVATION_MODIFIER", 140, 146]]], ["It is estimated that 53% of the world population lives in areas suitable for Dengue transmission resulting in 50-100 million Dengue infections per year, of which 500,000 proceed to Dengue hemorrhagic fever and 22,000 are fatal (Bhatt et al., 2013; Messina et al., 2019) .", [["Dengue", "DISEASE", 77, 83], ["Dengue infections", "DISEASE", 125, 142], ["Dengue hemorrhagic fever", "DISEASE", 181, 205], ["Dengue hemorrhagic fever", "SPECIES", 181, 205], ["Dengue transmission", "PROBLEM", 77, 96], ["Dengue hemorrhagic fever", "PROBLEM", 181, 205]]], ["ZIKV infection has been linked to serious neurological defects, including Guillain-Barr\u00e9 syndrome and microcephaly in newborns (Mendez et al., 2017) .", [["neurological", "ANATOMY", 42, 54], ["ZIKV infection", "DISEASE", 0, 14], ["neurological defects", "DISEASE", 42, 62], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 74, 97], ["microcephaly", "DISEASE", 102, 114], ["Guillain-Barr\u00e9", "ORGANISM", 74, 88], ["newborns", "ORGANISM", 118, 126], ["ZIKV", "SPECIES", 0, 4], ["ZIKV infection", "PROBLEM", 0, 14], ["serious neurological defects", "PROBLEM", 34, 62], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 74, 97], ["microcephaly", "PROBLEM", 102, 114], ["serious", "OBSERVATION_MODIFIER", 34, 41], ["neurological defects", "OBSERVATION", 42, 62], ["Barr\u00e9 syndrome", "OBSERVATION", 83, 97], ["microcephaly", "OBSERVATION", 102, 114]]], ["While ZIKV diagnoses were relatively rare until the early 2000s, the 2015-2016 pandemic in the Americas highlighted the potential for rapid spread of the disease vectors (Weaver et al., 2016) .INTRODUCTIONVaccines currently exist for only a limited range of flaviviruses (Collins and Metz, 2017 ).", [["flaviviruses", "DISEASE", 258, 270], ["flaviviruses", "ORGANISM", 258, 270], ["ZIKV", "SPECIES", 6, 10], ["the disease vectors", "PROBLEM", 150, 169]]], ["The first DENV vaccine, Dengvaxia, was approved by the FDA in early 2019 (Thomas and Yoon, 2019) .", [["Dengvaxia", "CHEMICAL", 24, 33], ["DENV", "SPECIES", 10, 14]]], ["However, its use remains limited to children with confirmed prior infection.", [["infection", "DISEASE", 66, 75], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["prior infection", "PROBLEM", 60, 75], ["infection", "OBSERVATION", 66, 75]]], ["In addition, no post-exposure therapeutic options are available for patients infected with these viruses; current treatments only attempt to alleviate the symptoms (Bernatchez et al., 2020; Lim, 2019; Lim et al., 2013) .", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["post-exposure therapeutic options", "TREATMENT", 16, 49], ["these viruses", "TREATMENT", 91, 104], ["current treatments", "TREATMENT", 106, 124], ["the symptoms", "PROBLEM", 151, 163], ["no", "UNCERTAINTY", 13, 15]]], ["Antiviral strategies often focus on directly targeting viral proteins.", [["viral proteins", "PROTEIN", 55, 69], ["Antiviral strategies", "TREATMENT", 0, 20]]], ["While molecules inhibiting for instance the flavivirus RNAdependent RNA polymerase NS5 or the protease NS3 have been identified, the high mutation rate of the virus allows for resistance to be developed quickly (Bernatchez et al., 2020; Carrasco-Hernandez et al., 2017; Garcia et al., 2017) .", [["NS3", "GENE_OR_GENE_PRODUCT", 103, 106], ["flavivirus RNAdependent RNA polymerase NS5", "PROTEIN", 44, 86], ["protease NS3", "PROTEIN", 94, 106], ["the flavivirus RNAdependent RNA polymerase NS5", "TREATMENT", 40, 86], ["the protease NS3", "TREATMENT", 90, 106], ["the high mutation rate", "PROBLEM", 129, 151], ["the virus", "PROBLEM", 155, 164]]], ["One increasing area of exploration for alternative therapeutic approaches is the targeting of host factors that are critical for virus propagation (Kaufmann et al., 2018) .", [["host factors", "PROTEIN", 94, 106], ["exploration", "TEST", 23, 34], ["alternative therapeutic approaches", "TREATMENT", 39, 73], ["host factors", "PROBLEM", 94, 106], ["virus propagation", "PROBLEM", 129, 146], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["area", "OBSERVATION_MODIFIER", 15, 19], ["exploration", "OBSERVATION", 23, 34]]], ["As these proteins are not under genetic control of the virus, development of resistance is much less likely (De Clercq, 2007; Geller et al., 2013 Geller et al., , 2007 .", [["the virus", "PROBLEM", 51, 60], ["resistance", "PROBLEM", 77, 87], ["resistance", "OBSERVATION", 77, 87]]], ["In addition, host-targeted therapeutics should be effective as broad-spectrum antivirals instead of targeting a single virus (Aviner and Frydman, 2020; Taguwa et al., 2019 Taguwa et al., , 2015 .INTRODUCTIONFlaviviruses contain a genome of positive-sense, single stranded RNA (+ssRNA) approximately 11kb in size.", [["single stranded RNA", "RNA", 256, 275], ["broad-spectrum antivirals", "TREATMENT", 63, 88], ["single stranded RNA", "PROBLEM", 256, 275], ["ssRNA", "PROBLEM", 278, 283], ["size", "OBSERVATION_MODIFIER", 307, 311]]], ["The viruses replicate and assemble around the endoplasmic reticulum (ER) membrane (Apte-Sengupta et al., 2014) .", [["endoplasmic reticulum", "ANATOMY", 46, 67], ["ER) membrane", "ANATOMY", 69, 81], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 46, 67], ["ER", "CELLULAR_COMPONENT", 69, 71], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["viruses", "OBSERVATION", 4, 11], ["endoplasmic reticulum", "ANATOMY", 46, 67]]], ["As the genome is translated after entry into the cell, the single polyprotein is inserted into the ER membrane and is co-and post-translationally processed into three structural (capsid, pre-membrane, and envelope) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) proteins (Perera and Kuhn, 2008) .", [["cell", "ANATOMY", 49, 53], ["ER membrane", "ANATOMY", 99, 110], ["genome", "CELLULAR_COMPONENT", 7, 13], ["cell", "CELL", 49, 53], ["ER", "GENE_OR_GENE_PRODUCT", 99, 101], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["capsid", "CELLULAR_COMPONENT", 179, 185], ["pre-membrane", "GENE_OR_GENE_PRODUCT", 187, 199], ["NS1", "GENE_OR_GENE_PRODUCT", 240, 243], ["NS2A", "GENE_OR_GENE_PRODUCT", 245, 249], ["NS2B", "GENE_OR_GENE_PRODUCT", 251, 255], ["NS3", "GENE_OR_GENE_PRODUCT", 257, 260], ["NS4A", "GENE_OR_GENE_PRODUCT", 262, 266], ["NS4B", "GENE_OR_GENE_PRODUCT", 268, 272], ["NS5", "GENE_OR_GENE_PRODUCT", 274, 277], ["ER", "PROTEIN", 99, 101], ["structural (capsid, pre-membrane, and envelope", "PROTEIN", 167, 213], ["NS1", "PROTEIN", 240, 243], ["NS2A", "PROTEIN", 245, 249], ["NS2B", "PROTEIN", 251, 255], ["NS3", "PROTEIN", 257, 260], ["NS4A", "PROTEIN", 262, 266], ["NS4B", "PROTEIN", 268, 272], ["NS5", "PROTEIN", 274, 277], ["the single polyprotein", "TREATMENT", 55, 77], ["NS1", "TEST", 240, 243], ["NS2A", "TEST", 245, 249], ["NS2B", "TEST", 251, 255], ["NS3", "TEST", 257, 260], ["NS4A", "TEST", 262, 266], ["NS4B", "TEST", 268, 272]]], ["The host proteostasis network has been implicated in the maintenance of individual viral proteins and virus evolution (Aviner and Frydman, 2020; Phillips et al., 2017; Ravindran, 2018; Reid et al., 2018) .", [["viral proteins", "PROTEIN", 83, 97], ["individual viral proteins", "PROBLEM", 72, 97], ["host proteostasis", "OBSERVATION", 4, 21]]], ["The proteostasis network is comprised of chaperones, co-chaperones and other protein quality control factors that control protein folding, assembly, post-translational modification, trafficking, and degradation.", [["chaperones", "PROTEIN", 41, 51], ["co-chaperones", "PROTEIN", 53, 66], ["protein quality control factors", "PROTEIN", 77, 108], ["chaperones", "TREATMENT", 41, 51], ["co-chaperones", "TREATMENT", 53, 66], ["other protein quality control factors", "TREATMENT", 71, 108], ["protein folding", "PROBLEM", 122, 137]]], ["Genetic screens have identified many proteostasis factors as essential for DENV replication, including several components of the oligosaccharyl transferase (OST) complex, as well as the ER membrane protein complex (Lin et al., 2019; Marceau et al., 2016; Ngo et al., 2019; Savidis et al., 2016) .", [["ER membrane", "ANATOMY", 186, 197], ["oligosaccharyl", "CHEMICAL", 129, 143], ["DENV", "ORGANISM", 75, 79], ["oligosaccharyl transferase", "GENE_OR_GENE_PRODUCT", 129, 155], ["OST", "GENE_OR_GENE_PRODUCT", 157, 160], ["ER", "GENE_OR_GENE_PRODUCT", 186, 188], ["proteostasis factors", "PROTEIN", 37, 57], ["oligosaccharyl transferase (OST) complex", "PROTEIN", 129, 169], ["ER membrane protein complex", "PROTEIN", 186, 213], ["DENV", "SPECIES", 75, 79], ["Genetic screens", "TEST", 0, 15], ["many proteostasis factors", "PROBLEM", 32, 57], ["DENV replication", "PROBLEM", 75, 91], ["the oligosaccharyl transferase", "TREATMENT", 125, 155]]], ["Aside from promoting biogenesis of viral proteins, these components also have additional roles in organizing viral replication centers at the ER membrane (Marceau et al., 2016; Ngo et al., 2019; Rothan and Kumar, 2019) .", [["ER membrane", "ANATOMY", 142, 153], ["ER membrane", "CELLULAR_COMPONENT", 142, 153], ["viral proteins", "PROTEIN", 35, 49], ["ER", "PROTEIN", 142, 144], ["viral proteins", "PROBLEM", 35, 49], ["viral proteins", "OBSERVATION", 35, 49], ["organizing", "OBSERVATION_MODIFIER", 98, 108], ["viral replication", "OBSERVATION", 109, 126]]], ["Additionally, diverse cellular chaperone and co-chaperone systems are required for all stages of the viral life cycle, including virus entry and disassembly, folding of individual viral proteins, as well as assembly and egress of new virions (Fischl and Bartenschlager, 2011; Heaton et al., 2016; Taguwa et al., 2019) .", [["cellular", "ANATOMY", 22, 30], ["cellular", "CELL", 22, 30], ["cellular chaperone", "PROTEIN", 22, 40], ["viral proteins", "PROTEIN", 180, 194], ["co-chaperone systems", "TREATMENT", 45, 65], ["the viral life cycle", "TREATMENT", 97, 117], ["virus entry", "PROBLEM", 129, 140], ["individual viral proteins", "PROBLEM", 169, 194], ["diverse", "OBSERVATION_MODIFIER", 14, 21], ["cellular chaperone", "OBSERVATION", 22, 40], ["viral proteins", "OBSERVATION", 180, 194]]], ["Pharmacologic inhibition of proteostasis factors, including the OST as well as cytosolic Hsp70 and Hsp90 chaperones, has been shown to be an effective strategy to reduce flavivirus infection in cell models (Heaton et al., 2016; Howe et al., 2016; Puschnik et al., 2017; Taguwa et al., 2019 Taguwa et al., , 2015 Yang et al., 2020) .INTRODUCTIONAs flavivirus replication and polyprotein translation occurs at the ER membrane, infection results in expansion of the ER and remodeling of the ER proteostasis environment (Ravindran et al., 2016; Rothan and Kumar, 2019; Stohlman et al., 1975) .INTRODUCTIONDENV infection leads to modulation of the unfolded protein response (UPR), the adaptive stress-response that remodels the ER proteostasis environment to counter stress caused by accumulation of misfolded proteins (Pe\u00f1a and Harris, 2011; Perera et al., 2017) .", [["cytosolic", "ANATOMY", 79, 88], ["cell", "ANATOMY", 194, 198], ["ER membrane", "ANATOMY", 412, 423], ["ER", "ANATOMY", 463, 465], ["ER", "ANATOMY", 488, 490], ["ER", "ANATOMY", 723, 725], ["flavivirus infection", "DISEASE", 170, 190], ["infection", "DISEASE", 425, 434], ["infection", "DISEASE", 606, 615], ["proteostasis factors", "GENE_OR_GENE_PRODUCT", 28, 48], ["OST", "GENE_OR_GENE_PRODUCT", 64, 67], ["Hsp70", "GENE_OR_GENE_PRODUCT", 89, 94], ["Hsp90", "GENE_OR_GENE_PRODUCT", 99, 104], ["cell", "CELL", 194, 198], ["ER membrane", "CELLULAR_COMPONENT", 412, 423], ["ER", "GENE_OR_GENE_PRODUCT", 463, 465], ["ER", "GENE_OR_GENE_PRODUCT", 488, 490], ["UPR", "GENE_OR_GENE_PRODUCT", 670, 673], ["ER", "GENE_OR_GENE_PRODUCT", 723, 725], ["proteostasis factors", "PROTEIN", 28, 48], ["OST", "PROTEIN", 64, 67], ["cytosolic Hsp70", "PROTEIN", 79, 94], ["Hsp90 chaperones", "PROTEIN", 99, 115], ["ER", "PROTEIN", 412, 414], ["ER", "PROTEIN", 463, 465], ["ER", "PROTEIN", 488, 490], ["UPR", "PROTEIN", 670, 673], ["ER", "PROTEIN", 723, 725], ["misfolded proteins", "PROTEIN", 795, 813], ["flavivirus", "SPECIES", 170, 180], ["proteostasis factors", "PROBLEM", 28, 48], ["the OST", "TREATMENT", 60, 67], ["cytosolic Hsp70", "TEST", 79, 94], ["Hsp90 chaperones", "TREATMENT", 99, 115], ["an effective strategy", "TREATMENT", 138, 159], ["flavivirus infection", "PROBLEM", 170, 190], ["INTRODUCTIONAs flavivirus replication", "TREATMENT", 332, 369], ["polyprotein translation", "TREATMENT", 374, 397], ["infection", "PROBLEM", 425, 434], ["INTRODUCTIONDENV infection", "PROBLEM", 589, 615], ["the unfolded protein response", "PROBLEM", 639, 668], ["misfolded proteins", "PROBLEM", 795, 813], ["flavivirus", "OBSERVATION", 170, 180], ["infection", "OBSERVATION", 425, 434], ["infection", "OBSERVATION", 606, 615], ["unfolded", "OBSERVATION_MODIFIER", 643, 651], ["protein response", "OBSERVATION", 652, 668], ["misfolded proteins", "OBSERVATION", 795, 813]]], ["The UPR consists of three overlapping but distinct signaling branches downstream of the stress-sensing receptors IRE1 (inositol-requiring enzyme 1), ATF6 (activating transcription factor 6), and PERK (Protein kinase R-like ER kinase) (Shoulders et al., 2013; Walter and Ron, 2011) .", [["inositol", "CHEMICAL", 119, 127], ["inositol", "CHEMICAL", 119, 127], ["IRE1", "GENE_OR_GENE_PRODUCT", 113, 117], ["inositol-requiring enzyme 1", "GENE_OR_GENE_PRODUCT", 119, 146], ["ATF6", "GENE_OR_GENE_PRODUCT", 149, 153], ["activating transcription factor 6", "GENE_OR_GENE_PRODUCT", 155, 188], ["PERK", "GENE_OR_GENE_PRODUCT", 195, 199], ["Protein kinase R-like ER kinase", "GENE_OR_GENE_PRODUCT", 201, 232], ["UPR", "PROTEIN", 4, 7], ["stress-sensing receptors", "PROTEIN", 88, 112], ["IRE1", "PROTEIN", 113, 117], ["inositol-requiring enzyme 1", "PROTEIN", 119, 146], ["ATF6", "PROTEIN", 149, 153], ["activating transcription factor 6", "PROTEIN", 155, 188], ["PERK", "PROTEIN", 195, 199], ["Protein kinase R", "PROTEIN", 201, 217], ["ER kinase", "PROTEIN", 223, 232], ["the stress", "TEST", 84, 94], ["inositol", "TEST", 119, 127], ["enzyme", "TEST", 138, 144], ["ATF6 (activating transcription factor", "TEST", 149, 186], ["PERK", "TEST", 195, 199], ["Protein kinase R", "TEST", 201, 217], ["distinct", "OBSERVATION_MODIFIER", 42, 50], ["signaling", "OBSERVATION_MODIFIER", 51, 60], ["branches", "OBSERVATION_MODIFIER", 61, 69], ["downstream", "OBSERVATION_MODIFIER", 70, 80], ["Shoulders", "ANATOMY", 235, 244]]], ["The first two branches primarily control the upregulation of chaperones and other proteostasis factors to expand the protein folding capacity of the ER.", [["ER", "ANATOMY", 149, 151], ["proteostasis factors", "GENE_OR_GENE_PRODUCT", 82, 102], ["ER", "GENE_OR_GENE_PRODUCT", 149, 151], ["chaperones", "PROTEIN", 61, 71], ["proteostasis factors", "PROTEIN", 82, 102], ["ER", "PROTEIN", 149, 151], ["other proteostasis factors", "PROBLEM", 76, 102], ["branches", "OBSERVATION_MODIFIER", 14, 22], ["upregulation", "OBSERVATION_MODIFIER", 45, 57]]], ["The PERK branch is responsible for translational attenuation via phosphorylation of eukaryotic initiation factor 2 alpha (eIF2a) and subsequent activation of the integrated stress response.", [["PERK", "GENE_OR_GENE_PRODUCT", 4, 8], ["eukaryotic initiation factor 2 alpha", "GENE_OR_GENE_PRODUCT", 84, 120], ["eIF2a", "GENE_OR_GENE_PRODUCT", 122, 127], ["PERK", "PROTEIN", 4, 8], ["eukaryotic initiation factor 2 alpha", "PROTEIN", 84, 120], ["eIF2a", "PROTEIN", 122, 127], ["translational attenuation", "PROBLEM", 35, 60], ["PERK", "OBSERVATION", 4, 8], ["branch", "ANATOMY_MODIFIER", 9, 15], ["responsible for", "UNCERTAINTY", 19, 34], ["translational attenuation", "OBSERVATION", 35, 60]]], ["DENV has been shown to upregulate the IRE1/XBP1s and ATF6 branches of the UPR, while suppressing activation of the PERK branch (Pe\u00f1a and Harris, 2011) .", [["DENV", "ORGANISM", 0, 4], ["IRE1", "GENE_OR_GENE_PRODUCT", 38, 42], ["XBP1s", "GENE_OR_GENE_PRODUCT", 43, 48], ["ATF6", "GENE_OR_GENE_PRODUCT", 53, 57], ["UPR", "GENE_OR_GENE_PRODUCT", 74, 77], ["PERK", "GENE_OR_GENE_PRODUCT", 115, 119], ["IRE1", "PROTEIN", 38, 42], ["XBP1s", "PROTEIN", 43, 48], ["ATF6", "PROTEIN", 53, 57], ["UPR", "PROTEIN", 74, 77], ["PERK branch", "PROTEIN", 115, 126], ["DENV", "SPECIES", 0, 4], ["DENV", "PROBLEM", 0, 4], ["branches", "ANATOMY_MODIFIER", 58, 66], ["UPR", "ANATOMY_MODIFIER", 74, 77], ["PERK", "ANATOMY_MODIFIER", 115, 119], ["branch", "ANATOMY_MODIFIER", 120, 126]]], ["The importance of UPR-dependent ER proteostasis remodeling for flavivirus infection has only been explored in knockout cell models.", [["ER", "ANATOMY", 32, 34], ["cell", "ANATOMY", 119, 123], ["flavivirus infection", "DISEASE", 63, 83], ["UPR", "GENE_OR_GENE_PRODUCT", 18, 21], ["ER", "GENE_OR_GENE_PRODUCT", 32, 34], ["cell", "CELL", 119, 123], ["UPR", "PROTEIN", 18, 21], ["ER", "PROTEIN", 32, 34], ["flavivirus", "SPECIES", 63, 73], ["UPR-dependent ER proteostasis remodeling", "TREATMENT", 18, 58], ["flavivirus infection", "PROBLEM", 63, 83], ["UPR-dependent", "OBSERVATION_MODIFIER", 18, 31]]], ["For example, the virus was less capable of propagating in IRE1 -/-MEF cells.", [["IRE1 -/-MEF cells", "ANATOMY", 58, 75], ["IRE1", "GENE_OR_GENE_PRODUCT", 58, 62], ["MEF cells", "CELL", 66, 75], ["IRE1 -/-MEF cells", "CELL_LINE", 58, 75], ["the virus", "PROBLEM", 13, 22], ["virus", "OBSERVATION", 17, 22], ["MEF cells", "OBSERVATION", 66, 75]]], ["In contrast, PERK knockout resulted in increased viral titers, while ATF6 knockout did not impact viral propagation.", [["PERK", "GENE_OR_GENE_PRODUCT", 13, 17], ["ATF6", "GENE_OR_GENE_PRODUCT", 69, 73], ["PERK", "PROTEIN", 13, 17], ["ATF6", "PROTEIN", 69, 73], ["PERK knockout", "TEST", 13, 26], ["increased viral titers", "PROBLEM", 39, 61], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["viral titers", "OBSERVATION", 49, 61], ["viral propagation", "OBSERVATION", 98, 115]]], ["(Pe\u00f1a and Harris, 2011) .INTRODUCTIONGiven the dependencies of DENV and other flaviviruses on UPR modulation and an enhanced ER proteostasis environment in the host cells during infection, we sought to explore whether these dependencies can be perturbed to impair viral infection.INTRODUCTIONPharmacologic remodeling of ER proteostasis pathways has become an attractive strategy at correcting imbalances associated with diverse phenotypes related to protein stress and misfolding without affecting endogenous protein maturation or causing toxicity (Blackwood et al., 2019; Chen et al., 2014; Cooley et al., 2014; Kroeger et al., 2018; Plate et al., 2016) .", [["ER", "ANATOMY", 125, 127], ["cells", "ANATOMY", 165, 170], ["infection", "DISEASE", 178, 187], ["viral infection", "DISEASE", 264, 279], ["toxicity", "DISEASE", 539, 547], ["DENV", "ORGANISM", 63, 67], ["UPR", "GENE_OR_GENE_PRODUCT", 94, 97], ["ER", "GENE_OR_GENE_PRODUCT", 125, 127], ["host cells", "CELL", 160, 170], ["ER", "GENE_OR_GENE_PRODUCT", 320, 322], ["ER", "PROTEIN", 125, 127], ["host cells", "CELL_TYPE", 160, 170], ["ER", "PROTEIN", 320, 322], ["DENV", "SPECIES", 63, 67], ["DENV", "PROBLEM", 63, 67], ["other flaviviruses", "PROBLEM", 72, 90], ["UPR modulation", "TREATMENT", 94, 108], ["an enhanced ER proteostasis environment", "PROBLEM", 113, 152], ["infection", "PROBLEM", 178, 187], ["these dependencies", "PROBLEM", 218, 236], ["viral infection", "PROBLEM", 264, 279], ["ER proteostasis pathways", "PROBLEM", 320, 344], ["correcting imbalances", "PROBLEM", 382, 403], ["diverse phenotypes", "PROBLEM", 420, 438], ["protein stress", "PROBLEM", 450, 464], ["misfolding", "PROBLEM", 469, 479], ["endogenous protein maturation", "PROBLEM", 498, 527], ["DENV", "OBSERVATION", 63, 67], ["proteostasis environment", "OBSERVATION", 128, 152], ["host cells", "OBSERVATION", 160, 170], ["viral", "OBSERVATION_MODIFIER", 264, 269], ["infection", "OBSERVATION", 270, 279]]], ["In particular, compound 147, which was developed as a preferential activator of the ATF6 pathway, has broadly beneficial effects at reducing secretion of amyloidogenic proteins and protecting against oxidative organ damage from ischemia/reperfusion (Blackwood et al., 2019; Plate et al., 2016) .INTRODUCTIONHere, we demonstrate that ER proteostasis remodeling by compound 147 serves as an effective strategy to reduce flavivirus infection.", [["organ", "ANATOMY", 210, 215], ["ER", "ANATOMY", 333, 335], ["compound 147", "CHEMICAL", 15, 27], ["organ damage", "DISEASE", 210, 222], ["ischemia", "DISEASE", 228, 236], ["compound 147", "CHEMICAL", 363, 375], ["flavivirus infection", "DISEASE", 418, 438], ["compound 147", "SIMPLE_CHEMICAL", 15, 27], ["ATF6", "GENE_OR_GENE_PRODUCT", 84, 88], ["organ", "ORGAN", 210, 215], ["ER", "GENE_OR_GENE_PRODUCT", 333, 335], ["flavivirus", "ORGANISM", 418, 428], ["ATF6", "PROTEIN", 84, 88], ["amyloidogenic proteins", "PROTEIN", 154, 176], ["ER", "PROTEIN", 333, 335], ["flavivirus", "SPECIES", 418, 428], ["amyloidogenic proteins", "PROBLEM", 154, 176], ["oxidative organ damage", "PROBLEM", 200, 222], ["ischemia", "PROBLEM", 228, 236], ["reperfusion", "PROBLEM", 237, 248], ["ER proteostasis remodeling", "PROBLEM", 333, 359], ["an effective strategy", "TREATMENT", 386, 407], ["flavivirus infection", "PROBLEM", 418, 438], ["amyloidogenic proteins", "OBSERVATION", 154, 176], ["ischemia", "OBSERVATION", 228, 236], ["reperfusion", "OBSERVATION_MODIFIER", 237, 248], ["flavivirus", "OBSERVATION", 418, 428]]], ["We determine that the 147 mediated reduction in DENV replication and assembly is surprisingly not mediated through activation of ATF6.", [["DENV", "ORGANISM", 48, 52], ["ATF6", "GENE_OR_GENE_PRODUCT", 129, 133], ["ATF6", "PROTEIN", 129, 133], ["DENV", "SPECIES", 48, 52], ["the 147 mediated reduction", "TREATMENT", 18, 44], ["DENV replication", "TREATMENT", 48, 64], ["DENV replication", "OBSERVATION", 48, 64]]], ["Instead, the activity is mediated by upstream covalent modifications of protein targets by 147.", [["protein targets", "TEST", 72, 87]]], ["Prior work identified protein disulfide isomerases (PDIs) as critical targets for the 147-dependent ATF6 activation , however, our data suggests PDIs are not responsible for the antiviral activity.", [["disulfide", "CHEMICAL", 30, 39], ["protein disulfide isomerases", "GENE_OR_GENE_PRODUCT", 22, 50], ["PDIs", "GENE_OR_GENE_PRODUCT", 52, 56], ["ATF6", "GENE_OR_GENE_PRODUCT", 100, 104], ["PDIs", "GENE_OR_GENE_PRODUCT", 145, 149], ["protein disulfide isomerases", "PROTEIN", 22, 50], ["PDIs", "PROTEIN", 52, 56], ["ATF6", "PROTEIN", 100, 104], ["PDIs", "PROTEIN", 145, 149], ["our data", "TEST", 127, 135], ["PDIs", "PROBLEM", 145, 149], ["not responsible for", "UNCERTAINTY", 154, 173], ["antiviral activity", "OBSERVATION", 178, 196]]], ["Finally, we show that 147 treatment can reduce proliferation of multiple DENV serotypes and several ZIKV strains, demonstrating that the pharmacologic agent could be a broadly effective strategy against flaviviruses and other viruses that depend on ER proteostasis processes.A Selective Modulator of the ATF6 Pathway Impairs Dengue Virus InfectionDENV is known to activate the UPR in infected host cells and was previously found to specifically upregulate the ATF6 and IRE1/XBP1s signaling arms, which transcriptionally upregulate ER protein quality control factors and adjust proteostasis capacity (Fig. 1A ) (Pe\u00f1a and Harris, 2011; Shoulders et al., 2013) .", [["ER", "ANATOMY", 249, 251], ["cells", "ANATOMY", 398, 403], ["flaviviruses", "DISEASE", 203, 215], ["Dengue", "DISEASE", 325, 331], ["DENV", "ORGANISM", 73, 77], ["ER", "GENE_OR_GENE_PRODUCT", 249, 251], ["ATF6", "GENE_OR_GENE_PRODUCT", 304, 308], ["Dengue Virus", "ORGANISM", 325, 337], ["UPR", "GENE_OR_GENE_PRODUCT", 377, 380], ["host cells", "CELL", 393, 403], ["ATF6", "GENE_OR_GENE_PRODUCT", 460, 464], ["IRE1", "GENE_OR_GENE_PRODUCT", 469, 473], ["XBP1s", "GENE_OR_GENE_PRODUCT", 474, 479], ["ER", "GENE_OR_GENE_PRODUCT", 531, 533], ["ER", "PROTEIN", 249, 251], ["ATF6", "PROTEIN", 304, 308], ["UPR", "PROTEIN", 377, 380], ["infected host cells", "CELL_TYPE", 384, 403], ["ATF6", "PROTEIN", 460, 464], ["IRE1", "PROTEIN", 469, 473], ["XBP1s", "PROTEIN", 474, 479], ["ER", "PROTEIN", 531, 533], ["DENV", "SPECIES", 73, 77], ["ZIKV", "SPECIES", 100, 104], ["Dengue Virus", "SPECIES", 325, 337], ["multiple DENV serotypes", "PROBLEM", 64, 87], ["several ZIKV strains", "PROBLEM", 92, 112], ["the pharmacologic agent", "TREATMENT", 133, 156], ["flaviviruses", "PROBLEM", 203, 215], ["other viruses", "PROBLEM", 220, 233], ["ER proteostasis processes", "PROBLEM", 249, 274], ["A Selective Modulator of the ATF6 Pathway", "TREATMENT", 275, 316], ["Dengue Virus InfectionDENV", "PROBLEM", 325, 351], ["the ATF6", "TEST", 456, 464], ["IRE1", "TEST", 469, 473], ["ER protein quality control factors", "PROBLEM", 531, 565], ["proteostasis capacity", "TEST", 577, 598], ["multiple", "OBSERVATION_MODIFIER", 64, 72], ["DENV serotypes", "OBSERVATION", 73, 87], ["infected host cells", "OBSERVATION", 384, 403], ["Shoulders", "ANATOMY", 634, 643]]], ["To confirm the activation of ER proteostasis pathways by DENV, we performed an infection time-course with DENV serotype 2 (DENV2) in Huh7 liver carcinoma cells and measured transcript levels of an ATF6-regulated gene (PDIA4) and an XBP1s-regulated gene (ERDJ4) by quantitative RT-PCR.", [["Huh7 liver carcinoma cells", "ANATOMY", 133, 159], ["infection", "DISEASE", 79, 88], ["liver carcinoma", "DISEASE", 138, 153], ["ER", "GENE_OR_GENE_PRODUCT", 29, 31], ["DENV serotype 2", "ORGANISM", 106, 121], ["DENV2", "ORGANISM", 123, 128], ["Huh7 liver carcinoma cells", "CELL", 133, 159], ["ATF6", "GENE_OR_GENE_PRODUCT", 197, 201], ["PDIA4", "GENE_OR_GENE_PRODUCT", 218, 223], ["XBP1s", "GENE_OR_GENE_PRODUCT", 232, 237], ["ERDJ4", "GENE_OR_GENE_PRODUCT", 254, 259], ["ER", "PROTEIN", 29, 31], ["Huh7 liver carcinoma cells", "CELL_LINE", 133, 159], ["ATF6-regulated gene", "DNA", 197, 216], ["PDIA4", "DNA", 218, 223], ["XBP1s-regulated gene", "DNA", 232, 252], ["ERDJ4", "DNA", 254, 259], ["DENV", "SPECIES", 57, 61], ["DENV2", "SPECIES", 123, 128], ["DENV", "PROBLEM", 57, 61], ["an infection time", "TEST", 76, 93], ["DENV serotype", "PROBLEM", 106, 119], ["Huh7 liver carcinoma cells", "PROBLEM", 133, 159], ["transcript levels", "TEST", 173, 190], ["an ATF6", "TEST", 194, 201], ["an XBP1s", "TEST", 229, 237], ["infection", "OBSERVATION", 79, 88], ["liver", "ANATOMY", 138, 143], ["carcinoma", "OBSERVATION", 144, 153]]], ["Both PDIA4 and ERDJ4 transcripts exhibited a time-dependent induction in response to DENV2 infection (Fig. 1B) .", [["DENV2 infection", "DISEASE", 85, 100], ["PDIA4", "GENE_OR_GENE_PRODUCT", 5, 10], ["ERDJ4", "GENE_OR_GENE_PRODUCT", 15, 20], ["DENV2", "ORGANISM", 85, 90], ["PDIA4 and ERDJ4 transcripts", "RNA", 5, 32], ["DENV2", "SPECIES", 85, 90], ["ERDJ4 transcripts", "TREATMENT", 15, 32], ["a time-dependent induction", "TREATMENT", 43, 69], ["DENV2 infection", "PROBLEM", 85, 100], ["DENV2 infection", "OBSERVATION", 85, 100]]], ["A smaller but similar time-dependent upregulation of ATF6 and XBP1s-regulated protein products could be observed by western blot (Fig. S1A ).", [["ATF6", "GENE_OR_GENE_PRODUCT", 53, 57], ["XBP1s", "GENE_OR_GENE_PRODUCT", 62, 67], ["S1A", "GENE_OR_GENE_PRODUCT", 135, 138], ["ATF6", "PROTEIN", 53, 57], ["XBP1s", "PROTEIN", 62, 67], ["protein products", "PROTEIN", 78, 94], ["ATF6 and XBP1s-regulated protein products", "TREATMENT", 53, 94], ["smaller", "OBSERVATION_MODIFIER", 2, 9], ["similar", "OBSERVATION_MODIFIER", 14, 21], ["time", "OBSERVATION_MODIFIER", 22, 26], ["dependent", "OBSERVATION_MODIFIER", 27, 36], ["upregulation", "OBSERVATION_MODIFIER", 37, 49]]], ["To corroborate these findings, we performed quantitative proteomics analysis of Huh7 cells at 24 and 36 hours post infection (hpi) with DENV2 to quantify global changes in protein expression ( Fig. S1B-C, Table S1 ).", [["Huh7 cells", "ANATOMY", 80, 90], ["Huh7 cells", "CELL", 80, 90], ["DENV2", "ORGANISM", 136, 141], ["S1B-C", "GENE_OR_GENE_PRODUCT", 198, 203], ["Table S1", "GENE_OR_GENE_PRODUCT", 205, 213], ["Huh7 cells", "CELL_LINE", 80, 90], ["S1B", "PROTEIN", 198, 201], ["DENV2", "SPECIES", 136, 141], ["quantitative proteomics analysis", "TEST", 44, 76], ["Huh7 cells", "PROBLEM", 80, 90], ["infection", "PROBLEM", 115, 124], ["DENV2", "PROBLEM", 136, 141], ["global changes in protein expression", "PROBLEM", 154, 190], ["Huh7 cells", "OBSERVATION", 80, 90], ["infection", "OBSERVATION", 115, 124], ["protein expression", "OBSERVATION", 172, 190], ["S1", "ANATOMY", 211, 213]]], ["We found that DENV2 activated specific factors involved in ER proteostasis maintenance, such as DNAJC10, BiP, and HYOU1.A Selective Modulator of the ATF6 Pathway Impairs Dengue Virus InfectionWe also filtered previously defined genesets consisting of ~20 specific genes for each of the UPR signaling branches to quantify the cumulative activation of ER proteostasis pathways ( Fig. 1C ) (Grandjean et al., 2019) .", [["ER", "ANATOMY", 59, 61], ["DENV2", "ORGANISM", 14, 19], ["ER", "GENE_OR_GENE_PRODUCT", 59, 61], ["DNAJC10", "GENE_OR_GENE_PRODUCT", 96, 103], ["BiP", "GENE_OR_GENE_PRODUCT", 105, 108], ["HYOU1", "GENE_OR_GENE_PRODUCT", 114, 119], ["ATF6", "GENE_OR_GENE_PRODUCT", 149, 153], ["Dengue Virus", "ORGANISM", 170, 182], ["UPR", "GENE_OR_GENE_PRODUCT", 286, 289], ["ER", "GENE_OR_GENE_PRODUCT", 350, 352], ["DENV2 activated specific factors", "PROTEIN", 14, 46], ["ER", "PROTEIN", 59, 61], ["DNAJC10", "PROTEIN", 96, 103], ["BiP", "PROTEIN", 105, 108], ["HYOU1", "PROTEIN", 114, 119], ["ATF6", "PROTEIN", 149, 153], ["ER", "PROTEIN", 350, 352], ["DENV2", "SPECIES", 14, 19], ["Dengue Virus", "SPECIES", 170, 182], ["DENV2", "PROBLEM", 14, 19], ["ER proteostasis maintenance", "TREATMENT", 59, 86], ["A Selective Modulator of the ATF6 Pathway", "TREATMENT", 120, 161], ["Dengue Virus InfectionWe", "PROBLEM", 170, 194], ["DENV2", "OBSERVATION", 14, 19], ["branches", "OBSERVATION_MODIFIER", 300, 308]]], ["This analysis indicated a mild stimulation of ATF6 and XBP1s-regulated proteins, while PERK-regulated proteins remained largely unchanged.", [["ATF6", "GENE_OR_GENE_PRODUCT", 46, 50], ["XBP1s", "GENE_OR_GENE_PRODUCT", 55, 60], ["PERK", "GENE_OR_GENE_PRODUCT", 87, 91], ["ATF6", "PROTEIN", 46, 50], ["XBP1s", "PROTEIN", 55, 60], ["regulated proteins", "PROTEIN", 61, 79], ["PERK", "PROTEIN", 87, 91], ["regulated proteins", "PROTEIN", 92, 110], ["This analysis", "TEST", 0, 13], ["a mild stimulation of ATF6", "PROBLEM", 24, 50], ["XBP1s", "TEST", 55, 60], ["PERK-regulated proteins", "TEST", 87, 110], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["stimulation", "OBSERVATION_MODIFIER", 31, 42], ["largely", "OBSERVATION_MODIFIER", 120, 127], ["unchanged", "OBSERVATION_MODIFIER", 128, 137]]], ["In contrast, we did not observe upregulation of cytosolic proteostasis factors that are under control of the heat shock response (HSR) (Vabulas et al., 2010) .", [["cytosolic", "ANATOMY", 48, 57], ["shock", "DISEASE", 114, 119], ["cytosolic proteostasis factors", "GENE_OR_GENE_PRODUCT", 48, 78], ["heat shock response", "GENE_OR_GENE_PRODUCT", 109, 128], ["cytosolic proteostasis factors", "PROTEIN", 48, 78], ["cytosolic proteostasis factors", "PROBLEM", 48, 78], ["the heat shock response", "PROBLEM", 105, 128], ["cytosolic proteostasis", "OBSERVATION", 48, 70]]], ["Overall, our results confirm that DENV2 preferentially remodels ER proteostasis pathways through ATF6 and IRE1/XBP1s-dependent upregulation of specific chaperones and protein folding factors.A Selective Modulator of the ATF6 Pathway Impairs Dengue Virus InfectionConsidering the dependencies of DENV and other flaviviruses on UPR activation, we determined the impact of the proteostasis regulators 147 (a preferential activator of the ATF6 branch), and Ceapin-A7 (Cp7) (a selective inhibitor of the ATF6 branch) on DENV infection ( Fig. 2A) .", [["Dengue Virus", "DISEASE", 241, 253], ["DENV infection", "DISEASE", 515, 529], ["DENV2", "ORGANISM", 34, 39], ["ER", "GENE_OR_GENE_PRODUCT", 64, 66], ["ATF6", "GENE_OR_GENE_PRODUCT", 97, 101], ["IRE1", "GENE_OR_GENE_PRODUCT", 106, 110], ["XBP1s", "GENE_OR_GENE_PRODUCT", 111, 116], ["protein folding factors", "GENE_OR_GENE_PRODUCT", 167, 190], ["ATF6", "GENE_OR_GENE_PRODUCT", 220, 224], ["Dengue Virus", "ORGANISM", 241, 253], ["DENV", "ORGANISM", 295, 299], ["UPR", "GENE_OR_GENE_PRODUCT", 326, 329], ["ATF6", "GENE_OR_GENE_PRODUCT", 435, 439], ["Ceapin-A7", "GENE_OR_GENE_PRODUCT", 453, 462], ["Cp7", "GENE_OR_GENE_PRODUCT", 464, 467], ["ATF6", "GENE_OR_GENE_PRODUCT", 499, 503], ["ER", "PROTEIN", 64, 66], ["ATF6", "PROTEIN", 97, 101], ["IRE1", "PROTEIN", 106, 110], ["XBP1s", "PROTEIN", 111, 116], ["protein folding factors", "PROTEIN", 167, 190], ["ATF6", "PROTEIN", 220, 224], ["proteostasis regulators 147", "PROTEIN", 374, 401], ["ATF6 branch", "PROTEIN", 435, 446], ["Ceapin", "PROTEIN", 453, 459], ["Cp7", "PROTEIN", 464, 467], ["ATF6 branch", "PROTEIN", 499, 510], ["DENV2", "SPECIES", 34, 39], ["DENV", "SPECIES", 295, 299], ["DENV", "SPECIES", 515, 519], ["DENV2", "PROBLEM", 34, 39], ["ATF6", "TEST", 97, 101], ["IRE1", "TEST", 106, 110], ["XBP1s", "TEST", 111, 116], ["protein folding factors", "PROBLEM", 167, 190], ["A Selective Modulator of the ATF6 Pathway", "TREATMENT", 191, 232], ["Dengue Virus Infection", "PROBLEM", 241, 263], ["DENV", "PROBLEM", 295, 299], ["other flaviviruses", "PROBLEM", 304, 322], ["UPR activation", "TEST", 326, 340], ["the proteostasis regulators", "PROBLEM", 370, 397], ["Ceapin", "TEST", 453, 459], ["a selective inhibitor of the ATF6 branch", "TREATMENT", 470, 510], ["DENV infection", "PROBLEM", 515, 529], ["protein folding", "OBSERVATION", 167, 182], ["DENV", "OBSERVATION", 295, 299], ["branch", "ANATOMY_MODIFIER", 440, 446], ["DENV infection", "OBSERVATION", 515, 529]]], ["We pre-treated Huh7 cells with the respective compounds 16h prior to infection by DENV2 to induce or inhibit UPR-dependent proteostasis remodeling, and we re-treated immediately after infection.", [["Huh7 cells", "ANATOMY", 15, 25], ["infection", "DISEASE", 69, 78], ["infection", "DISEASE", 184, 193], ["Huh7 cells", "CELL", 15, 25], ["DENV2", "ORGANISM", 82, 87], ["UPR", "GENE_OR_GENE_PRODUCT", 109, 112], ["Huh7 cells", "CELL_LINE", 15, 25], ["UPR", "PROTEIN", 109, 112], ["DENV2", "SPECIES", 82, 87], ["Huh7 cells", "TREATMENT", 15, 25], ["infection", "PROBLEM", 69, 78], ["DENV2", "PROBLEM", 82, 87], ["UPR-dependent proteostasis remodeling", "PROBLEM", 109, 146], ["infection", "PROBLEM", 184, 193], ["Huh7 cells", "OBSERVATION", 15, 25], ["dependent", "OBSERVATION_MODIFIER", 113, 122], ["proteostasis remodeling", "OBSERVATION", 123, 146]]], ["Quantification of DENV viral titers by a focus forming assay demonstrated a significant reduction in infection with compound 147 at 24 and 36 hpi (Fig. 2B) .", [["infection", "DISEASE", 101, 110], ["compound 147", "CHEMICAL", 116, 128], ["DENV", "ORGANISM", 18, 22], ["DENV", "SPECIES", 18, 22], ["DENV viral titers", "PROBLEM", 18, 35], ["a focus forming assay", "TEST", 39, 60], ["a significant reduction in infection", "PROBLEM", 74, 110], ["DENV", "OBSERVATION", 18, 22], ["viral titers", "OBSERVATION", 23, 35], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["reduction", "OBSERVATION_MODIFIER", 88, 97], ["infection", "OBSERVATION", 101, 110]]], ["In contrast, Cp7 treatment only resulted in a small reduction in viral titers at 24 hpi but the infection recovered at 36 hpi.", [["Cp7", "CHEMICAL", 13, 16], ["infection", "DISEASE", 96, 105], ["Cp7", "CHEMICAL", 13, 16], ["Cp7", "SIMPLE_CHEMICAL", 13, 16], ["Cp7 treatment", "TREATMENT", 13, 26], ["a small reduction in viral titers", "PROBLEM", 44, 77], ["the infection", "PROBLEM", 92, 105], ["small", "OBSERVATION_MODIFIER", 46, 51], ["reduction", "OBSERVATION_MODIFIER", 52, 61], ["viral titers", "OBSERVATION", 65, 77], ["infection", "OBSERVATION", 96, 105]]], ["Cell viability experiments indicated that the compounds did not induce a large amount of cell toxicity in Huh7 cells consistent with previous results in other cell lines (Fig. S2A ) (Plate et al., 2016) .", [["Cell", "ANATOMY", 0, 4], ["cell", "ANATOMY", 89, 93], ["Huh7 cells", "ANATOMY", 106, 116], ["cell lines", "ANATOMY", 159, 169], ["toxicity", "DISEASE", 94, 102], ["Cell", "CELL", 0, 4], ["cell", "CELL", 89, 93], ["Huh7 cells", "CELL", 106, 116], ["cell lines", "CELL", 159, 169], ["Fig. S2A", "CELL", 171, 179], ["Huh7 cells", "CELL_LINE", 106, 116], ["cell lines", "CELL_LINE", 159, 169], ["Cell viability experiments", "TEST", 0, 26], ["cell toxicity in Huh7 cells", "PROBLEM", 89, 116], ["large", "OBSERVATION_MODIFIER", 73, 78], ["amount", "OBSERVATION_MODIFIER", 79, 85], ["cell toxicity", "OBSERVATION", 89, 102], ["Huh7 cells", "OBSERVATION", 106, 116], ["cell lines", "OBSERVATION", 159, 169]]], ["We also conducted dose-response studies with 147 demonstrating that the compound was effective at reducing DENV titers at an IC50 of approximately 1 \u00b5M (Fig. S2B) .", [["DENV", "ORGANISM", 107, 111], ["DENV", "SPECIES", 107, 111], ["response studies", "TEST", 23, 39], ["the compound", "PROBLEM", 68, 80], ["an IC50", "TEST", 122, 129]]], ["We observed that cell viability was maintained above 90% at this concentration (Fig. S2C) .A Selective Modulator of the ATF6 Pathway Impairs Dengue Virus InfectionThese results demonstrate that modulation of the ER proteostasis network with the preferential ATF6 activator 147 could represent an effective strategy to impair DENV2 infection.A Selective Modulator of the ATF6 Pathway Impairs Dengue Virus InfectionThe ER plays critical roles in several stages of the viral life cycle including replication of viral RNA at replication centers on the cytosolic side of the ER membrane, translation and proteolytic processing of the viral polyprotein in the ER membrane, as well as the folding, assembly and secretion of new virions Neufeldt et al., 2018) .", [["cell", "ANATOMY", 17, 21], ["cytosolic", "ANATOMY", 548, 557], ["ER membrane", "ANATOMY", 570, 581], ["ER membrane", "ANATOMY", 654, 665], ["Dengue Virus Infection", "DISEASE", 141, 163], ["DENV2 infection", "DISEASE", 325, 340], ["Dengue", "DISEASE", 391, 397], ["cell", "CELL", 17, 21], ["ATF6", "GENE_OR_GENE_PRODUCT", 120, 124], ["Dengue Virus", "ORGANISM", 141, 153], ["ER", "GENE_OR_GENE_PRODUCT", 212, 214], ["ATF6 activator 147", "GENE_OR_GENE_PRODUCT", 258, 276], ["DENV2", "ORGANISM", 325, 330], ["ATF6", "GENE_OR_GENE_PRODUCT", 370, 374], ["Dengue Virus", "ORGANISM", 391, 403], ["ER", "GENE_OR_GENE_PRODUCT", 417, 419], ["ER", "GENE_OR_GENE_PRODUCT", 570, 572], ["membrane", "CELLULAR_COMPONENT", 573, 581], ["ER", "GENE_OR_GENE_PRODUCT", 654, 656], ["membrane", "CELLULAR_COMPONENT", 657, 665], ["ATF6", "PROTEIN", 120, 124], ["ER", "PROTEIN", 212, 214], ["ATF6", "PROTEIN", 258, 262], ["ATF6", "PROTEIN", 370, 374], ["ER", "PROTEIN", 417, 419], ["viral RNA", "RNA", 508, 517], ["ER", "PROTEIN", 570, 572], ["viral polyprotein", "PROTEIN", 629, 646], ["ER", "PROTEIN", 654, 656], ["DENV2", "SPECIES", 325, 330], ["cell viability", "TEST", 17, 31], ["Selective Modulator of the ATF6 Pathway", "TREATMENT", 93, 132], ["Dengue Virus Infection", "PROBLEM", 141, 163], ["the preferential ATF6 activator", "TREATMENT", 241, 272], ["impair DENV2 infection", "PROBLEM", 318, 340], ["A Selective Modulator of the ATF6 Pathway", "TREATMENT", 341, 382], ["Dengue Virus Infection", "PROBLEM", 391, 413], ["the viral life cycle", "TREATMENT", 462, 482], ["viral RNA", "PROBLEM", 508, 517], ["proteolytic processing", "TREATMENT", 599, 621], ["the viral polyprotein", "PROBLEM", 625, 646], ["cell viability", "OBSERVATION", 17, 31], ["DENV2", "OBSERVATION_MODIFIER", 325, 330], ["infection", "OBSERVATION", 331, 340], ["viral RNA", "OBSERVATION", 508, 517], ["ER membrane", "ANATOMY", 570, 581], ["viral polyprotein", "OBSERVATION", 629, 646]]], ["To determine at what stage in the viral life cycle the compound treatment impaired viral propagation, we investigated the impact of compound 147 on viral RNA (vRNA) and protein levels ( Fig. 2C-D) .", [["impaired viral propagation", "DISEASE", 74, 100], ["viral RNA", "RNA", 148, 157], ["the compound treatment", "TREATMENT", 51, 73], ["impaired viral propagation", "PROBLEM", 74, 100], ["viral RNA", "TEST", 148, 157], ["protein levels", "TEST", 169, 183], ["viral propagation", "OBSERVATION", 83, 100]]], ["Quantification of vRNA by qPCR indicated a modest but significant reduction of 50% at 24 hpi, which was attenuated to 30% reduction at 36 hpi ( Fig. 2E) .", [["vRNA", "CELLULAR_COMPONENT", 18, 22], ["vRNA", "RNA", 18, 22], ["vRNA", "PROBLEM", 18, 22], ["qPCR", "TEST", 26, 30], ["significant reduction", "PROBLEM", 54, 75], ["vRNA", "OBSERVATION", 18, 22], ["modest", "OBSERVATION_MODIFIER", 43, 49], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["reduction", "OBSERVATION_MODIFIER", 66, 75]]], ["Western blot quantification of NS3 and NS5 viral protein in Huh7 cell lysates from DENV2 infected cells showed a 35 -80 % reduction in viral non-structural proteins in response to 147 treatment (Fig. 2F, Fig. S2D ).", [["Huh7 cell lysates", "ANATOMY", 60, 77], ["cells", "ANATOMY", 98, 103], ["NS3", "GENE_OR_GENE_PRODUCT", 31, 34], ["NS5", "GENE_OR_GENE_PRODUCT", 39, 42], ["Huh7 cell lysates", "CELL", 60, 77], ["DENV2", "ORGANISM", 83, 88], ["cells", "CELL", 98, 103], ["NS3", "PROTEIN", 31, 34], ["NS5 viral protein", "PROTEIN", 39, 56], ["DENV2 infected cells", "CELL_LINE", 83, 103], ["viral non-structural proteins", "PROTEIN", 135, 164], ["DENV2", "SPECIES", 83, 88], ["NS3", "TREATMENT", 31, 34], ["NS5 viral protein", "TREATMENT", 39, 56], ["Huh7 cell lysates", "TEST", 60, 77], ["DENV2 infected cells", "TEST", 83, 103], ["viral non-structural proteins", "PROBLEM", 135, 164], ["Huh7 cell", "OBSERVATION", 60, 69], ["viral non-structural proteins", "OBSERVATION", 135, 164]]], ["This highlighted that the ER proteostasis regulator exerted a more pronounced effect on viral protein production relative to replication of vRNA.", [["ER", "GENE_OR_GENE_PRODUCT", 26, 28], ["vRNA", "CELLULAR_COMPONENT", 140, 144], ["ER", "PROTEIN", 26, 28], ["viral protein", "PROTEIN", 88, 101], ["vRNA", "RNA", 140, 144], ["the ER proteostasis regulator", "PROBLEM", 22, 51], ["viral protein production", "PROBLEM", 88, 112], ["vRNA", "PROBLEM", 140, 144], ["more pronounced", "OBSERVATION_MODIFIER", 62, 77], ["viral protein", "OBSERVATION", 88, 101], ["vRNA", "OBSERVATION", 140, 144]]], ["In contrast, infectious viral titers showed a far greater reduction reaching 98% at 12 hpi and sustaining 80% reduction at 36 hpi (Fig. 2G) .", [["infectious viral titers", "TEST", 13, 36], ["greater", "OBSERVATION_MODIFIER", 50, 57], ["reduction", "OBSERVATION_MODIFIER", 58, 67]]], ["The intensified effect of 147 on viral titers compared to vRNA and protein levels suggests that the compound predominantly acts on a stage subsequent to translation of viral proteins, which would be consistent with disruption of viral maturation or secretion pathways through modulation of ER proteostasis.", [["ER", "ANATOMY", 290, 292], ["ER", "GENE_OR_GENE_PRODUCT", 290, 292], ["viral proteins", "PROTEIN", 168, 182], ["ER", "PROTEIN", 290, 292], ["viral titers", "TEST", 33, 45], ["vRNA and protein levels", "TEST", 58, 81], ["the compound predominantly acts", "PROBLEM", 96, 127], ["viral proteins", "PROBLEM", 168, 182], ["viral maturation", "PROBLEM", 229, 245], ["secretion pathways", "PROBLEM", 249, 267], ["ER proteostasis", "PROBLEM", 290, 305], ["intensified", "OBSERVATION_MODIFIER", 4, 15], ["effect", "OBSERVATION_MODIFIER", 16, 22], ["compound", "OBSERVATION_MODIFIER", 100, 108], ["predominantly", "OBSERVATION_MODIFIER", 109, 122], ["viral proteins", "OBSERVATION", 168, 182], ["consistent with", "UNCERTAINTY", 199, 214], ["viral maturation", "OBSERVATION", 229, 245], ["proteostasis", "OBSERVATION", 293, 305]]], ["Lastly, we confirmed that 147 did not impair viral entry.", [["viral", "OBSERVATION", 45, 50]]], ["Omission of the pretreatment prior to infection and treatment of Huh7 cells with the compound only after infection still resulted in a comparable reduction in viral protein and titers, confirming that the compound must act at a post-entry stage ( Fig. S2E-G) .Inhibition of DENV infection by 147 is only partially dependent on ATF6Given that flavivirus infection activates the ATF6 pathway, it seemed surprising that preactivation could reduce viral propagation.", [["Huh7 cells", "ANATOMY", 65, 75], ["infection", "DISEASE", 38, 47], ["infection", "DISEASE", 105, 114], ["infection", "DISEASE", 279, 288], ["flavivirus infection", "DISEASE", 342, 362], ["Huh7 cells", "CELL", 65, 75], ["DENV", "ORGANISM", 274, 278], ["ATF6Given", "GENE_OR_GENE_PRODUCT", 327, 336], ["flavivirus", "ORGANISM", 342, 352], ["ATF6", "GENE_OR_GENE_PRODUCT", 377, 381], ["Huh7 cells", "CELL_LINE", 65, 75], ["viral protein", "PROTEIN", 159, 172], ["ATF6", "PROTEIN", 377, 381], ["DENV", "SPECIES", 274, 278], ["the pretreatment", "PROBLEM", 12, 28], ["infection", "PROBLEM", 38, 47], ["treatment", "TREATMENT", 52, 61], ["Huh7 cells", "PROBLEM", 65, 75], ["infection", "PROBLEM", 105, 114], ["a comparable reduction in viral protein and titers", "PROBLEM", 133, 183], ["DENV infection", "PROBLEM", 274, 288], ["partially dependent", "PROBLEM", 304, 323], ["ATF6Given", "TREATMENT", 327, 336], ["flavivirus infection", "PROBLEM", 342, 362], ["viral propagation", "PROBLEM", 444, 461], ["infection", "OBSERVATION", 38, 47], ["Huh7 cells", "OBSERVATION", 65, 75], ["infection", "OBSERVATION", 105, 114], ["reduction", "OBSERVATION_MODIFIER", 146, 155], ["viral protein", "OBSERVATION", 159, 172], ["DENV", "OBSERVATION_MODIFIER", 274, 278], ["infection", "OBSERVATION", 279, 288], ["partially dependent", "OBSERVATION_MODIFIER", 304, 323], ["flavivirus", "OBSERVATION", 342, 352], ["viral propagation", "OBSERVATION", 444, 461]]], ["We therefore sought to investigate whether ATF6 activation and induction of ATF6-targeted proteostasis factors was required for the 147-dependent inhibition of DENV infection.", [["DENV infection", "DISEASE", 160, 174], ["ATF6", "GENE_OR_GENE_PRODUCT", 43, 47], ["ATF6", "GENE_OR_GENE_PRODUCT", 76, 80], ["proteostasis factors", "GENE_OR_GENE_PRODUCT", 90, 110], ["DENV", "ORGANISM", 160, 164], ["ATF6", "PROTEIN", 43, 47], ["ATF6", "PROTEIN", 76, 80], ["proteostasis factors", "PROTEIN", 90, 110], ["DENV", "SPECIES", 160, 164], ["ATF6 activation", "PROBLEM", 43, 58], ["ATF6", "TEST", 76, 80], ["targeted proteostasis factors", "PROBLEM", 81, 110], ["DENV infection", "PROBLEM", 160, 174], ["DENV", "OBSERVATION_MODIFIER", 160, 164], ["infection", "OBSERVATION", 165, 174]]], ["We first confirmed by qPCR and quantitative Western blot analysis that treatment with 147 activated the ATF6 regulated gene HSPA5 (BiP) in Huh7 cells (Fig. S3A) .", [["Huh7 cells", "ANATOMY", 139, 149], ["ATF6", "GENE_OR_GENE_PRODUCT", 104, 108], ["HSPA5", "GENE_OR_GENE_PRODUCT", 124, 129], ["BiP", "GENE_OR_GENE_PRODUCT", 131, 134], ["Huh7 cells", "CELL", 139, 149], ["Fig. S3A", "CELL", 151, 159], ["ATF6 regulated gene HSPA5", "DNA", 104, 129], ["BiP", "DNA", 131, 134], ["Huh7 cells", "CELL_LINE", 139, 149], ["qPCR", "TEST", 22, 26], ["blot analysis", "TEST", 52, 65], ["treatment", "TREATMENT", 71, 80], ["the ATF6 regulated gene HSPA5 (BiP) in Huh7 cells", "TREATMENT", 100, 149], ["Huh7", "ANATOMY", 139, 143]]], ["To probe the impact of ATF6 activation on the compound activity, we took advantage of the ATF6 inhibitor Cp7, which inhibits ATF6 .", [["Cp7", "CHEMICAL", 105, 108], ["ATF6", "GENE_OR_GENE_PRODUCT", 23, 27], ["ATF6", "GENE_OR_GENE_PRODUCT", 90, 94], ["Cp7", "GENE_OR_GENE_PRODUCT", 105, 108], ["ATF6", "GENE_OR_GENE_PRODUCT", 125, 129], ["ATF6", "PROTEIN", 23, 27], ["ATF6", "PROTEIN", 90, 94], ["ATF6", "PROTEIN", 125, 129], ["ATF6 activation", "TREATMENT", 23, 38], ["the ATF6 inhibitor Cp7", "TREATMENT", 86, 108]]], ["Cp7 mediates a neomorphic interaction between ATF6 and the peroxisomal membrane protein ABCD3, keeping ATF6 in a traffickingincompetent oligomeric state, which cannot be activated by 147 (Fig. 3A ) (Torres et al., 2019) .", [["peroxisomal membrane", "ANATOMY", 59, 79], ["Cp7", "CHEMICAL", 0, 3], ["Cp7", "GENE_OR_GENE_PRODUCT", 0, 3], ["ATF6", "GENE_OR_GENE_PRODUCT", 46, 50], ["peroxisomal membrane", "CELLULAR_COMPONENT", 59, 79], ["ABCD3", "GENE_OR_GENE_PRODUCT", 88, 93], ["ATF6", "GENE_OR_GENE_PRODUCT", 103, 107], ["Cp7", "PROTEIN", 0, 3], ["ATF6", "PROTEIN", 46, 50], ["peroxisomal membrane protein", "PROTEIN", 59, 87], ["ABCD3", "PROTEIN", 88, 93], ["ATF6", "PROTEIN", 103, 107], ["traffickingincompetent oligomeric state", "PROTEIN", 113, 152], ["the peroxisomal membrane protein ABCD3", "TEST", 55, 93]]], ["We confirmed by qPCR and Western blot that co-treatment with 147 and Cp7 could fully attenuate the 147-dependent induction of ATF6 target genes in Huh7 cells ( Fig. S3A) .", [["Huh7 cells", "ANATOMY", 147, 157], ["Cp7", "CHEMICAL", 69, 72], ["Cp7", "CHEMICAL", 69, 72], ["Cp7", "SIMPLE_CHEMICAL", 69, 72], ["ATF6", "GENE_OR_GENE_PRODUCT", 126, 130], ["Huh7 cells", "CELL", 147, 157], ["Fig. S3A", "CELL", 160, 168], ["ATF6 target genes", "DNA", 126, 143], ["Huh7 cells", "CELL_LINE", 147, 157], ["qPCR", "TEST", 16, 20], ["co-treatment", "TREATMENT", 43, 55], ["ATF6 target genes in Huh7 cells", "PROBLEM", 126, 157], ["Huh7 cells", "OBSERVATION", 147, 157]]], ["We then investigated the addition of Cp7 on the 147-mediated reduction of DENV propagation.", [["Cp7", "CHEMICAL", 37, 40], ["Cp7", "CHEMICAL", 37, 40], ["Cp7", "SIMPLE_CHEMICAL", 37, 40], ["DENV", "ORGANISM", 74, 78], ["Cp7", "PROTEIN", 37, 40], ["DENV", "SPECIES", 74, 78], ["Cp7", "PROBLEM", 37, 40], ["DENV propagation", "TREATMENT", 74, 90], ["DENV propagation", "OBSERVATION", 74, 90]]], ["Co-treatment of Cp7 did not diminish the reduction in vRNA or NS3 protein ( Fig. 3B-C) .", [["Cp7", "CHEMICAL", 16, 19], ["Cp7", "CHEMICAL", 16, 19], ["Cp7", "SIMPLE_CHEMICAL", 16, 19], ["NS3", "GENE_OR_GENE_PRODUCT", 62, 65], ["NS3 protein", "PROTEIN", 62, 73], ["Fig. 3B-C", "PROTEIN", 76, 85], ["Cp7", "PROBLEM", 16, 19], ["the reduction", "PROBLEM", 37, 50], ["vRNA", "PROBLEM", 54, 58], ["NS3 protein", "TEST", 62, 73], ["reduction", "OBSERVATION_MODIFIER", 41, 50]]], ["Furthermore, the addition of Cp7 only partially recovered the DENV2 viral titers at 24hpi (Fig. 3D) .", [["Cp7", "CHEMICAL", 29, 32], ["Cp7", "CHEMICAL", 29, 32], ["Cp7", "GENE_OR_GENE_PRODUCT", 29, 32], ["DENV2", "ORGANISM", 62, 67], ["Cp7", "PROTEIN", 29, 32], ["DENV2", "SPECIES", 62, 67], ["the DENV2 viral titers", "PROBLEM", 58, 80]]], ["These results highlight that the reduction in viral titers could not be fully attributed to the 147-mediated induction of ATF6 target genes.Inhibition of DENV infection by 147 is only partially dependent on ATF6To further probe whether the reduced viral propagation could be ascribed to activation of the ATF6 pathway, we took advantage of an orthogonal chemical genetic approach to selectively induce the ATF6 pathway independent of global ER stress.", [["infection", "DISEASE", 159, 168], ["ATF6", "GENE_OR_GENE_PRODUCT", 122, 126], ["DENV", "ORGANISM", 154, 158], ["ATF6To", "GENE_OR_GENE_PRODUCT", 207, 213], ["ATF6", "GENE_OR_GENE_PRODUCT", 305, 309], ["ATF6", "GENE_OR_GENE_PRODUCT", 406, 410], ["ER", "GENE_OR_GENE_PRODUCT", 441, 443], ["ATF6 target genes", "DNA", 122, 139], ["ATF6To", "PROTEIN", 207, 213], ["ATF6", "PROTEIN", 305, 309], ["ATF6", "PROTEIN", 406, 410], ["ER", "PROTEIN", 441, 443], ["DENV", "SPECIES", 154, 158], ["the reduction in viral titers", "PROBLEM", 29, 58], ["DENV infection", "PROBLEM", 154, 168], ["partially dependent", "PROBLEM", 184, 203], ["the reduced viral propagation", "PROBLEM", 236, 265], ["an orthogonal chemical genetic approach", "TREATMENT", 340, 379], ["global ER stress", "PROBLEM", 434, 450], ["reduction", "OBSERVATION_MODIFIER", 33, 42], ["viral titers", "OBSERVATION", 46, 58], ["DENV", "OBSERVATION_MODIFIER", 154, 158], ["infection", "OBSERVATION", 159, 168], ["reduced", "OBSERVATION_MODIFIER", 240, 247], ["viral", "OBSERVATION", 248, 253]]], ["We transiently transfected a destabilized DHFR.ATF6 construct into Huh7 cells.", [["Huh7 cells", "ANATOMY", 67, 77], ["DHFR", "GENE_OR_GENE_PRODUCT", 42, 46], ["ATF6", "GENE_OR_GENE_PRODUCT", 47, 51], ["Huh7 cells", "CELL", 67, 77], ["DHFR", "PROTEIN", 42, 46], ["ATF6", "PROTEIN", 47, 51], ["Huh7 cells", "CELL_LINE", 67, 77], ["a destabilized DHFR", "TREATMENT", 27, 46], ["destabilized DHFR", "OBSERVATION", 29, 46], ["Huh7 cells", "OBSERVATION", 67, 77]]], ["This construct is constitutively degraded in the absence of a small molecule ligand, but can be stabilized through addition of trimethoprim (TMP) leading to accumulation of DHFR.ATF6 and selective induction of ATF6-regulated genes ( Fig. 3E ) (Shoulders et al., 2013) .", [["trimethoprim", "CHEMICAL", 127, 139], ["TMP", "CHEMICAL", 141, 144], ["trimethoprim", "CHEMICAL", 127, 139], ["TMP", "CHEMICAL", 141, 144], ["trimethoprim", "SIMPLE_CHEMICAL", 127, 139], ["TMP", "SIMPLE_CHEMICAL", 141, 144], ["DHFR", "GENE_OR_GENE_PRODUCT", 173, 177], ["ATF6", "GENE_OR_GENE_PRODUCT", 178, 182], ["ATF6", "GENE_OR_GENE_PRODUCT", 210, 214], ["DHFR", "PROTEIN", 173, 177], ["ATF6", "PROTEIN", 178, 182], ["ATF6", "PROTEIN", 210, 214], ["regulated genes", "DNA", 215, 230], ["a small molecule ligand", "PROBLEM", 60, 83], ["trimethoprim (TMP)", "TREATMENT", 127, 145], ["accumulation of DHFR", "PROBLEM", 157, 177], ["ATF6", "TREATMENT", 178, 182], ["selective induction of ATF6", "TREATMENT", 187, 214], ["constitutively", "OBSERVATION_MODIFIER", 18, 32], ["degraded", "OBSERVATION_MODIFIER", 33, 41], ["accumulation of DHFR", "OBSERVATION", 157, 177], ["Shoulders", "ANATOMY", 244, 253]]], ["We confirmed TMP-dependent upregulation of ATF6-regulated targets BiP, PDIA4, and GRP94 in Huh7 cells ( Fig. S3B-C) .", [["Huh7 cells", "ANATOMY", 91, 101], ["TMP", "CHEMICAL", 13, 16], ["TMP", "CHEMICAL", 13, 16], ["TMP", "SIMPLE_CHEMICAL", 13, 16], ["ATF6", "GENE_OR_GENE_PRODUCT", 43, 47], ["BiP", "GENE_OR_GENE_PRODUCT", 66, 69], ["PDIA4", "GENE_OR_GENE_PRODUCT", 71, 76], ["GRP94", "GENE_OR_GENE_PRODUCT", 82, 87], ["Huh7 cells", "CELL", 91, 101], ["Fig. S3B-C", "CELL", 104, 114], ["ATF6", "PROTEIN", 43, 47], ["BiP", "PROTEIN", 66, 69], ["PDIA4", "PROTEIN", 71, 76], ["GRP94", "PROTEIN", 82, 87], ["Huh7 cells", "CELL_LINE", 91, 101], ["TMP", "TEST", 13, 16], ["ATF6", "TEST", 43, 47], ["BiP", "TEST", 66, 69], ["PDIA4", "TEST", 71, 76], ["Huh7 cells", "TEST", 91, 101], ["Huh7 cells", "OBSERVATION", 91, 101]]], ["Next, we pre-treated Huh7 cells with TMP to activate DHFR.ATF6, infected cells with DENV2, and quantified propagation of the virus by monitoring viral protein levels by Western blot and measuring infectious titers.", [["Huh7 cells", "ANATOMY", 21, 31], ["cells", "ANATOMY", 73, 78], ["TMP", "CHEMICAL", 37, 40], ["TMP", "CHEMICAL", 37, 40], ["Huh7 cells", "CELL", 21, 31], ["TMP", "SIMPLE_CHEMICAL", 37, 40], ["DHFR", "GENE_OR_GENE_PRODUCT", 53, 57], ["ATF6", "GENE_OR_GENE_PRODUCT", 58, 62], ["cells", "CELL", 73, 78], ["DENV2", "ORGANISM", 84, 89], ["Huh7 cells", "CELL_LINE", 21, 31], ["DHFR", "PROTEIN", 53, 57], ["ATF6", "PROTEIN", 58, 62], ["viral protein", "PROTEIN", 145, 158], ["DENV2", "SPECIES", 84, 89], ["Huh7 cells", "TREATMENT", 21, 31], ["TMP", "TREATMENT", 37, 40], ["ATF6", "PROBLEM", 58, 62], ["infected cells", "PROBLEM", 64, 78], ["DENV2", "PROBLEM", 84, 89], ["the virus", "PROBLEM", 121, 130], ["monitoring viral protein levels", "TEST", 134, 165], ["Western blot", "TEST", 169, 181], ["measuring infectious titers", "PROBLEM", 186, 213], ["Huh7 cells", "OBSERVATION", 21, 31], ["infected cells", "OBSERVATION", 64, 78], ["infectious", "OBSERVATION_MODIFIER", 196, 206]]], ["Chemicalgenetic ATF6 activation did not lead to a measurable reduction in viral protein levels ( Fig. 3F ).", [["ATF6", "GENE_OR_GENE_PRODUCT", 16, 20], ["ATF6", "PROTEIN", 16, 20], ["viral protein", "PROTEIN", 74, 87], ["Chemicalgenetic ATF6 activation", "PROBLEM", 0, 31], ["a measurable reduction in viral protein levels", "PROBLEM", 48, 94], ["measurable", "OBSERVATION_MODIFIER", 50, 60], ["reduction", "OBSERVATION_MODIFIER", 61, 70], ["viral protein", "OBSERVATION", 74, 87]]], ["At the same time, a moderate decrease in viral titers could be observed, but this reduction in viral propagation was much lower than seen with 147 treatment (Fig. 3G) .Inhibition of DENV infection by 147 is only partially dependent on ATF6Together, the results from the ATF6 inhibitor and chemical-genetic ATF6 activation indicate that induction of ATF6-regulated ER proteostasis fators does not impact vRNA replication or production of viral proteins, and only partially accounts for the reduction in DENV2 viral titers.Reduced DENV propagation requires 147 to covalently target protein thiolsConsidering that reduced viral propagation in response to 147 was only partially mediated by ATF6 activation, we sought to explore other mechanisms of how the molecule could impair the virus.", [["infection", "DISEASE", 187, 196], ["thiols", "CHEMICAL", 588, 594], ["DENV", "ORGANISM", 182, 186], ["ATF6Together", "GENE_OR_GENE_PRODUCT", 235, 247], ["ATF6", "GENE_OR_GENE_PRODUCT", 270, 274], ["ATF6", "GENE_OR_GENE_PRODUCT", 306, 310], ["ATF6", "GENE_OR_GENE_PRODUCT", 349, 353], ["ER", "GENE_OR_GENE_PRODUCT", 364, 366], ["vRNA", "CELLULAR_COMPONENT", 403, 407], ["DENV2", "ORGANISM", 502, 507], ["ATF6", "GENE_OR_GENE_PRODUCT", 687, 691], ["ATF6", "PROTEIN", 270, 274], ["ATF6", "PROTEIN", 306, 310], ["ATF6", "PROTEIN", 349, 353], ["ER", "PROTEIN", 364, 366], ["viral proteins", "PROTEIN", 437, 451], ["ATF6", "PROTEIN", 687, 691], ["DENV", "SPECIES", 182, 186], ["DENV2", "SPECIES", 502, 507], ["DENV", "SPECIES", 529, 533], ["a moderate decrease in viral titers", "PROBLEM", 18, 53], ["this reduction in viral propagation", "PROBLEM", 77, 112], ["DENV infection", "PROBLEM", 182, 196], ["the ATF6 inhibitor", "TEST", 266, 284], ["ATF6", "TEST", 349, 353], ["vRNA replication", "PROBLEM", 403, 419], ["viral proteins", "PROBLEM", 437, 451], ["the reduction in DENV2 viral titers", "PROBLEM", 485, 520], ["Reduced DENV propagation", "PROBLEM", 521, 545], ["protein thiols", "TEST", 580, 594], ["reduced viral propagation", "PROBLEM", 611, 636], ["the virus", "PROBLEM", 775, 784], ["moderate", "OBSERVATION_MODIFIER", 20, 28], ["decrease", "OBSERVATION_MODIFIER", 29, 37], ["viral titers", "OBSERVATION", 41, 53], ["viral propagation", "OBSERVATION", 95, 112], ["DENV", "OBSERVATION_MODIFIER", 182, 186], ["infection", "OBSERVATION", 187, 196], ["viral proteins", "OBSERVATION", 437, 451], ["DENV2 viral titers", "OBSERVATION", 502, 520], ["DENV", "OBSERVATION", 529, 533], ["reduced", "OBSERVATION_MODIFIER", 611, 618], ["viral propagation", "OBSERVATION", 619, 636]]], ["Previous studies showed that 147 is a prodrug and requires metabolic activation in cells to generate a reactive p-quinone methide that can then form protein adducts with reactive cysteine residues ( Fig. 4A ) (Palmer et al., 2020; Paxman et al., 2018; Plate et al., 2016) .", [["cells", "ANATOMY", 83, 88], ["p-quinone", "CHEMICAL", 112, 121], ["cysteine", "CHEMICAL", 179, 187], ["cells", "CELL", 83, 88], ["p-quinone methide", "SIMPLE_CHEMICAL", 112, 129], ["Previous studies", "TEST", 0, 16], ["metabolic activation in cells", "TREATMENT", 59, 88], ["a reactive p-quinone methide", "TREATMENT", 101, 129], ["reactive cysteine residues", "PROBLEM", 170, 196], ["metabolic activation", "OBSERVATION", 59, 79], ["reactive cysteine residues", "OBSERVATION", 170, 196]]], ["In several cell types, ER-resident protein disulfide isomerases (PDIs) were identified as the common protein targets of 147, and this modulation of PDIs was linked to the activation of ATF6 .", [["cell", "ANATOMY", 11, 15], ["disulfide", "CHEMICAL", 43, 52], ["cell", "CELL", 11, 15], ["ER", "GENE_OR_GENE_PRODUCT", 23, 25], ["protein disulfide isomerases", "GENE_OR_GENE_PRODUCT", 35, 63], ["PDIs", "GENE_OR_GENE_PRODUCT", 65, 69], ["PDIs", "GENE_OR_GENE_PRODUCT", 148, 152], ["ATF6", "GENE_OR_GENE_PRODUCT", 185, 189], ["ER", "PROTEIN", 23, 25], ["protein disulfide isomerases", "PROTEIN", 35, 63], ["PDIs", "PROTEIN", 65, 69], ["PDIs", "PROTEIN", 148, 152], ["ATF6", "PROTEIN", 185, 189], ["the common protein targets", "TEST", 90, 116], ["this modulation of PDIs", "PROBLEM", 129, 152], ["several cell types", "OBSERVATION", 3, 21]]], ["To explore whether covalent targeting of reactive thiols by 147 is required for the reduction in DENV propagation, we blocked the covalent modifications through addition of an excess of the small-molecule thiol 2-mercaptoethanol (BME) to the cells treated with 147 (Fig. 4A) .", [["cells", "ANATOMY", 242, 247], ["thiols", "CHEMICAL", 50, 56], ["thiol 2-mercaptoethanol", "CHEMICAL", 205, 228], ["BME", "CHEMICAL", 230, 233], ["thiols", "CHEMICAL", 50, 56], ["thiol 2-mercaptoethanol", "CHEMICAL", 205, 228], ["BME", "CHEMICAL", 230, 233], ["reactive thiols", "SIMPLE_CHEMICAL", 41, 56], ["thiol 2-mercaptoethanol", "SIMPLE_CHEMICAL", 205, 228], ["BME", "SIMPLE_CHEMICAL", 230, 233], ["cells", "CELL", 242, 247], ["DENV", "SPECIES", 97, 101], ["reactive thiols", "TREATMENT", 41, 56], ["the reduction", "TREATMENT", 80, 93], ["DENV propagation", "TREATMENT", 97, 113], ["the covalent modifications", "TREATMENT", 126, 152], ["the small-molecule thiol", "TREATMENT", 186, 210], ["mercaptoethanol (BME", "TREATMENT", 213, 233], ["reactive thiols", "OBSERVATION", 41, 56], ["DENV", "OBSERVATION", 97, 101], ["small", "OBSERVATION_MODIFIER", 190, 195], ["cells", "ANATOMY", 242, 247]]], ["We confirmed that this addition did not impair cell viability (Fig. S4B) , and that BME alone only had a minimal effect on viral protein levels (Fig. S4A) .", [["cell", "ANATOMY", 47, 51], ["BME", "CHEMICAL", 84, 87], ["BME", "CHEMICAL", 84, 87], ["cell", "CELL", 47, 51], ["BME", "SIMPLE_CHEMICAL", 84, 87], ["viral protein", "PROTEIN", 123, 136], ["S4A", "PROTEIN", 150, 153], ["impair cell viability", "PROBLEM", 40, 61], ["viral protein levels", "TEST", 123, 143], ["cell viability", "OBSERVATION", 47, 61], ["minimal", "OBSERVATION_MODIFIER", 105, 112]]], ["When BME was added to DENV infected cells that were treated with 147, this resulted in a partial to complete recovery of NS5 protein at 24 and 36hpi, respectively (Fig. 4B) .", [["cells", "ANATOMY", 36, 41], ["BME", "CHEMICAL", 5, 8], ["BME", "SIMPLE_CHEMICAL", 5, 8], ["DENV", "ORGANISM", 22, 26], ["cells", "CELL", 36, 41], ["NS5", "GENE_OR_GENE_PRODUCT", 121, 124], ["DENV infected cells", "CELL_TYPE", 22, 41], ["NS5 protein", "PROTEIN", 121, 132], ["DENV", "SPECIES", 22, 26], ["DENV infected cells", "PROBLEM", 22, 41], ["NS5 protein", "TEST", 121, 132], ["infected cells", "OBSERVATION", 27, 41]]], ["Similarly, the reduction in DENV2 viral titers was partially attenuated by the addition of BME (Fig. 4C) .", [["BME", "CHEMICAL", 91, 94], ["DENV2", "ORGANISM", 28, 33], ["DENV2", "SPECIES", 28, 33], ["the reduction in DENV2 viral titers", "PROBLEM", 11, 46], ["reduction", "OBSERVATION_MODIFIER", 15, 24], ["DENV2", "OBSERVATION_MODIFIER", 28, 33], ["viral titers", "OBSERVATION", 34, 46]]], ["These results indicate that the targeting of cellular thiol groups is required for the inhibition of virus propagation.Reduced DENV propagation requires 147 to covalently target protein thiolsWe next explored whether targeting of specific PDIs proteins by 147 was required for the reduced viral replication.", [["cellular", "ANATOMY", 45, 53], ["thiol", "CHEMICAL", 54, 59], ["thiol", "CHEMICAL", 54, 59], ["thiols", "CHEMICAL", 186, 192], ["cellular", "CELL", 45, 53], ["PDIs", "GENE_OR_GENE_PRODUCT", 239, 243], ["PDIs proteins", "PROTEIN", 239, 252], ["DENV", "SPECIES", 127, 131], ["cellular thiol groups", "TREATMENT", 45, 66], ["virus propagation", "TREATMENT", 101, 118], ["Reduced DENV propagation", "PROBLEM", 119, 143], ["protein thiols", "TEST", 178, 192], ["specific PDIs proteins", "TEST", 230, 252], ["the reduced viral replication", "TREATMENT", 277, 306], ["virus", "OBSERVATION", 101, 106], ["DENV", "OBSERVATION", 127, 131], ["viral replication", "OBSERVATION", 289, 306]]], ["Previous studies determined the covalent targets of 147 in HEK293T, HepG2, and ALLC plasma cells .", [["HEK293T", "ANATOMY", 59, 66], ["HepG2", "ANATOMY", 68, 73], ["ALLC plasma cells", "ANATOMY", 79, 96], ["HEK293T", "CELL", 59, 66], ["HepG2", "CELL", 68, 73], ["ALLC plasma cells", "CELL", 79, 96], ["HEK293T", "CELL_LINE", 59, 66], ["HepG2", "CELL_LINE", 68, 73], ["ALLC plasma cells", "CELL_LINE", 79, 96], ["Previous studies", "TEST", 0, 16], ["the covalent targets", "TEST", 28, 48], ["HEK293T", "TEST", 59, 66], ["HepG2", "TEST", 68, 73], ["ALLC plasma cells", "PROBLEM", 79, 96], ["HepG2", "ANATOMY", 68, 73], ["plasma cells", "OBSERVATION", 84, 96]]], ["However, it was conceivable that the metabolic activation mechanism differs in cell types and could result in alternative targets.", [["cell", "ANATOMY", 79, 83], ["cell", "CELL", 79, 83], ["the metabolic activation mechanism", "PROBLEM", 33, 67], ["metabolic activation", "OBSERVATION", 37, 57]]], ["We therefore determined whether 147 could similarly target PDIs in Huh7 cells.", [["Huh7 cells", "ANATOMY", 67, 77], ["PDIs", "GENE_OR_GENE_PRODUCT", 59, 63], ["Huh7 cells", "CELL", 67, 77], ["Huh7 cells", "CELL_LINE", 67, 77], ["target PDIs in Huh7 cells", "PROBLEM", 52, 77], ["Huh7 cells", "OBSERVATION", 67, 77]]], ["We took advantage of the active analog 147-20, which contains an alkyne handle that enables further Click chemistry derivatization with desthiobiotin after protein labeling, followed by isolation of the targeted proteins on streptavidin resin (Fig. 5A) .", [["desthiobiotin", "CHEMICAL", 136, 149], ["alkyne", "CHEMICAL", 65, 71], ["desthiobiotin", "CHEMICAL", 136, 149], ["alkyne", "SIMPLE_CHEMICAL", 65, 71], ["desthiobiotin", "SIMPLE_CHEMICAL", 136, 149], ["streptavidin resin", "SIMPLE_CHEMICAL", 224, 242], ["targeted proteins", "PROTEIN", 203, 220], ["an alkyne handle", "TREATMENT", 62, 78], ["further Click chemistry derivatization", "TREATMENT", 92, 130], ["desthiobiotin", "TREATMENT", 136, 149], ["protein labeling", "TREATMENT", 156, 172], ["streptavidin resin", "TREATMENT", 224, 242]]], ["The desthiobiotin probe also contained a TAMRA fluorophore that allowed gel-based visualization of the targeted proteins (Fig. 5B) .", [["TAMRA", "CHEMICAL", 41, 46], ["desthiobiotin", "SIMPLE_CHEMICAL", 4, 17], ["TAMRA", "SIMPLE_CHEMICAL", 41, 46], ["desthiobiotin probe", "DNA", 4, 23], ["targeted proteins", "PROTEIN", 103, 120], ["Fig. 5B", "PROTEIN", 122, 129], ["The desthiobiotin probe", "TREATMENT", 0, 23], ["a TAMRA fluorophore", "TREATMENT", 39, 58]]], ["We confirmed that 147-20 retained activity reducing DENV titer levels and NS3 protein levels in infected cells ( Fig. S5A-B) .", [["cells", "ANATOMY", 105, 110], ["S5A-B", "CHEMICAL", 118, 123], ["DENV", "ORGANISM", 52, 56], ["NS3", "GENE_OR_GENE_PRODUCT", 74, 77], ["cells", "CELL", 105, 110], ["S5A-B", "GENE_OR_GENE_PRODUCT", 118, 123], ["NS3", "PROTEIN", 74, 77], ["infected cells", "CELL_TYPE", 96, 110], ["S5A", "PROTEIN", 118, 121], ["DENV", "SPECIES", 52, 56], ["DENV titer levels", "TEST", 52, 69], ["NS3 protein levels", "TEST", 74, 92], ["infected cells", "PROBLEM", 96, 110], ["infected cells", "OBSERVATION", 96, 110]]], ["In contrast, treatment with 147-4, an inactive analog where generation of the quinone methide is blocked by the trifluoromethyl group, did not reduce infection.", [["147-4", "CHEMICAL", 28, 33], ["trifluoromethyl", "CHEMICAL", 112, 127], ["infection", "DISEASE", 150, 159], ["quinone methide", "CHEMICAL", 78, 93], ["trifluoromethyl", "CHEMICAL", 112, 127], ["147-4", "SIMPLE_CHEMICAL", 28, 33], ["quinone methide", "SIMPLE_CHEMICAL", 78, 93], ["treatment", "TREATMENT", 13, 22], ["an inactive analog", "TREATMENT", 35, 53], ["the quinone methide", "TREATMENT", 74, 93], ["infection", "PROBLEM", 150, 159], ["infection", "OBSERVATION", 150, 159]]], ["We probed for the presence of specific PDIs (PDIA4, PDIA1, PDIA6), which were identified as 147 targets in other cell lines.", [["cell lines", "ANATOMY", 113, 123], ["PDIs", "GENE_OR_GENE_PRODUCT", 39, 43], ["PDIA4", "GENE_OR_GENE_PRODUCT", 45, 50], ["PDIA1", "GENE_OR_GENE_PRODUCT", 52, 57], ["PDIA6", "GENE_OR_GENE_PRODUCT", 59, 64], ["cell lines", "CELL", 113, 123], ["PDIs", "PROTEIN", 39, 43], ["PDIA4", "PROTEIN", 45, 50], ["PDIA1", "PROTEIN", 52, 57], ["PDIA6", "PROTEIN", 59, 64], ["cell lines", "CELL_LINE", 113, 123], ["cell lines", "OBSERVATION", 113, 123]]], ["These proteins were clearly detectable at molecular weights of prominent labeled bands that were competed by 147, confirming them as targets in Huh7 cells (Fig. 5B, S5C ) .", [["Huh7 cells", "ANATOMY", 144, 154], ["Huh7 cells", "CELL", 144, 154], ["Fig. 5B", "CELL", 156, 163], ["S5C", "CELL", 165, 168], ["Huh7 cells", "CELL_LINE", 144, 154], ["S5C", "CELL_LINE", 165, 168], ["These proteins", "TEST", 0, 14], ["prominent labeled bands", "PROBLEM", 63, 86], ["Huh7 cells", "TEST", 144, 154], ["Huh7 cells", "OBSERVATION", 144, 154]]], ["In DENV-infected cells that were treated with 147-20, no additional labeled protein bands were observed, indicating that viral proteins are not directly targeted by the compound (Fig. S5D) .Reduced DENV propagation requires 147 to covalently target protein thiolsConsidering the targeting of multiple PDI enzymes, we were interested in whether the inhibition of PDIs could have an important role in the reduction of viral propagation.Reduced DENV propagation requires 147 to covalently target protein thiolsWe created stable knockdown cell lines of several PDIs using shRNAs (Fig. S5E) .", [["cells", "ANATOMY", 17, 22], ["cell lines", "ANATOMY", 535, 545], ["PDIs", "ANATOMY", 557, 561], ["DENV-infected", "DISEASE", 3, 16], ["thiols", "CHEMICAL", 257, 263], ["thiols", "CHEMICAL", 501, 507], ["DENV", "ORGANISM", 3, 7], ["cells", "CELL", 17, 22], ["PDI", "GENE_OR_GENE_PRODUCT", 301, 304], ["PDIs", "GENE_OR_GENE_PRODUCT", 362, 366], ["cell lines", "CELL", 535, 545], ["PDIs", "CANCER", 557, 561], ["DENV-infected cells", "CELL_LINE", 3, 22], ["viral proteins", "PROTEIN", 121, 135], ["PDI enzymes", "PROTEIN", 301, 312], ["PDIs", "PROTEIN", 362, 366], ["knockdown cell lines", "CELL_LINE", 525, 545], ["PDIs", "CELL_LINE", 557, 561], ["shRNAs", "DNA", 568, 574], ["DENV", "SPECIES", 3, 7], ["DENV", "SPECIES", 198, 202], ["DENV", "SPECIES", 442, 446], ["DENV", "PROBLEM", 3, 7], ["infected cells", "PROBLEM", 8, 22], ["additional labeled protein bands", "PROBLEM", 57, 89], ["viral proteins", "PROBLEM", 121, 135], ["Reduced DENV propagation", "PROBLEM", 190, 214], ["protein thiols", "TEST", 249, 263], ["multiple PDI enzymes", "TEST", 292, 312], ["the inhibition of PDIs", "PROBLEM", 344, 366], ["viral propagation", "TREATMENT", 416, 433], ["Reduced DENV propagation", "PROBLEM", 434, 458], ["protein thiols", "TEST", 493, 507], ["DENV", "OBSERVATION", 3, 7], ["infected cells", "OBSERVATION", 8, 22], ["viral proteins", "OBSERVATION", 121, 135], ["DENV", "OBSERVATION", 198, 202], ["viral propagation", "OBSERVATION", 416, 433], ["DENV", "OBSERVATION", 442, 446], ["stable", "OBSERVATION_MODIFIER", 518, 524], ["knockdown cell lines", "OBSERVATION", 525, 545]]], ["These cell lines were then infected with DENV2 and treated with 147 to assess the effect of PDI knockdown on propagation of the virus.", [["cell lines", "ANATOMY", 6, 16], ["cell lines", "CELL", 6, 16], ["DENV2", "ORGANISM", 41, 46], ["PDI", "GENE_OR_GENE_PRODUCT", 92, 95], ["cell lines", "CELL_LINE", 6, 16], ["PDI", "PROTEIN", 92, 95], ["DENV2", "SPECIES", 41, 46], ["DENV2", "PROBLEM", 41, 46], ["PDI knockdown", "TREATMENT", 92, 105], ["the virus", "PROBLEM", 124, 133], ["cell lines", "OBSERVATION", 6, 16], ["infected", "OBSERVATION_MODIFIER", 27, 35]]], ["Individual knockdown of PDIA1 (P4HB), PDIA4, or PDIA6 did not result in a decrease in viral titers indicating that none of these individual PDIs are essential for viral propagation (Fig. S5F) .", [["PDIA1", "GENE_OR_GENE_PRODUCT", 24, 29], ["P4HB", "GENE_OR_GENE_PRODUCT", 31, 35], ["PDIA4", "GENE_OR_GENE_PRODUCT", 38, 43], ["PDIA6", "GENE_OR_GENE_PRODUCT", 48, 53], ["PDIs", "GENE_OR_GENE_PRODUCT", 140, 144], ["PDIA1", "PROTEIN", 24, 29], ["P4HB", "PROTEIN", 31, 35], ["PDIA4", "PROTEIN", 38, 43], ["PDIA6", "PROTEIN", 48, 53], ["PDIs", "DNA", 140, 144], ["a decrease in viral titers", "PROBLEM", 72, 98], ["these individual PDIs", "PROBLEM", 123, 144], ["viral propagation", "PROBLEM", 163, 180], ["knockdown", "OBSERVATION_MODIFIER", 11, 20], ["decrease", "OBSERVATION_MODIFIER", 74, 82], ["viral titers", "OBSERVATION", 86, 98]]], ["Only knockdown of PDIA3 resulted in a small reduction in viral titers.", [["PDIA3", "CHEMICAL", 18, 23], ["PDIA3", "GENE_OR_GENE_PRODUCT", 18, 23], ["PDIA3", "PROTEIN", 18, 23], ["knockdown of PDIA3", "PROBLEM", 5, 23], ["a small reduction in viral titers", "PROBLEM", 36, 69], ["small", "OBSERVATION_MODIFIER", 38, 43], ["reduction", "OBSERVATION_MODIFIER", 44, 53], ["viral titers", "OBSERVATION", 57, 69]]], ["Next, we measured viral infections in the knockout cell lines in the presence of 147 to determine whether particular PDIs are required for the 147-mediated virus inhibition.", [["cell lines", "ANATOMY", 51, 61], ["viral infections", "DISEASE", 18, 34], ["cell lines", "CELL", 51, 61], ["PDIs", "GENE_OR_GENE_PRODUCT", 117, 121], ["knockout cell lines", "CELL_LINE", 42, 61], ["PDIs", "PROTEIN", 117, 121], ["viral infections", "PROBLEM", 18, 34], ["the knockout cell lines", "TREATMENT", 38, 61], ["particular PDIs", "PROBLEM", 106, 121], ["the 147-mediated virus inhibition", "TREATMENT", 139, 172], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infections", "OBSERVATION", 24, 34], ["knockout cell lines", "OBSERVATION", 42, 61]]], ["We observed no measurable attenuation in the reduced viral titers with any single PDI knockdown, including the PDIA3 knockdown, suggesting that no individual PDIs are responsible for the 147-mediated effect (Fig. S5F) .Reduced DENV propagation requires 147 to covalently target protein thiolsTo further explore whether PDI inhibition could be responsible for the reduction in DENV infection, we took advantage of several published small-molecule inhibitors of PDIA1 ( Fig. 5C ) (Banerjee et al., 2013; Cole et al., 2018; Hoffstrom et al., 2010) .", [["DENV infection", "DISEASE", 376, 390], ["thiols", "CHEMICAL", 286, 292], ["PDI", "GENE_OR_GENE_PRODUCT", 82, 85], ["PDIA3", "GENE_OR_GENE_PRODUCT", 111, 116], ["PDIs", "GENE_OR_GENE_PRODUCT", 158, 162], ["PDI", "GENE_OR_GENE_PRODUCT", 319, 322], ["DENV", "ORGANISM", 376, 380], ["PDIA1", "SIMPLE_CHEMICAL", 460, 465], ["PDI", "PROTEIN", 82, 85], ["PDIA3", "PROTEIN", 111, 116], ["PDI", "PROTEIN", 319, 322], ["PDIA1", "PROTEIN", 460, 465], ["DENV", "SPECIES", 227, 231], ["DENV", "SPECIES", 376, 380], ["measurable attenuation", "PROBLEM", 15, 37], ["the reduced viral titers", "PROBLEM", 41, 65], ["any single PDI knockdown", "TREATMENT", 71, 95], ["the PDIA3 knockdown", "PROBLEM", 107, 126], ["individual PDIs", "PROBLEM", 147, 162], ["Reduced DENV propagation", "PROBLEM", 219, 243], ["protein thiols", "TEST", 278, 292], ["PDI inhibition", "TREATMENT", 319, 333], ["DENV infection", "PROBLEM", 376, 390], ["several published small-molecule inhibitors", "TREATMENT", 413, 456], ["no", "UNCERTAINTY", 12, 14], ["measurable", "OBSERVATION_MODIFIER", 15, 25], ["attenuation", "OBSERVATION_MODIFIER", 26, 37], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["viral titers", "OBSERVATION", 53, 65], ["knockdown", "OBSERVATION", 86, 95], ["PDIA3 knockdown", "OBSERVATION", 111, 126], ["DENV", "OBSERVATION", 227, 231], ["DENV", "OBSERVATION_MODIFIER", 376, 380], ["infection", "OBSERVATION", 381, 390]]], ["Importantly, these molecules display different degrees of specificity towards PDIA1 relative to other PDIs, mirroring the polypharmacology observed with 147.", [["PDIA1", "GENE_OR_GENE_PRODUCT", 78, 83], ["PDIs", "PATHOLOGICAL_FORMATION", 102, 106], ["PDIA1", "PROTEIN", 78, 83], ["different degrees of specificity towards PDIA1", "PROBLEM", 37, 83], ["other PDIs", "PROBLEM", 96, 106], ["different degrees", "OBSERVATION_MODIFIER", 37, 54]]], ["We profiled the specific PDIs targeted by the compounds in Huh7 cells by modifying the alkyne handles on the molecule with a fluorophore.", [["Huh7 cells", "ANATOMY", 59, 69], ["alkyne", "CHEMICAL", 87, 93], ["PDIs", "GENE_OR_GENE_PRODUCT", 25, 29], ["Huh7 cells", "CELL", 59, 69], ["PDIs", "DNA", 25, 29], ["Huh7 cells", "CELL_LINE", 59, 69], ["Huh7 cells", "TREATMENT", 59, 69], ["a fluorophore", "TREATMENT", 123, 136]]], ["KSC-34 displayed the greatest preference for PDIA1, while Rb-11-ca also labeled PDIA4, PDIA6, and several other proteins (Fig. 5SG) .", [["KSC-34", "CHEMICAL", 0, 6], ["KSC-34", "CELL", 0, 6], ["PDIA1", "GENE_OR_GENE_PRODUCT", 45, 50], ["Rb", "GENE_OR_GENE_PRODUCT", 58, 60], ["PDIA4", "GENE_OR_GENE_PRODUCT", 80, 85], ["PDIA6", "GENE_OR_GENE_PRODUCT", 87, 92], ["KSC", "PROTEIN", 0, 3], ["PDIA1", "PROTEIN", 45, 50], ["Rb", "PROTEIN", 58, 60], ["PDIA4", "PROTEIN", 80, 85], ["PDIA6", "PROTEIN", 87, 92], ["Fig. 5SG", "PROTEIN", 122, 130], ["KSC", "TEST", 0, 3], ["PDIA1", "TEST", 45, 50], ["Rb", "TEST", 58, 60], ["PDIA6", "TEST", 87, 92]]], ["This is consistent with observations in other cell types and the development of KSC-34 as a more specific derivative of Rb-11-ca (Cole et al., 2018) .", [["cell", "ANATOMY", 46, 50], ["KSC-34", "CHEMICAL", 80, 86], ["KSC-34", "CHEMICAL", 80, 86], ["cell", "CELL", 46, 50], ["KSC-34", "CELL", 80, 86], ["Rb", "GENE_OR_GENE_PRODUCT", 120, 122], ["Rb", "PROTEIN", 120, 122], ["KSC", "TEST", 80, 83], ["consistent with", "UNCERTAINTY", 8, 23], ["cell types", "OBSERVATION", 46, 56]]], ["16F16 does not contain an alkyne handle but previous studies show even broader reactivity towards PDIs than Rb-11-ca (Hoffstrom et al., 2010) .", [["16F16", "CHEMICAL", 0, 5], ["alkyne", "CHEMICAL", 26, 32], ["PDIs", "SIMPLE_CHEMICAL", 98, 102], ["Rb-11-ca", "SIMPLE_CHEMICAL", 108, 116], ["Rb", "PROTEIN", 108, 110], ["previous studies", "TEST", 44, 60], ["Rb", "TEST", 108, 110]]], ["We then tested the effect of the compounds on DENV2 infection in Huh7 cells using the same treatment regime as for 147.", [["Huh7 cells", "ANATOMY", 65, 75], ["DENV2 infection", "DISEASE", 46, 61], ["DENV2", "ORGANISM", 46, 51], ["Huh7 cells", "CELL", 65, 75], ["Huh7 cells", "CELL_LINE", 65, 75], ["DENV2", "SPECIES", 46, 51], ["the compounds", "PROBLEM", 29, 42], ["DENV2 infection", "PROBLEM", 46, 61], ["Huh7 cells", "TREATMENT", 65, 75], ["the same treatment regime", "TREATMENT", 82, 107], ["DENV2", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 52, 61], ["Huh7 cells", "OBSERVATION", 65, 75]]], ["KSC-34 and 16F16 were unable to reduce viral NS3 protein levels (Fig. 5D ).", [["16F16", "GENE_OR_GENE_PRODUCT", 11, 16], ["16F16", "PROTEIN", 11, 16], ["viral NS3 protein", "PROTEIN", 39, 56], ["KSC", "TEST", 0, 3], ["viral NS3 protein levels", "TEST", 39, 63]]], ["Rb-11-ca was able to lower viral protein production by 40%; however, this reduction did not translate into lower viral titers ( Fig. 5E) .", [["Rb-11-ca", "CHEMICAL", 0, 8], ["Rb", "GENE_OR_GENE_PRODUCT", 0, 2], ["Rb", "PROTEIN", 0, 2], ["viral protein", "PROTEIN", 27, 40], ["Rb", "TEST", 0, 2]]], ["Reduction in viral protein levels with Rb-11-ca could be attributed to compound toxicity, as we observed a 40% reduction in cell viability (Fig. S5H) .", [["cell", "ANATOMY", 124, 128], ["Rb-11-ca", "CHEMICAL", 39, 47], ["toxicity", "DISEASE", 80, 88], ["Rb", "GENE_OR_GENE_PRODUCT", 39, 41], ["cell", "CELL", 124, 128], ["Rb", "PROTEIN", 39, 41], ["viral protein levels", "TEST", 13, 33], ["Rb", "TEST", 39, 41], ["ca", "PROBLEM", 45, 47], ["compound toxicity", "PROBLEM", 71, 88], ["a 40% reduction in cell viability", "TREATMENT", 105, 138], ["viral protein levels", "OBSERVATION", 13, 33], ["compound toxicity", "OBSERVATION", 71, 88], ["cell viability", "OBSERVATION", 124, 138]]], ["These results indicate that targeting of individual PDIs is not solely responsible for the reduced viral titers by 147 and that these existing PDI inhibitors are not effective at inhibiting DENV replication.Reduced DENV propagation requires 147 to covalently target protein thiolsTo identify additional mechanisms that could contribute to the 147-mediated reduction in DENV viral propagation, we turned to untargeted quantitative proteomics of the affinity-enriched samples to identify additional protein targets.", [["samples", "ANATOMY", 466, 473], ["thiols", "CHEMICAL", 274, 280], ["PDIs", "GENE_OR_GENE_PRODUCT", 52, 56], ["PDI", "GENE_OR_GENE_PRODUCT", 143, 146], ["DENV", "ORGANISM", 190, 194], ["DENV", "ORGANISM", 369, 373], ["DENV", "SPECIES", 190, 194], ["DENV", "SPECIES", 215, 219], ["DENV", "SPECIES", 369, 373], ["individual PDIs", "PROBLEM", 41, 56], ["the reduced viral titers", "PROBLEM", 87, 111], ["PDI inhibitors", "TREATMENT", 143, 157], ["DENV replication", "TREATMENT", 190, 206], ["Reduced DENV propagation", "PROBLEM", 207, 231], ["protein thiols", "TEST", 266, 280], ["the 147-mediated reduction", "TREATMENT", 339, 365], ["DENV viral propagation", "PROBLEM", 369, 391], ["DENV", "OBSERVATION", 215, 219], ["DENV", "OBSERVATION", 369, 373], ["viral propagation", "OBSERVATION", 374, 391]]], ["We used tandem mass tags for relative quantification of proteins in the 147-20 enriched samples relative to the competition samples (147-20 treated with 3-fold excess 147) (Fig. 6A ).", [["samples", "ANATOMY", 88, 95], ["samples", "ANATOMY", 124, 131], ["tandem mass tags", "TEST", 8, 24], ["proteins", "TEST", 56, 64], ["the competition samples", "TEST", 108, 131]]], ["This analysis confirmed that PDIs were the most highly enriched proteins that were covalently targeted by 147-20 (Fig. 6B, Fig. S6A , Table S2 ).", [["PDIs", "SIMPLE_CHEMICAL", 29, 33], ["This analysis", "TEST", 0, 13], ["PDIs", "PROBLEM", 29, 33]]], ["While labeling of PDIA4, PDIA6, and PDIA1 was confirmed above, we identified additional targeted PDIs (TXNDC5, PDIA3, TXM1) and two other highly enriched protein targets (GSTO1 and ALDH1A1).", [["PDIA4", "GENE_OR_GENE_PRODUCT", 18, 23], ["PDIA6", "GENE_OR_GENE_PRODUCT", 25, 30], ["PDIA1", "GENE_OR_GENE_PRODUCT", 36, 41], ["PDIs", "GENE_OR_GENE_PRODUCT", 97, 101], ["TXNDC5", "GENE_OR_GENE_PRODUCT", 103, 109], ["PDIA3", "GENE_OR_GENE_PRODUCT", 111, 116], ["TXM1", "GENE_OR_GENE_PRODUCT", 118, 122], ["GSTO1", "GENE_OR_GENE_PRODUCT", 171, 176], ["ALDH1A1", "GENE_OR_GENE_PRODUCT", 181, 188], ["PDIA4", "PROTEIN", 18, 23], ["PDIA6", "PROTEIN", 25, 30], ["PDIA1", "PROTEIN", 36, 41], ["PDIs", "PROTEIN", 97, 101], ["TXNDC5", "PROTEIN", 103, 109], ["PDIA3", "PROTEIN", 111, 116], ["TXM1", "PROTEIN", 118, 122], ["protein targets", "PROTEIN", 154, 169], ["GSTO1", "DNA", 171, 176], ["ALDH1A1", "PROTEIN", 181, 188]]], ["We compared these targets to previous datasets of 147-20 targets in HEK293T, HepG2, and ALMC-2 plasma cells (Fig. 6C, Fig. S6B ) .", [["HEK293T", "ANATOMY", 68, 75], ["HepG2", "ANATOMY", 77, 82], ["ALMC-2 plasma cells", "ANATOMY", 88, 107], ["HEK293T", "CELL", 68, 75], ["HepG2", "CELL", 77, 82], ["ALMC-2 plasma cells", "CELL", 88, 107], ["Fig. 6C", "CELL", 109, 116], ["Fig. S6B", "CELL", 118, 126], ["147-20 targets", "DNA", 50, 64], ["HEK293T", "CELL_LINE", 68, 75], ["HepG2", "CELL_LINE", 77, 82], ["ALMC-2 plasma cells", "CELL_LINE", 88, 107], ["previous datasets", "TEST", 29, 46], ["HEK293T", "TEST", 68, 75], ["HepG2", "TEST", 77, 82], ["ALMC", "TEST", 88, 92], ["plasma cells", "TEST", 95, 107]]], ["The additional proteins were targets specific to Huh7 cells and were not observed in other cell types, suggesting that they could have a unique role in the reduction in virus propagation in the Huh7 cells.Compound 147 is effective against other DENV strains and Zika virusStudies until this point were carried out with Dengue serotype 2 BID-V533 (isolated in 2005 in Nicaragua) in Huh7 cells.", [["Huh7 cells", "ANATOMY", 49, 59], ["cell", "ANATOMY", 91, 95], ["Huh7 cells", "ANATOMY", 194, 204], ["Huh7 cells", "ANATOMY", 381, 391], ["Compound 147", "CHEMICAL", 205, 217], ["serotype 2 BID-V533", "CHEMICAL", 326, 345], ["Huh7 cells", "CELL", 49, 59], ["cell", "CELL", 91, 95], ["Huh7 cells", "CELL", 194, 204], ["Compound 147", "SIMPLE_CHEMICAL", 205, 217], ["DENV strains", "ORGANISM", 245, 257], ["Zika virusStudies", "ORGANISM", 262, 279], ["Huh7 cells", "CELL", 381, 391], ["Huh7 cells", "CELL_LINE", 49, 59], ["Huh7 cells", "CELL_LINE", 194, 204], ["Huh7 cells", "CELL_LINE", 381, 391], ["DENV", "SPECIES", 245, 249], ["Dengue serotype 2 BID-V533", "SPECIES", 319, 345], ["The additional proteins", "PROBLEM", 0, 23], ["Huh7 cells", "TEST", 49, 59], ["virus propagation in the Huh7 cells", "PROBLEM", 169, 204], ["other DENV strains", "PROBLEM", 239, 257], ["Zika virusStudies", "PROBLEM", 262, 279], ["Dengue serotype", "TREATMENT", 319, 334], ["reduction", "OBSERVATION_MODIFIER", 156, 165], ["virus propagation", "OBSERVATION", 169, 186], ["Huh7 cells", "OBSERVATION", 194, 204], ["Huh7 cells", "OBSERVATION", 381, 391]]], ["To determine the scope of 147 antiviral activity, we tested the effect against DENV-2 propagation in HepG2 cells, another liver carcinoma cell line commonly used as an infection model.", [["HepG2 cells", "ANATOMY", 101, 112], ["liver carcinoma cell line", "ANATOMY", 122, 147], ["liver carcinoma", "DISEASE", 122, 137], ["infection", "DISEASE", 168, 177], ["DENV-2", "ORGANISM", 79, 85], ["HepG2 cells", "CELL", 101, 112], ["liver carcinoma cell line", "CELL", 122, 147], ["HepG2 cells", "CELL_LINE", 101, 112], ["liver carcinoma cell line", "CELL_LINE", 122, 147], ["DENV-2", "SPECIES", 79, 85], ["the scope", "TEST", 13, 22], ["antiviral activity", "TREATMENT", 30, 48], ["DENV", "PROBLEM", 79, 83], ["2 propagation in HepG2 cells", "PROBLEM", 84, 112], ["another liver carcinoma cell line", "PROBLEM", 114, 147], ["an infection model", "PROBLEM", 165, 183], ["HepG2", "ANATOMY", 101, 106], ["liver", "ANATOMY", 122, 127], ["carcinoma cell line", "OBSERVATION", 128, 147], ["infection", "OBSERVATION", 168, 177]]], ["Prior data also showed that 147 treatment is non-toxic in HepG2 cells and can reduce amyloidogenic protein secretion (Plate et al., 2016) .", [["HepG2 cells", "ANATOMY", 58, 69], ["HepG2 cells", "CELL", 58, 69], ["HepG2 cells", "CELL_LINE", 58, 69], ["amyloidogenic protein", "PROTEIN", 85, 106], ["Prior data", "TEST", 0, 10], ["non-toxic in HepG2 cells", "PROBLEM", 45, 69], ["amyloidogenic protein secretion", "PROBLEM", 85, 116]]], ["When testing the impact on DENV titers in HepG2 cells, 147 treatment resulted in a significant reduction in DENV propagation 48 hpi ( Figure 7A) .", [["HepG2 cells", "ANATOMY", 42, 53], ["DENV", "ORGANISM", 27, 31], ["HepG2 cells", "CELL", 42, 53], ["HepG2 cells", "CELL_LINE", 42, 53], ["DENV", "SPECIES", 27, 31], ["DENV", "SPECIES", 108, 112], ["DENV titers", "TEST", 27, 38], ["HepG2 cells", "TREATMENT", 42, 53], ["treatment", "TREATMENT", 59, 68], ["a significant reduction", "TREATMENT", 81, 104], ["DENV propagation", "PROBLEM", 108, 124], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["reduction", "OBSERVATION_MODIFIER", 95, 104], ["DENV", "OBSERVATION", 108, 112]]], ["A similar decrease in protein levels was also detected (Fig. S7A) .", [["S7A", "PROTEIN", 61, 64], ["A similar decrease in protein levels", "PROBLEM", 0, 36], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["decrease", "OBSERVATION_MODIFIER", 10, 18], ["protein levels", "OBSERVATION", 22, 36]]], ["Next, we proceeded to test whether the compound could be more broadly effective against other DENV strains.", [["DENV", "SPECIES", 94, 98], ["other DENV strains", "PROBLEM", 88, 106], ["DENV strains", "OBSERVATION", 94, 106]]], ["We tested 147 against a different DENV-2 strain (16681, isolated in 1984 in Thailand) as well as against strains from DENV serotypes 3 and 4 (Kinney et al., 1997) .", [["DENV-2", "ORGANISM", 34, 40], ["DENV-2", "SPECIES", 34, 40], ["a different DENV-2 strain", "PROBLEM", 22, 47], ["strains", "PROBLEM", 105, 112], ["DENV serotypes", "PROBLEM", 118, 132], ["DENV", "OBSERVATION", 34, 38], ["DENV", "OBSERVATION", 118, 122]]], ["Treatment with compound 147 was able to reduce viral titers consistently greater than 95% (Fig. 7B-D) and protein levels were similarly reduced (Fig. S7B) .", [["compound 147", "CHEMICAL", 15, 27], ["compound 147", "SIMPLE_CHEMICAL", 15, 27], ["viral titers", "TEST", 47, 59], ["Fig", "TEST", 91, 94], ["7B-D)", "TEST", 96, 101], ["protein levels", "TEST", 106, 120]]], ["Finally, we sought to test whether compound 147 could be useful to treat other flaviviruses.", [["compound 147", "CHEMICAL", 35, 47], ["flaviviruses", "DISEASE", 79, 91], ["other flaviviruses", "PROBLEM", 73, 91], ["flaviviruses", "OBSERVATION", 79, 91]]], ["We measured the effect against two different strains of Zika virus; MR766 (isolated from Eastern Africa in the 1950s), and PRVABC59 (isolated from Puerto Rico in 2015) (Dick and Kitchen, 1952; Lanciotti et al., 2016) .", [["MR766", "CHEMICAL", 68, 73], ["Zika virus", "ORGANISM", 56, 66], ["MR766", "ORGANISM", 68, 73], ["Zika virus", "SPECIES", 56, 66], ["Zika virus", "SPECIES", 56, 66], ["Zika virus", "PROBLEM", 56, 66], ["Zika virus", "OBSERVATION", 56, 66]]], ["The molecule displayed similar activity at reducing ZIKV titers and protein levels for both strains (Fig. 7E-F, Fig. S7C-D) .", [["7E-F", "CHEMICAL", 106, 110], ["7E-F", "SIMPLE_CHEMICAL", 106, 110], ["S7C-D", "SIMPLE_CHEMICAL", 117, 122], ["ZIKV", "PROTEIN", 52, 56], ["ZIKV titers", "TEST", 52, 63], ["protein levels", "TEST", 68, 82], ["both strains (Fig", "PROBLEM", 87, 104], ["similar", "OBSERVATION_MODIFIER", 23, 30], ["activity", "OBSERVATION_MODIFIER", 31, 39]]], ["These results provide evidence that compound 147 is broadly active against flaviviruses in multiple cell lines, thus facilitating its potential application as an extensive host-centered antiviral agent.DISCUSSIONThe continued health burden from arbovirus infections, such as Dengue and Zika, combined with the lack of effective vaccines and therapeutics against these viruses, highlights a need for the development of new antiviral strategies.", [["cell lines", "ANATOMY", 100, 110], ["compound 147", "CHEMICAL", 36, 48], ["arbovirus infections", "DISEASE", 245, 265], ["Dengue", "DISEASE", 275, 281], ["Zika", "DISEASE", 286, 290], ["cell lines", "CELL", 100, 110], ["multiple cell lines", "CELL_LINE", 91, 110], ["flaviviruses", "PROBLEM", 75, 87], ["multiple cell lines", "TREATMENT", 91, 110], ["an extensive host-centered antiviral agent", "TREATMENT", 159, 201], ["The continued health burden", "PROBLEM", 212, 239], ["arbovirus infections", "PROBLEM", 245, 265], ["Dengue", "PROBLEM", 275, 281], ["Zika", "PROBLEM", 286, 290], ["effective vaccines", "TREATMENT", 318, 336], ["therapeutics", "TREATMENT", 341, 353], ["these viruses", "PROBLEM", 362, 375], ["new antiviral strategies", "TREATMENT", 418, 442], ["multiple cell lines", "OBSERVATION", 91, 110], ["arbovirus infections", "OBSERVATION", 245, 265], ["new", "OBSERVATION_MODIFIER", 418, 421], ["antiviral strategies", "OBSERVATION", 422, 442]]], ["Therapeutic methods which target host factors required for viral propagation provide a path unlikely to elicit drug resistance and may act broadly across several virus species (Aviner and Frydman, 2020; Geller et al., 2013 Geller et al., , 2007 .", [["host factors", "PROTEIN", 33, 45], ["Therapeutic methods", "TREATMENT", 0, 19], ["viral propagation", "TREATMENT", 59, 76], ["drug resistance", "PROBLEM", 111, 126], ["several virus species", "PROBLEM", 154, 175]]], ["However, a challenge remains to target host factors that selectively impair viral replication without causing toxicity to the host cell and infected organism.", [["cell", "ANATOMY", 131, 135], ["toxicity", "DISEASE", 110, 118], ["host cell", "CELL", 126, 135], ["viral replication", "TREATMENT", 76, 93], ["the host cell", "PROBLEM", 122, 135], ["infected organism", "PROBLEM", 140, 157], ["host cell", "OBSERVATION", 126, 135], ["infected organism", "OBSERVATION", 140, 157]]], ["Prior studies with 147 have already indicated that the compound has broad potential to safely ameliorate proteostasis imbalances that are associated a variety of disease conditions (Blackwood et al., 2019; Plate et al., 2016) .", [["Prior studies", "TEST", 0, 13], ["proteostasis imbalances", "PROBLEM", 105, 128], ["disease conditions", "PROBLEM", 162, 180], ["variety", "OBSERVATION_MODIFIER", 151, 158]]], ["The compound is effective at reducing the secretion and aggregation of amyloidogenic proteins, such as immunoglobulin light chains and transthyretin (Plate et al., 2016) .", [["immunoglobulin light chains", "GENE_OR_GENE_PRODUCT", 103, 130], ["transthyretin", "GENE_OR_GENE_PRODUCT", 135, 148], ["amyloidogenic proteins", "PROTEIN", 71, 93], ["immunoglobulin light chains", "PROTEIN", 103, 130], ["transthyretin", "PROTEIN", 135, 148], ["the secretion", "PROBLEM", 38, 51], ["amyloidogenic proteins", "PROBLEM", 71, 93], ["immunoglobulin light chains", "TREATMENT", 103, 130], ["transthyretin", "TEST", 135, 148], ["compound", "OBSERVATION_MODIFIER", 4, 12], ["effective", "OBSERVATION_MODIFIER", 16, 25], ["amyloidogenic proteins", "OBSERVATION", 71, 93]]], ["In addition, selective remodeling of ER proteostasis pathways through an ATF6-dependent mechanism by 147 was shown to prevent oxidative organ damage in mouse models of ischemia/reperfusion (Blackwood et al., 2019) .", [["organ", "ANATOMY", 136, 141], ["organ damage", "DISEASE", 136, 148], ["ischemia", "DISEASE", 168, 176], ["ER", "GENE_OR_GENE_PRODUCT", 37, 39], ["ATF6", "GENE_OR_GENE_PRODUCT", 73, 77], ["organ", "ORGAN", 136, 141], ["mouse", "ORGANISM", 152, 157], ["ER", "PROTEIN", 37, 39], ["ATF6", "PROTEIN", 73, 77], ["mouse", "SPECIES", 152, 157], ["mouse", "SPECIES", 152, 157], ["ER proteostasis pathways", "TREATMENT", 37, 61], ["an ATF6", "TEST", 70, 77], ["oxidative organ damage", "PROBLEM", 126, 148], ["ischemia", "PROBLEM", 168, 176], ["reperfusion", "PROBLEM", 177, 188], ["selective", "OBSERVATION_MODIFIER", 13, 22], ["remodeling", "OBSERVATION", 23, 33], ["proteostasis", "OBSERVATION", 40, 52], ["organ", "ANATOMY", 136, 141], ["damage", "OBSERVATION", 142, 148], ["ischemia", "OBSERVATION", 168, 176], ["reperfusion", "OBSERVATION_MODIFIER", 177, 188]]], ["The same study also showed that 147 could be safely administered to mice through IV injections and was able to activate ER proteostasis pathways in multiple tissues, including liver, kidney and heart (Blackwood et al., 2019) .DISCUSSIONHere, we further expand the therapeutic potential for compound 147 by establishing that the small molecule serves as a promising strategy to target multiple flaviviruses without causing significant toxicity in the host cell.DISCUSSIONTreatment with the small molecule proteostasis regulator, 147, resulted in a decrease in DENV vRNA, protein, and titer levels.", [["tissues", "ANATOMY", 157, 164], ["liver", "ANATOMY", 176, 181], ["kidney", "ANATOMY", 183, 189], ["heart", "ANATOMY", 194, 199], ["cell", "ANATOMY", 455, 459], ["compound 147", "CHEMICAL", 290, 302], ["flaviviruses", "DISEASE", 393, 405], ["toxicity", "DISEASE", 434, 442], ["mice", "ORGANISM", 68, 72], ["ER", "GENE_OR_GENE_PRODUCT", 120, 122], ["tissues", "TISSUE", 157, 164], ["liver", "ORGAN", 176, 181], ["kidney", "ORGAN", 183, 189], ["heart", "ORGAN", 194, 199], ["host cell", "CELL", 450, 459], ["ER", "PROTEIN", 120, 122], ["host cell", "CELL_TYPE", 450, 459], ["small molecule proteostasis regulator", "PROTEIN", 489, 526], ["DENV vRNA", "RNA", 559, 568], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["DENV", "SPECIES", 559, 563], ["The same study", "TEST", 0, 14], ["IV injections", "TREATMENT", 81, 94], ["the small molecule serves", "PROBLEM", 324, 349], ["multiple flaviviruses", "PROBLEM", 384, 405], ["significant toxicity in the host cell", "PROBLEM", 422, 459], ["a decrease in DENV vRNA", "PROBLEM", 545, 568], ["protein", "TEST", 570, 577], ["titer levels", "TEST", 583, 595], ["multiple tissues", "OBSERVATION", 148, 164], ["liver", "ANATOMY", 176, 181], ["kidney", "ANATOMY", 183, 189], ["heart", "ANATOMY", 194, 199], ["small", "OBSERVATION_MODIFIER", 328, 333], ["flaviviruses", "OBSERVATION", 393, 405], ["significant", "OBSERVATION_MODIFIER", 422, 433], ["toxicity", "OBSERVATION", 434, 442], ["host cell", "OBSERVATION", 450, 459], ["small", "OBSERVATION_MODIFIER", 489, 494], ["decrease", "OBSERVATION_MODIFIER", 547, 555], ["DENV vRNA", "OBSERVATION", 559, 568]]], ["The titer levels were the most affected, indicating that the compound was most active at preventing the assembly and secretion of mature infectious virions.", [["virions", "ANATOMY", 148, 155], ["The titer levels", "TEST", 0, 16], ["mature infectious virions", "PROBLEM", 130, 155], ["most affected", "OBSERVATION_MODIFIER", 26, 39], ["mature", "OBSERVATION_MODIFIER", 130, 136], ["infectious", "OBSERVATION", 137, 147]]], ["This is consistent with the compound targeting critical proteostasis processes that could be required for production of infectious virions and are thus, crucial to the viral life cycle (Fischl and Bartenschlager, 2011; Heaton et al., 2016) .DISCUSSION147 was designed as a preferential activator of the ATF6 branch of the UPR.", [["virions", "ANATOMY", 131, 138], ["ATF6", "GENE_OR_GENE_PRODUCT", 303, 307], ["UPR", "GENE_OR_GENE_PRODUCT", 322, 325], ["ATF6 branch", "PROTEIN", 303, 314], ["UPR", "PROTEIN", 322, 325], ["the compound targeting critical proteostasis processes", "PROBLEM", 24, 78], ["infectious virions", "PROBLEM", 120, 138], ["consistent with", "UNCERTAINTY", 8, 23], ["proteostasis", "OBSERVATION", 56, 68], ["infectious", "OBSERVATION", 120, 130], ["branch", "ANATOMY_MODIFIER", 308, 314], ["UPR", "ANATOMY_MODIFIER", 322, 325]]], ["Given that DENV innately activates the ATF6 signaling pathway, it was unexpected that small molecule activation of ATF6 could impair virus propagation.", [["DENV", "ORGANISM", 11, 15], ["ATF6", "GENE_OR_GENE_PRODUCT", 39, 43], ["ATF6", "GENE_OR_GENE_PRODUCT", 115, 119], ["ATF6", "PROTEIN", 39, 43], ["ATF6", "PROTEIN", 115, 119], ["DENV", "SPECIES", 11, 15], ["DENV", "PROBLEM", 11, 15], ["small molecule activation of ATF6", "PROBLEM", 86, 119], ["DENV", "OBSERVATION", 11, 15], ["small", "OBSERVATION_MODIFIER", 86, 91], ["molecule activation", "OBSERVATION", 92, 111]]], ["However, addition of the ATF6 inhibitor Cp7 was not effective at reducing virus replication, indicating that ATF6 activation did not mediate the antiviral effect.", [["Cp7", "CHEMICAL", 40, 43], ["Cp7", "CHEMICAL", 40, 43], ["ATF6", "GENE_OR_GENE_PRODUCT", 25, 29], ["Cp7", "SIMPLE_CHEMICAL", 40, 43], ["ATF6", "GENE_OR_GENE_PRODUCT", 109, 113], ["ATF6", "PROTEIN", 25, 29], ["ATF6", "PROTEIN", 109, 113], ["the ATF6 inhibitor Cp7", "TREATMENT", 21, 43], ["reducing virus replication", "TREATMENT", 65, 91], ["ATF6 activation", "PROBLEM", 109, 124], ["the antiviral effect", "PROBLEM", 141, 161], ["antiviral effect", "OBSERVATION", 145, 161]]], ["Cp7 on its own also did not reduce virus infection, which is consistent with prior knockout of ATF6 not affecting DENV propagation (Pe\u00f1a and Harris, 2011) .", [["Cp7", "CHEMICAL", 0, 3], ["infection", "DISEASE", 41, 50], ["Cp7", "GENE_OR_GENE_PRODUCT", 0, 3], ["ATF6", "GENE_OR_GENE_PRODUCT", 95, 99], ["Cp7", "PROTEIN", 0, 3], ["ATF6", "PROTEIN", 95, 99], ["DENV", "SPECIES", 114, 118], ["Cp7", "TEST", 0, 3], ["virus infection", "PROBLEM", 35, 50], ["prior knockout of ATF6", "PROBLEM", 77, 99], ["virus", "OBSERVATION", 35, 40], ["consistent with", "UNCERTAINTY", 61, 76]]], ["These results prompted us to examine alternative mechanisms for the antiviral effects by investigating the specific protein targets of 147.DISCUSSIONPrior work showed that 147 is a prodrug that is metabolically oxidized to an iminoquinone or quinone methide, which covalently targets nucleophilic cysteine residues on cellular protein (Palmer et al., 2020; Paxman et al., 2018; Plate et al., 2016) .", [["cellular", "ANATOMY", 318, 326], ["iminoquinone", "CHEMICAL", 226, 238], ["quinone", "CHEMICAL", 242, 249], ["iminoquinone", "CHEMICAL", 226, 238], ["quinone", "CHEMICAL", 242, 249], ["cysteine", "CHEMICAL", 297, 305], ["iminoquinone", "SIMPLE_CHEMICAL", 226, 238], ["quinone methide", "SIMPLE_CHEMICAL", 242, 257], ["cellular", "CELL", 318, 326], ["cellular protein", "PROTEIN", 318, 334], ["alternative mechanisms", "TREATMENT", 37, 59], ["the antiviral effects", "TREATMENT", 64, 85], ["the specific protein targets", "TEST", 103, 131], ["an iminoquinone or quinone methide", "TREATMENT", 223, 257], ["nucleophilic cysteine residues", "PROBLEM", 284, 314]]], ["We showed that the antiviral activity of 147 could be attenuated with BME treatment, demonstrating that the metabolic activation mechanism and covalent targeting of reactive thiols is similarly required to reduce virus infection.", [["BME", "CHEMICAL", 70, 73], ["thiols", "CHEMICAL", 174, 180], ["infection", "DISEASE", 219, 228], ["BME", "CHEMICAL", 70, 73], ["thiols", "CHEMICAL", 174, 180], ["BME", "SIMPLE_CHEMICAL", 70, 73], ["reactive thiols", "SIMPLE_CHEMICAL", 165, 180], ["the antiviral activity", "TEST", 15, 37], ["BME treatment", "TREATMENT", 70, 83], ["the metabolic activation mechanism", "PROBLEM", 104, 138], ["reactive thiols", "PROBLEM", 165, 180], ["virus infection", "PROBLEM", 213, 228], ["antiviral activity", "OBSERVATION", 19, 37], ["metabolic activation", "OBSERVATION", 108, 128], ["reactive thiols", "OBSERVATION", 165, 180]]], ["We repeated the chemoproteomic target identification in Huh7 cells using an analog of 147 and identified a similar set of PDIs, including PDIA1, PDIA4, and PDIA6, as targets in this cell line.", [["Huh7 cells", "ANATOMY", 56, 66], ["cell line", "ANATOMY", 182, 191], ["Huh7 cells", "CELL", 56, 66], ["PDIs", "GENE_OR_GENE_PRODUCT", 122, 126], ["PDIA1", "GENE_OR_GENE_PRODUCT", 138, 143], ["PDIA4", "GENE_OR_GENE_PRODUCT", 145, 150], ["PDIA6", "GENE_OR_GENE_PRODUCT", 156, 161], ["cell line", "CELL", 182, 191], ["Huh7 cells", "CELL_LINE", 56, 66], ["PDIs", "DNA", 122, 126], ["PDIA1", "PROTEIN", 138, 143], ["PDIA4", "PROTEIN", 145, 150], ["PDIA6", "PROTEIN", 156, 161], ["Huh7 cells", "TEST", 56, 66], ["an analog", "TEST", 73, 82], ["PDIs", "TEST", 122, 126], ["PDIA1", "TEST", 138, 143], ["PDIA4", "TEST", 145, 150], ["PDIA6", "TREATMENT", 156, 161], ["this cell line", "TREATMENT", 177, 191], ["Huh7 cells", "OBSERVATION", 56, 66], ["cell line", "OBSERVATION", 182, 191]]], ["However, knockdown of individual PDIs was not sufficient to reduce viral titers suggesting that these individual PDIs are not responsible for the inhibition of viral infection.", [["viral infection", "DISEASE", 160, 175], ["PDIs", "GENE_OR_GENE_PRODUCT", 33, 37], ["PDIs", "GENE_OR_GENE_PRODUCT", 113, 117], ["knockdown of individual PDIs", "PROBLEM", 9, 37], ["viral titers", "PROBLEM", 67, 79], ["these individual PDIs", "PROBLEM", 96, 117], ["viral infection", "PROBLEM", 160, 175], ["not responsible for", "UNCERTAINTY", 122, 141], ["viral", "OBSERVATION_MODIFIER", 160, 165], ["infection", "OBSERVATION", 166, 175]]], ["This raises the possibility that 1) polypharmacologic targeting of multiple PDIs may be necessary to sufficiently impair virus propagation, or 2) alternative 147-targets are responsible for the antiviral effects.DISCUSSIONWe addressed whether inhibition of multiple PDIs could be required by testing the effect of existing PDI inhibitors that display varying selectivity towards PDIA1/P4HB and additional PDIs also modified by 147.", [["PDIs", "GENE_OR_GENE_PRODUCT", 76, 80], ["PDIs", "GENE_OR_GENE_PRODUCT", 266, 270], ["PDI", "GENE_OR_GENE_PRODUCT", 323, 326], ["PDIA1", "GENE_OR_GENE_PRODUCT", 379, 384], ["P4HB", "SIMPLE_CHEMICAL", 385, 389], ["PDIs", "SIMPLE_CHEMICAL", 405, 409], ["PDIA1", "PROTEIN", 379, 384], ["P4HB", "PROTEIN", 385, 389], ["polypharmacologic targeting of multiple PDIs", "PROBLEM", 36, 80], ["impair virus propagation", "PROBLEM", 114, 138], ["the antiviral effects", "PROBLEM", 190, 211], ["multiple PDIs", "TREATMENT", 257, 270], ["existing PDI inhibitors", "TREATMENT", 314, 337], ["PDIA1/P4HB", "TREATMENT", 379, 389], ["additional PDIs", "TREATMENT", 394, 409], ["raises the possibility", "UNCERTAINTY", 5, 27], ["antiviral effects", "OBSERVATION", 194, 211]]], ["None of the PDI inhibitor compounds significantly reduced DENV viral titers, suggesting that 147 elicits its antiviral activity through an alternative mechanism of action.", [["PDI", "GENE_OR_GENE_PRODUCT", 12, 15], ["DENV", "ORGANISM", 58, 62], ["DENV", "SPECIES", 58, 62], ["the PDI inhibitor", "TREATMENT", 8, 25], ["reduced DENV viral titers", "PROBLEM", 50, 75], ["viral titers", "OBSERVATION", 63, 75]]], ["Importantly, one of the compounds, Rb-11-ca, exhibited considerably more toxicity in Huh7 cells, even at the highest concentration that we tested for 147.", [["Huh7 cells", "ANATOMY", 85, 95], ["Rb-11-ca", "CHEMICAL", 35, 43], ["toxicity", "DISEASE", 73, 81], ["Rb-11-ca", "SIMPLE_CHEMICAL", 35, 43], ["Huh7 cells", "CELL", 85, 95], ["Rb", "PROTEIN", 35, 37], ["Huh7 cells", "CELL_LINE", 85, 95], ["the compounds", "TEST", 20, 33], ["Rb", "TEST", 35, 37], ["considerably more toxicity in Huh7 cells", "PROBLEM", 55, 95], ["considerably", "OBSERVATION_MODIFIER", 55, 67], ["more toxicity", "OBSERVATION_MODIFIER", 68, 81], ["Huh7 cells", "OBSERVATION", 85, 95]]], ["Toxicity has also been observed for other PDI inhibitors (Langsjoen et al., 2017) .DISCUSSIONThis further highlights the unique properties of compound 147.", [["Toxicity", "DISEASE", 0, 8], ["compound 147", "CHEMICAL", 142, 154], ["PDI", "GENE_OR_GENE_PRODUCT", 42, 45], ["other PDI inhibitors", "TREATMENT", 36, 56]]], ["The low toxicity could be explained by previous observations showing that less than 25% of the PDIA4 pool is labeled by the compound, indicating that PDIs are not globally inhibited by the molecule .", [["toxicity", "DISEASE", 8, 16], ["PDIA4", "GENE_OR_GENE_PRODUCT", 95, 100], ["PDIs", "SIMPLE_CHEMICAL", 150, 154], ["PDIA4", "PROTEIN", 95, 100], ["The low toxicity", "PROBLEM", 0, 16], ["previous observations", "TEST", 39, 60], ["PDIs", "PROBLEM", 150, 154], ["low toxicity", "OBSERVATION_MODIFIER", 4, 16], ["could be explained", "UNCERTAINTY", 17, 35], ["less", "OBSERVATION_MODIFIER", 74, 78]]], ["Furthermore, endogenous protein secretion and formation of disulfide bonds in secreted proteins, including fully assembled immunoglobulins, is not affected by 147 (Plate et al., 2016) .", [["disulfide", "CHEMICAL", 59, 68], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 123, 138], ["secreted proteins", "PROTEIN", 78, 95], ["immunoglobulins", "PROTEIN", 123, 138], ["endogenous protein secretion", "PROBLEM", 13, 41], ["disulfide bonds in secreted proteins", "PROBLEM", 59, 95], ["endogenous protein secretion", "OBSERVATION", 13, 41], ["disulfide bonds", "OBSERVATION", 59, 74], ["immunoglobulins", "OBSERVATION", 123, 138]]], ["This lack of perturbation to normal proteostasis processes and selective inhibition of viral propagation makes 147 an ideal candidate for a host-centered antiviral strategy.DISCUSSIONTo address the second possibility that alternative protein targets besides the most prominent PDIs could be responsible for reduction in virus propagation, we compared our identified targets in Huh7 cells to the prior list of covalently modified proteins in other cell lines .", [["Huh7 cells", "ANATOMY", 377, 387], ["cell lines", "ANATOMY", 447, 457], ["PDIs", "GENE_OR_GENE_PRODUCT", 277, 281], ["Huh7 cells", "CELL", 377, 387], ["cell lines", "CELL", 447, 457], ["PDIs", "PROTEIN", 277, 281], ["Huh7 cells", "CELL_LINE", 377, 387], ["covalently modified proteins", "PROTEIN", 409, 437], ["cell lines", "CELL_LINE", 447, 457], ["perturbation to normal proteostasis processes", "PROBLEM", 13, 58], ["viral propagation", "TREATMENT", 87, 104], ["a host-centered antiviral strategy", "TREATMENT", 138, 172], ["alternative protein targets", "TREATMENT", 222, 249], ["reduction in virus propagation", "PROBLEM", 307, 337], ["Huh7 cells", "TREATMENT", 377, 387], ["covalently modified proteins", "TREATMENT", 409, 437], ["other cell lines", "TREATMENT", 441, 457], ["normal proteostasis", "OBSERVATION", 29, 48], ["most prominent", "OBSERVATION_MODIFIER", 262, 276], ["virus", "OBSERVATION", 320, 325], ["Huh7 cells", "OBSERVATION", 377, 387], ["cell lines", "OBSERVATION", 447, 457]]], ["In addition to the PDIs studied above, additional members of the PDI family were identified (TXNDC5, TXM1), as well as two unique proteins that were identified only in Huh7 cells: ALDH1A1 and GSTO1.", [["Huh7 cells", "ANATOMY", 168, 178], ["PDI", "GENE_OR_GENE_PRODUCT", 65, 68], ["TXNDC5", "GENE_OR_GENE_PRODUCT", 93, 99], ["TXM1", "GENE_OR_GENE_PRODUCT", 101, 105], ["Huh7 cells", "CELL", 168, 178], ["ALDH1A1", "GENE_OR_GENE_PRODUCT", 180, 187], ["GSTO1", "GENE_OR_GENE_PRODUCT", 192, 197], ["PDIs", "PROTEIN", 19, 23], ["PDI family", "PROTEIN", 65, 75], ["TXNDC5", "PROTEIN", 93, 99], ["TXM1", "PROTEIN", 101, 105], ["Huh7 cells", "CELL_LINE", 168, 178], ["ALDH1A1", "PROTEIN", 180, 187], ["GSTO1", "PROTEIN", 192, 197], ["ALDH1A1", "TEST", 180, 187], ["GSTO1", "TEST", 192, 197], ["Huh7 cells", "OBSERVATION", 168, 178]]], ["These new targets also have catalytic Cys residues that are likely modified by 147.", [["Cys", "CHEMICAL", 38, 41], ["catalytic Cys residues", "PROBLEM", 28, 50], ["catalytic Cys", "OBSERVATION", 28, 41]]], ["Ongoing studies are directed at determining the potential role of these protein targets in the 147-mediated antiviral mechanism.DISCUSSIONThe recent COVID-19 pandemic has refocused attention to the need for broadspectrum antiviral agents that could inhibit future virus threats (Carrasco-Hernandez et al., 2017) .", [["Ongoing studies", "TEST", 0, 15], ["these protein targets", "TEST", 66, 87], ["broadspectrum antiviral agents", "TREATMENT", 207, 237]]], ["Targeting essential host pathways that are commonly hijacked by virus infection without causing significant host toxicity is recognized as one important strategy to combat future infection with unknown pathogens.", [["infection", "DISEASE", 70, 79], ["toxicity", "DISEASE", 113, 121], ["infection", "DISEASE", 179, 188], ["essential host pathways", "PROBLEM", 10, 33], ["virus infection", "PROBLEM", 64, 79], ["significant host toxicity", "PROBLEM", 96, 121], ["future infection", "PROBLEM", 172, 188], ["unknown pathogens", "PROBLEM", 194, 211], ["host pathways", "OBSERVATION", 20, 33], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["host toxicity", "OBSERVATION", 108, 121]]], ["We determined that compound 147 has broad antiviral activity against multiple DENV strains and serotypes and that the compound is also effective against multiple ZIKV strains.", [["compound 147", "CHEMICAL", 19, 31], ["DENV", "ORGANISM", 78, 82], ["ZIKV strains", "ORGANISM", 162, 174], ["DENV", "SPECIES", 78, 82], ["ZIKV", "SPECIES", 162, 166], ["broad antiviral activity", "TREATMENT", 36, 60], ["multiple DENV strains", "PROBLEM", 69, 90], ["serotypes", "PROBLEM", 95, 104], ["multiple ZIKV strains", "PROBLEM", 153, 174], ["antiviral activity", "OBSERVATION_MODIFIER", 42, 60], ["DENV strains", "OBSERVATION", 78, 90], ["ZIKV strains", "OBSERVATION", 162, 174]]], ["These results highlight broad utility of the proteostasis regulator compound to reduce flavivirus infection by targeting conserved host cell processes that are commonly exploited by the virus.", [["cell", "ANATOMY", 136, 140], ["flavivirus infection", "DISEASE", 87, 107], ["cell", "CELL", 136, 140], ["flavivirus", "SPECIES", 87, 97], ["the proteostasis regulator", "PROBLEM", 41, 67], ["flavivirus infection", "PROBLEM", 87, 107], ["targeting conserved host cell processes", "PROBLEM", 111, 150], ["the virus", "PROBLEM", 182, 191], ["broad", "OBSERVATION_MODIFIER", 24, 29], ["host cell processes", "OBSERVATION", 131, 150]]], ["Our results here now provide an entirely new therapeutic application of 147 as a broad antiviral agent to reduce flavivirus infections.Lentivirus:The 3 rd generation system was used for production.", [["flavivirus infections", "DISEASE", 113, 134], ["flavivirus", "ORGANISM", 113, 123], ["Lentivirus", "ORGANISM", 135, 145], ["Lentivirus", "SPECIES", 135, 145], ["a broad antiviral agent", "TREATMENT", 79, 102], ["flavivirus infections", "PROBLEM", 113, 134], ["The 3 rd generation system", "TREATMENT", 146, 172], ["flavivirus", "OBSERVATION", 113, 123]]], ["Respective shRNA plasmids were transfected into HEK293T cells together with lentivirus packaging plasmids RRG, VSVG, and Rev using the calcium phosphate method as described .", [["plasmids", "ANATOMY", 17, 25], ["HEK293T cells", "ANATOMY", 48, 61], ["plasmids", "ANATOMY", 97, 105], ["calcium phosphate", "CHEMICAL", 135, 152], ["calcium phosphate", "CHEMICAL", 135, 152], ["HEK293T cells", "CELL", 48, 61], ["lentivirus", "ORGANISM", 76, 86], ["RRG", "GENE_OR_GENE_PRODUCT", 106, 109], ["VSVG", "GENE_OR_GENE_PRODUCT", 111, 115], ["Rev", "GENE_OR_GENE_PRODUCT", 121, 124], ["calcium", "SIMPLE_CHEMICAL", 135, 142], ["shRNA plasmids", "DNA", 11, 25], ["HEK293T cells", "CELL_LINE", 48, 61], ["lentivirus packaging plasmids", "DNA", 76, 105], ["RRG", "DNA", 106, 109], ["VSVG", "DNA", 111, 115], ["Rev", "DNA", 121, 124], ["lentivirus", "SPECIES", 76, 86], ["Respective shRNA plasmids", "TREATMENT", 0, 25], ["HEK293T cells", "TREATMENT", 48, 61], ["lentivirus packaging plasmids", "TREATMENT", 76, 105], ["the calcium phosphate method", "TREATMENT", 131, 159]]], ["Supernatants were collected 3 days post transfection, and cleared at 3700xg for 10 minutes.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12]]], ["To generate respective shRNA stable knockdown cell lines in Huh7 cells, lentiviruses prepared with pools of 2-3 shRNAs per target were added to Huh7 cells and media containing 4 \u00b5g/mL final concentration polybrene.", [["cell lines", "ANATOMY", 46, 56], ["Huh7 cells", "ANATOMY", 60, 70], ["Huh7 cells", "ANATOMY", 144, 154], ["polybrene", "CHEMICAL", 204, 213], ["polybrene", "CHEMICAL", 204, 213], ["cell lines", "CELL", 46, 56], ["Huh7 cells", "CELL", 60, 70], ["lentiviruses", "ORGANISM", 72, 84], ["Huh7 cells", "CELL", 144, 154], ["polybrene", "SIMPLE_CHEMICAL", 204, 213], ["shRNA stable knockdown cell lines", "CELL_LINE", 23, 56], ["Huh7 cells", "CELL_LINE", 60, 70], ["Huh7 cells", "CELL_LINE", 144, 154], ["knockdown cell lines", "TREATMENT", 36, 56], ["Huh7 cells", "TREATMENT", 60, 70], ["lentiviruses", "PROBLEM", 72, 84], ["pools of 2-3 shRNAs", "TREATMENT", 99, 118], ["Huh7 cells", "TREATMENT", 144, 154], ["media", "TREATMENT", 159, 164], ["final concentration polybrene", "TREATMENT", 184, 213], ["respective shRNA", "OBSERVATION", 12, 28], ["stable", "OBSERVATION_MODIFIER", 29, 35], ["knockdown cell lines", "OBSERVATION", 36, 56], ["Huh7 cells", "OBSERVATION", 60, 70], ["lentiviruses", "OBSERVATION", 72, 84], ["Huh7 cells", "OBSERVATION", 144, 154]]], ["Selection proceeded for 1 week under puromycin (5 \u00b5g/mL).Viral Focus Forming AssayConfluent Vero cells in 96 well plates were inoculated with 10-fold serial dilutions of DENV or ZIKV in BA-1 diluent (1xM199 media, 5% BSA, 1x L-glutamine, 1x penicillin/streptomycin, 0.04% sodium bicarbonate, 50 mM Tris) for 2 hours.", [["Vero cells", "ANATOMY", 92, 102], ["puromycin", "CHEMICAL", 37, 46], ["ZIKV", "CHEMICAL", 178, 182], ["BA-1 diluent", "CHEMICAL", 186, 198], ["1xM199", "CHEMICAL", 200, 206], ["L-glutamine", "CHEMICAL", 225, 236], ["penicillin", "CHEMICAL", 241, 251], ["streptomycin", "CHEMICAL", 252, 264], ["sodium bicarbonate", "CHEMICAL", 272, 290], ["puromycin", "CHEMICAL", 37, 46], ["L-glutamine", "CHEMICAL", 225, 236], ["penicillin", "CHEMICAL", 241, 251], ["streptomycin", "CHEMICAL", 252, 264], ["sodium bicarbonate", "CHEMICAL", 272, 290], ["Tris", "CHEMICAL", 298, 302], ["puromycin", "SIMPLE_CHEMICAL", 37, 46], ["AssayConfluent Vero cells", "CELL", 77, 102], ["DENV", "ORGANISM", 170, 174], ["ZIKV", "SIMPLE_CHEMICAL", 178, 182], ["1xM199", "SIMPLE_CHEMICAL", 200, 206], ["BSA", "SIMPLE_CHEMICAL", 217, 220], ["L-glutamine", "SIMPLE_CHEMICAL", 225, 236], ["penicillin", "SIMPLE_CHEMICAL", 241, 251], ["streptomycin", "SIMPLE_CHEMICAL", 252, 264], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 272, 290], ["Viral Focus Forming AssayConfluent Vero cells", "CELL_LINE", 57, 102], ["DENV", "SPECIES", 170, 174], ["ZIKV", "SPECIES", 178, 182], ["puromycin", "TREATMENT", 37, 46], ["Viral Focus", "TEST", 57, 68], ["AssayConfluent Vero cells", "TEST", 77, 102], ["DENV", "PROBLEM", 170, 174], ["ZIKV in BA", "TEST", 178, 188], ["BSA", "TEST", 217, 220], ["1x L-glutamine", "TREATMENT", 222, 236], ["penicillin", "TREATMENT", 241, 251], ["streptomycin", "TREATMENT", 252, 264], ["0.04% sodium bicarbonate", "TREATMENT", 266, 290], ["Vero cells", "OBSERVATION", 92, 102]]], ["The cells were overlaid with a 1:1 mixture of 2x nutrient overlay (2x Earle's Balanced Salt Solution, 2x Ye-Lah Medium, 4% FBS, 0.4% sodium bicarbonate, 0.1 mg/mL gentamycin, 0.5 mg/mL amphotericin B) + 2.4% methylcellulose in water.", [["cells", "ANATOMY", 4, 9], ["sodium bicarbonate", "CHEMICAL", 133, 151], ["gentamycin", "CHEMICAL", 163, 173], ["amphotericin B", "CHEMICAL", 185, 199], ["methylcellulose", "CHEMICAL", 208, 223], ["sodium bicarbonate", "CHEMICAL", 133, 151], ["gentamycin", "CHEMICAL", 163, 173], ["amphotericin B", "CHEMICAL", 185, 199], ["methylcellulose", "CHEMICAL", 208, 223], ["cells", "CELL", 4, 9], ["FBS", "ORGANISM_SUBSTANCE", 123, 126], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 133, 151], ["gentamycin", "SIMPLE_CHEMICAL", 163, 173], ["amphotericin B", "SIMPLE_CHEMICAL", 185, 199], ["methylcellulose", "SIMPLE_CHEMICAL", 208, 223], ["a 1:1 mixture", "TREATMENT", 29, 42], ["2x nutrient overlay", "TREATMENT", 46, 65], ["Earle's Balanced Salt Solution", "TREATMENT", 70, 100], ["sodium bicarbonate", "TREATMENT", 133, 151], ["gentamycin", "TREATMENT", 163, 173], ["amphotericin B", "TREATMENT", 185, 199]]], ["After 2 days (ZIKV, DENV3, DENV4) or 3 days (DENV2), overlay was removed, and cells were fixed in ice cold 85% acetone for 30 minutes.", [["cells", "ANATOMY", 78, 83], ["acetone", "CHEMICAL", 111, 118], ["acetone", "CHEMICAL", 111, 118], ["DENV2", "ORGANISM", 45, 50], ["cells", "CELL", 78, 83], ["acetone", "SIMPLE_CHEMICAL", 111, 118], ["ZIKV", "SPECIES", 14, 18], ["DENV2", "SPECIES", 45, 50]]], ["Infectious foci were stained with a primary pan-flavivirus 4G2Viral Focus Forming Assayantibody (1:1000 in 5% BSA, TBST) and secondary HRP antibody (1:1000 in 5% milk, TBST), then visualized using 400 \u00b5L 8 mg/mL 3-amino-9-ethylcarbazole (Sigma) in 10 mL 50 mM sodium acetate (Fisher) + 4 \u00b5L 30% H2O2 (Fisher) and exposed for 15-45 minutes until foci were visible.SDS-PAGE Gels and ImmunoblottingCell pellets were lysed in RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% SDS, 1%SDS-PAGE Gels and ImmunoblottingTriton-X-100, 0.5% sodium deoxycholate) + Roche cOmplete protease inhibitor.", [["foci", "ANATOMY", 11, 15], ["milk", "ANATOMY", 162, 166], ["foci", "ANATOMY", 345, 349], ["Cell", "ANATOMY", 395, 399], ["3-amino-9-ethylcarbazole", "CHEMICAL", 212, 236], ["sodium acetate", "CHEMICAL", 260, 274], ["H2O2", "CHEMICAL", 295, 299], ["NaCl", "CHEMICAL", 461, 465], ["ImmunoblottingTriton-X-100", "CHEMICAL", 497, 523], ["sodium deoxycholate", "CHEMICAL", 530, 549], ["3-amino-9-ethylcarbazole", "CHEMICAL", 212, 236], ["sodium acetate", "CHEMICAL", 260, 274], ["H2O2", "CHEMICAL", 295, 299], ["NaCl", "CHEMICAL", 461, 465], ["sodium deoxycholate", "CHEMICAL", 530, 549], ["BSA", "SIMPLE_CHEMICAL", 110, 113], ["HRP antibody", "SIMPLE_CHEMICAL", 135, 147], ["milk", "ORGANISM_SUBSTANCE", 162, 166], ["3-amino-9-ethylcarbazole", "SIMPLE_CHEMICAL", 212, 236], ["Sigma", "SIMPLE_CHEMICAL", 238, 243], ["sodium acetate", "SIMPLE_CHEMICAL", 260, 274], ["H2O2", "SIMPLE_CHEMICAL", 295, 299], ["Cell", "CELL", 395, 399], ["SDS-PAGE Gels", "SIMPLE_CHEMICAL", 479, 492], ["ImmunoblottingTriton-X-100", "SIMPLE_CHEMICAL", 497, 523], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 530, 549], ["HRP antibody", "PROTEIN", 135, 147], ["Infectious foci", "PROBLEM", 0, 15], ["Assayantibody", "TEST", 82, 95], ["BSA", "TEST", 110, 113], ["TBST", "TEST", 115, 119], ["secondary HRP antibody", "TEST", 125, 147], ["amino", "TREATMENT", 214, 219], ["mM sodium acetate", "TREATMENT", 257, 274], ["foci", "PROBLEM", 345, 349], ["SDS-PAGE Gels", "TREATMENT", 363, 376], ["ImmunoblottingCell pellets", "TREATMENT", 381, 407], ["Tris pH", "TEST", 441, 448], ["NaCl", "TEST", 461, 465], ["SDS", "TEST", 472, 475], ["SDS", "TEST", 479, 482], ["Gels", "TEST", 488, 492], ["ImmunoblottingTriton", "TEST", 497, 517], ["sodium deoxycholate", "TREATMENT", 530, 549], ["Roche cOmplete protease inhibitor", "TREATMENT", 553, 586], ["foci", "OBSERVATION", 345, 349]]], ["Cells were left on ice for at least 10 minutes and lysate was cleared at 17,000xg for 10 minutes.SDS-PAGE Gels and ImmunoblottingCleared lysate concentrations were normalized and gel samples were separated by SDS-PAGE.", [["Cells", "ANATOMY", 0, 5], ["lysate", "ANATOMY", 51, 57], ["lysate", "ANATOMY", 137, 143], ["samples", "ANATOMY", 183, 190], ["Cells", "CELL", 0, 5], ["ice", "TREATMENT", 19, 22], ["lysate", "TEST", 51, 57], ["SDS-PAGE Gels", "TREATMENT", 97, 110], ["ImmunoblottingCleared lysate concentrations", "TREATMENT", 115, 158], ["gel samples", "TEST", 179, 190], ["left", "ANATOMY_MODIFIER", 11, 15]]], ["Gels were transferred to PVDF membranes using standard settings on the TransBlot Turbo (BioRad).", [["PVDF membranes", "ANATOMY", 25, 39], ["PVDF", "CHEMICAL", 25, 29], ["Gels", "SIMPLE_CHEMICAL", 0, 4], ["membranes", "CELLULAR_COMPONENT", 30, 39]]], ["Blots were blocked in 5% non-fat dry milk in Tris-buffered saline (TBST, 50mM Tris pH 7,4, 150mM NaCl, 0.1 % Tween-20) for 30 minutes before applying antibodies.", [["Tris-buffered", "CHEMICAL", 45, 58], ["NaCl", "CHEMICAL", 97, 101], ["Tween-20", "CHEMICAL", 109, 117], ["Tris", "CHEMICAL", 45, 49], ["NaCl", "CHEMICAL", 97, 101], ["Tween-20", "CHEMICAL", 109, 117], ["fat", "TISSUE", 29, 32], ["milk", "ORGANISM_SUBSTANCE", 37, 41], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 45, 65], ["antibodies", "PROTEIN", 150, 160], ["Blots", "TEST", 0, 5], ["Tris-buffered saline", "TREATMENT", 45, 65], ["TBST", "TEST", 67, 71], ["50mM Tris pH", "TREATMENT", 73, 85], ["NaCl", "TEST", 97, 101]]], ["Primary antibodies (in 5% BSA, TBST) were applied at room temperature for 2 hours or at 4\u00baC overnight.", [["BSA", "SIMPLE_CHEMICAL", 26, 29], ["Primary antibodies", "PROTEIN", 0, 18], ["Primary antibodies", "TREATMENT", 0, 18]]], ["Secondary antibodies (in 5% milk, TBST)SDS-PAGE Gels and Immunoblottingwere applied at room temperature for 30 minutes or at 4\u00baC for 1 hour.", [["milk", "ORGANISM_SUBSTANCE", 28, 32], ["antibodies", "PROTEIN", 10, 20], ["Secondary antibodies", "PROBLEM", 0, 20], ["TBST)SDS", "TREATMENT", 34, 42], ["PAGE Gels", "TREATMENT", 43, 52], ["Immunoblottingwere", "TREATMENT", 57, 75]]], ["All primary antibodies plus the anti-mouse HRP secondary were used at a 1:1000 dilution; all secondary antibodies were used at a 1:10,000 dilution.Quantitative RT-PCRRNA was prepared from cell pellets using the Zymo Quick-RNA miniprep kit. cDNA was synthesized from 500 ng total cellular RNA using random primers (IDT), oligo-dT primers (IDT), and Promega M-MLV reverse transcriptase. qPCR analysis was performed usingCell Viability AssaysCell viability was determined using the CellTiter-Glo reagent (Promega).", [["cell", "ANATOMY", 188, 192], ["cellular", "ANATOMY", 279, 287], ["Cell", "ANATOMY", 418, 422], ["Cell", "ANATOMY", 439, 443], ["HRP", "GENE_OR_GENE_PRODUCT", 43, 46], ["cell", "CELL", 188, 192], ["Zymo", "GENE_OR_GENE_PRODUCT", 211, 215], ["cellular", "CELL", 279, 287], ["Cell", "CELL", 418, 422], ["Cell", "CELL", 439, 443], ["Promega", "ORGANISM", 502, 509], ["primary antibodies", "PROTEIN", 4, 22], ["anti-mouse HRP", "PROTEIN", 32, 46], ["secondary antibodies", "PROTEIN", 93, 113], ["RT-PCRRNA", "DNA", 160, 169], ["cDNA", "DNA", 240, 244], ["cellular RNA", "RNA", 279, 291], ["oligo-dT primers", "DNA", 320, 336], ["MLV reverse transcriptase", "PROTEIN", 358, 383], ["anti-mouse", "SPECIES", 32, 42], ["All primary antibodies", "TREATMENT", 0, 22], ["the anti-mouse HRP", "TREATMENT", 28, 46], ["a 1:1000 dilution", "TREATMENT", 70, 87], ["all secondary antibodies", "TREATMENT", 89, 113], ["PCRRNA", "PROBLEM", 163, 169], ["cell pellets", "TREATMENT", 188, 200], ["the Zymo", "TEST", 207, 215], ["total cellular RNA", "TREATMENT", 273, 291], ["random primers", "TREATMENT", 298, 312], ["IDT", "TEST", 314, 317], ["oligo-dT primers", "TREATMENT", 320, 336], ["qPCR analysis", "TEST", 385, 398], ["Cell Viability", "TEST", 418, 432], ["Cell viability", "TEST", 439, 453], ["the CellTiter", "TREATMENT", 475, 488], ["Glo reagent (Promega)", "TREATMENT", 489, 510]]], ["Huh7 cells were seeded into 96 well plates into 100 \u00b5L culture media.", [["Huh7 cells", "ANATOMY", 0, 10], ["Huh7 cells", "CELL", 0, 10], ["Huh7 cells", "CELL_LINE", 0, 10], ["Huh7 cells", "TREATMENT", 0, 10]]], ["100x dilutions of compounds were prepared in culture media.", [["compounds", "TREATMENT", 18, 27]]], ["11 \u00b5L of each compound dilution was added to wells in triplicate.", [["each compound dilution", "TREATMENT", 9, 31]]], ["16 hours after treatment, media was removed and cells were infected as described above (for -DENV samples, no virus was added).", [["cells", "ANATOMY", 48, 53], ["samples", "ANATOMY", 98, 105], ["cells", "CELL", 48, 53], ["DENV", "ORGANISM", 93, 97], ["DENV", "SPECIES", 93, 97], ["treatment", "TREATMENT", 15, 24], ["media", "TREATMENT", 26, 31], ["cells", "PROBLEM", 48, 53], ["DENV samples", "TEST", 93, 105], ["virus", "PROBLEM", 110, 115]]], ["Media was replaced 24 hours after infection and 100 \u00b5L Cell Titer Glo reagent was added.", [["Cell", "ANATOMY", 55, 59], ["infection", "DISEASE", 34, 43], ["infection", "PROBLEM", 34, 43], ["\u00b5L Cell Titer Glo reagent", "TREATMENT", 52, 77]]], ["Plates were gently shaken for 10 minutes, then luminescence was measured for each well on a Synergy HT plate reader.", [["HT", "DISEASE", 100, 102], ["a Synergy HT plate", "TREATMENT", 90, 108]]], ["Luminescence values for each condition and/or compound treatment were averaged and normalized to a DMSO control.", [["DMSO", "CHEMICAL", 99, 103], ["DMSO", "CHEMICAL", 99, 103], ["Luminescence values", "TEST", 0, 19], ["each condition", "PROBLEM", 24, 38], ["compound treatment", "TREATMENT", 46, 64], ["a DMSO control", "TREATMENT", 97, 111]]], ["Where multiple independent replicates are indicated in legends, samples were averaged, and standard error of the mean was propagated.Enrichment of Covalent Protein TargetsHuh7 cells were treated with 3 \u00b5M 147-20 or a combination of 3 \u00b5M 147-20 and 9 \u00b5M 147.", [["Huh7 cells", "ANATOMY", 171, 181], ["Huh7 cells", "CELL", 171, 181], ["Huh7 cells", "CELL_LINE", 171, 181], ["Huh7 cells", "TEST", 171, 181], ["Covalent Protein", "OBSERVATION", 147, 163], ["Targets", "OBSERVATION_MODIFIER", 164, 171], ["Huh7 cells", "OBSERVATION", 171, 181]]], ["Cells were harvested 16-18 hours post-treatment and lysed as described above.Enrichment of Covalent Protein TargetsClick chemistry using 100 \u00b5M Cy5 azide or TAMRA desthiobiotin azide was performed with 1.6 mM BTTAA, 0.8 mM copper sulfate, and 5 mM sodium ascorbate for 1 hour at 37\u00baC, shaking at 500 rpm.", [["Cells", "ANATOMY", 0, 5], ["Cy5 azide", "CHEMICAL", 144, 153], ["TAMRA", "CHEMICAL", 157, 162], ["desthiobiotin azide", "CHEMICAL", 163, 182], ["BTTAA", "CHEMICAL", 209, 214], ["copper sulfate", "CHEMICAL", 223, 237], ["sodium ascorbate", "CHEMICAL", 248, 264], ["Cy5 azide", "CHEMICAL", 144, 153], ["desthiobiotin azide", "CHEMICAL", 163, 182], ["BTTAA", "CHEMICAL", 209, 214], ["copper sulfate", "CHEMICAL", 223, 237], ["sodium ascorbate", "CHEMICAL", 248, 264], ["Cells", "CELL", 0, 5], ["Cy5 azide", "SIMPLE_CHEMICAL", 144, 153], ["TAMRA desthiobiotin azide", "SIMPLE_CHEMICAL", 157, 182], ["BTTAA", "SIMPLE_CHEMICAL", 209, 214], ["copper sulfate", "SIMPLE_CHEMICAL", 223, 237], ["sodium ascorbate", "SIMPLE_CHEMICAL", 248, 264], ["Cells", "TEST", 0, 5], ["treatment", "TREATMENT", 38, 47], ["Covalent Protein Targets", "TREATMENT", 91, 115], ["Click chemistry", "TEST", 115, 130], ["100 \u00b5M Cy5 azide", "TREATMENT", 137, 153], ["TAMRA desthiobiotin azide", "TREATMENT", 157, 182], ["1.6 mM BTTAA", "TREATMENT", 202, 214], ["0.8 mM copper sulfate", "TREATMENT", 216, 237], ["5 mM sodium ascorbate", "TREATMENT", 243, 264], ["shaking", "PROBLEM", 285, 292], ["Covalent Protein Targets", "OBSERVATION", 91, 115]]], ["For detection, samples from Cy5 reactions were run directly on SDS-PAGE gels for analysis.Enrichment of Covalent Protein TargetsFor enrichment of proteins, excess reagents were removed via methanol/chloroform precipitation; protein was washed twice with methanol before resuspension in 6 M urea.Enrichment of Covalent Protein TargetsSamples were diluted in PBS and added to pre-washed (in PBS) streptavidin agarose beads (Thermo Scientific).", [["samples", "ANATOMY", 15, 22], ["methanol/chloroform", "CHEMICAL", 189, 208], ["methanol", "CHEMICAL", 254, 262], ["urea", "CHEMICAL", 290, 294], ["methanol", "CHEMICAL", 189, 197], ["chloroform", "CHEMICAL", 198, 208], ["methanol", "CHEMICAL", 254, 262], ["urea", "CHEMICAL", 290, 294], ["Cy5", "SIMPLE_CHEMICAL", 28, 31], ["methanol", "SIMPLE_CHEMICAL", 189, 197], ["chloroform", "SIMPLE_CHEMICAL", 198, 208], ["methanol", "SIMPLE_CHEMICAL", 254, 262], ["urea", "SIMPLE_CHEMICAL", 290, 294], ["streptavidin agarose beads", "SIMPLE_CHEMICAL", 394, 420], ["samples from Cy5 reactions", "TEST", 15, 41], ["SDS", "TEST", 63, 66], ["analysis", "TEST", 81, 89], ["Covalent Protein Targets", "TREATMENT", 104, 128], ["proteins", "PROBLEM", 146, 154], ["excess reagents", "TREATMENT", 156, 171], ["methanol/chloroform precipitation", "TREATMENT", 189, 222], ["protein", "TREATMENT", 224, 231], ["methanol", "TREATMENT", 254, 262], ["resuspension", "TREATMENT", 270, 282], ["Covalent Protein TargetsSamples", "TREATMENT", 309, 340], ["PBS", "TREATMENT", 357, 360], ["streptavidin agarose beads", "TREATMENT", 394, 420], ["Covalent Protein Targets", "OBSERVATION", 104, 128], ["Covalent Protein Targets", "OBSERVATION", 309, 333]]], ["Pulldowns were rotated for 1 hour at room temperature.Enrichment of Covalent Protein TargetsSupernatant was removed and beads were washed six times in PBS and 1% SDS.Enrichment of Covalent Protein TargetsSamples were eluted two times by incubation with 50 mM biotin, pH 7.2, in 1% SDS (PBS) for 10 minutes.Mass Spectrometry Sample PreparationProtein lysate from DENV infected and non-infected Huh7 cells (10 \u00b5g of protein as measured using Bio-Rad protein assay dye reagent) was aliquoted and purified using methanol/chloroform precipitation.", [["Huh7 cells", "ANATOMY", 393, 403], ["biotin", "CHEMICAL", 259, 265], ["DENV infected", "DISEASE", 362, 375], ["methanol/chloroform", "CHEMICAL", 508, 527], ["biotin", "CHEMICAL", 259, 265], ["methanol", "CHEMICAL", 508, 516], ["chloroform", "CHEMICAL", 517, 527], ["biotin", "SIMPLE_CHEMICAL", 259, 265], ["DENV", "ORGANISM", 362, 366], ["Huh7 cells", "CELL", 393, 403], ["methanol", "SIMPLE_CHEMICAL", 508, 516], ["chloroform", "SIMPLE_CHEMICAL", 517, 527], ["non-infected Huh7 cells", "CELL_LINE", 380, 403], ["DENV", "SPECIES", 362, 366], ["Enrichment of Covalent Protein TargetsSupernatant", "TREATMENT", 54, 103], ["beads", "TREATMENT", 120, 125], ["Covalent Protein Targets", "TREATMENT", 180, 204], ["Samples", "TEST", 204, 211], ["pH", "TEST", 267, 269], ["Mass Spectrometry", "TEST", 306, 323], ["Sample", "TEST", 324, 330], ["PreparationProtein", "TEST", 331, 349], ["lysate", "TEST", 350, 356], ["DENV infected", "PROBLEM", 362, 375], ["non-infected Huh7 cells", "PROBLEM", 380, 403], ["protein", "TEST", 414, 421], ["Bio-Rad protein assay dye reagent", "TREATMENT", 440, 473], ["methanol/chloroform precipitation", "TREATMENT", 508, 541], ["Covalent Protein", "OBSERVATION", 68, 84], ["Targets", "OBSERVATION_MODIFIER", 85, 92], ["Supernatant", "OBSERVATION_MODIFIER", 92, 103], ["beads", "OBSERVATION_MODIFIER", 120, 125], ["Covalent Protein", "OBSERVATION", 180, 196], ["DENV", "OBSERVATION_MODIFIER", 362, 366], ["infected", "OBSERVATION_MODIFIER", 367, 375], ["non-infected", "OBSERVATION_MODIFIER", 380, 392], ["Huh7 cells", "OBSERVATION", 393, 403]]], ["Streptavidin-enriched samples for target identification were used without normalization and purified by methanol/chloroform precipitation.", [["samples", "ANATOMY", 22, 29], ["Streptavidin", "CHEMICAL", 0, 12], ["methanol/chloroform", "CHEMICAL", 104, 123], ["methanol", "CHEMICAL", 104, 112], ["chloroform", "CHEMICAL", 113, 123], ["Streptavidin", "SIMPLE_CHEMICAL", 0, 12], ["samples", "CANCER", 22, 29], ["methanol", "SIMPLE_CHEMICAL", 104, 112], ["chloroform", "SIMPLE_CHEMICAL", 113, 123], ["Streptavidin", "TEST", 0, 12], ["target identification", "TEST", 34, 55], ["methanol/chloroform precipitation", "TREATMENT", 104, 137]]], ["Mass spectrometry samples were prepared as described previously (Blackwood et al., 2019) .Mass Spectrometry Sample PreparationBriefly, protein was resuspended in 3 \u00b5L 1% Rapigest (Waters) and diluted with water and 0.5 M HEPES.", [["HEPES", "CHEMICAL", 221, 226], ["Mass spectrometry samples", "TEST", 0, 25], ["protein", "TEST", 135, 142]]], ["Proteins were reduced with 5 mM TCEP (Thermo Scientific) andMass Spectrometry Sample Preparationsubsequently alkylated with 10 mM iodoacetamide (Sigma).", [["iodoacetamide", "CHEMICAL", 130, 143], ["TCEP", "CHEMICAL", 32, 36], ["iodoacetamide", "CHEMICAL", 130, 143], ["TCEP", "SIMPLE_CHEMICAL", 32, 36], ["iodoacetamide", "SIMPLE_CHEMICAL", 130, 143], ["Proteins", "TEST", 0, 8], ["5 mM TCEP", "TREATMENT", 27, 36], ["Mass Spectrometry Sample", "TREATMENT", 60, 84], ["10 mM iodoacetamide", "TREATMENT", 124, 143], ["reduced", "OBSERVATION_MODIFIER", 14, 21]]], ["Proteins were digested in sequencing-grade trypsin (Thermo Scientific) overnight at 37\u00baC while shaking at 750 rpm.Mass Spectrometry Sample PreparationPeptides were labeled for 1 hour at room temperature using 11-plex tandem mass tag (TMT) reagents (Thermo Scientific) resuspended in 40% acetonitrile.", [["acetonitrile", "CHEMICAL", 287, 299], ["acetonitrile", "CHEMICAL", 287, 299], ["trypsin", "GENE_OR_GENE_PRODUCT", 43, 50], ["acetonitrile", "SIMPLE_CHEMICAL", 287, 299], ["trypsin", "PROTEIN", 43, 50], ["Proteins", "TEST", 0, 8], ["sequencing", "TEST", 26, 36], ["grade trypsin", "PROBLEM", 37, 50], ["plex tandem mass tag", "TREATMENT", 212, 232], ["40% acetonitrile", "TREATMENT", 283, 299]]], ["Labeling reactions were quenched with 0.4% ammonium bicarbonate for 1 hour at room temperature.Mass Spectrometry Sample PreparationSamples were combined and acidified to pH 2 by addition of 5% formic acid.", [["ammonium bicarbonate", "CHEMICAL", 43, 63], ["formic acid", "CHEMICAL", 193, 204], ["ammonium bicarbonate", "CHEMICAL", 43, 63], ["formic acid", "CHEMICAL", 193, 204], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 43, 63], ["formic acid", "SIMPLE_CHEMICAL", 193, 204], ["Labeling reactions", "PROBLEM", 0, 18], ["0.4% ammonium bicarbonate", "TREATMENT", 38, 63], ["Mass Spectrometry", "TEST", 95, 112], ["Sample PreparationSamples", "TEST", 113, 138], ["pH", "TEST", 170, 172], ["5% formic acid", "TREATMENT", 190, 204]]], ["Pooled samples were concentrated using a SpeedVac and resuspended in 94.9% water/5% acetonitrile/0.1% formic acid.", [["samples", "ANATOMY", 7, 14], ["SpeedVac", "CHEMICAL", 41, 49], ["acetonitrile", "CHEMICAL", 84, 96], ["formic acid", "CHEMICAL", 102, 113], ["acetonitrile", "CHEMICAL", 84, 96], ["formic acid", "CHEMICAL", 102, 113], ["acetonitrile", "SIMPLE_CHEMICAL", 84, 96], ["formic acid", "SIMPLE_CHEMICAL", 102, 113], ["Pooled samples", "TEST", 0, 14], ["a SpeedVac", "TREATMENT", 39, 49], ["5% acetonitrile", "TREATMENT", 81, 96], ["formic acid", "TREATMENT", 102, 113]]], ["Rapigest cleavage products were pelleted by centrifugation at 14,000xg for 30 minutes.Mass Spectrometry Data AcquisitionDigested peptides (20 \u00b5g) were loaded onto a triphasic column filled sequentially with 1.5 or 2.5 cm layers of 5 \u00b5m 100 \u00c5 C18 resin (Phenomenex), Luna 5 \u00b5m 100 \u00c5 strong cation exchange resin (Phenomenex) and a second layer of C18 resin using a high pressure chamber (Fonslow et al., 2012Mass Spectrometry Data AnalysisPeptide and protein identification, and TMT reporter ion quantification was analyzed using Proteome Discover 2.4.", [["cation", "SIMPLE_CHEMICAL", 289, 295], ["Rapigest cleavage products", "TREATMENT", 0, 26], ["peptides", "TEST", 129, 137], ["Luna", "TEST", 266, 270], ["strong cation exchange resin (Phenomenex", "TREATMENT", 282, 322], ["a second layer of C18 resin", "TREATMENT", 328, 355], ["a high pressure chamber", "TREATMENT", 362, 385], ["AnalysisPeptide", "TEST", 430, 445], ["protein identification", "TEST", 450, 472], ["TMT reporter ion quantification", "TEST", 478, 509], ["Proteome Discover", "TEST", 529, 546], ["high", "OBSERVATION_MODIFIER", 364, 368], ["pressure chamber", "OBSERVATION", 369, 385]]], ["Searches were carried out with the SEQUEST node using a human proteome database (UniProt) with DENV proteins added manually and the following parameters: 20ppm precursor mass tolerance, minimum peptide length of 6 amino acids, trypsin cleavage with a maximum of 2 missed cleavages, static modifications of +57.0215Da (carbamidomethylation at C) and +229.1629 (TMT6/11plex), and dynamic modification of +15.995 (oxidation at M), N-terminal methionine loss (-131.040) , and Nterminal acetylation (+42.011).", [["amino acids", "CHEMICAL", 214, 225], ["methionine", "CHEMICAL", 439, 449], ["amino acids", "CHEMICAL", 214, 225], ["methionine", "CHEMICAL", 439, 449], ["Nterminal", "CHEMICAL", 472, 481], ["human", "ORGANISM", 56, 61], ["amino acids", "AMINO_ACID", 214, 225], ["trypsin", "GENE_OR_GENE_PRODUCT", 227, 234], ["methionine", "AMINO_ACID", 439, 449], ["Nterminal acetylation", "GENE_OR_GENE_PRODUCT", 472, 493], ["DENV proteins", "PROTEIN", 95, 108], ["trypsin", "PROTEIN", 227, 234], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["DENV proteins", "TREATMENT", 95, 108], ["precursor mass tolerance", "PROBLEM", 160, 184], ["6 amino acids", "TREATMENT", 212, 225], ["trypsin cleavage", "TREATMENT", 227, 243], ["N-terminal methionine loss", "PROBLEM", 428, 454], ["methionine loss", "OBSERVATION", 439, 454]]], ["Search results were filtered with Percolator using a decoy database of reversed sequences with a peptide false discovery rate of 1% and a minimum of 2 peptides for protein identification.", [["protein identification", "TEST", 164, 186]]], ["TMT intensities were quantified using the reporter ion quantification node with TMT intensities from each channel being normalized using the total peptide amount, quantitative value correction enabled to correct for TMT impurities, and co-isolation threshold set to 25%.", [["TMT intensities", "TEST", 0, 15], ["TMT intensities", "TEST", 80, 95], ["the total peptide amount", "TREATMENT", 137, 161], ["quantitative value correction", "PROBLEM", 163, 192], ["TMT impurities", "PROBLEM", 216, 230], ["co-isolation threshold", "TEST", 236, 258], ["node", "OBSERVATION", 70, 74]]], ["Intensities for each protein were A. Schematic overview of the UPR showing the three signaling branches: IRE1/XBP1s, PERK, and ATF6.", [["UPR", "GENE_OR_GENE_PRODUCT", 63, 66], ["IRE1", "GENE_OR_GENE_PRODUCT", 105, 109], ["XBP1s", "GENE_OR_GENE_PRODUCT", 110, 115], ["PERK", "GENE_OR_GENE_PRODUCT", 117, 121], ["ATF6", "GENE_OR_GENE_PRODUCT", 127, 131], ["UPR", "PROTEIN", 63, 66], ["IRE1", "PROTEIN", 105, 109], ["XBP1s", "PROTEIN", 110, 115], ["PERK", "PROTEIN", 117, 121], ["ATF6", "PROTEIN", 127, 131], ["each protein", "TEST", 16, 28], ["the UPR", "TEST", 59, 66], ["IRE1", "TEST", 105, 109], ["XBP1s", "TEST", 110, 115], ["PERK", "TEST", 117, 121], ["branches", "ANATOMY_MODIFIER", 95, 103]]], ["Prior work showed that DENV increased activity of the IRE1/Xbp1s and ATF6 branches, while simultaneously preventing activation of the PERK branch (Pena and Harris, 2011) .", [["DENV", "ORGANISM", 23, 27], ["IRE1", "GENE_OR_GENE_PRODUCT", 54, 58], ["Xbp1s", "GENE_OR_GENE_PRODUCT", 59, 64], ["ATF6", "GENE_OR_GENE_PRODUCT", 69, 73], ["PERK", "GENE_OR_GENE_PRODUCT", 134, 138], ["IRE1", "PROTEIN", 54, 58], ["Xbp1s", "PROTEIN", 59, 64], ["ATF6", "PROTEIN", 69, 73], ["PERK branch", "PROTEIN", 134, 145], ["DENV", "SPECIES", 23, 27], ["DENV", "PROBLEM", 23, 27], ["ATF6 branches", "TREATMENT", 69, 82], ["DENV", "OBSERVATION", 23, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["activity", "OBSERVATION_MODIFIER", 38, 46], ["branches", "ANATOMY_MODIFIER", 74, 82], ["branch", "ANATOMY_MODIFIER", 139, 145]]], ["B. Time course of qPCR data showing transcriptional upregulation of an IRE1/XBP1s target (ERdj4) and an ATF6 target (PDIA4) in response to DENV activation (MOI 3) in Huh7 cells.", [["Huh7 cells", "ANATOMY", 166, 176], ["IRE1", "GENE_OR_GENE_PRODUCT", 71, 75], ["XBP1s", "GENE_OR_GENE_PRODUCT", 76, 81], ["ERdj4", "GENE_OR_GENE_PRODUCT", 90, 95], ["ATF6", "GENE_OR_GENE_PRODUCT", 104, 108], ["PDIA4", "GENE_OR_GENE_PRODUCT", 117, 122], ["Huh7 cells", "CELL", 166, 176], ["IRE1", "PROTEIN", 71, 75], ["XBP1s target", "PROTEIN", 76, 88], ["ERdj4", "PROTEIN", 90, 95], ["ATF6 target", "DNA", 104, 115], ["PDIA4", "PROTEIN", 117, 122], ["Huh7 cells", "CELL_LINE", 166, 176], ["DENV", "SPECIES", 139, 143], ["qPCR data", "TEST", 18, 27], ["transcriptional upregulation", "PROBLEM", 36, 64], ["an IRE1", "TEST", 68, 75], ["an ATF6 target (PDIA4)", "TREATMENT", 101, 123], ["DENV activation", "PROBLEM", 139, 154], ["DENV activation", "OBSERVATION", 139, 154], ["Huh7 cells", "OBSERVATION", 166, 176]]], ["Error bars shows SEM from 2 to 3 biological replicates and pvalues from two-tailed unpaired student t-tests are displayed.", [["Error bars", "TEST", 0, 10], ["SEM", "TEST", 17, 20], ["SEM", "OBSERVATION_MODIFIER", 17, 20]]], ["C. Box plots of proteomics data showing the aggregate upregulation of IRE1/XBP1s and ATF6 protein targets at 24 and 36 hpi.", [["IRE1", "GENE_OR_GENE_PRODUCT", 70, 74], ["XBP1s", "GENE_OR_GENE_PRODUCT", 75, 80], ["ATF6", "GENE_OR_GENE_PRODUCT", 85, 89], ["IRE1", "PROTEIN", 70, 74], ["XBP1s", "PROTEIN", 75, 80], ["ATF6", "PROTEIN", 85, 89], ["Box plots", "TEST", 3, 12], ["proteomics data", "TEST", 16, 31], ["IRE1/XBP1s", "TREATMENT", 70, 80], ["ATF6 protein targets", "TEST", 85, 105]]], ["PERK and cytosolic heat-shock response (HSR) targets are not affected.", [["cytosolic", "ANATOMY", 9, 18], ["PERK", "GENE_OR_GENE_PRODUCT", 0, 4], ["cytosolic heat-shock response", "GENE_OR_GENE_PRODUCT", 9, 38], ["PERK", "PROTEIN", 0, 4], ["PERK", "TEST", 0, 4], ["cytosolic heat", "TEST", 9, 23], ["shock response", "PROBLEM", 24, 38], ["cytosolic heat", "OBSERVATION", 9, 23], ["shock response", "OBSERVATION", 24, 38]]], ["Huh7 cells were infected with DENV (MOI 3) for 24h or 36h.", [["Huh7 cells", "ANATOMY", 0, 10], ["Huh7 cells", "CELL", 0, 10], ["Huh7 cells", "CELL_LINE", 0, 10], ["DENV", "SPECIES", 30, 34], ["Huh7 cells", "PROBLEM", 0, 10], ["DENV", "PROBLEM", 30, 34]]], ["Genesets for UPR and HSR pathways were defined based on prior transcriptional profiles (Grandjean et al., 2019) . p-values from two-tailed Wilcoxon signed rank tests are indicated.", [["UPR", "GENE_OR_GENE_PRODUCT", 13, 16], ["HSR", "GENE_OR_GENE_PRODUCT", 21, 24], ["UPR", "PROTEIN", 13, 16], ["HSR", "PROTEIN", 21, 24], ["UPR and HSR pathways", "PROBLEM", 13, 33], ["p-values", "TEST", 114, 122], ["tailed Wilcoxon signed rank tests", "TEST", 132, 165]]], ["Cell-wide proteomics data comparing DENV infected to non-infected Huh7 cells is shown in Fig. S1B -C.Figure 1 -figure supplement 1.", [["Cell", "ANATOMY", 0, 4], ["Huh7 cells", "ANATOMY", 66, 76], ["DENV infected", "DISEASE", 36, 49], ["Cell", "CELL", 0, 4], ["DENV", "ORGANISM", 36, 40], ["Huh7 cells", "CELL", 66, 76], ["non-infected Huh7 cells", "CELL_LINE", 53, 76], ["DENV", "SPECIES", 36, 40], ["Cell", "TEST", 0, 4], ["DENV", "PROBLEM", 36, 40], ["non-infected Huh7 cells", "PROBLEM", 53, 76], ["S1B", "TEST", 94, 97], ["Huh7 cells", "OBSERVATION", 66, 76], ["Fig", "OBSERVATION_MODIFIER", 89, 92]]], ["DENV infection induces the UPR.A. Western Blot showing time course of ATF6 upregulation over the course of DENV infection.", [["DENV infection", "DISEASE", 0, 14], ["DENV infection", "DISEASE", 107, 121], ["DENV", "ORGANISM", 0, 4], ["ATF6", "GENE_OR_GENE_PRODUCT", 70, 74], ["DENV", "ORGANISM", 107, 111], ["UPR", "PROTEIN", 27, 30], ["ATF6", "PROTEIN", 70, 74], ["DENV", "SPECIES", 0, 4], ["DENV", "SPECIES", 107, 111], ["DENV infection", "PROBLEM", 0, 14], ["ATF6 upregulation", "TREATMENT", 70, 87], ["DENV infection", "PROBLEM", 107, 121], ["infection", "OBSERVATION", 5, 14], ["DENV", "OBSERVATION_MODIFIER", 107, 111], ["infection", "OBSERVATION", 112, 121]]], ["Cells were infected with DENV-2 strain BID-V533 at MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DENV-2", "ORGANISM", 25, 31], ["DENV-2 strain BID-V533", "SPECIES", 25, 47], ["DENV", "PROBLEM", 25, 29]]], ["Media was replaced and samples were taken at indicated timepoints postinfection.", [["samples", "ANATOMY", 23, 30], ["samples", "TEST", 23, 30]]], ["Cells were lysed, and protein samples were run on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 85, 99], ["PVDF", "CHEMICAL", 85, 89], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 50, 53], ["PVDF membranes", "TREATMENT", 85, 99], ["PVDF membranes", "OBSERVATION", 85, 99]]], ["Actin is included as a loading control.Figure 1 -figure supplement 1.", [["Actin", "GENE_OR_GENE_PRODUCT", 0, 5], ["Actin", "PROTEIN", 0, 5], ["a loading control", "TREATMENT", 21, 38]]], ["DENV infection induces the UPR.B.-C. Waterfall plots of proteomics data from samples infected with DENV-2 for 24 hours (B.) and 36 hours (C.), showing the presence of DENV proteins and upregulation of IRE1/XBP1s, ATF6, and PERK branches of the UPR.", [["samples", "ANATOMY", 77, 84], ["DENV infection", "DISEASE", 0, 14], ["DENV", "ORGANISM", 0, 4], ["DENV-2", "ORGANISM", 99, 105], ["DENV", "ORGANISM", 167, 171], ["IRE1", "GENE_OR_GENE_PRODUCT", 201, 205], ["XBP1s", "GENE_OR_GENE_PRODUCT", 206, 211], ["ATF6", "GENE_OR_GENE_PRODUCT", 213, 217], ["PERK", "GENE_OR_GENE_PRODUCT", 223, 227], ["UPR", "GENE_OR_GENE_PRODUCT", 244, 247], ["UPR", "PROTEIN", 27, 30], ["DENV proteins", "PROTEIN", 167, 180], ["IRE1", "PROTEIN", 201, 205], ["XBP1s", "PROTEIN", 206, 211], ["ATF6", "PROTEIN", 213, 217], ["PERK branches", "PROTEIN", 223, 236], ["UPR", "PROTEIN", 244, 247], ["DENV", "SPECIES", 0, 4], ["DENV-2", "SPECIES", 99, 105], ["DENV", "SPECIES", 167, 171], ["DENV infection", "PROBLEM", 0, 14], ["proteomics data", "TEST", 56, 71], ["DENV", "PROBLEM", 99, 103], ["DENV proteins", "PROBLEM", 167, 180], ["IRE1", "TEST", 201, 205], ["XBP1s", "TEST", 206, 211], ["ATF6", "TEST", 213, 217], ["infection", "OBSERVATION", 5, 14], ["DENV", "OBSERVATION", 167, 171], ["PERK", "OBSERVATION", 223, 227], ["branches", "ANATOMY_MODIFIER", 228, 236], ["UPR", "ANATOMY_MODIFIER", 244, 247]]], ["Cells were infected with DENV-2 strain BID-V533 at a MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DENV-2", "ORGANISM", 25, 31], ["DENV-2 strain BID-V533", "SPECIES", 25, 47], ["DENV", "PROBLEM", 25, 29]]], ["Media was replaced and samples were collected at 24 or 36 hpi.", [["samples", "ANATOMY", 23, 30], ["samples", "TEST", 23, 30]]], ["Gene upregulation was quantified using TMT11plex reagents and comparison is between DENV-infected cells vs. noninfected cells.", [["cells", "ANATOMY", 98, 103], ["cells", "ANATOMY", 120, 125], ["DENV-infected", "DISEASE", 84, 97], ["DENV", "ORGANISM", 84, 88], ["cells", "CELL", 98, 103], ["cells", "CELL", 120, 125], ["noninfected cells", "CELL_TYPE", 108, 125], ["Gene upregulation", "PROBLEM", 0, 17], ["TMT11plex reagents", "TREATMENT", 39, 57], ["DENV", "PROBLEM", 84, 88], ["infected cells", "PROBLEM", 89, 103], ["noninfected cells", "PROBLEM", 108, 125], ["infected cells", "OBSERVATION", 89, 103], ["cells", "OBSERVATION", 120, 125]]], ["Source data is included in Table S1 .", [["Source data", "TEST", 0, 11], ["S1", "ANATOMY", 33, 35]]], ["Media and treatments were replaced, and viability was measured 24hpi using the Promega Cell Titer Glo reagent.", [["treatments", "TREATMENT", 10, 20], ["the Promega Cell Titer Glo reagent", "TREATMENT", 75, 109]]], ["Graphs represent six independent biological replicates across two days of measurement.", [["six", "OBSERVATION_MODIFIER", 17, 20]]], ["Error bars represent SEM.", [["SEM", "OBSERVATION", 21, 24]]], ["B. A dose-response curve shows DENV is sensitive to 147 treatment with an IC50 of approximately 1 \u00b5M.", [["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["DENV", "ORGANISM", 31, 35], ["DENV", "SPECIES", 31, 35], ["response curve", "TEST", 10, 24], ["DENV", "PROBLEM", 31, 35], ["an IC50", "TREATMENT", 71, 78], ["DENV", "OBSERVATION", 31, 35]]], ["Cells were treated with the indicated concentrations of 147 for 16 hours, then infected with DENV-2 strain BID-V533 at a MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["BID-V533", "CHEMICAL", 107, 115], ["Cells", "CELL", 0, 5], ["DENV-2", "ORGANISM", 93, 99], ["BID-V533", "SIMPLE_CHEMICAL", 107, 115], ["DENV-2 strain BID-V533", "SPECIES", 93, 115], ["DENV", "PROBLEM", 93, 97]]], ["Media and treatments were replaced, and cells were collected 24 hpi.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["treatments", "TREATMENT", 10, 20]]], ["Cells were lysed, and protein samples were run on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 85, 99], ["PVDF", "CHEMICAL", 85, 89], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 50, 53], ["PVDF membranes", "TREATMENT", 85, 99], ["PVDF membranes", "OBSERVATION", 85, 99]]], ["Western blot intensities were normalized to a GAPDH loading control.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 46, 51], ["GAPDH", "PROTEIN", 46, 51], ["Western blot intensities", "PROBLEM", 0, 24], ["a GAPDH loading control", "TREATMENT", 44, 67]]], ["Graphs represent 2-4 independent biological replicates.", [["Graphs", "TEST", 0, 6]]], ["Error bars represent SEM.", [["SEM", "OBSERVATION", 21, 24]]], ["C. Increasing 147 concentration causes decreasing cell viability.", [["cell", "ANATOMY", 50, 54], ["cell", "CELL", 50, 54], ["decreasing cell viability", "PROBLEM", 39, 64], ["Increasing", "OBSERVATION_MODIFIER", 3, 13], ["147 concentration", "OBSERVATION_MODIFIER", 14, 31], ["decreasing cell viability", "OBSERVATION", 39, 64]]], ["No decrease in viability was seen with 147-4 or Ceapin-A7 (Cp7).", [["Ceapin-A7", "SIMPLE_CHEMICAL", 48, 57], ["Cp7", "SIMPLE_CHEMICAL", 59, 62], ["decrease in viability", "PROBLEM", 3, 24], ["Ceapin", "TEST", 48, 54], ["decrease", "OBSERVATION_MODIFIER", 3, 11], ["viability", "OBSERVATION_MODIFIER", 15, 24]]], ["Cells were pretreated with the indicated concentrations of 147 for 16h, then infected (where indicated) with DENV-2 strain BID-V533 at a MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DENV-2", "ORGANISM", 109, 115], ["BID-V533", "SIMPLE_CHEMICAL", 123, 131], ["DENV-2 strain BID-V533", "SPECIES", 109, 131], ["DENV", "PROBLEM", 109, 113]]], ["Media and treatments were replaced, and viability was measured 24 hpi using the Promega Cell Titer Glo reagent.", [["treatments", "TREATMENT", 10, 20], ["the Promega Cell Titer Glo reagent", "TREATMENT", 76, 110]]], ["Error bars represent SEM.", [["SEM", "OBSERVATION", 21, 24]]], ["D. Representative western blot showing 147 attenuates DENV protein levels.", [["DENV", "ORGANISM", 54, 58], ["DENV protein", "PROTEIN", 54, 66], ["DENV", "SPECIES", 54, 58], ["western blot", "TEST", 18, 30], ["DENV protein levels", "TEST", 54, 73]]], ["Cells were pretreated with 10 \u00b5M 147, 6 \u00b5M Cp7, or both for 16h, then infected with DENV-2 strain BID-V533 at MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cp7", "SIMPLE_CHEMICAL", 43, 46], ["DENV-2", "ORGANISM", 84, 90], ["BID-V533", "SIMPLE_CHEMICAL", 98, 106], ["DENV-2 strain BID-V533", "SPECIES", 84, 106], ["DENV", "PROBLEM", 84, 88], ["DENV", "OBSERVATION", 84, 88]]], ["Media and treatments were replaced, and cells were collected at indicated timepoints.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["Media", "TREATMENT", 0, 5], ["treatments", "TREATMENT", 10, 20]]], ["Cells were lysed, and protein samples were run on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 85, 99], ["PVDF", "CHEMICAL", 85, 89], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 50, 53], ["PVDF membranes", "TREATMENT", 85, 99], ["PVDF membranes", "OBSERVATION", 85, 99]]], ["GAPDH is included as a loading control.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["GAPDH", "PROBLEM", 0, 5], ["a loading control", "TREATMENT", 21, 38]]], ["No visualization of DENV protein could be seen at 12 hpi.", [["DENV", "ORGANISM", 20, 24], ["DENV protein", "PROTEIN", 20, 32], ["DENV", "SPECIES", 20, 24], ["DENV protein", "PROBLEM", 20, 32], ["DENV", "OBSERVATION", 20, 24]]], ["Cells are only treated post-infection with 10 \u00b5M 147, and focus forming units are quantified 24 hpi.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["F. Quantification of western blots with treatment only post-entry shows similar phenotype to treatment pre-and post-entry.", [["treatment", "TREATMENT", 40, 49]]], ["Cells were only treated post-infection with 10 \u00b5M 147, and cells were harvested 24 hpi.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 59, 64], ["Cells", "CELL", 0, 5], ["cells", "CELL", 59, 64]]], ["Cells were lysed, and protein samples were run on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 85, 99], ["PVDF", "CHEMICAL", 85, 89], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 50, 53], ["PVDF membranes", "TREATMENT", 85, 99], ["PVDF membranes", "OBSERVATION", 85, 99]]], ["Normalization to GAPDH was included as a loading control.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 17, 22], ["GAPDH", "PROTEIN", 17, 22], ["GAPDH", "TEST", 17, 22], ["a loading control", "TREATMENT", 39, 56]]], ["Error bars represent SEM and p-value from an unpaired t-test is shown.", [["p-value", "TEST", 29, 36], ["an unpaired t-test", "TEST", 42, 60], ["SEM", "OBSERVATION_MODIFIER", 21, 24]]], ["G. Graph showing reduction in viral titers for only post-entry treatment.", [["G", "GENE_OR_GENE_PRODUCT", 0, 1], ["Graph", "TEST", 3, 8], ["reduction in viral titers", "PROBLEM", 17, 42], ["entry treatment", "TREATMENT", 57, 72], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["viral titers", "OBSERVATION", 30, 42]]], ["Cells were treated as in E-F and viral titers were determined by focus forming assay.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["E-F", "SIMPLE_CHEMICAL", 25, 28], ["viral", "ORGANISM", 33, 38], ["viral titers", "TEST", 33, 45]]], ["Error bars represent SEM and p-value from a ratio paired t-test is shown.Figure 3 -(with 1 supplement).", [["SEM", "TEST", 21, 24], ["p-value", "TEST", 29, 36], ["a ratio paired t-test", "TEST", 42, 63], ["Figure", "TEST", 73, 79], ["SEM", "OBSERVATION_MODIFIER", 21, 24]]], ["ATF6 inhibition does not attenuate the 147mediated reduction in DENV replication.A. Ceapin-A7 (Cp7) acts as an ATF6 inhibitor downstream of 147 by tethering inactive ATF6 to the peroxisomal membrane protein ABCD3 preventing ATF6 trafficking to the Golgi and activation through S1/S2 cleavage.", [["peroxisomal membrane", "ANATOMY", 178, 198], ["Golgi", "ANATOMY", 248, 253], ["Cp7", "CHEMICAL", 95, 98], ["ATF6", "GENE_OR_GENE_PRODUCT", 0, 4], ["DENV", "ORGANISM", 64, 68], ["Ceapin-A7", "GENE_OR_GENE_PRODUCT", 84, 93], ["Cp7", "GENE_OR_GENE_PRODUCT", 95, 98], ["ATF6", "GENE_OR_GENE_PRODUCT", 111, 115], ["ATF6", "GENE_OR_GENE_PRODUCT", 166, 170], ["peroxisomal membrane", "CELLULAR_COMPONENT", 178, 198], ["ABCD3", "GENE_OR_GENE_PRODUCT", 207, 212], ["ATF6", "GENE_OR_GENE_PRODUCT", 224, 228], ["Golgi", "CELLULAR_COMPONENT", 248, 253], ["S2", "GENE_OR_GENE_PRODUCT", 280, 282], ["ATF6", "PROTEIN", 0, 4], ["ATF6", "PROTEIN", 111, 115], ["ATF6", "PROTEIN", 166, 170], ["peroxisomal membrane protein", "PROTEIN", 178, 206], ["ABCD3", "PROTEIN", 207, 212], ["ATF6", "PROTEIN", 224, 228], ["S1", "PROTEIN", 277, 279], ["S2", "PROTEIN", 280, 282], ["DENV", "SPECIES", 64, 68], ["A. Ceapin-A7", "SPECIES", 81, 93], ["the 147mediated reduction", "TREATMENT", 35, 60], ["DENV replication", "TREATMENT", 64, 80], ["Ceapin", "TEST", 84, 90], ["an ATF6 inhibitor downstream", "TEST", 108, 136], ["ATF6 trafficking", "TREATMENT", 224, 240], ["S1/S2 cleavage", "TREATMENT", 277, 291], ["DENV replication", "OBSERVATION", 64, 80], ["S2", "ANATOMY", 280, 282]]], ["B. Bar graph showing the reduction in vRNA levels in response to 147 and Cp7 treatment measured by qPCR in Huh7 cells infected with DENV as outlined in Fig. 2D .", [["Huh7 cells", "ANATOMY", 107, 117], ["Cp7", "CHEMICAL", 73, 76], ["Cp7", "CHEMICAL", 73, 76], ["Cp7", "SIMPLE_CHEMICAL", 73, 76], ["Huh7 cells", "CELL", 107, 117], ["DENV", "ORGANISM", 132, 136], ["Huh7 cells", "CELL_LINE", 107, 117], ["DENV", "SPECIES", 132, 136], ["Bar graph", "TEST", 3, 12], ["the reduction", "PROBLEM", 21, 34], ["vRNA levels", "TEST", 38, 49], ["Cp7 treatment", "TREATMENT", 73, 86], ["DENV", "PROBLEM", 132, 136], ["reduction", "OBSERVATION_MODIFIER", 25, 34], ["vRNA levels", "OBSERVATION", 38, 49], ["DENV", "OBSERVATION", 132, 136]]], ["Cp7 does not attenuate the 147-mediate reduction.", [["Cp7", "CHEMICAL", 0, 3], ["Cp7", "CHEMICAL", 0, 3], ["Cp7", "SIMPLE_CHEMICAL", 0, 3], ["the 147-mediate reduction", "TREATMENT", 23, 48], ["reduction", "OBSERVATION_MODIFIER", 39, 48]]], ["Error bars correspond to SEM from 3 biological replicates and p-values from unpaired t-tests are shown.", [["Error bars", "PROBLEM", 0, 10], ["SEM", "TEST", 25, 28], ["p-values from unpaired t-tests", "TEST", 62, 92]]], ["C. Bar graph showing the reduction in NS3 viral protein levels in response to 147 and Cp7 treatment measured by Western blot in Huh7 cells infected with DENV as outlined in Fig. 2D .", [["Huh7 cells", "ANATOMY", 128, 138], ["Cp7", "CHEMICAL", 86, 89], ["Cp7", "CHEMICAL", 86, 89], ["Cp7", "SIMPLE_CHEMICAL", 86, 89], ["Huh7 cells", "CELL", 128, 138], ["DENV", "ORGANISM", 153, 157], ["NS3 viral protein", "PROTEIN", 38, 55], ["Huh7 cells", "CELL_LINE", 128, 138], ["DENV", "SPECIES", 153, 157], ["Bar graph", "TEST", 3, 12], ["the reduction", "PROBLEM", 21, 34], ["NS3 viral protein levels", "TEST", 38, 62], ["Cp7 treatment", "TREATMENT", 86, 99], ["DENV", "PROBLEM", 153, 157], ["reduction", "OBSERVATION_MODIFIER", 25, 34], ["DENV", "OBSERVATION", 153, 157]]], ["Cp7 does not attenuate the 147-mediate reduction.", [["Cp7", "CHEMICAL", 0, 3], ["Cp7", "CHEMICAL", 0, 3], ["Cp7", "SIMPLE_CHEMICAL", 0, 3], ["the 147-mediate reduction", "TREATMENT", 23, 48], ["reduction", "OBSERVATION_MODIFIER", 39, 48]]], ["Error bars correspond to SEM from 3 biological replicates and p-values from unpaired t-tests are shown.", [["Error bars", "PROBLEM", 0, 10], ["SEM", "TEST", 25, 28], ["p-values from unpaired t-tests", "TEST", 62, 92]]], ["D. Bar graph showing the reduction in DENV viral titers in response to 147 and Cp7 treatment in Huh7 cells infected with DENV as outlined in Fig. 2D A. Schematic outlining the metabolic activation mechanisms of 147.", [["Huh7 cells", "ANATOMY", 96, 106], ["Cp7", "CHEMICAL", 79, 82], ["Cp7", "CHEMICAL", 79, 82], ["DENV", "ORGANISM", 38, 42], ["Cp7", "SIMPLE_CHEMICAL", 79, 82], ["Huh7 cells", "CELL", 96, 106], ["DENV", "ORGANISM", 121, 125], ["Huh7 cells", "CELL_LINE", 96, 106], ["DENV", "SPECIES", 38, 42], ["DENV", "SPECIES", 121, 125], ["Bar graph", "TEST", 3, 12], ["the reduction", "PROBLEM", 21, 34], ["DENV viral titers", "PROBLEM", 38, 55], ["Cp7 treatment", "TREATMENT", 79, 92], ["Huh7 cells", "TREATMENT", 96, 106], ["DENV", "PROBLEM", 121, 125], ["reduction", "OBSERVATION_MODIFIER", 25, 34], ["DENV", "OBSERVATION_MODIFIER", 38, 42], ["viral titers", "OBSERVATION", 43, 55], ["DENV", "OBSERVATION", 121, 125], ["metabolic activation", "OBSERVATION", 176, 196]]], ["After oxidation by P450 enzymes, the generated p-quinone methide can react with thiol nucleophiles such as cysteine residues on cellular protein targets.", [["cellular", "ANATOMY", 128, 136], ["p-quinone methide", "CHEMICAL", 47, 64], ["thiol nucleophiles", "CHEMICAL", 80, 98], ["cysteine", "CHEMICAL", 107, 115], ["p-quinone methide", "CHEMICAL", 47, 64], ["thiol", "CHEMICAL", 80, 85], ["cysteine", "CHEMICAL", 107, 115], ["P450 enzymes", "GENE_OR_GENE_PRODUCT", 19, 31], ["p-quinone methide", "SIMPLE_CHEMICAL", 47, 64], ["thiol nucleophiles", "SIMPLE_CHEMICAL", 80, 98], ["cysteine", "AMINO_ACID", 107, 115], ["cellular", "CELL", 128, 136], ["P450 enzymes", "PROTEIN", 19, 31], ["cellular protein targets", "PROTEIN", 128, 152], ["P450 enzymes", "TEST", 19, 31], ["the generated p-quinone methide", "TREATMENT", 33, 64], ["thiol nucleophiles", "TREATMENT", 80, 98], ["cysteine residues", "TREATMENT", 107, 124], ["cellular protein targets", "TREATMENT", 128, 152]]], ["Addition of exogenous free thiols such as 2-mercaptoethanol (BME) can quench the active form of 147 before it reacts with protein targets.", [["thiols", "CHEMICAL", 27, 33], ["2-mercaptoethanol", "CHEMICAL", 42, 59], ["BME", "CHEMICAL", 61, 64], ["thiols", "CHEMICAL", 27, 33], ["2-mercaptoethanol", "CHEMICAL", 42, 59], ["BME", "CHEMICAL", 61, 64], ["free thiols", "SIMPLE_CHEMICAL", 22, 33], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 42, 59], ["BME", "SIMPLE_CHEMICAL", 61, 64], ["exogenous free thiols", "TREATMENT", 12, 33], ["2-mercaptoethanol (BME)", "TREATMENT", 42, 65], ["protein targets", "TEST", 122, 137]]], ["B. Graph showing reduction in DENV NS3 and NS5 protein levels in response to 147 treatment and addition of BME.", [["BME", "CHEMICAL", 107, 110], ["DENV NS3", "ORGANISM", 30, 38], ["NS5", "GENE_OR_GENE_PRODUCT", 43, 46], ["DENV NS3", "PROTEIN", 30, 38], ["NS5 protein", "PROTEIN", 43, 54], ["DENV", "SPECIES", 30, 34], ["B. Graph", "TEST", 0, 8], ["DENV NS3", "TREATMENT", 30, 38], ["NS5 protein levels", "TEST", 43, 61], ["treatment", "TREATMENT", 81, 90], ["BME", "PROBLEM", 107, 110], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["DENV NS3", "OBSERVATION", 30, 38]]], ["Huh7 cells were pretreated with 147 and or 55\u00b5M BME 16 hours prior to DENV infection (MOI 3).", [["Huh7 cells", "ANATOMY", 0, 10], ["DENV infection", "DISEASE", 70, 84], ["Huh7 cells", "CELL", 0, 10], ["Huh7 cells", "CELL_LINE", 0, 10], ["DENV", "SPECIES", 70, 74], ["Huh7 cells", "PROBLEM", 0, 10], ["DENV infection", "PROBLEM", 70, 84], ["infection", "OBSERVATION", 75, 84]]], ["Protein levels were quantified by Western blot.", [["Protein levels", "TEST", 0, 14]]], ["Error bars show SEM and p-values from unpaired t-tests are shown.", [["Error bars", "TEST", 0, 10], ["SEM", "TEST", 16, 19], ["p-values", "TEST", 24, 32], ["unpaired t-tests", "TEST", 38, 54], ["SEM", "OBSERVATION_MODIFIER", 16, 19]]], ["C. Bar graph showing DENV viral titer levels in response to 147 treatment and rescue through addition of BME.", [["BME", "CHEMICAL", 105, 108], ["DENV", "SPECIES", 21, 25], ["Bar graph", "TEST", 3, 12], ["DENV viral titer levels", "PROBLEM", 21, 44], ["treatment", "TREATMENT", 64, 73], ["BME", "PROBLEM", 105, 108], ["DENV", "OBSERVATION", 21, 25], ["viral titer", "OBSERVATION", 26, 37]]], ["Huh7 cells were pretreated with 147 and or 55\u00b5M BME A. Western blot data showing BME does not reduce DENV propagation in Huh7 cells.", [["Huh7 cells", "ANATOMY", 0, 10], ["Huh7 cells", "ANATOMY", 121, 131], ["BME", "CHEMICAL", 81, 84], ["Huh7 cells", "CELL", 0, 10], ["Huh7 cells", "CELL", 121, 131], ["Huh7 cells", "CELL_LINE", 0, 10], ["Huh7 cells", "CELL_LINE", 121, 131], ["DENV", "SPECIES", 101, 105], ["Huh7 cells", "PROBLEM", 0, 10], ["blot data", "TEST", 63, 72], ["BME", "PROBLEM", 81, 84], ["DENV propagation in Huh7 cells", "PROBLEM", 101, 131], ["Huh7 cells", "OBSERVATION", 121, 131]]], ["Cells were pretreated for 16h, then infected (where indicated) with DENV-2 strain BID-V533 at MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DENV-2", "ORGANISM", 68, 74], ["BID-V533", "SIMPLE_CHEMICAL", 82, 90], ["DENV-2 strain BID-V533", "SPECIES", 68, 90], ["DENV", "PROBLEM", 68, 72]]], ["Media and treatments were replaced, and cells were collected 24hpi.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["treatments", "TREATMENT", 10, 20]]], ["Cells were lysed, and protein samples were run out on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 89, 103], ["PVDF", "CHEMICAL", 89, 93], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 94, 103], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 54, 57], ["PVDF membranes", "TREATMENT", 89, 103]]], ["B. Cell viability data showing 147/BME treatment only modestly affects Huh7 cell viability over the course of treatment.", [["Cell", "ANATOMY", 3, 7], ["Huh7 cell", "ANATOMY", 71, 80], ["BME", "CHEMICAL", 35, 38], ["Cell", "CELL", 3, 7], ["Huh7 cell", "CELL", 71, 80], ["Huh7 cell", "CELL_LINE", 71, 80], ["B. Cell viability data", "TEST", 0, 22], ["BME treatment", "TREATMENT", 35, 48], ["Huh7 cell viability", "PROBLEM", 71, 90], ["treatment", "TREATMENT", 110, 119], ["Cell viability", "OBSERVATION", 3, 17], ["Huh7 cell viability", "OBSERVATION", 71, 90]]], ["Cells were pretreated for 16h, then infected (where indicated) with DENV-2 strain BID-V533 at MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["DENV-2", "ORGANISM", 68, 74], ["BID-V533", "SIMPLE_CHEMICAL", 82, 90], ["DENV-2 strain BID-V533", "SPECIES", 68, 90], ["DENV", "PROBLEM", 68, 72]]], ["Media and treatments were replaced, and viability was measured 24hpi using the Promega Cell Titer Glo reagent.", [["treatments", "TREATMENT", 10, 20], ["the Promega Cell Titer Glo reagent", "TREATMENT", 75, 109]]], ["Graphs represent three to six biological replicates.", [["Graphs", "TEST", 0, 6]]], ["Error bars represent SEM.Figure 5 -(with 1 supplement).", [["SEM", "OBSERVATION", 21, 24]]], ["Modification of individual protein disulfide isomerases by 147 is not sufficient to reduce viral infection.A. Illustration of the chemoproteomic workflow for target identification using chemical derivatives of 147.", [["viral infection", "DISEASE", 91, 106], ["disulfide", "CHEMICAL", 35, 44], ["protein disulfide isomerases", "GENE_OR_GENE_PRODUCT", 27, 55], ["protein disulfide isomerases", "PROTEIN", 27, 55], ["individual protein disulfide isomerases", "TEST", 16, 55], ["viral infection", "PROBLEM", 91, 106], ["the chemoproteomic workflow", "TREATMENT", 126, 153], ["chemical derivatives", "TREATMENT", 186, 206], ["infection", "OBSERVATION", 97, 106]]], ["Cells are treated with 147-20, an alkyne analog of 147 which retains activity and can covalently label proteins as outlined in Fig. 4A .", [["Cells", "ANATOMY", 0, 5], ["alkyne", "CHEMICAL", 34, 40], ["Cells", "CELL", 0, 5], ["147-20", "SIMPLE_CHEMICAL", 23, 29], ["alkyne", "SIMPLE_CHEMICAL", 34, 40], ["an alkyne analog", "TEST", 31, 47]]], ["The alkyne handle enables derivatization with either a fluorophore or biotin azide for detection or affinity purification of protein targets.", [["biotin azide", "CHEMICAL", 70, 82], ["alkyne", "CHEMICAL", 4, 10], ["biotin azide", "CHEMICAL", 70, 82], ["alkyne", "SIMPLE_CHEMICAL", 4, 10], ["biotin azide", "SIMPLE_CHEMICAL", 70, 82], ["derivatization", "TREATMENT", 26, 40], ["a fluorophore", "TREATMENT", 53, 66], ["biotin azide", "TREATMENT", 70, 82], ["affinity purification of protein targets", "PROBLEM", 100, 140]]], ["B. Fluorescence SDS-PAGE image identifying proteins labeled by 147-20 in Huh7 cells.", [["Huh7 cells", "ANATOMY", 73, 83], ["Huh7 cells", "CELL", 73, 83], ["Huh7 cells", "CELL_LINE", 73, 83], ["Fluorescence SDS", "TEST", 3, 19], ["proteins", "TEST", 43, 51]]], ["Huh7 cells were treated with 147-20 (3\u00b5M) and 3-fold excess competitor (active 147, or inactive 147-4) for 18 hours.", [["Huh7 cells", "ANATOMY", 0, 10], ["Huh7 cells", "CELL", 0, 10], ["Huh7 cells", "CELL_LINE", 0, 10], ["Huh7 cells", "TEST", 0, 10]]], ["Labeled proteins in cell lysates were derivatized with a TAMRA-desthiobiotin azide, proteins resolved on SDS-PAGE and a fluorescence image of the gel is shown.", [["cell lysates", "ANATOMY", 20, 32], ["TAMRA-desthiobiotin azide", "CHEMICAL", 57, 82], ["TAMRA-desthiobiotin azide", "CHEMICAL", 57, 82], ["cell lysates", "ORGANISM_SUBSTANCE", 20, 32], ["TAMRA-desthiobiotin azide", "SIMPLE_CHEMICAL", 57, 82], ["Labeled proteins in cell lysates", "PROBLEM", 0, 32], ["a TAMRA", "TREATMENT", 55, 62], ["desthiobiotin azide", "TREATMENT", 63, 82], ["SDS", "TEST", 105, 108], ["a fluorescence image", "TEST", 118, 138], ["cell lysates", "OBSERVATION", 20, 32]]], ["The pattern of labeled proteins reveals similar targets as seen in other cell lines .", [["cell lines", "ANATOMY", 73, 83], ["cell lines", "CELL", 73, 83], ["labeled proteins", "PROTEIN", 15, 31], ["cell lines", "CELL_LINE", 73, 83], ["labeled proteins", "TEST", 15, 31], ["similar targets", "OBSERVATION", 40, 55], ["cell lines", "OBSERVATION", 73, 83]]], ["The location of PDIA4, PDIA6, and PDIA1/P4HB is indicated.", [["PDIA4", "GENE_OR_GENE_PRODUCT", 16, 21], ["PDIA6", "GENE_OR_GENE_PRODUCT", 23, 28], ["PDIA1", "GENE_OR_GENE_PRODUCT", 34, 39], ["P4HB", "GENE_OR_GENE_PRODUCT", 40, 44], ["PDIA4", "PROTEIN", 16, 21], ["PDIA6", "PROTEIN", 23, 28], ["PDIA1", "PROTEIN", 34, 39], ["P4HB", "PROTEIN", 40, 44], ["PDIA6", "TREATMENT", 23, 28], ["PDIA1/P4HB", "TREATMENT", 34, 44]]], ["Fig. S5C shows images of Western blot overlays probing for individual PDI targets.", [["PDI", "GENE_OR_GENE_PRODUCT", 70, 73], ["S5C", "DNA", 5, 8], ["PDI", "PROTEIN", 70, 73], ["individual PDI targets", "TEST", 59, 81]]], ["C. A. Illustration of the workflow for the chemoproteomic target identification.", [["C. A.", "SPECIES", 0, 5], ["the chemoproteomic target identification", "TEST", 39, 79]]], ["Huh7 cells were treated with 3\u00b5M 147-20 alone or in competition with 9\u00b5M 147 for 18 hours.", [["Huh7 cells", "ANATOMY", 0, 10], ["3\u00b5M 147-20", "CHEMICAL", 29, 39], ["Huh7 cells", "CELL", 0, 10], ["Huh7 cells", "CELL_LINE", 0, 10], ["Huh7 cells", "TREATMENT", 0, 10]]], ["Cell lysates were labeled with a TAMRA-desthiobiotin probe, labeled proteins were isolated on streptavidin beads, eluted and digested with trypsin.", [["Cell lysates", "ANATOMY", 0, 12], ["TAMRA", "CHEMICAL", 33, 38], ["TAMRA", "CHEMICAL", 33, 38], ["Cell lysates", "ORGANISM_SUBSTANCE", 0, 12], ["TAMRA", "SIMPLE_CHEMICAL", 33, 38], ["desthiobiotin", "SIMPLE_CHEMICAL", 39, 52], ["streptavidin", "GENE_OR_GENE_PRODUCT", 94, 106], ["trypsin", "GENE_OR_GENE_PRODUCT", 139, 146], ["TAMRA-desthiobiotin probe", "DNA", 33, 58], ["trypsin", "PROTEIN", 139, 146], ["Cell lysates", "TEST", 0, 12], ["a TAMRA-desthiobiotin probe", "TREATMENT", 31, 58], ["streptavidin beads", "TREATMENT", 94, 112], ["trypsin", "TREATMENT", 139, 146]]], ["Individual samples were then labeled with tandem mass tags, pooled and subjected to LC-MS/MS for identification of proteins and quantitative comparison of proteins in the 147-20 treated compared to the 147-20/147 competition.", [["samples", "ANATOMY", 11, 18], ["Individual samples", "TEST", 0, 18], ["tandem mass tags", "PROBLEM", 42, 58], ["LC", "TEST", 84, 86], ["MS", "PROBLEM", 90, 92], ["proteins", "PROBLEM", 115, 123], ["proteins", "TEST", 155, 163]]], ["B. Graph showing the most highly enriched proteins targets in the 147-20 treated samples compared to the competition with 147.", [["samples", "ANATOMY", 81, 88], ["B. Graph", "TEST", 0, 8]]], ["The full data is shown in Fig. S6A .Figure 5 -(with 1 supplement).", [["S6A", "GENE_OR_GENE_PRODUCT", 31, 34], ["S6A", "PROTEIN", 31, 34]]], ["Modification of individual protein disulfide isomerases by 147 is not sufficient to reduce viral infection.High-confidence targets were filtered that displayed a log2 enrichment ratio greater than two standard deviations of the distribution of enrichment ratios across four biological replicates.", [["viral infection", "DISEASE", 91, 106], ["disulfide", "CHEMICAL", 35, 44], ["protein disulfide isomerases", "GENE_OR_GENE_PRODUCT", 27, 55], ["protein disulfide isomerases", "PROTEIN", 27, 55], ["individual protein disulfide isomerases", "TEST", 16, 55], ["viral infection", "PROBLEM", 91, 106], ["a log2 enrichment ratio", "TEST", 160, 183], ["infection", "OBSERVATION", 97, 106], ["greater", "OBSERVATION_MODIFIER", 184, 191], ["distribution", "OBSERVATION_MODIFIER", 228, 240], ["enrichment ratios", "OBSERVATION", 244, 261]]], ["C. Venn diagram showing the comparison of high-confidence protein targets of 147-20 in Huh7 cells and other cells lines (HEK293T, HepG2 and ALMC-2) identified in a prior study .", [["Huh7 cells", "ANATOMY", 87, 97], ["cells lines", "ANATOMY", 108, 119], ["HEK293T", "ANATOMY", 121, 128], ["HepG2", "ANATOMY", 130, 135], ["ALMC-2", "ANATOMY", 140, 146], ["Huh7 cells", "CELL", 87, 97], ["cells lines", "CELL", 108, 119], ["HEK293T", "CELL", 121, 128], ["HepG2", "CELL", 130, 135], ["ALMC-2", "CELL", 140, 146], ["Huh7 cells", "CELL_LINE", 87, 97], ["cells lines", "CELL_LINE", 108, 119], ["HEK293T", "CELL_LINE", 121, 128], ["HepG2", "CELL_LINE", 130, 135], ["ALMC-2", "CELL_LINE", 140, 146], ["Venn diagram", "TEST", 3, 15], ["confidence protein targets", "TEST", 47, 73], ["Huh7 cells", "TEST", 87, 97], ["other cells lines", "TEST", 102, 119], ["HEK293T", "TEST", 121, 128], ["HepG2", "TEST", 130, 135], ["ALMC", "TEST", 140, 144], ["a prior study", "TEST", 162, 175], ["cells lines", "OBSERVATION", 108, 119]]], ["Fig. S6B shows the overlapping targets with individual cell lines.Figure 6 -supplement 1.", [["cell lines", "ANATOMY", 55, 65], ["cell lines", "CELL", 55, 65], ["S6B", "PROTEIN", 5, 8], ["cell lines", "CELL_LINE", 55, 65], ["individual cell lines", "TREATMENT", 44, 65], ["individual cell lines", "OBSERVATION", 44, 65]]], ["Identification of covalent protein target of 147 in Huh7 cellsA.", [["Huh7 cellsA", "ANATOMY", 52, 63], ["Huh7 cellsA", "CELL", 52, 63], ["Huh7 cellsA", "CELL_LINE", 52, 63], ["covalent protein target", "TEST", 18, 41], ["covalent protein target", "OBSERVATION", 18, 41]]], ["Chemoproteomic target identification for 147-20 shows an enrichment of several PDIs compared to the 147-competition control.", [["PDIs", "PATHOLOGICAL_FORMATION", 79, 83], ["Chemoproteomic target identification", "TEST", 0, 36], ["several PDIs", "PROBLEM", 71, 83], ["enrichment", "OBSERVATION", 57, 67]]], ["Quantitative proteomics using TMT-11plex reagents was used to compare log2 intensities across 4 replicates of probe (147-20 alone) versus probe in competition with excess parent compound 147.", [["Quantitative proteomics", "TEST", 0, 23], ["TMT-11plex reagents", "TREATMENT", 30, 49]]], ["Targets were ordered from most enriched (high log2 fold change) to least enriched (low log2 fold change).", [["low log2 fold", "OBSERVATION_MODIFIER", 83, 96]]], ["Protein disulfide isomerases (PDIs, highlighted as red dots) were among the most enriched targets identified.", [["disulfide", "CHEMICAL", 8, 17], ["Protein disulfide isomerases", "GENE_OR_GENE_PRODUCT", 0, 28], ["PDIs", "SIMPLE_CHEMICAL", 30, 34], ["Protein disulfide isomerases", "PROTEIN", 0, 28], ["PDIs", "PROTEIN", 30, 34], ["Protein disulfide isomerases", "TEST", 0, 28], ["PDIs", "TEST", 30, 34], ["red dots", "TEST", 51, 59]]], ["B. Venn diagram of highly enriched targets found in Huh7 cells in this study compared to HEK293T, HepG2, and ALMC-2 cells in a previous study .", [["Huh7 cells", "ANATOMY", 52, 62], ["HEK293T", "ANATOMY", 89, 96], ["HepG2", "ANATOMY", 98, 103], ["ALMC-2 cells", "ANATOMY", 109, 121], ["Huh7 cells", "CELL", 52, 62], ["HEK293T", "CELL", 89, 96], ["HepG2", "CELL", 98, 103], ["ALMC-2 cells", "CELL", 109, 121], ["Huh7 cells", "CELL_LINE", 52, 62], ["HEK293T", "CELL_LINE", 89, 96], ["HepG2", "CELL_LINE", 98, 103], ["ALMC-2 cells", "CELL_LINE", 109, 121], ["B. Venn diagram", "TEST", 0, 15], ["Huh7 cells", "PROBLEM", 52, 62], ["this study", "TEST", 66, 76], ["HEK293T", "TEST", 89, 96], ["HepG2", "TEST", 98, 103], ["ALMC", "TEST", 109, 113], ["a previous study", "TEST", 125, 141], ["Huh7 cells", "OBSERVATION", 52, 62]]], ["Previous target ID studies were comparable to the study conducted herein.", [["Previous target ID studies", "TEST", 0, 26], ["the study", "TEST", 46, 55]]], ["E.-F. Compound 147 is similarly active at reducing infection of Zika virus.", [["infection", "DISEASE", 51, 60], ["Zika virus", "ORGANISM", 64, 74], ["Zika virus", "SPECIES", 64, 74], ["Zika virus", "PROBLEM", 64, 74], ["active", "OBSERVATION_MODIFIER", 32, 38], ["infection", "OBSERVATION", 51, 60], ["Zika virus", "OBSERVATION", 64, 74]]], ["Huh7 cells were pretreated with 147 (10\u00b5M) for 16 hours prior to infection with ZIKV strain MR766 (E) or ZIKV strain PRVABC59 (F).", [["Huh7 cells", "ANATOMY", 0, 10], ["infection", "DISEASE", 65, 74], ["Huh7 cells", "CELL", 0, 10], ["Huh7 cells", "CELL_LINE", 0, 10], ["ZIKV", "SPECIES", 80, 84], ["ZIKV", "SPECIES", 105, 109], ["Huh7 cells", "PROBLEM", 0, 10], ["infection", "PROBLEM", 65, 74], ["ZIKV strain", "PROBLEM", 80, 91]]], ["Viral titers were determined 24 hours hpi by focus forming assay.", [["Viral", "ORGANISM", 0, 5], ["Viral titers", "TEST", 0, 12]]], ["All error bars show SEM from 3 biological replicates and p-values from ratio paired t-tests are shown.Figure 7 -supplement 1.", [["All error bars", "TEST", 0, 14], ["SEM", "TEST", 20, 23], ["p-values from ratio paired t-tests", "TEST", 57, 91]]], ["Reduction of viral proteins in DENV and ZIKV strains by compound 147A.", [["compound 147A", "CHEMICAL", 56, 69], ["DENV", "ORGANISM", 31, 35], ["ZIKV strains", "ORGANISM", 40, 52], ["compound 147A", "ORGANISM", 56, 69], ["viral proteins", "PROTEIN", 13, 27], ["DENV", "SPECIES", 31, 35], ["ZIKV", "SPECIES", 40, 44], ["viral proteins", "PROBLEM", 13, 27], ["DENV", "PROBLEM", 31, 35], ["ZIKV strains", "PROBLEM", 40, 52], ["viral proteins", "OBSERVATION", 13, 27], ["DENV", "OBSERVATION", 31, 35]]], ["Representative western blot showing similar phenotype in HepG2 cells as in Huh7 cells.", [["HepG2 cells", "ANATOMY", 57, 68], ["Huh7 cells", "ANATOMY", 75, 85], ["HepG2 cells", "CELL", 57, 68], ["Huh7 cells", "CELL", 75, 85], ["HepG2 cells", "CELL_LINE", 57, 68], ["Huh7 cells", "CELL_LINE", 75, 85], ["Representative western blot", "TEST", 0, 27], ["similar phenotype in HepG2 cells", "PROBLEM", 36, 68], ["Huh7 cells", "PROBLEM", 75, 85], ["HepG2 cells", "OBSERVATION", 57, 68], ["Huh7 cells", "OBSERVATION", 75, 85]]], ["HepG2 cells were pretreated with 10 \u00b5M 147 for 16h, then infected with DENV-2 strain BID-V533 at MOI of 3 for 3 hours.", [["HepG2 cells", "ANATOMY", 0, 11], ["HepG2 cells", "CELL", 0, 11], ["DENV-2", "ORGANISM", 71, 77], ["BID-V533", "SIMPLE_CHEMICAL", 85, 93], ["HepG2 cells", "CELL_LINE", 0, 11], ["DENV-2 strain BID-V533", "SPECIES", 71, 93], ["HepG2 cells", "PROBLEM", 0, 11], ["DENV", "PROBLEM", 71, 75], ["DENV", "OBSERVATION", 71, 75]]], ["Media and treatments were replaced, and cells were collected at 24 and 48 hpi.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["treatments", "TREATMENT", 10, 20]]], ["Cells were lysed, and protein samples were run on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 85, 99], ["PVDF", "CHEMICAL", 85, 89], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 50, 53], ["PVDF membranes", "TREATMENT", 85, 99], ["PVDF membranes", "OBSERVATION", 85, 99]]], ["GAPDH is included as a loading control.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["GAPDH", "PROBLEM", 0, 5], ["a loading control", "TREATMENT", 21, 38]]], ["B. Representative western blot showing attenuation of DENV-2 16681 viral protein levels on treatment with 147.", [["DENV-2 16681", "ORGANISM", 54, 66], ["DENV-2 16681", "SPECIES", 54, 66], ["DENV", "TEST", 54, 58], ["viral protein levels", "TEST", 67, 87], ["treatment", "TREATMENT", 91, 100], ["attenuation", "OBSERVATION_MODIFIER", 39, 50], ["DENV", "OBSERVATION", 54, 58]]], ["Cells were pretreated with 10 \u00b5M 147 for 16h, then infected with DENV-2 strain 16681 at MOI of 3 for 3 hours.", [["Cells", "ANATOMY", 0, 5], ["DENV-2 strain 16681", "CHEMICAL", 65, 84], ["Cells", "CELL", 0, 5], ["DENV-2 strain 16681", "SPECIES", 65, 84], ["DENV", "PROBLEM", 65, 69], ["DENV", "OBSERVATION", 65, 69]]], ["Media and treatments were replaced, and cells were collected at 24hpi.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["Media", "TREATMENT", 0, 5], ["treatments", "TREATMENT", 10, 20]]], ["Cells were lysed, and protein samples were run on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 85, 99], ["PVDF", "CHEMICAL", 85, 89], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 50, 53], ["PVDF membranes", "TREATMENT", 85, 99], ["PVDF membranes", "OBSERVATION", 85, 99]]], ["GAPDH is included as a loading control.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["GAPDH", "PROBLEM", 0, 5], ["a loading control", "TREATMENT", 21, 38]]], ["C. Representative Western Blot showing attenuation of ZIKV PRVABC59 viral envelope (E) protein levels on treatment with 147.", [["ZIKV PRVABC59 viral envelope (E)", "GENE_OR_GENE_PRODUCT", 54, 86], ["ZIKV PRVABC59 viral envelope (E) protein", "PROTEIN", 54, 94], ["ZIKV", "SPECIES", 54, 58], ["ZIKV", "PROBLEM", 54, 58], ["protein levels", "TEST", 87, 101], ["treatment", "TREATMENT", 105, 114]]], ["Cells were pretreated with 10 \u00b5M 147 for 16h, then infected with ZIKV strain PRVABC59 at MOI of 0.5 for 1 hour.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ZIKV", "SPECIES", 65, 69], ["ZIKV strain", "TREATMENT", 65, 76]]], ["Media and treatments were replaced, and cells were collected at 24hpi.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["Media", "TREATMENT", 0, 5], ["treatments", "TREATMENT", 10, 20]]], ["Cells were lysed, and protein samples were run on SDS-PAGE gels and visualized using PVDF membranes.", [["Cells", "ANATOMY", 0, 5], ["samples", "ANATOMY", 30, 37], ["PVDF membranes", "ANATOMY", 85, 99], ["PVDF", "CHEMICAL", 85, 89], ["Cells", "CELL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 90, 99], ["Cells", "TEST", 0, 5], ["protein samples", "TEST", 22, 37], ["SDS", "TEST", 50, 53], ["PVDF membranes", "TREATMENT", 85, 99], ["PVDF membranes", "OBSERVATION", 85, 99]]], ["GAPDH is included as a loading control.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["GAPDH", "PROBLEM", 0, 5], ["a loading control", "TREATMENT", 21, 38]]], ["D. Representative Western Blot showing attenuation of ZIKV MR766 viral E protein levels on treatment with 147.", [["ZIKV MR766", "PROTEIN", 54, 64], ["viral E protein", "PROTEIN", 65, 80], ["ZIKV", "SPECIES", 54, 58], ["ZIKV", "TEST", 54, 58], ["viral E protein levels", "TEST", 65, 87], ["treatment", "TREATMENT", 91, 100]]], ["Cells were pretreated with 10 \u00b5M 147 for 16h, then infected with ZIKV strain MR766 at MOI of 0.5 for 1 hour.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ZIKV", "SPECIES", 65, 69], ["ZIKV strain", "PROBLEM", 65, 76]]], ["Media and treatments were replaced, and cells were collected at 24hpi.", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["Media", "TREATMENT", 0, 5], ["treatments", "TREATMENT", 10, 20]]], ["Cells were lysed, and protein", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["protein", "TEST", 22, 29]]]], "PMC7110850": [["Conflict of interest statementNone of the authors of this paper has a financial or personal relationship with other people or organisations that could inappropriately influence or bias the content of the paper.", [["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122]]]], "871d968e0f62e451f974de9748c8a7354beb84af": [["IntroductionGiardia duodenalis (syn: G. lamblia) infections are highly prevalent in domestic ruminants throughout the world (reviewed by O'Handley and Olson, 2006) .", [["IntroductionGiardia duodenalis", "CHEMICAL", 0, 30], ["G. lamblia) infections", "DISEASE", 37, 59], ["IntroductionGiardia duodenalis", "ORGANISM", 0, 30], ["syn: G. lamblia", "ORGANISM", 32, 47], ["IntroductionGiardia duodenalis", "SPECIES", 0, 30], ["G. lamblia", "SPECIES", 37, 47], ["IntroductionGiardia duodenalis", "SPECIES", 0, 30], ["G. lamblia", "SPECIES", 37, 47], ["lamblia) infections", "PROBLEM", 40, 59]]], ["Typically, infections occur in ruminants around one month of age and are chronic or reoccurring, with cyst excretion continuing for months after initial infection. www.elsevier.com/locate/vetpar Veterinary Parasitology 146 (2007) [182] [183] [184] [185] [186] [187] [188] As with other hosts, the clinical signs associated with G. duodenalis infections in ruminants can vary.", [["cyst", "ANATOMY", 102, 106], ["infections", "DISEASE", 11, 21], ["infection", "DISEASE", 153, 162], ["G. duodenalis infections", "DISEASE", 328, 352], ["[182] [183] [184] [185] [186] [187] [188] As", "CHEMICAL", 230, 274], ["cyst", "PATHOLOGICAL_FORMATION", 102, 106], ["G. duodenalis", "ORGANISM", 328, 341], ["G. duodenalis", "SPECIES", 328, 341], ["G. duodenalis", "SPECIES", 328, 341], ["infections", "PROBLEM", 11, 21], ["cyst excretion", "PROBLEM", 102, 116], ["initial infection", "PROBLEM", 145, 162], ["the clinical signs", "TEST", 293, 311], ["G. duodenalis infections", "PROBLEM", 328, 352], ["infections", "OBSERVATION", 11, 21], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["cyst", "OBSERVATION", 102, 106], ["infection", "OBSERVATION", 153, 162], ["infections", "OBSERVATION", 342, 352]]], ["Subclinical infections are often reported; however, G. duodenalis infections are also associated with the occurrence of diarrhea and ill thrift in calves (O'Handley et al., 1999; Geurden et al., 2006) .", [["Subclinical infections", "DISEASE", 0, 22], ["G. duodenalis infections", "DISEASE", 52, 76], ["diarrhea", "DISEASE", 120, 128], ["ill thrift", "DISEASE", 133, 143], ["G. duodenalis", "ORGANISM", 52, 65], ["calves", "ORGANISM", 147, 153], ["G. duodenalis", "SPECIES", 52, 65], ["calves", "SPECIES", 147, 153], ["G. duodenalis", "SPECIES", 52, 65], ["Subclinical infections", "PROBLEM", 0, 22], ["G. duodenalis infections", "PROBLEM", 52, 76], ["diarrhea", "PROBLEM", 120, 128], ["ill thrift in calves", "PROBLEM", 133, 153], ["infections", "OBSERVATION", 12, 22], ["duodenalis infections", "OBSERVATION", 55, 76], ["diarrhea", "OBSERVATION", 120, 128]]], ["More importantly, previous research has shown that G. duodenalis infections can result in significant production losses in lambs, thus raising concern that giardiasis may be a production limiting disease in livestock (Olson et al., 1995; O'Handley et al., 2000a; Aloisio et al., 2006) .", [["G. duodenalis infections", "DISEASE", 51, 75], ["giardiasis", "DISEASE", 156, 166], ["G. duodenalis", "ORGANISM", 51, 64], ["lambs", "ORGANISM", 123, 128], ["G. duodenalis", "SPECIES", 51, 64], ["G. duodenalis", "SPECIES", 51, 64], ["G. duodenalis infections", "PROBLEM", 51, 75], ["significant production losses in lambs", "PROBLEM", 90, 128], ["giardiasis", "PROBLEM", 156, 166], ["a production limiting disease", "PROBLEM", 174, 203], ["duodenalis infections", "OBSERVATION", 54, 75], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["production losses", "OBSERVATION", 102, 119], ["giardiasis", "OBSERVATION", 156, 166]]], ["Additionally, although ruminants are most commonly infected by the livestock specific G. duodenalis of genetic assemblage E, they can also be infected with G. duodenalis of the zoonotic genetic assemblage A. Thus, domestic livestock have the potential to serve as a reservoir for human giardiasis (O'Handley et al., 2000b; Trout et al., 2004; Uehlinger et al., 2006) .IntroductionDue to the high prevalence, potential production impact, and zoonotic potential of G. duodenalis infections in domestic ruminants, recent research has examined the potential for controlling G. duodenalis infections in ruminants through chemotherapy.", [["giardiasis", "DISEASE", 286, 296], ["G. duodenalis infections", "DISEASE", 463, 487], ["G. duodenalis infections", "DISEASE", 570, 594], ["G. duodenalis", "ORGANISM", 86, 99], ["G. duodenalis", "ORGANISM", 156, 169], ["human", "ORGANISM", 280, 285], ["G. duodenalis", "ORGANISM", 463, 476], ["G. duodenalis", "ORGANISM", 570, 583], ["G. duodenalis", "SPECIES", 86, 99], ["G. duodenalis", "SPECIES", 156, 169], ["human", "SPECIES", 280, 285], ["G. duodenalis", "SPECIES", 463, 476], ["G. duodenalis", "SPECIES", 570, 583], ["ruminants", "SPECIES", 23, 32], ["G. duodenalis", "SPECIES", 86, 99], ["G. duodenalis", "SPECIES", 156, 169], ["human", "SPECIES", 280, 285], ["G. duodenalis", "SPECIES", 463, 476], ["G. duodenalis", "SPECIES", 570, 583], ["human giardiasis", "PROBLEM", 280, 296], ["G. duodenalis infections", "PROBLEM", 463, 487], ["G. duodenalis infections", "PROBLEM", 570, 594], ["chemotherapy", "TREATMENT", 616, 628], ["high prevalence", "OBSERVATION_MODIFIER", 391, 406], ["duodenalis infections", "OBSERVATION", 466, 487], ["infections", "OBSERVATION", 584, 594]]], ["Paromomycin and the benzimidazole drugs, such as fenbendazole, show efficacy against giardiasis in dairy calves (Xiao et al., 1996; O'Handley et al., 1997; Geurden et al., 2006) .", [["Paromomycin", "CHEMICAL", 0, 11], ["benzimidazole", "CHEMICAL", 20, 33], ["fenbendazole", "CHEMICAL", 49, 61], ["giardiasis", "DISEASE", 85, 95], ["Paromomycin", "CHEMICAL", 0, 11], ["benzimidazole", "CHEMICAL", 20, 33], ["fenbendazole", "CHEMICAL", 49, 61], ["Paromomycin", "SIMPLE_CHEMICAL", 0, 11], ["benzimidazole drugs", "SIMPLE_CHEMICAL", 20, 39], ["fenbendazole", "SIMPLE_CHEMICAL", 49, 61], ["calves", "ORGANISM", 105, 111], ["calves", "SPECIES", 105, 111], ["Paromomycin", "TREATMENT", 0, 11], ["the benzimidazole drugs", "TREATMENT", 16, 39], ["fenbendazole", "TREATMENT", 49, 61], ["giardiasis", "PROBLEM", 85, 95]]], ["However, due to the high level of G. duodenalis cysts in their environment, calves are readily reinfected immediately following treatment (O'Handley et al., 2000a) .", [["cysts", "ANATOMY", 48, 53], ["G. duodenalis cysts", "DISEASE", 34, 53], ["G. duodenalis", "ORGANISM", 34, 47], ["calves", "ORGANISM", 76, 82], ["G. duodenalis", "SPECIES", 34, 47], ["calves", "SPECIES", 76, 82], ["G. duodenalis", "SPECIES", 34, 47], ["calves", "SPECIES", 76, 82], ["G. duodenalis cysts", "PROBLEM", 34, 53], ["duodenalis cysts", "OBSERVATION", 37, 53], ["calves", "ANATOMY", 76, 82], ["reinfected", "OBSERVATION", 95, 105]]], ["Continuous administration of drugs, such as fenbendazole or paromomycin may allow for long-term control of giardiasis in ruminants.", [["fenbendazole", "CHEMICAL", 44, 56], ["paromomycin", "CHEMICAL", 60, 71], ["giardiasis", "DISEASE", 107, 117], ["fenbendazole", "CHEMICAL", 44, 56], ["paromomycin", "CHEMICAL", 60, 71], ["fenbendazole", "SIMPLE_CHEMICAL", 44, 56], ["paromomycin", "SIMPLE_CHEMICAL", 60, 71], ["drugs", "TREATMENT", 29, 34], ["fenbendazole", "TREATMENT", 44, 56], ["paromomycin", "TREATMENT", 60, 71], ["long-term control", "TREATMENT", 86, 103], ["giardiasis", "PROBLEM", 107, 117], ["giardiasis", "OBSERVATION", 107, 117]]], ["However, this type of treatment regimen is likely not useful or economically feasible for livestock producers.", [["treatment regimen", "TREATMENT", 22, 39], ["livestock producers", "TREATMENT", 90, 109], ["likely not", "UNCERTAINTY", 43, 53]]], ["A vaccine to prevent and control G. duodenalis in domestic ruminants could be a practical and costeffective approach.", [["G. duodenalis", "DISEASE", 33, 46], ["G. duodenalis", "ORGANISM", 33, 46], ["G. duodenalis", "SPECIES", 33, 46], ["G. duodenalis", "SPECIES", 33, 46], ["A vaccine", "TREATMENT", 0, 9], ["G. duodenalis", "PROBLEM", 33, 46], ["a practical and costeffective approach", "TREATMENT", 78, 116], ["duodenalis", "OBSERVATION", 36, 46]]], ["Currently, a sonicated whole G. duodenalis vaccine, made with trophozoites isolated from sheep, is available for dogs and cats in North America (Olson et al., 2000) .", [["trophozoites", "ANATOMY", 62, 74], ["G. duodenalis", "ORGANISM", 29, 42], ["sheep", "ORGANISM", 89, 94], ["dogs", "ORGANISM", 113, 117], ["cats", "ORGANISM", 122, 126], ["G. duodenalis", "SPECIES", 29, 42], ["sheep", "SPECIES", 89, 94], ["dogs", "SPECIES", 113, 117], ["cats", "SPECIES", 122, 126], ["G. duodenalis", "SPECIES", 29, 42], ["sheep", "SPECIES", 89, 94], ["a sonicated whole G. duodenalis vaccine", "TREATMENT", 11, 50], ["trophozoites", "TREATMENT", 62, 74]]], ["Clinical trials demonstrated that sub-cutaneous administration of this vaccine in young, growing dogs and cats results in the reduction of G. duodenalis cyst in the feces, elimination or reduction of G. duodenalis trophozoites in the intestines, prevention of clinical disease, and significantly higher weight gains compared to non-vaccinated animals (Olson et al., 1996 .", [["cutaneous", "ANATOMY", 38, 47], ["cyst", "ANATOMY", 153, 157], ["feces", "ANATOMY", 165, 170], ["intestines", "ANATOMY", 234, 244], ["G. duodenalis cyst", "DISEASE", 139, 157], ["weight gains", "DISEASE", 303, 315], ["dogs", "ORGANISM", 97, 101], ["cats", "ORGANISM", 106, 110], ["G. duodenalis", "ORGANISM", 139, 152], ["cyst", "PATHOLOGICAL_FORMATION", 153, 157], ["feces", "ORGANISM_SUBDIVISION", 165, 170], ["G. duodenalis", "ORGANISM", 200, 213], ["trophozoites", "ORGANISM", 214, 226], ["intestines", "ORGAN", 234, 244], ["dogs", "SPECIES", 97, 101], ["cats", "SPECIES", 106, 110], ["G. duodenalis", "SPECIES", 139, 152], ["G. duodenalis", "SPECIES", 200, 213], ["G. duodenalis", "SPECIES", 139, 152], ["G. duodenalis", "SPECIES", 200, 213], ["Clinical trials", "TEST", 0, 15], ["sub-cutaneous administration", "TREATMENT", 34, 62], ["this vaccine", "TREATMENT", 66, 78], ["G. duodenalis cyst", "PROBLEM", 139, 157], ["G. duodenalis trophozoites in the intestines", "PROBLEM", 200, 244], ["clinical disease", "PROBLEM", 260, 276], ["significantly higher weight gains", "PROBLEM", 282, 315], ["duodenalis cyst", "OBSERVATION", 142, 157], ["feces", "ANATOMY", 165, 170], ["reduction", "OBSERVATION_MODIFIER", 187, 196], ["duodenalis trophozoites", "OBSERVATION", 203, 226], ["intestines", "ANATOMY", 234, 244]]], ["Provided this vaccine had similar efficacy in domestic ruminants, it could reduce or eliminate the role of domestic ruminants as reservoirs for G. duodenalis infections in humans and may provide an economic benefit to livestock producers by preventing production losses associated with giardiasis.", [["G. duodenalis infections", "DISEASE", 144, 168], ["giardiasis", "DISEASE", 286, 296], ["G. duodenalis", "ORGANISM", 144, 157], ["humans", "ORGANISM", 172, 178], ["G. duodenalis", "SPECIES", 144, 157], ["humans", "SPECIES", 172, 178], ["ruminants", "SPECIES", 55, 64], ["ruminants", "SPECIES", 116, 125], ["G. duodenalis", "SPECIES", 144, 157], ["humans", "SPECIES", 172, 178], ["this vaccine", "TREATMENT", 9, 21], ["G. duodenalis infections in humans", "PROBLEM", 144, 178], ["livestock producers", "TREATMENT", 218, 237], ["production losses", "PROBLEM", 252, 269], ["giardiasis", "PROBLEM", 286, 296], ["infections", "OBSERVATION", 158, 168], ["production losses", "OBSERVATION", 252, 269], ["giardiasis", "OBSERVATION", 286, 296]]], ["Therefore, this study evaluates the efficacy of a G. duodenalis vaccine in preventing giardiasis in calves.Calves and husbandryTwelve Holstein-Friesian bull calves, <14 days old, were purchased from eight local dairy farmers.", [["G. duodenalis", "CHEMICAL", 50, 63], ["giardiasis", "DISEASE", 86, 96], ["G. duodenalis", "ORGANISM", 50, 63], ["calves", "ORGANISM", 100, 106], ["Calves", "ORGANISM", 107, 113], ["calves", "ORGANISM", 157, 163], ["G. duodenalis", "SPECIES", 50, 63], ["calves", "SPECIES", 100, 106], ["Calves", "SPECIES", 107, 113], ["calves", "SPECIES", 157, 163], ["G. duodenalis", "SPECIES", 50, 63], ["Holstein-Friesian bull calves", "SPECIES", 134, 163], ["this study", "TEST", 11, 21], ["a G. duodenalis vaccine", "TREATMENT", 48, 71], ["giardiasis in calves", "PROBLEM", 86, 106], ["giardiasis", "OBSERVATION", 86, 96]]], ["All calves were obtained and transported to the Atlantic Veterinary College (AVC) on day \u00c010 of study, following a satisfactory physical examination.", [["calves", "ORGANISM", 4, 10], ["calves", "SPECIES", 4, 10], ["study", "TEST", 96, 101], ["a satisfactory physical examination", "TEST", 113, 148], ["calves", "ANATOMY", 4, 10]]], ["Calves were further evaluated for failure of passive transfer (FPT) of immunity by determining their serum total protein concentrations and were included in the study if their serum protein concentration was !5 g/dL (Calloway et al., 2002) .", [["serum", "ANATOMY", 101, 106], ["serum", "ANATOMY", 176, 181], ["Calves", "ORGANISM", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["serum", "ORGANISM_SUBSTANCE", 176, 181], ["serum protein", "PROTEIN", 176, 189], ["Calves", "SPECIES", 0, 6], ["their serum total protein concentrations", "TEST", 95, 135], ["the study", "TEST", 157, 166], ["their serum protein concentration", "TEST", 170, 203]]], ["Only bovine virus diarrhea virusnegative calves, determined by Buffy coat virus isolation, were included in the study.Calves and husbandryUpon arrival at the AVC, calves were housed individually in the isolation unit of the veterinary hospital.", [["diarrhea", "DISEASE", 18, 26], ["bovine virus diarrhea", "ORGANISM", 5, 26], ["calves", "ORGANISM", 41, 47], ["Buffy coat virus", "ORGANISM", 63, 79], ["Calves", "ORGANISM", 118, 124], ["calves", "ORGANISM", 163, 169], ["bovine", "SPECIES", 5, 11], ["virus diarrhea", "SPECIES", 12, 26], ["calves", "SPECIES", 41, 47], ["Buffy coat virus", "SPECIES", 63, 79], ["Calves", "SPECIES", 118, 124], ["calves", "SPECIES", 163, 169], ["Buffy coat virus", "SPECIES", 63, 79], ["bovine virus diarrhea virusnegative calves", "PROBLEM", 5, 47], ["Buffy coat virus isolation", "TREATMENT", 63, 89], ["the study", "TEST", 108, 117], ["bovine virus", "OBSERVATION", 5, 17], ["Buffy coat virus isolation", "OBSERVATION", 63, 89], ["AVC", "ANATOMY", 158, 161], ["calves", "ANATOMY", 163, 169]]], ["The pens consisted of concrete floors and solid walls, which prevented contact between animals.", [["solid walls", "ANATOMY", 42, 53], ["solid walls", "PATHOLOGICAL_FORMATION", 42, 53], ["The pens", "TREATMENT", 0, 8], ["solid walls", "OBSERVATION", 42, 53]]], ["Manure and wet bedding were removed daily and replaced with fresh bedding (wood shavings).", [["Manure and wet bedding", "TREATMENT", 0, 22], ["fresh bedding (wood shavings", "TREATMENT", 60, 88], ["wet", "OBSERVATION_MODIFIER", 11, 14], ["bedding", "OBSERVATION", 15, 22]]], ["Calves were fed a commercial milk replacer twice daily and a feed concentrate according to manufacturers' instructions.", [["Calves", "ORGANISM", 0, 6], ["milk", "ORGANISM_SUBSTANCE", 29, 33], ["Calves", "SPECIES", 0, 6], ["a commercial milk replacer", "TREATMENT", 16, 42], ["a feed concentrate", "TREATMENT", 59, 77]]], ["The calves received approximately 0.25 kg loose hay every day and had ad libitum access to fresh water (filtered, flocculated, and chlorinated municipal water).Calves and husbandryTo eliminate any existing Giardia duodenalis infections prior to vaccination, and to ensure that calves remained free of G. duodenalis until vaccination day, calves were treated with 7.5 mg/kg of fenbendazole per Os (SafeGuard 1 10% Suspension, CDMV, St. Hyacinthe, Canada) daily, starting on day \u00c010 until the day of vaccination (day 0).Calves and husbandryMedical attention was required during the study for calves with respiratory tract problems and diarrhea.", [["respiratory tract", "ANATOMY", 602, 619], ["Giardia duodenalis infections", "DISEASE", 206, 235], ["fenbendazole per Os", "CHEMICAL", 376, 395], ["respiratory tract problems", "DISEASE", 602, 628], ["diarrhea", "DISEASE", 633, 641], ["fenbendazole", "CHEMICAL", 376, 388], ["calves", "ORGANISM", 4, 10], ["Calves", "ORGANISM", 160, 166], ["Giardia duodenalis", "ORGANISM", 206, 224], ["calves", "ORGANISM", 277, 283], ["G. duodenalis", "ORGANISM", 301, 314], ["calves", "ORGANISM", 338, 344], ["fenbendazole", "SIMPLE_CHEMICAL", 376, 388], ["Calves", "ORGANISM", 518, 524], ["calves", "ORGANISM", 590, 596], ["tract", "ORGANISM_SUBDIVISION", 614, 619], ["calves", "SPECIES", 4, 10], ["Calves", "SPECIES", 160, 166], ["Giardia duodenalis", "SPECIES", 206, 224], ["calves", "SPECIES", 277, 283], ["G. duodenalis", "SPECIES", 301, 314], ["calves", "SPECIES", 338, 344], ["Calves", "SPECIES", 518, 524], ["calves", "SPECIES", 590, 596], ["Giardia duodenalis", "SPECIES", 206, 224], ["calves", "SPECIES", 277, 283], ["G. duodenalis", "SPECIES", 301, 314], ["calves", "SPECIES", 338, 344], ["any existing Giardia duodenalis infections", "PROBLEM", 193, 235], ["vaccination", "TREATMENT", 245, 256], ["G. duodenalis", "PROBLEM", 301, 314], ["fenbendazole", "TREATMENT", 376, 388], ["the study", "TEST", 576, 585], ["respiratory tract problems", "PROBLEM", 602, 628], ["diarrhea", "PROBLEM", 633, 641], ["calves", "ANATOMY", 4, 10], ["Giardia duodenalis", "OBSERVATION", 206, 224], ["respiratory tract", "ANATOMY", 602, 619], ["diarrhea", "OBSERVATION", 633, 641]]], ["Respiratory problems were treated with florfenicol and, in case of high fever, with ketoprofen, a non-steroidal anti-inflammatory drug.", [["non-steroidal", "ANATOMY", 98, 111], ["Respiratory problems", "DISEASE", 0, 20], ["florfenicol", "CHEMICAL", 39, 50], ["fever", "DISEASE", 72, 77], ["ketoprofen", "CHEMICAL", 84, 94], ["florfenicol", "CHEMICAL", 39, 50], ["ketoprofen", "CHEMICAL", 84, 94], ["florfenicol", "SIMPLE_CHEMICAL", 39, 50], ["ketoprofen", "SIMPLE_CHEMICAL", 84, 94], ["Respiratory problems", "PROBLEM", 0, 20], ["florfenicol", "TREATMENT", 39, 50], ["high fever", "PROBLEM", 67, 77], ["ketoprofen", "TREATMENT", 84, 94], ["a non-steroidal anti-inflammatory drug", "TREATMENT", 96, 134]]], ["Supportive care was given to diarrheic calves if needed in the form of oral electrolytes.", [["oral", "ANATOMY", 71, 75], ["calves", "ORGANISM", 39, 45], ["oral", "ORGANISM_SUBDIVISION", 71, 75], ["calves", "SPECIES", 39, 45], ["Supportive care", "TREATMENT", 0, 15], ["diarrheic calves", "TREATMENT", 29, 45], ["oral electrolytes", "TEST", 71, 88]]], ["The research project was carried out under the guidelines of the University of Prince Edward Island Animal Care Committee, which bases approval of animal research on the guidelines of the Canadian Council of Animal Care (CCAC).", [["Animal Care (CCAC)", "TREATMENT", 208, 226]]], ["Three days after vaccination, one diarrheic calf died.", [["calf", "ORGANISM", 44, 48], ["calf", "SPECIES", 44, 48], ["vaccination", "TREATMENT", 17, 28], ["calf", "ANATOMY", 44, 48], ["died", "OBSERVATION", 49, 53]]], ["The results of this calf were excluded from the study, reducing the number of vaccinated calves to five.Group allocation, vaccination, and challenge procedureCalves confirmed negative for Giardia duodenalis (absence of G. duodenalis cysts in fecal samples taken on 4 consecutive days) (day \u00c07), were randomly allocated into two groups of six, and moved to the AVC Research Barn, where each group was housed in separate but identical rooms.", [["cysts", "ANATOMY", 233, 238], ["fecal samples", "ANATOMY", 242, 255], ["Giardia duodenalis", "DISEASE", 188, 206], ["calf", "ORGANISM", 20, 24], ["calves", "ORGANISM", 89, 95], ["Giardia duodenalis", "ORGANISM", 188, 206], ["G. duodenalis", "ORGANISM", 219, 232], ["calf", "SPECIES", 20, 24], ["calves", "SPECIES", 89, 95], ["Giardia duodenalis", "SPECIES", 188, 206], ["G. duodenalis", "SPECIES", 219, 232], ["Giardia duodenalis", "SPECIES", 188, 206], ["G. duodenalis", "SPECIES", 219, 232], ["the study", "TEST", 44, 53], ["Group allocation", "TREATMENT", 104, 120], ["vaccination", "TREATMENT", 122, 133], ["challenge procedureCalves", "TEST", 139, 164], ["Giardia duodenalis", "PROBLEM", 188, 206], ["G. duodenalis cysts", "PROBLEM", 219, 238], ["fecal samples", "TEST", 242, 255], ["calf", "ANATOMY", 20, 24], ["negative for", "UNCERTAINTY", 175, 187], ["Giardia duodenalis", "OBSERVATION", 188, 206], ["fecal", "ANATOMY", 242, 247]]], ["Prior to moving, calves were thoroughly washed with water and a commercially available liquid soap to prevent the mechanical introduction of G. duodenalis cysts into the rooms.", [["cysts", "ANATOMY", 155, 160], ["calves", "ORGANISM", 17, 23], ["duodenalis", "ORGANISM", 144, 154], ["calves", "SPECIES", 17, 23], ["G. duodenalis", "SPECIES", 141, 154], ["G. duodenalis", "SPECIES", 141, 154], ["water", "TREATMENT", 52, 57], ["a commercially available liquid soap", "TREATMENT", 62, 98], ["G. duodenalis cysts", "PROBLEM", 141, 160], ["duodenalis cysts", "OBSERVATION", 144, 160]]], ["The two rooms were sanitized with a quaternary ammonium disinfectant (Quatricide 1 PV-15, Pharmacal Research Laboratories Inc., Naugatuck, USA) and allowed to dry completely prior to the start of the study.", [["quaternary ammonium", "CHEMICAL", 36, 55], ["ammonium", "CHEMICAL", 47, 55], ["a quaternary ammonium disinfectant", "TREATMENT", 34, 68], ["the study", "TEST", 196, 205]]], ["Each calf was housed in an individual pen that allowed no contact with the neighboring animal.", [["calf", "ORGANISM", 5, 9], ["calf", "SPECIES", 5, 9], ["calf", "ANATOMY", 5, 9]]], ["Each calf was assigned a water and a feed bucket, which were cleaned and disinfected regularly.", [["calf", "ORGANISM", 5, 9], ["calf", "SPECIES", 5, 9], ["a feed bucket", "TREATMENT", 35, 48], ["calf", "ANATOMY", 5, 9]]], ["The feeding and husbandry protocols remained unchanged.", [["husbandry protocols", "TREATMENT", 16, 35], ["unchanged", "OBSERVATION_MODIFIER", 45, 54]]], ["Calves were allowed to acclimatize to their new housing for 7 days (days \u00c07 to 0).", [["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6]]], ["Strict isolation procedures were followed to make certain G. duodenalis cysts were not introduced into the calves' environment.", [["cysts", "ANATOMY", 72, 77], ["G. duodenalis", "ORGANISM", 58, 71], ["calves", "ORGANISM", 107, 113], ["G. duodenalis", "SPECIES", 58, 71], ["calves", "SPECIES", 107, 113], ["G. duodenalis", "SPECIES", 58, 71], ["Strict isolation procedures", "TREATMENT", 0, 27], ["certain G. duodenalis cysts", "PROBLEM", 50, 77], ["cysts", "OBSERVATION", 72, 77]]], ["This included the use of clean coveralls, sanitized footwear, and glove changing between animals.Group allocation, vaccination, and challenge procedureFollowing the 7-day acclimation period, one group of calves was injected with a sonicated whole G. duodenalis trophozoite vaccine (GiardiaVax TM , Wyeth Animal Health, Guelph, Canada) (day 0).", [["GiardiaVax", "CHEMICAL", 282, 292], ["calves", "ORGANISM", 204, 210], ["calves", "SPECIES", 204, 210], ["G. duodenalis", "SPECIES", 247, 260], ["G. duodenalis", "SPECIES", 247, 260], ["clean coveralls, sanitized footwear", "TREATMENT", 25, 60], ["glove", "TREATMENT", 66, 71], ["Group allocation", "TREATMENT", 97, 113], ["vaccination", "TREATMENT", 115, 126], ["challenge procedure", "TREATMENT", 132, 151], ["a sonicated whole G. duodenalis trophozoite vaccine", "TREATMENT", 229, 280], ["GiardiaVax TM", "TREATMENT", 282, 295]]], ["One dose (1 mL, according to manufacturer's instructions for use in dogs) was subcutaneously injected into the neck using a 16-gauge needle.", [["subcutaneously", "ANATOMY", 78, 92], ["neck", "ANATOMY", 111, 115], ["dogs", "ORGANISM", 68, 72], ["neck", "ORGAN", 111, 115], ["dogs", "SPECIES", 68, 72], ["a 16-gauge needle", "TREATMENT", 122, 139], ["neck", "ANATOMY", 111, 115]]], ["Calves in the other group received a subcutaneous injection (1 mL) of sterile phosphate-buffered-saline (PBS) mixed with adjuvant (Adju-Phos 1 , aluminum-phosphate, Accurate Chemical and Scientific Corp., Westbury, USA).", [["subcutaneous", "ANATOMY", 37, 49], ["phosphate", "CHEMICAL", 78, 87], ["Adju-Phos 1 , aluminum-phosphate", "CHEMICAL", 131, 163], ["phosphate", "CHEMICAL", 78, 87], ["aluminum-phosphate", "CHEMICAL", 145, 163], ["Calves", "ORGANISM", 0, 6], ["phosphate-buffered-saline", "SIMPLE_CHEMICAL", 78, 103], ["PBS", "SIMPLE_CHEMICAL", 105, 108], ["Adju-Phos 1", "SIMPLE_CHEMICAL", 131, 142], ["aluminum-phosphate", "SIMPLE_CHEMICAL", 145, 163], ["Calves", "SPECIES", 0, 6], ["a subcutaneous injection", "TREATMENT", 35, 59], ["sterile phosphate", "TREATMENT", 70, 87], ["buffered-saline (PBS)", "TREATMENT", 88, 109], ["adjuvant (Adju-Phos", "TREATMENT", 121, 140], ["aluminum-phosphate", "TREATMENT", 145, 163]]], ["Allocation of vaccination and saline injection to the two groups was made randomly and was blinded to the researchers and caregivers.", [["saline", "SIMPLE_CHEMICAL", 30, 36], ["vaccination", "TREATMENT", 14, 25], ["saline injection", "TREATMENT", 30, 46]]], ["Twenty-eight days after the initial injection (day 28), the vaccination and saline injections were repeated.Group allocation, vaccination, and challenge procedureEleven days after the second injection (day 39), calves in both groups were challenged with an oral inoculation of approximately 1 \u00c2 10 5 G. duodenalis cysts.", [["oral", "ANATOMY", 257, 261], ["cysts", "ANATOMY", 314, 319], ["duodenalis cysts", "DISEASE", 303, 319], ["saline", "SIMPLE_CHEMICAL", 76, 82], ["calves", "ORGANISM", 211, 217], ["oral", "ORGANISM_SUBDIVISION", 257, 261], ["duodenalis", "ORGANISM", 303, 313], ["cysts", "PATHOLOGICAL_FORMATION", 314, 319], ["calves", "SPECIES", 211, 217], ["G. duodenalis", "SPECIES", 300, 313], ["G. duodenalis", "SPECIES", 300, 313], ["the initial injection", "TREATMENT", 24, 45], ["the vaccination and saline injections", "TREATMENT", 56, 93], ["Group allocation", "TREATMENT", 108, 124], ["vaccination", "TREATMENT", 126, 137], ["challenge procedure", "TREATMENT", 143, 162], ["the second injection", "TREATMENT", 180, 200], ["an oral inoculation", "TREATMENT", 254, 273], ["duodenalis cysts", "PROBLEM", 303, 319], ["duodenalis", "ANATOMY", 303, 313], ["cysts", "OBSERVATION", 314, 319]]], ["The day before G. duodenalis challenge, feces were collected directly from the rectum of a calf known to be naturally infected with G. duodenalis.", [["feces", "ANATOMY", 40, 45], ["rectum", "ANATOMY", 79, 85], ["G. duodenalis", "ORGANISM", 15, 28], ["feces", "ORGANISM_SUBSTANCE", 40, 45], ["rectum", "ORGAN", 79, 85], ["calf", "ORGANISM", 91, 95], ["G. duodenalis", "ORGANISM", 132, 145], ["G. duodenalis", "SPECIES", 15, 28], ["calf", "SPECIES", 91, 95], ["G. duodenalis", "SPECIES", 132, 145], ["G. duodenalis", "SPECIES", 15, 28], ["G. duodenalis", "SPECIES", 132, 145], ["feces", "PROBLEM", 40, 45], ["G. duodenalis", "PROBLEM", 132, 145], ["feces", "OBSERVATION", 40, 45], ["rectum", "ANATOMY", 79, 85], ["calf", "ANATOMY", 91, 95], ["infected", "OBSERVATION", 118, 126], ["duodenalis", "OBSERVATION", 135, 145]]], ["Cysts from that calf were isolated and enumerated by epifluorescence microscopy using the method of O' Handley et al. (1999) .", [["Cysts", "ANATOMY", 0, 5], ["calf", "ANATOMY", 16, 20], ["calf", "ORGANISM", 16, 20], ["calf", "SPECIES", 16, 20], ["Cysts from that calf", "PROBLEM", 0, 20], ["epifluorescence microscopy", "TEST", 53, 79], ["calf", "ANATOMY", 16, 20]]], ["Polymerase chain reaction (PCR) and sequencing of the 16S-rRNA was carried out for the inoculum according to the method of Appelbee et al. (2003) , and the cysts corresponded to G. duodenalis of assemblage E. Doses comprising 1 \u00c2 10 5 cysts were mixed in 5 mL of phosphatebuffered-saline.", [["cysts", "ANATOMY", 156, 161], ["cysts", "ANATOMY", 235, 240], ["phosphatebuffered", "CHEMICAL", 263, 280], ["cysts", "PATHOLOGICAL_FORMATION", 156, 161], ["G. duodenalis", "ORGANISM", 178, 191], ["cysts", "CANCER", 235, 240], ["phosphatebuffered-saline", "SIMPLE_CHEMICAL", 263, 287], ["16S", "DNA", 54, 57], ["G. duodenalis", "SPECIES", 178, 191], ["G. duodenalis", "SPECIES", 178, 191], ["Polymerase chain reaction", "PROBLEM", 0, 25], ["PCR", "TEST", 27, 30], ["sequencing", "TEST", 36, 46], ["the 16S-rRNA", "TEST", 50, 62], ["the inoculum", "PROBLEM", 83, 95], ["the cysts", "PROBLEM", 152, 161], ["G. duodenalis", "PROBLEM", 178, 191], ["phosphatebuffered-saline", "TREATMENT", 263, 287], ["cysts", "OBSERVATION", 156, 161]]], ["Disposable 5 mL syringes were used to orally inoculate each calf individually.Fecal sample collection and processionTo monitor that calves were free of Giardia duodenalis prior to vaccination, fecal samples were collected from the rectum of each calf daily and examined for G. duodenalis cysts until the day of vaccination (day 0), starting on day \u00c010 (start of study).", [["Fecal sample", "ANATOMY", 78, 90], ["fecal samples", "ANATOMY", 193, 206], ["rectum", "ANATOMY", 231, 237], ["cysts", "ANATOMY", 288, 293], ["Giardia duodenalis", "DISEASE", 152, 170], ["G. duodenalis cysts", "DISEASE", 274, 293], ["calf", "ORGANISM_SUBDIVISION", 60, 64], ["Fecal", "ORGANISM_SUBSTANCE", 78, 83], ["calves", "ORGANISM", 132, 138], ["Giardia duodenalis", "ORGANISM", 152, 170], ["fecal samples", "ORGANISM_SUBSTANCE", 193, 206], ["rectum", "ORGAN", 231, 237], ["calf", "ORGANISM", 246, 250], ["duodenalis", "ORGANISM", 277, 287], ["calf", "SPECIES", 60, 64], ["calves", "SPECIES", 132, 138], ["Giardia duodenalis", "SPECIES", 152, 170], ["calf", "SPECIES", 246, 250], ["G. duodenalis", "SPECIES", 274, 287], ["calves", "SPECIES", 132, 138], ["Giardia duodenalis", "SPECIES", 152, 170], ["G. duodenalis", "SPECIES", 274, 287], ["Disposable 5 mL syringes", "TREATMENT", 0, 24], ["Fecal sample collection", "PROBLEM", 78, 101], ["procession", "TEST", 106, 116], ["Giardia duodenalis", "PROBLEM", 152, 170], ["vaccination", "TREATMENT", 180, 191], ["fecal samples", "TEST", 193, 206], ["G. duodenalis cysts", "PROBLEM", 274, 293], ["calf", "ANATOMY", 60, 64], ["sample", "OBSERVATION_MODIFIER", 84, 90], ["collection", "OBSERVATION", 91, 101], ["rectum", "ANATOMY", 231, 237], ["calf", "ANATOMY", 246, 250], ["duodenalis", "ANATOMY", 277, 287], ["cysts", "OBSERVATION", 288, 293]]], ["After vaccination, fecal samples were collected every 3 days to screen for potential G. duodenalis infections.", [["fecal samples", "ANATOMY", 19, 32], ["G. duodenalis infections", "DISEASE", 85, 109], ["fecal samples", "ORGANISM_SUBSTANCE", 19, 32], ["G. duodenalis", "ORGANISM", 85, 98], ["G. duodenalis", "SPECIES", 85, 98], ["G. duodenalis", "SPECIES", 85, 98], ["vaccination", "TREATMENT", 6, 17], ["fecal samples", "TEST", 19, 32], ["potential G. duodenalis infections", "PROBLEM", 75, 109], ["duodenalis infections", "OBSERVATION", 88, 109]]], ["To compare G. duodenalis cyst excretion levels more accurately between groups following G. duodenalis cyst challenge, fecal samples were collected daily from each calf, starting on the day of challenge (day 39) until the study was terminated (day 53).", [["cyst", "ANATOMY", 25, 29], ["cyst", "ANATOMY", 102, 106], ["fecal samples", "ANATOMY", 118, 131], ["G. duodenalis", "ORGANISM", 11, 24], ["cyst", "PATHOLOGICAL_FORMATION", 25, 29], ["G. duodenalis", "ORGANISM", 88, 101], ["fecal samples", "ORGANISM_SUBSTANCE", 118, 131], ["calf", "ORGANISM_SUBDIVISION", 163, 167], ["G. duodenalis", "SPECIES", 11, 24], ["G. duodenalis", "SPECIES", 88, 101], ["calf", "SPECIES", 163, 167], ["G. duodenalis", "SPECIES", 11, 24], ["G. duodenalis", "SPECIES", 88, 101], ["G. duodenalis cyst excretion levels", "PROBLEM", 11, 46], ["G. duodenalis cyst challenge", "PROBLEM", 88, 116], ["fecal samples", "TEST", 118, 131], ["the study", "TEST", 217, 226], ["cyst", "OBSERVATION", 25, 29], ["cyst", "OBSERVATION", 102, 106], ["fecal", "ANATOMY", 118, 123], ["calf", "ANATOMY", 163, 167]]], ["Fecal consistency was monitored for every sample and was scored as either normal (feces holds its form) or abnormal (feces takes shape of the collection container) (O'Handley et al., 1999) .", [["Fecal", "ANATOMY", 0, 5], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["feces", "ORGANISM_SUBDIVISION", 82, 87], ["feces", "ORGANISM_SUBDIVISION", 117, 122], ["Fecal consistency", "TEST", 0, 17], ["abnormal (feces", "PROBLEM", 107, 122], ["normal", "OBSERVATION", 74, 80]]], ["Giardia duodenalis cysts were isolated from the feces and enumerated by epifluorescence microscopy according to the method of O' Handley et al. (1999) .Intestinal trophozoite countCalves were euthanized on day 53 with an intravenous injection of pentobarbital.", [["cysts", "ANATOMY", 19, 24], ["feces", "ANATOMY", 48, 53], ["Intestinal trophozoite", "ANATOMY", 152, 174], ["intravenous", "ANATOMY", 221, 232], ["Giardia duodenalis cysts", "DISEASE", 0, 24], ["pentobarbital", "CHEMICAL", 246, 259], ["pentobarbital", "CHEMICAL", 246, 259], ["Giardia duodenalis", "ORGANISM", 0, 18], ["feces", "ORGANISM_SUBSTANCE", 48, 53], ["Intestinal trophozoite", "CELL", 152, 174], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 221, 232], ["pentobarbital", "SIMPLE_CHEMICAL", 246, 259], ["Giardia duodenalis", "SPECIES", 0, 18], ["Calves", "SPECIES", 180, 186], ["Giardia duodenalis", "SPECIES", 0, 18], ["Giardia duodenalis cysts", "PROBLEM", 0, 24], ["epifluorescence microscopy", "TEST", 72, 98], ["an intravenous injection of pentobarbital", "TREATMENT", 218, 259], ["duodenalis", "OBSERVATION_MODIFIER", 8, 18], ["cysts", "OBSERVATION", 19, 24], ["feces", "OBSERVATION_MODIFIER", 48, 53], ["trophozoite count", "OBSERVATION", 163, 180]]], ["The method of O'Handley et al. (2001) was used to enumerate G. duodenalis trophozoites from the intestines of each calf.", [["trophozoites", "ANATOMY", 74, 86], ["intestines", "ANATOMY", 96, 106], ["duodenalis", "ORGANISM", 63, 73], ["intestines", "ORGAN", 96, 106], ["calf", "ORGANISM_SUBDIVISION", 115, 119], ["G. duodenalis", "SPECIES", 60, 73], ["calf", "SPECIES", 115, 119], ["G. duodenalis", "SPECIES", 60, 73], ["duodenalis trophozoites", "OBSERVATION", 63, 86], ["intestines", "ANATOMY", 96, 106], ["each", "ANATOMY_MODIFIER", 110, 114], ["calf", "ANATOMY", 115, 119]]], ["In addition, samples of duodenum, proximal jejunum, distal jejunum, and ileum (each 5 cm in length) were immediately placed in 10% buffered formalin.", [["samples", "ANATOMY", 13, 20], ["duodenum", "ANATOMY", 24, 32], ["proximal jejunum", "ANATOMY", 34, 50], ["distal jejunum", "ANATOMY", 52, 66], ["ileum", "ANATOMY", 72, 77], ["formalin", "CHEMICAL", 140, 148], ["formalin", "CHEMICAL", 140, 148], ["duodenum", "MULTI-TISSUE_STRUCTURE", 24, 32], ["jejunum", "MULTI-TISSUE_STRUCTURE", 43, 50], ["jejunum", "MULTI-TISSUE_STRUCTURE", 59, 66], ["ileum", "ORGAN", 72, 77], ["formalin", "SIMPLE_CHEMICAL", 140, 148], ["duodenum", "ANATOMY", 24, 32], ["proximal", "ANATOMY_MODIFIER", 34, 42], ["jejunum", "ANATOMY", 43, 50], ["distal", "ANATOMY_MODIFIER", 52, 58], ["jejunum", "ANATOMY", 59, 66], ["ileum", "ANATOMY", 72, 77], ["5 cm", "OBSERVATION_MODIFIER", 84, 88]]], ["Following 48 h of fixation, tissues were trimmed and processed for histological examination.", [["tissues", "ANATOMY", 28, 35], ["tissues", "TISSUE", 28, 35], ["fixation", "TREATMENT", 18, 26], ["histological examination", "TEST", 67, 91], ["fixation", "OBSERVATION", 18, 26], ["tissues", "ANATOMY", 28, 35]]], ["All tissues were stained with haematoxylin and eosin stain for initial evaluation.", [["tissues", "ANATOMY", 4, 11], ["haematoxylin", "CHEMICAL", 30, 42], ["eosin", "CHEMICAL", 47, 52], ["tissues", "TISSUE", 4, 11], ["haematoxylin", "SIMPLE_CHEMICAL", 30, 42], ["eosin", "GENE_OR_GENE_PRODUCT", 47, 52], ["haematoxylin", "TEST", 30, 42], ["eosin stain", "TEST", 47, 58], ["initial evaluation", "TEST", 63, 81], ["tissues", "ANATOMY", 4, 11]]], ["Additional slides were examined using a Giemsa preparation.", [["a Giemsa preparation", "TREATMENT", 38, 58]]], ["All sections of intestines were examined under a light microscope.", [["sections", "ANATOMY", 4, 12], ["intestines", "ANATOMY", 16, 26], ["intestines", "ORGAN", 16, 26], ["a light microscope", "TEST", 47, 65], ["intestines", "ANATOMY", 16, 26]]], ["Sections were evaluated subjectively for specific increases in lymphocyte, plasma cell and eosinophil populations.", [["lymphocyte", "ANATOMY", 63, 73], ["plasma cell", "ANATOMY", 75, 86], ["eosinophil", "ANATOMY", 91, 101], ["lymphocyte", "CELL", 63, 73], ["plasma cell", "CELL", 75, 86], ["eosinophil", "CELL", 91, 101], ["lymphocyte", "CELL_TYPE", 63, 73], ["plasma cell", "CELL_TYPE", 75, 86], ["eosinophil populations", "CELL_TYPE", 91, 113], ["lymphocyte", "TEST", 63, 73], ["plasma cell", "TEST", 75, 86], ["eosinophil populations", "TREATMENT", 91, 113], ["lymphocyte", "ANATOMY", 63, 73], ["plasma cell", "OBSERVATION", 75, 86], ["eosinophil populations", "OBSERVATION", 91, 113]]], ["All sections were judged either normal or abnormal based on cellular infiltrates; degrees of enteritis were graded as minimal, mild, moderate or severe.", [["sections", "ANATOMY", 4, 12], ["cellular", "ANATOMY", 60, 68], ["enteritis", "DISEASE", 93, 102], ["cellular", "CELL", 60, 68], ["All sections", "TEST", 0, 12], ["abnormal based on cellular infiltrates", "PROBLEM", 42, 80], ["enteritis", "PROBLEM", 93, 102], ["normal", "OBSERVATION", 32, 38], ["abnormal", "OBSERVATION_MODIFIER", 42, 50], ["cellular", "OBSERVATION_MODIFIER", 60, 68], ["infiltrates", "OBSERVATION", 69, 80], ["degrees", "OBSERVATION_MODIFIER", 82, 89], ["enteritis", "OBSERVATION", 93, 102], ["minimal", "OBSERVATION_MODIFIER", 118, 125], ["mild", "OBSERVATION_MODIFIER", 127, 131], ["moderate", "OBSERVATION_MODIFIER", 133, 141], ["severe", "OBSERVATION_MODIFIER", 145, 151]]], ["Sections which contained protozoal structures were noted.Humoral immune responseBlood samples were collected from each calf by venipuncture once a week, beginning on the day of arrival at the AVC (day \u00c010) until the day of challenge with G. duodenalis cysts (day 39).", [["Blood samples", "ANATOMY", 80, 93], ["cysts", "ANATOMY", 252, 257], ["G. duodenalis cysts", "DISEASE", 238, 257], ["protozoal structures", "PATHOLOGICAL_FORMATION", 25, 45], ["Blood samples", "ORGANISM_SUBSTANCE", 80, 93], ["calf", "ORGANISM_SUBDIVISION", 119, 123], ["duodenalis", "ORGANISM", 241, 251], ["calf", "SPECIES", 119, 123], ["G. duodenalis", "SPECIES", 238, 251], ["G. duodenalis", "SPECIES", 238, 251], ["protozoal structures", "PROBLEM", 25, 45], ["Blood samples", "TEST", 80, 93], ["G. duodenalis cysts", "PROBLEM", 238, 257], ["protozoal structures", "OBSERVATION", 25, 45], ["cysts", "OBSERVATION", 252, 257]]], ["After challenge, venous blood samples were collected twice-weekly until the day of euthanasia (day 53).", [["venous blood samples", "ANATOMY", 17, 37], ["venous blood samples", "ORGANISM_SUBSTANCE", 17, 37], ["venous blood samples", "TEST", 17, 37], ["venous", "ANATOMY", 17, 23]]], ["G. duodenalis-specific antibodies in the serum were determined for each calf using a G. duodenalis-ELISA, designed previously for use with bovine serum diluted at 1:100 (O'Handley et al., 2003) .Data analysesDifferences in antibody titers (OD values) between vaccinated and non-vaccinated calves were assessed using repeated measure ANOVA.", [["serum", "ANATOMY", 41, 46], ["serum", "ANATOMY", 146, 151], ["G. duodenalis", "ORGANISM", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["calf", "ORGANISM_SUBDIVISION", 72, 76], ["G. duodenalis", "ORGANISM", 85, 98], ["bovine", "ORGANISM", 139, 145], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["calves", "ORGANISM", 289, 295], ["G. duodenalis-specific antibodies", "PROTEIN", 0, 33], ["G. duodenalis", "SPECIES", 0, 13], ["calf", "SPECIES", 72, 76], ["G. duodenalis", "SPECIES", 85, 98], ["bovine", "SPECIES", 139, 145], ["calves", "SPECIES", 289, 295], ["G. duodenalis", "SPECIES", 0, 13], ["G. duodenalis", "SPECIES", 85, 98], ["bovine", "SPECIES", 139, 145], ["non-vaccinated", "SPECIES", 274, 288], ["G. duodenalis", "TEST", 0, 13], ["specific antibodies", "TEST", 14, 33], ["the serum", "TEST", 37, 46], ["bovine serum", "TEST", 139, 151], ["Data analyses", "TEST", 195, 208], ["antibody titers", "TEST", 223, 238], ["OD values", "TEST", 240, 249], ["vaccinated and non-vaccinated calves", "TREATMENT", 259, 295], ["duodenalis", "OBSERVATION", 3, 13], ["calf", "ANATOMY", 72, 76]]], ["Only titers measured after vaccination or PBS-injection, respectively, were included in that analysis.", [["vaccination", "TREATMENT", 27, 38], ["PBS-injection", "TREATMENT", 42, 55]]], ["To approximate the normal distribution, trophozoite and cyst counts were naturally log-transformed.", [["trophozoite", "ANATOMY", 40, 51], ["cyst", "ANATOMY", 56, 60], ["trophozoite", "CELL", 40, 51], ["cyst", "PATHOLOGICAL_FORMATION", 56, 60], ["cyst counts", "TEST", 56, 67], ["normal", "OBSERVATION", 19, 25], ["distribution", "OBSERVATION_MODIFIER", 26, 38], ["trophozoite", "OBSERVATION_MODIFIER", 40, 51], ["cyst", "OBSERVATION", 56, 60]]], ["The geometric mean was calculated for the trophozoite counts in each intestinal segment.", [["trophozoite", "ANATOMY", 42, 53], ["intestinal", "ANATOMY", 69, 79], ["trophozoite", "CELL", 42, 53], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 69, 87], ["The geometric mean", "TEST", 0, 18], ["the trophozoite counts", "TEST", 38, 60], ["trophozoite counts", "OBSERVATION", 42, 60], ["intestinal", "ANATOMY", 69, 79], ["segment", "ANATOMY_MODIFIER", 80, 87]]], ["To analyze geometric means and to perform natural logtransformation, the value 1 was added to the intestinal trophozoite and the fecal cyst counts.", [["intestinal trophozoite", "ANATOMY", 98, 120], ["fecal cyst", "ANATOMY", 129, 139], ["intestinal trophozoite", "CELL", 98, 120], ["fecal cyst", "PATHOLOGICAL_FORMATION", 129, 139], ["natural logtransformation", "PROBLEM", 42, 67], ["the intestinal trophozoite", "PROBLEM", 94, 120], ["the fecal cyst counts", "TEST", 125, 146], ["intestinal", "ANATOMY", 98, 108], ["trophozoite", "OBSERVATION", 109, 120], ["fecal", "ANATOMY", 129, 134], ["cyst", "OBSERVATION", 135, 139]]], ["Mean numbers of cysts shed in vaccinated and non-vaccinated calves were compared using the non-parametric Wilcoxon test.", [["cysts", "ANATOMY", 16, 21], ["calves", "ORGANISM", 60, 66], ["calves", "SPECIES", 60, 66], ["Mean numbers", "TEST", 0, 12], ["cysts", "PROBLEM", 16, 21], ["vaccinated and non-vaccinated calves", "TREATMENT", 30, 66], ["the non-parametric Wilcoxon test", "TEST", 87, 119], ["cysts", "OBSERVATION", 16, 21]]], ["For this test, only the fecal cyst counts from days 7 to 14 after challenge were included.", [["fecal cyst", "ANATOMY", 24, 34], ["fecal cyst", "MULTI-TISSUE_STRUCTURE", 24, 34], ["this test", "TEST", 4, 13], ["the fecal cyst counts", "TEST", 20, 41], ["fecal", "ANATOMY", 24, 29], ["cyst", "OBSERVATION", 30, 34]]], ["The same test was also applied to compare trophozoite counts between the vaccinated and non-vaccinated calves in each intestinal segment.", [["trophozoite", "ANATOMY", 42, 53], ["intestinal", "ANATOMY", 118, 128], ["trophozoite", "CELL", 42, 53], ["calves", "ORGANISM", 103, 109], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 118, 136], ["calves", "SPECIES", 103, 109], ["non-vaccinated", "SPECIES", 88, 102], ["The same test", "TEST", 0, 13], ["trophozoite counts", "TEST", 42, 60], ["the vaccinated and non-vaccinated calves", "TREATMENT", 69, 109], ["non-vaccinated calves", "OBSERVATION", 88, 109], ["each", "ANATOMY_MODIFIER", 113, 117], ["intestinal", "ANATOMY", 118, 128], ["segment", "ANATOMY_MODIFIER", 129, 136]]], ["Analyses were performed using STATA TM 9.2 (StataCorp, College Station, Texas, USA).", [["Analyses", "TEST", 0, 8], ["STATA TM", "TEST", 30, 38]]], ["Values of P < 0.05 were considered statistically significant.Humoral immune responseAt the start of the study, mean serum titer OD values were 1.24 and 1.37 for the vaccinated and nonvaccinated group, respectively (Fig. 1) .", [["serum", "ANATOMY", 116, 121], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["nonvaccinated", "SPECIES", 180, 193], ["Values", "TEST", 0, 6], ["P", "TEST", 10, 11], ["the study", "TEST", 100, 109], ["mean serum titer OD values", "TEST", 111, 137]]], ["Serum antibody titers decreased during the first 2 weeks of the study and were lowest at 0.83 and 0.85 in the vaccinated and nonvaccinated group, respectively, 4 days after vaccination or PBS-injection.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["nonvaccinated", "SPECIES", 125, 138], ["Serum antibody titers", "TEST", 0, 21], ["the study", "TEST", 60, 69], ["vaccination", "TREATMENT", 173, 184], ["PBS", "TREATMENT", 188, 191], ["injection", "TREATMENT", 192, 201]]], ["After vaccination, antibody titers increased in the vaccinated calves and were significantly higher than in the non-vaccinated calves ( Fig. 1 ; P = 0.006).", [["calves", "ORGANISM", 63, 69], ["calves", "ORGANISM", 127, 133], ["calves", "SPECIES", 63, 69], ["calves", "SPECIES", 127, 133], ["vaccination", "TREATMENT", 6, 17], ["antibody titers", "TEST", 19, 34], ["P", "TEST", 145, 146], ["significantly", "OBSERVATION_MODIFIER", 79, 92], ["higher", "OBSERVATION_MODIFIER", 93, 99], ["non-vaccinated calves", "ANATOMY", 112, 133]]], ["Antibody titer in the vaccinated group increased over time, while they remained relatively stable in the non-vaccinated group (P < 0.001).Giardia cyst excretion after challengeNo Giardia duodenalis cysts were observed in any of the calves before oral challenge.", [["cyst", "ANATOMY", 146, 150], ["cysts", "ANATOMY", 198, 203], ["oral", "ANATOMY", 246, 250], ["Giardia duodenalis cysts", "DISEASE", 179, 203], ["Giardia cyst", "PATHOLOGICAL_FORMATION", 138, 150], ["challengeNo", "ORGANISM", 167, 178], ["Giardia duodenalis", "ORGANISM", 179, 197], ["calves", "ORGANISM", 232, 238], ["oral", "ORGANISM_SUBDIVISION", 246, 250], ["Giardia duodenalis", "SPECIES", 179, 197], ["calves", "SPECIES", 232, 238], ["Giardia duodenalis", "SPECIES", 179, 197], ["Antibody titer", "TEST", 0, 14], ["Giardia cyst excretion", "PROBLEM", 138, 160], ["challengeNo Giardia duodenalis cysts", "PROBLEM", 167, 203], ["oral challenge", "TREATMENT", 246, 260], ["stable", "OBSERVATION_MODIFIER", 91, 97], ["cyst", "OBSERVATION", 146, 150], ["duodenalis cysts", "OBSERVATION", 187, 203], ["calves", "ANATOMY", 232, 238]]], ["Cyst excretion increased 7 days after challenge, and 10 days after challenge all calves from both groups were shedding G. duodenalis cysts.", [["Cyst", "ANATOMY", 0, 4], ["cysts", "ANATOMY", 133, 138], ["G. duodenalis cysts", "DISEASE", 119, 138], ["Cyst", "ORGANISM_SUBSTANCE", 0, 4], ["calves", "ORGANISM", 81, 87], ["G. duodenalis", "ORGANISM", 119, 132], ["calves", "SPECIES", 81, 87], ["G. duodenalis", "SPECIES", 119, 132], ["G. duodenalis", "SPECIES", 119, 132], ["Cyst excretion", "PROBLEM", 0, 14], ["shedding G. duodenalis cysts", "PROBLEM", 110, 138], ["excretion", "OBSERVATION_MODIFIER", 5, 14], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["7 days", "OBSERVATION_MODIFIER", 25, 31], ["duodenalis cysts", "OBSERVATION", 122, 138]]], ["Mean numbers of cysts shed in the feces tended to be higher in the vaccinated calves compared to the non-vaccinated calves ( Fig. 2 ; P = 0.07).", [["cysts", "ANATOMY", 16, 21], ["feces", "ANATOMY", 34, 39], ["feces", "ORGANISM_SUBDIVISION", 34, 39], ["calves", "ORGANISM", 78, 84], ["calves", "ORGANISM", 116, 122], ["calves", "SPECIES", 78, 84], ["calves", "SPECIES", 116, 122], ["calves", "SPECIES", 116, 122], ["Mean numbers", "TEST", 0, 12], ["cysts", "PROBLEM", 16, 21], ["Fig.", "TEST", 125, 129], ["P", "TEST", 134, 135], ["numbers", "OBSERVATION_MODIFIER", 5, 12], ["cysts", "OBSERVATION", 16, 21], ["feces", "ANATOMY", 34, 39], ["higher", "OBSERVATION_MODIFIER", 53, 59]]], ["Mean numbers of cysts shed in vaccinated and non-vaccinated calves between days seven to fourteen after challenge were 7.8 cysts/g of feces (95% confidence interval: 6.1-9.6) and 5.6 cysts/g of feces (95% confidence interval: 3.4-7.8), respectively.Trophozoite countGeometric mean G. duodenalis trophozoite count per centimeter was higher in all sections of the small intestines in vaccinated compared to non-vaccinated calves ( Table 1 ).", [["cysts", "ANATOMY", 16, 21], ["trophozoite", "ANATOMY", 295, 306], ["sections", "ANATOMY", 346, 354], ["small intestines", "ANATOMY", 362, 378], ["calves", "ORGANISM", 60, 66], ["feces", "ORGANISM", 134, 139], ["feces", "ORGANISM", 194, 199], ["duodenalis", "ORGANISM", 284, 294], ["trophozoite", "CELL", 295, 306], ["small intestines", "ORGAN", 362, 378], ["calves", "ORGANISM", 420, 426], ["calves", "SPECIES", 60, 66], ["G. duodenalis", "SPECIES", 281, 294], ["calves", "SPECIES", 420, 426], ["G. duodenalis", "SPECIES", 281, 294], ["calves", "SPECIES", 420, 426], ["Mean numbers", "TEST", 0, 12], ["cysts", "PROBLEM", 16, 21], ["cysts", "TEST", 123, 128], ["feces", "TEST", 134, 139], ["interval", "TEST", 156, 164], ["cysts", "TEST", 183, 188], ["feces", "TEST", 194, 199], ["interval", "TEST", 216, 224], ["Trophozoite count", "TEST", 249, 266], ["Geometric mean G. duodenalis trophozoite count", "TEST", 266, 312], ["the small intestines", "PROBLEM", 358, 378], ["cysts", "OBSERVATION", 16, 21], ["5.6 cysts", "OBSERVATION_MODIFIER", 179, 188], ["duodenalis trophozoite", "OBSERVATION", 284, 306], ["higher", "OBSERVATION_MODIFIER", 332, 338], ["small intestines", "ANATOMY", 362, 378]]], ["The Wilcoxon test was, however, not significant for the differences between the counts of the vaccinated and non-vaccinated groups in any intestinal segment (smallest P = 0.26 in distal jejunum).Histology of intestinal sectionsTwo calves demonstrated changes in the duodenum consistent with moderate enteritis; one calf was in the vaccinated group and one calf was not vaccinated.", [["intestinal", "ANATOMY", 138, 148], ["distal jejunum", "ANATOMY", 179, 193], ["intestinal sections", "ANATOMY", 208, 227], ["duodenum", "ANATOMY", 266, 274], ["enteritis", "DISEASE", 300, 309], ["intestinal segment", "MULTI-TISSUE_STRUCTURE", 138, 156], ["jejunum", "ORGAN", 186, 193], ["intestinal sections", "MULTI-TISSUE_STRUCTURE", 208, 227], ["calves", "ORGANISM", 231, 237], ["duodenum", "ORGAN", 266, 274], ["calf", "ORGANISM", 315, 319], ["calf", "ORGANISM", 356, 360], ["calves", "SPECIES", 231, 237], ["calf", "SPECIES", 315, 319], ["calf", "SPECIES", 356, 360], ["The Wilcoxon test", "TEST", 0, 17], ["the counts", "TEST", 76, 86], ["changes in the duodenum", "PROBLEM", 251, 274], ["moderate enteritis", "PROBLEM", 291, 309], ["intestinal segment", "ANATOMY", 138, 156], ["smallest", "OBSERVATION_MODIFIER", 158, 166], ["distal", "ANATOMY_MODIFIER", 179, 185], ["jejunum", "ANATOMY", 186, 193], ["intestinal", "ANATOMY", 208, 218], ["duodenum", "ANATOMY", 266, 274], ["consistent with", "UNCERTAINTY", 275, 290], ["moderate", "OBSERVATION_MODIFIER", 291, 299], ["enteritis", "OBSERVATION", 300, 309], ["calf", "ANATOMY", 315, 319], ["calf", "ANATOMY", 356, 360]]], ["No abnormalities were found upon examination of other histological preparations from any of the other calves and no trophozoites were found in any of the slides.Clinical signs and fecal scoreIn the vaccinated group, two calves experienced diarrhea and respiratory tract problems before G. duodenalis challenge, while two other calves in this group had only respiratory tract problems or diarrhea before G. duodenalis challenge.", [["trophozoites", "ANATOMY", 116, 128], ["fecal", "ANATOMY", 180, 185], ["respiratory tract", "ANATOMY", 252, 269], ["respiratory tract", "ANATOMY", 357, 374], ["diarrhea", "DISEASE", 239, 247], ["respiratory tract problems", "DISEASE", 252, 278], ["respiratory tract problems", "DISEASE", 357, 383], ["diarrhea", "DISEASE", 387, 395], ["calves", "ORGANISM", 102, 108], ["trophozoites", "CELL", 116, 128], ["fecal", "ORGANISM_SUBSTANCE", 180, 185], ["calves", "ORGANISM", 220, 226], ["tract", "ORGANISM_SUBDIVISION", 264, 269], ["G. duodenalis", "ORGANISM", 286, 299], ["calves", "ORGANISM", 327, 333], ["respiratory tract", "ORGANISM_SUBDIVISION", 357, 374], ["G. duodenalis", "ORGANISM", 403, 416], ["calves", "SPECIES", 102, 108], ["calves", "SPECIES", 220, 226], ["G. duodenalis", "SPECIES", 286, 299], ["calves", "SPECIES", 327, 333], ["G. duodenalis", "SPECIES", 403, 416], ["G. duodenalis", "SPECIES", 286, 299], ["G. duodenalis", "SPECIES", 403, 416], ["abnormalities", "PROBLEM", 3, 16], ["examination", "TEST", 33, 44], ["other histological preparations", "TEST", 48, 79], ["trophozoites", "PROBLEM", 116, 128], ["Clinical signs", "TEST", 161, 175], ["fecal score", "TEST", 180, 191], ["diarrhea", "PROBLEM", 239, 247], ["respiratory tract problems", "PROBLEM", 252, 278], ["G. duodenalis challenge", "PROBLEM", 286, 309], ["respiratory tract problems", "PROBLEM", 357, 383], ["diarrhea", "PROBLEM", 387, 395], ["G. duodenalis challenge", "PROBLEM", 403, 426], ["abnormalities", "OBSERVATION", 3, 16], ["no", "UNCERTAINTY", 113, 115], ["trophozoites", "OBSERVATION", 116, 128], ["fecal score", "OBSERVATION", 180, 191], ["respiratory tract", "ANATOMY", 252, 269], ["respiratory tract", "ANATOMY", 357, 374]]], ["One calf in the nonvaccinated group had diarrhea and respiratory tract problems before challenge, while three calves in this group had only respiratory tract problems or diarrhea before G. duodenalis challenge.", [["respiratory tract", "ANATOMY", 53, 70], ["respiratory tract", "ANATOMY", 140, 157], ["diarrhea", "DISEASE", 40, 48], ["respiratory tract problems", "DISEASE", 53, 79], ["respiratory tract problems", "DISEASE", 140, 166], ["diarrhea", "DISEASE", 170, 178], ["calf", "ORGANISM", 4, 8], ["tract", "ORGANISM_SUBDIVISION", 65, 70], ["calves", "ORGANISM", 110, 116], ["respiratory tract", "ORGANISM_SUBDIVISION", 140, 157], ["G. duodenalis", "ORGANISM", 186, 199], ["calf", "SPECIES", 4, 8], ["calves", "SPECIES", 110, 116], ["G. duodenalis", "SPECIES", 186, 199], ["G. duodenalis", "SPECIES", 186, 199], ["diarrhea", "PROBLEM", 40, 48], ["respiratory tract problems", "PROBLEM", 53, 79], ["respiratory tract problems", "PROBLEM", 140, 166], ["diarrhea", "PROBLEM", 170, 178], ["G. duodenalis challenge", "PROBLEM", 186, 209], ["calf", "ANATOMY", 4, 8], ["respiratory tract", "ANATOMY", 53, 70], ["respiratory tract", "ANATOMY", 140, 157]]], ["No G. duodenalis cysts were detected in the feces of the five calves that experienced diarrhea before challenge with G. duodenalis cysts.", [["cysts", "ANATOMY", 17, 22], ["feces", "ANATOMY", 44, 49], ["cysts", "ANATOMY", 131, 136], ["G. duodenalis cysts", "DISEASE", 3, 22], ["diarrhea", "DISEASE", 86, 94], ["G. duodenalis cysts", "DISEASE", 117, 136], ["G. duodenalis", "ORGANISM", 3, 16], ["feces", "ORGANISM_SUBDIVISION", 44, 49], ["calves", "ORGANISM", 62, 68], ["G. duodenalis", "ORGANISM", 117, 130], ["G. duodenalis", "SPECIES", 3, 16], ["calves", "SPECIES", 62, 68], ["G. duodenalis", "SPECIES", 117, 130], ["G. duodenalis", "SPECIES", 3, 16], ["G. duodenalis", "SPECIES", 117, 130], ["G. duodenalis cysts", "PROBLEM", 3, 22], ["diarrhea", "PROBLEM", 86, 94], ["G. duodenalis cysts", "PROBLEM", 117, 136], ["duodenalis", "OBSERVATION_MODIFIER", 6, 16], ["cysts", "OBSERVATION", 17, 22], ["feces", "ANATOMY_MODIFIER", 44, 49], ["five calves", "ANATOMY", 57, 68], ["diarrhea", "OBSERVATION", 86, 94], ["duodenalis cysts", "OBSERVATION", 120, 136]]], ["Cryptosporidium parvum oocysts were observed in the feces of four of these calves.", [["oocysts", "ANATOMY", 23, 30], ["feces", "ANATOMY", 52, 57], ["Cryptosporidium parvum oocysts", "DISEASE", 0, 30], ["Cryptosporidium parvum", "ORGANISM", 0, 22], ["oocysts", "ORGANISM", 23, 30], ["feces", "ORGANISM_SUBDIVISION", 52, 57], ["calves", "ORGANISM", 75, 81], ["Cryptosporidium parvum", "SPECIES", 0, 22], ["calves", "SPECIES", 75, 81], ["Cryptosporidium parvum", "SPECIES", 0, 22], ["Cryptosporidium parvum oocysts", "PROBLEM", 0, 30], ["parvum oocysts", "OBSERVATION", 16, 30], ["feces", "ANATOMY_MODIFIER", 52, 57], ["four", "ANATOMY_MODIFIER", 61, 65], ["calves", "ANATOMY", 75, 81]]], ["One calf in the non-vaccinated group that experienced diarrhea before challenge had a short bout of diarrhea on the fourth day after challenge.", [["diarrhea", "DISEASE", 54, 62], ["diarrhea", "DISEASE", 100, 108], ["calf", "ORGANISM", 4, 8], ["calf", "SPECIES", 4, 8], ["diarrhea", "PROBLEM", 54, 62], ["diarrhea", "PROBLEM", 100, 108], ["calf", "ANATOMY", 4, 8], ["diarrhea", "OBSERVATION", 100, 108]]], ["No G. duodenalis cysts or C. parvum oocysts were detected in the feces of this calf.", [["cysts", "ANATOMY", 17, 22], ["feces", "ANATOMY", 65, 70], ["G. duodenalis cysts", "DISEASE", 3, 22], ["G. duodenalis", "ORGANISM", 3, 16], ["C. parvum", "ORGANISM", 26, 35], ["oocysts", "ORGANISM", 36, 43], ["feces", "ORGANISM_SUBDIVISION", 65, 70], ["calf", "ORGANISM_SUBDIVISION", 79, 83], ["G. duodenalis", "SPECIES", 3, 16], ["C. parvum", "SPECIES", 26, 35], ["calf", "SPECIES", 79, 83], ["G. duodenalis", "SPECIES", 3, 16], ["C. parvum", "SPECIES", 26, 35], ["G. duodenalis cysts", "PROBLEM", 3, 22], ["C. parvum oocysts", "PROBLEM", 26, 43], ["duodenalis", "OBSERVATION_MODIFIER", 6, 16], ["cysts", "OBSERVATION", 17, 22], ["C.", "OBSERVATION_MODIFIER", 26, 28], ["parvum oocysts", "OBSERVATION", 29, 43], ["feces", "ANATOMY_MODIFIER", 65, 70], ["calf", "ANATOMY", 79, 83]]], ["Further diagnostic tests to pursue other causes of diarrhea were not performed in any of the calves.", [["diarrhea", "DISEASE", 51, 59], ["calves", "ORGANISM", 93, 99], ["calves", "SPECIES", 93, 99], ["Further diagnostic tests", "TEST", 0, 24], ["diarrhea", "PROBLEM", 51, 59], ["diarrhea", "OBSERVATION", 51, 59], ["calves", "ANATOMY", 93, 99]]], ["Diagnostic Services at the AVC performed a postmortem examination of the calf that died after vaccination.", [["calf", "ORGANISM", 73, 77], ["calf", "SPECIES", 73, 77], ["a postmortem examination", "TEST", 41, 65], ["vaccination", "TREATMENT", 94, 105], ["calf", "ANATOMY", 73, 77]]], ["The clinical signs, gross and microscopic findings observed were consistent with an acute neonatal diarrhea, dehydration, and cardiovascular collapse.", [["cardiovascular", "ANATOMY", 126, 140], ["diarrhea", "DISEASE", 99, 107], ["dehydration", "DISEASE", 109, 120], ["cardiovascular collapse", "DISEASE", 126, 149], ["The clinical signs", "TEST", 0, 18], ["microscopic findings", "TEST", 30, 50], ["an acute neonatal diarrhea", "PROBLEM", 81, 107], ["dehydration", "PROBLEM", 109, 120], ["cardiovascular collapse", "PROBLEM", 126, 149], ["consistent with", "UNCERTAINTY", 65, 80], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["neonatal", "OBSERVATION_MODIFIER", 90, 98], ["diarrhea", "OBSERVATION", 99, 107], ["dehydration", "OBSERVATION", 109, 120], ["cardiovascular", "ANATOMY", 126, 140], ["collapse", "OBSERVATION", 141, 149]]], ["The etiologic agents detected from submitted specimens were C. parvum and coronavirus.Clinical signs and fecal scoreThere was no difference in fecal scores between the two groups.", [["specimens", "ANATOMY", 45, 54], ["fecal", "ANATOMY", 105, 110], ["fecal", "ANATOMY", 143, 148], ["C. parvum", "ORGANISM", 60, 69], ["coronavirus", "ORGANISM", 74, 85], ["fecal", "ORGANISM_SUBSTANCE", 105, 110], ["fecal", "ORGANISM_SUBSTANCE", 143, 148], ["C. parvum", "SPECIES", 60, 69], ["C. parvum", "SPECIES", 60, 69], ["submitted specimens", "TEST", 35, 54], ["C. parvum", "PROBLEM", 60, 69], ["coronavirus", "PROBLEM", 74, 85], ["Clinical signs", "TEST", 86, 100], ["fecal score", "TEST", 105, 116], ["difference in fecal scores", "PROBLEM", 129, 155], ["fecal score", "OBSERVATION", 105, 116], ["no", "UNCERTAINTY", 126, 128], ["difference", "OBSERVATION_MODIFIER", 129, 139], ["fecal scores", "OBSERVATION", 143, 155]]], ["All calves continued to eat after the challenge and severe clinical signs were not observed after infection with G. duodenalis.DiscussionDespite a significantly higher humoral immune response in vaccinated compared to non-vaccinated calves, subcutaneous vaccination against giardiasis in calves was not efficacious in reducing cyst shedding.", [["subcutaneous", "ANATOMY", 241, 253], ["cyst", "ANATOMY", 327, 331], ["infection", "DISEASE", 98, 107], ["giardiasis", "DISEASE", 274, 284], ["calves", "ORGANISM", 4, 10], ["G. duodenalis", "ORGANISM", 113, 126], ["calves", "ORGANISM", 233, 239], ["calves", "ORGANISM", 288, 294], ["cyst", "ORGAN", 327, 331], ["calves", "SPECIES", 4, 10], ["G. duodenalis", "SPECIES", 113, 126], ["calves", "SPECIES", 233, 239], ["calves", "SPECIES", 288, 294], ["G. duodenalis", "SPECIES", 113, 126], ["calves", "SPECIES", 233, 239], ["calves", "SPECIES", 288, 294], ["severe clinical signs", "PROBLEM", 52, 73], ["infection", "PROBLEM", 98, 107], ["G. duodenalis", "PROBLEM", 113, 126], ["a significantly higher humoral immune response", "PROBLEM", 145, 191], ["non-vaccinated calves", "TREATMENT", 218, 239], ["subcutaneous vaccination", "TREATMENT", 241, 265], ["giardiasis in calves", "PROBLEM", 274, 294], ["reducing cyst shedding", "PROBLEM", 318, 340], ["calves", "OBSERVATION", 4, 10], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["duodenalis", "OBSERVATION", 116, 126], ["subcutaneous", "ANATOMY", 241, 253], ["not", "UNCERTAINTY", 299, 302], ["efficacious", "OBSERVATION_MODIFIER", 303, 314], ["cyst", "OBSERVATION", 327, 331]]], ["There were no significant differences between vaccinated and non-vaccinated calves with respect to the number of trophozoites present per cm of small intestine.", [["trophozoites", "ANATOMY", 113, 125], ["small intestine", "ANATOMY", 144, 159], ["calves", "ORGANISM", 76, 82], ["trophozoites", "CELL", 113, 125], ["small intestine", "ORGAN", 144, 159], ["calves", "SPECIES", 76, 82], ["significant differences between vaccinated and non-vaccinated calves", "PROBLEM", 14, 82], ["trophozoites", "PROBLEM", 113, 125], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["trophozoites", "OBSERVATION", 113, 125], ["small intestine", "ANATOMY", 144, 159]]], ["All calves shed G. duodenalis cysts after challenge and vaccinated calves had a tendency to shed more cysts than non-vaccinated calves.", [["cysts", "ANATOMY", 30, 35], ["cysts", "ANATOMY", 102, 107], ["G. duodenalis cysts", "DISEASE", 16, 35], ["cysts", "DISEASE", 102, 107], ["calves", "ORGANISM", 4, 10], ["G. duodenalis", "ORGANISM", 16, 29], ["calves", "ORGANISM", 67, 73], ["calves", "ORGANISM", 128, 134], ["calves", "SPECIES", 4, 10], ["G. duodenalis", "SPECIES", 16, 29], ["calves", "SPECIES", 67, 73], ["calves", "SPECIES", 128, 134], ["G. duodenalis", "SPECIES", 16, 29], ["duodenalis cysts", "PROBLEM", 19, 35], ["vaccinated calves", "PROBLEM", 56, 73], ["a tendency to shed more cysts than non-vaccinated calves", "PROBLEM", 78, 134], ["duodenalis", "OBSERVATION_MODIFIER", 19, 29], ["cysts", "OBSERVATION", 30, 35], ["more", "OBSERVATION_MODIFIER", 97, 101], ["cysts", "OBSERVATION", 102, 107]]], ["There were no severe clinical signs observed due to giardiasis.DiscussionIn dogs and cats, subcutaneous administration of a G. duodenalis vaccine resulted in a reduced number of cysts shed in the feces, a lower number of trophozoites in the intestines, an increased feed intake as well as weight gain and a shorter time during which abnormal feces were passed (Olson et al., 1996 .", [["subcutaneous", "ANATOMY", 91, 103], ["cysts", "ANATOMY", 178, 183], ["feces", "ANATOMY", 196, 201], ["trophozoites", "ANATOMY", 221, 233], ["intestines", "ANATOMY", 241, 251], ["feces", "ANATOMY", 342, 347], ["giardiasis", "DISEASE", 52, 62], ["G. duodenalis", "CHEMICAL", 124, 137], ["cysts", "DISEASE", 178, 183], ["weight gain", "DISEASE", 289, 300], ["dogs", "ORGANISM", 76, 80], ["cats", "ORGANISM", 85, 89], ["G. duodenalis", "ORGANISM", 124, 137], ["cysts", "PATHOLOGICAL_FORMATION", 178, 183], ["feces", "ORGANISM_SUBDIVISION", 196, 201], ["trophozoites", "CELL", 221, 233], ["intestines", "ORGAN", 241, 251], ["feces", "ORGANISM_SUBSTANCE", 342, 347], ["dogs", "SPECIES", 76, 80], ["cats", "SPECIES", 85, 89], ["G. duodenalis", "SPECIES", 124, 137], ["G. duodenalis", "SPECIES", 124, 137], ["severe clinical signs", "PROBLEM", 14, 35], ["giardiasis", "PROBLEM", 52, 62], ["cats", "TREATMENT", 85, 89], ["subcutaneous administration", "TREATMENT", 91, 118], ["a G. duodenalis vaccine", "TREATMENT", 122, 145], ["a reduced number of cysts", "PROBLEM", 158, 183], ["trophozoites in the intestines", "PROBLEM", 221, 251], ["weight gain", "PROBLEM", 289, 300], ["abnormal feces", "PROBLEM", 333, 347], ["no", "UNCERTAINTY", 11, 13], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["giardiasis", "OBSERVATION", 52, 62], ["reduced", "OBSERVATION_MODIFIER", 160, 167], ["number", "OBSERVATION_MODIFIER", 168, 174], ["cysts", "OBSERVATION", 178, 183], ["feces", "ANATOMY", 196, 201], ["lower number", "OBSERVATION_MODIFIER", 205, 217], ["trophozoites", "OBSERVATION", 221, 233], ["intestines", "ANATOMY", 241, 251], ["increased", "OBSERVATION_MODIFIER", 256, 265], ["feed intake", "OBSERVATION", 266, 277]]], ["A study has also been conducted on the use of a G. duodenalis vaccine as a therapeutic agent in dogs and cats.", [["G. duodenalis", "ORGANISM", 48, 61], ["dogs", "ORGANISM", 96, 100], ["cats", "ORGANISM", 105, 109], ["G. duodenalis", "SPECIES", 48, 61], ["dogs", "SPECIES", 96, 100], ["cats", "SPECIES", 105, 109], ["G. duodenalis", "SPECIES", 48, 61], ["A study", "TEST", 0, 7], ["a G. duodenalis vaccine", "TREATMENT", 46, 69]]], ["Olson et al. (2001) found that dogs which suffered from chronic giardiasis and which had received treatments with a G. duodenalis vaccine ceased to shed fecal cysts, and clinical signs disappeared.", [["fecal cysts", "ANATOMY", 153, 164], ["giardiasis", "DISEASE", 64, 74], ["fecal cysts", "DISEASE", 153, 164], ["dogs", "ORGANISM", 31, 35], ["G. duodenalis", "ORGANISM", 116, 129], ["fecal cysts", "PATHOLOGICAL_FORMATION", 153, 164], ["dogs", "SPECIES", 31, 35], ["G. duodenalis", "SPECIES", 116, 129], ["G. duodenalis", "SPECIES", 116, 129], ["chronic giardiasis", "PROBLEM", 56, 74], ["treatments", "TREATMENT", 98, 108], ["a G. duodenalis vaccine", "TREATMENT", 114, 137], ["fecal cysts", "PROBLEM", 153, 164], ["clinical signs", "TEST", 170, 184], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["giardiasis", "OBSERVATION", 64, 74], ["fecal", "ANATOMY", 153, 158], ["cysts", "OBSERVATION", 159, 164]]], ["However, numerous other studies have failed to demonstrate a significant effect (Payne et al., 2002; Stein et al., 2003; Anderson et al., 2004) .", [["numerous other studies", "TEST", 9, 31], ["significant", "OBSERVATION_MODIFIER", 61, 72]]], ["Reminiscent of the results presented in this paper, Anderson et al. (2004) reported that more dogs in the vaccinated group shed G. duodenalis compared to the non-vaccinated group, although fewer vaccinated dogs were positive for G. duodenalis at the end of that study.", [["G. duodenalis", "DISEASE", 128, 141], ["dogs", "ORGANISM", 94, 98], ["G. duodenalis", "ORGANISM", 128, 141], ["dogs", "ORGANISM", 206, 210], ["G. duodenalis", "ORGANISM", 229, 242], ["dogs", "SPECIES", 94, 98], ["G. duodenalis", "SPECIES", 128, 141], ["dogs", "SPECIES", 206, 210], ["G. duodenalis", "SPECIES", 229, 242], ["G. duodenalis", "SPECIES", 128, 141], ["G. duodenalis", "SPECIES", 229, 242], ["G. duodenalis", "PROBLEM", 128, 141], ["fewer vaccinated dogs", "PROBLEM", 189, 210], ["G. duodenalis", "PROBLEM", 229, 242], ["that study", "TEST", 257, 267], ["duodenalis", "ANATOMY", 131, 141], ["duodenalis", "OBSERVATION", 232, 242]]], ["To our knowledge, use of a vaccine against giardiasis in calves has not been reported previously.DiscussionWe can only speculate as to why this vaccine failed to prevent G. duodenalis infection in calves.", [["giardiasis", "DISEASE", 43, 53], ["G. duodenalis infection", "DISEASE", 170, 193], ["calves", "ORGANISM", 57, 63], ["G. duodenalis", "ORGANISM", 170, 183], ["calves", "ORGANISM", 197, 203], ["calves", "SPECIES", 57, 63], ["G. duodenalis", "SPECIES", 170, 183], ["calves", "SPECIES", 197, 203], ["G. duodenalis", "SPECIES", 170, 183], ["a vaccine", "TREATMENT", 25, 34], ["giardiasis in calves", "PROBLEM", 43, 63], ["this vaccine", "TREATMENT", 139, 151], ["G. duodenalis infection in calves", "PROBLEM", 170, 203], ["duodenalis", "OBSERVATION_MODIFIER", 173, 183], ["infection", "OBSERVATION", 184, 193], ["calves", "ANATOMY", 197, 203]]], ["The vaccine failure in the calves may have been due to the large inoculation dose used for challenge or due to continuous exposure to cysts within the environment following challenge, despite regular cleaning and disinfection.", [["cysts", "ANATOMY", 134, 139], ["cysts", "DISEASE", 134, 139], ["calves", "ORGANISM", 27, 33], ["calves", "SPECIES", 27, 33], ["The vaccine failure in the calves", "PROBLEM", 0, 33], ["the large inoculation dose", "TREATMENT", 55, 81], ["cysts", "PROBLEM", 134, 139], ["regular cleaning", "TREATMENT", 192, 208], ["disinfection", "TREATMENT", 213, 225], ["failure", "OBSERVATION", 12, 19], ["calves", "ANATOMY", 27, 33], ["large", "OBSERVATION_MODIFIER", 59, 64], ["inoculation", "OBSERVATION", 65, 76], ["cysts", "OBSERVATION", 134, 139]]], ["However, higher challenge doses (10 6 G. duodenalis cysts) were used in other vaccination studies where the vaccine was efficacious (Olson et al., 1996 .", [["cysts", "ANATOMY", 52, 57], ["duodenalis", "ORGANISM", 41, 51], ["cysts", "PATHOLOGICAL_FORMATION", 52, 57], ["G. duodenalis", "SPECIES", 38, 51], ["G. duodenalis", "SPECIES", 38, 51], ["duodenalis cysts", "PROBLEM", 41, 57], ["other vaccination studies", "TEST", 72, 97], ["the vaccine", "TREATMENT", 104, 115]]], ["Antibody titers in dogs and cats increased rapidly within 3 weeks of vaccination (Olson et al., 1996 .", [["dogs", "ORGANISM", 19, 23], ["cats", "ORGANISM", 28, 32], ["dogs", "SPECIES", 19, 23], ["cats", "SPECIES", 28, 32], ["Antibody titers", "TEST", 0, 15], ["vaccination", "TREATMENT", 69, 80]]], ["Titers increased more rapidly after a booster injection on day 21.", [["a booster injection", "TREATMENT", 36, 55]]], ["In our study, calves were given a booster injection on day 28, 4 weeks after initial vaccination, and 1 week later than in the cats and dogs.", [["calves", "ORGANISM", 14, 20], ["cats", "ORGANISM", 127, 131], ["dogs", "ORGANISM", 136, 140], ["calves", "SPECIES", 14, 20], ["cats", "SPECIES", 127, 131], ["dogs", "SPECIES", 136, 140], ["calves", "SPECIES", 14, 20], ["cats", "SPECIES", 127, 131], ["our study", "TEST", 3, 12], ["a booster injection", "TREATMENT", 32, 51], ["initial vaccination", "TREATMENT", 77, 96], ["calves", "ANATOMY", 14, 20]]], ["Nevertheless, the serological response in the calves followed a similar trend as in the dogs and cats: the titers increased within a week after vaccination and increased more rapidly after a booster injection.", [["calves", "ORGANISM", 46, 52], ["dogs", "ORGANISM", 88, 92], ["cats", "ORGANISM", 97, 101], ["calves", "SPECIES", 46, 52], ["dogs", "SPECIES", 88, 92], ["cats", "SPECIES", 97, 101], ["vaccination", "TREATMENT", 144, 155], ["a booster injection", "TREATMENT", 189, 208], ["calves", "ANATOMY", 46, 52], ["increased", "OBSERVATION_MODIFIER", 160, 169]]], ["It is possible that the presence of maternal antibodies in the calves could have interfered with vaccination in this study.", [["calves", "ORGANISM", 63, 69], ["maternal antibodies", "PROTEIN", 36, 55], ["calves", "SPECIES", 63, 69], ["maternal antibodies in the calves", "PROBLEM", 36, 69], ["vaccination", "TREATMENT", 97, 108], ["this study", "TEST", 112, 122], ["antibodies", "OBSERVATION", 45, 55], ["calves", "ANATOMY", 63, 69]]], ["Both groups had a similar mean antibody titer, presumably maternal antibodies, at the beginning of the study, which declined prior to vaccination.", [["maternal antibodies", "PROTEIN", 58, 77], ["a similar mean antibody titer", "PROBLEM", 16, 45], ["maternal antibodies", "PROBLEM", 58, 77], ["the study", "TEST", 99, 108], ["vaccination", "TREATMENT", 134, 145]]], ["Although a previous study has demonstrated that maternal antibodies to G. duodenalis decline within 30 days in dairy calves, sufficient maternal antibodies may have been present when vaccinations were carried out in this group of calves.", [["G. duodenalis", "DISEASE", 71, 84], ["G. duodenalis", "ORGANISM", 71, 84], ["calves", "ORGANISM", 117, 123], ["calves", "ORGANISM", 230, 236], ["maternal antibodies", "PROTEIN", 48, 67], ["maternal antibodies", "PROTEIN", 136, 155], ["G. duodenalis", "SPECIES", 71, 84], ["calves", "SPECIES", 117, 123], ["calves", "SPECIES", 230, 236], ["G. duodenalis", "SPECIES", 71, 84], ["dairy", "SPECIES", 111, 116], ["a previous study", "TEST", 9, 25], ["maternal antibodies", "PROBLEM", 48, 67], ["duodenalis decline", "PROBLEM", 74, 92], ["sufficient maternal antibodies", "PROBLEM", 125, 155], ["vaccinations", "TREATMENT", 183, 195], ["calves", "ANATOMY", 230, 236]]], ["However, the impact of maternal antibodies on vaccine efficacy is controversial, and recent studies have indicated good vaccine efficacy despite administration in the presence of maternal antibodies (Martelli et al., 2006; Zimmerman et al., 2006) , while other studies reported a negative impact of maternal antibodies on vaccine efficacy.", [["maternal antibodies", "PROTEIN", 23, 42], ["maternal antibodies", "PROTEIN", 179, 198], ["maternal antibodies", "PROTEIN", 299, 318], ["maternal antibodies", "TREATMENT", 23, 42], ["vaccine efficacy", "TREATMENT", 46, 62], ["recent studies", "TEST", 85, 99], ["maternal antibodies", "PROBLEM", 179, 198], ["other studies", "TEST", 255, 268], ["maternal antibodies", "PROBLEM", 299, 318], ["vaccine efficacy", "TREATMENT", 322, 338]]], ["Few studies have examined the immune response of ruminants following G. duodenalis infection, but a weak serum immune response was observed following natural infection in both lambs and calves and this is thought to account, in part, for the chronicity of infection in ruminants (Yanke et al., 1998; O'Handley et al., 2003) .", [["serum", "ANATOMY", 105, 110], ["G. duodenalis infection", "DISEASE", 69, 92], ["natural infection", "DISEASE", 150, 167], ["infection", "DISEASE", 256, 265], ["ruminants", "ORGANISM", 49, 58], ["G. duodenalis", "ORGANISM", 69, 82], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["lambs", "ORGANISM", 176, 181], ["calves", "ORGANISM", 186, 192], ["G. duodenalis", "SPECIES", 69, 82], ["lambs", "SPECIES", 176, 181], ["calves", "SPECIES", 186, 192], ["ruminants", "SPECIES", 49, 58], ["G. duodenalis", "SPECIES", 69, 82], ["Few studies", "TEST", 0, 11], ["G. duodenalis infection", "PROBLEM", 69, 92], ["a weak serum immune response", "PROBLEM", 98, 126], ["natural infection in both lambs and calves", "PROBLEM", 150, 192], ["infection", "PROBLEM", 256, 265], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 158, 167], ["both", "ANATOMY_MODIFIER", 171, 175], ["lambs", "ANATOMY", 176, 181], ["calves", "ANATOMY", 186, 192], ["infection", "OBSERVATION", 256, 265]]], ["Although calves mounted a serological immune response following vaccination, it is possible that vaccination did not stimulate immunity locally within the gut, and a localized immune response is important in the elimination of infection (Gottstein et al., 1990) .", [["gut", "ANATOMY", 155, 158], ["infection", "DISEASE", 227, 236], ["calves", "ORGANISM", 9, 15], ["gut", "ORGANISM_SUBDIVISION", 155, 158], ["calves", "SPECIES", 9, 15], ["calves", "SPECIES", 9, 15], ["vaccination", "TREATMENT", 64, 75], ["vaccination", "TREATMENT", 97, 108], ["a localized immune response", "PROBLEM", 164, 191], ["infection", "PROBLEM", 227, 236], ["gut", "ANATOMY", 155, 158], ["immune response", "OBSERVATION", 176, 191], ["infection", "OBSERVATION", 227, 236]]], ["In addition, recent research has shown that ruminants are most commonly infected with G. duodenalis corresponding to the genetic assemblage E (O'Handley et al., 2000b; Appelbee et al., 2003; Trout et al., 2004 Trout et al., , 2005 Trout et al., , 2006 , which was also the genotype used to challenge the calves in this study.", [["ruminants", "ORGANISM", 44, 53], ["G. duodenalis", "ORGANISM", 86, 99], ["calves", "ORGANISM", 304, 310], ["G. duodenalis", "SPECIES", 86, 99], ["calves", "SPECIES", 304, 310], ["ruminants", "SPECIES", 44, 53], ["G. duodenalis", "SPECIES", 86, 99], ["G. duodenalis", "PROBLEM", 86, 99], ["the genotype", "PROBLEM", 269, 281], ["this study", "TEST", 314, 324], ["calves", "ANATOMY", 304, 310]]], ["Although the genotype of G. duodenalis comprising the vaccine is not known, it would not be assemblage E as this assemblage has yet to be cultured in vitro.", [["G. duodenalis", "CHEMICAL", 25, 38], ["G. duodenalis", "ORGANISM", 25, 38], ["G. duodenalis", "SPECIES", 25, 38], ["G. duodenalis", "SPECIES", 25, 38], ["G. duodenalis", "PROBLEM", 25, 38], ["the vaccine", "TREATMENT", 50, 61]]], ["Thus, antigenic differences between the genetic assemblages could account for the failure of this vaccine to prevent G. duodenalis infection in calves.", [["G. duodenalis infection", "DISEASE", 117, 140], ["G. duodenalis", "ORGANISM", 117, 130], ["calves", "ORGANISM", 144, 150], ["G. duodenalis", "SPECIES", 117, 130], ["calves", "SPECIES", 144, 150], ["G. duodenalis", "SPECIES", 117, 130], ["the genetic assemblages", "PROBLEM", 36, 59], ["the failure", "PROBLEM", 78, 89], ["this vaccine", "TREATMENT", 93, 105], ["G. duodenalis infection in calves", "PROBLEM", 117, 150], ["duodenalis", "OBSERVATION_MODIFIER", 120, 130], ["infection", "OBSERVATION", 131, 140]]]], "PMC7261425": []}